FINAL PROGRAM - EpiSouth

14th International Congress 

on Infectious Diseases (ICID) 

MIAMI, FLORIDA • USA • MARCH 9-12, 2010 

Organized by the International Society 

for Infectious Diseases 

FINAL PROGRAM 

With the 

4th Regional Conference of the International Society of Travel Medicine 

SLAMVI 

Sociedad Latinoamericana 

de Medicina del Viajero 

II Congreso Latinoamericano de Medicina del Viajero 

In collaboration with the 

Infectious Diseases Society of America (IDSA) 

Pan American Association for Infectious Diseases (API) 

Latin American Society of Pediatric Infectious Disease (SLIPE)

THURSDAYMARCH 2010 

FOR MORE INFORMATION, 

THE GLOBAL IMPACT 

OF HPV INFECTION 

AND RELATED DISEASES 

CONSEQUENCESAND STRATEGIES 

FORPREVENTION 

HYATTREGENCYMIAMI 

SOUTHHALLRIVERFRONTHALLLOBBYLEVEL 

MIAMIFLORIDA 

PM–PM 

REGISTRATIONANDLUNCH 

PM–PM 

SYMPOSIUM 

ACTIVITYCHAIRPERSON 

Mark A. Kane, MD, MPH 

Retired Director, Children’s Vaccine Program 

Program for Appropriate Technology in Health (PATH) 

Founding President, Global Fund for Children’s Vaccines 

Consultant in Vaccinology 

Mercer Island, Washington 

FACULTY 

Maura L. Gillison, MD, PhD 

Professor of Medicine 

Jeg Coughlin Chair of Cancer Research 

The Ohio State University 

James Cancer Hospital and Solove Research Institute 

Columbus, Ohio 

Joel M. Palefsky, MD 

Professor of Medicine 

Associate Dean for Clinical and Translational Research 

Co-Director, UCSF Clinical and Translational Sciences Institute 

University of California, San Francisco 

San Francisco, California 

LUNCH 

WILL BE 

PROVIDED 

O N S I T E 

REGISTRATION 

IS AVAILABLE 

Accreditation Statement 

SciMed is accredited by the Accreditation Council for 

Continuing Medical Education (ACCME) to provide 

continuing medical education for physicians. 

PLEASE VISIT 

Sponsored by 

Supported by an educational grant from

14th International Congress 

on Infectious Diseases (ICID) 

MIAMI, FLORIDA • USA • MARCH 9-12, 2010 

FINAL PROGRAM

Time Schedule 

14th International Congress on Infectious Diseases 

Congress Registration & Information 13:00 – 17:00 Monday March 8, 2010 

8:00 – 18:30 Tuesday March 9, 2010 

8:00 – 18:00 Wednesday March 10, 2010 

8:00 – 18:00 Thursday March 11, 2010 

8:00 – 18:00 Friday March 12, 2010 

ISTM Certificate in Travel Health 13:00 – 18:00 Monday March 8, 2010 

Examination (CTH) 

Opening Ceremony 18:30 – 20:00 Tuesday March 9, 2010 

Welcome Reception 20:00 Tuesday March 9, 2010 

Scientific Sessions 9:00 – 17:45 Tuesday March 9, 2010 

through 

Friday March 12, 2010 

Poster Sessions 13:30 – 14:30 Wednesday March 10, 2010 

through 


Meet-the-Expert Sessions 7:45 – 8:45 Tuesday March 9, 2010 

through 


Business Meeting (lunch provided) 12:45 – 13:45 Friday March 12, 2010 

Commercial Exhibition 9:00 – 17:30 Wednesday March 10, 2010 

through 


ii ~ Final Program

ii ~ Final Program 

14th International Congress on Infectious Diseases


Final Program ~ 1

Introduction by ISID 


Dear Colleagues, 

Welcome to Miami and the 14th International Congress on Infectious Diseases! 

It is an honor this year to hold the 14th ICID in conjunction with the 4th Regional Conference of the 

International Society of Travel Medicine and the II Congreso Latinoamericano de Medicina del Viajero. 

This assembly highlights the truly global scope of both the presentations and the participants, one of the 

unique features of the ICID. 

Our Program Committee has once again put together an exceptional scientific program with a blend of 

pure science, epidemiology, clinical medicine and microbiology. You will learn about new strategies to 

manage challenging public health and clinical infectious diseases issues and gain insight into the biological 

mechanisms of disease and health. The ICID is distinguished by a strong regional focus and this year has 

a particularly robust travel medicine track. The breadth of infectious diseases will be highlighted in the 

plenary lectures, which will cover topics ranging from historical infectious diseases discoveries to global public 

health policies. 

Over 1,500 abstracts were submitted to the 14th ICID Program Committee for consideration. Just over 1,050 

were accepted for poster presentation with an additional 50 accepted for oral presentation. Fifteen individuals 

will be recognized with awards for their outstanding research thanks to support from Novartis, Sanofi Pasteur, 

the US CDC and the ISID. In addition, twelve promising young women researchers from Latin America and 

the Caribbean are here thanks to a travel grant provided by Sanofi Pasteur. 

Our coming together at the ICID will most certainly create excellent possibilities for exchange of ideas, 

opinions, and the initiation or continuation of collaborative research partnerships. Please make the most of 

new and old opportunities for friendship and enjoy your visit to Miami. 

Raúl Istúriz MD 

President, International Society for Infectious Diseases (ISID) 

Final Program ~ 3

Introduction by ISTM 


Dear Colleagues, 

Bienvenidos a Miami! 

The International Society of Travel Medicine (ISTM) welcomes you to RCISTM4, the 4th Regional Conference 

of the ISTM on March 9–12, 2010, in Miami, Florida, USA. We are delighted to be co-sponsors with the Sociedad 

Latinoamericana de Medicina del Viajero (SLAMVI) for their 2nd Congress. This travel medicine program 

is planned in parallel with the 14th International Congress on Infectious Diseases (ICID) organized by the 

International Society of Infectious Diseases (ISID). 

You will be joining your friends and colleagues from around the world at this years meeting. The program 

committees have organized a state of the art educational experience with multiple tracks guaranteed to 

offer something of interest for all attendees. There will be engaging plenary sessions, symposia, meet the 

expert, primary research and workshops for all levels of background training and expertise. Please refer to 

www.istm.org for updates to the program and additional information to enhance your participation in this 

important meeting on travel medicine and infectious diseases. 

Miami in March promises to be a delightful destination with warm weather, bright sun, and the famous Miami 

beaches close by. It is a very international city with a Latin American flavor. 

We wish you a productive, educational, and pleasurable stay in Miami. We also hope to see you at our next 

biennial worldwide meeting CISTM12 in Boston in May 2011. 

With best regards, 

Alan J. Magill MD, FACP, FIDSA 

President, International Society for Travel Medicine (ISTM) 

2009-2011 

David O. Freedman, MD, FIDSA 

Secretary-Treasurer, ISTM 

4 ~ Final Program

Introduction by SLAMVI 


Dear Colleagues and Friends: 

Welcome to the II Congreso Latinoamericano de Medicina del Viajero by SLAMVI, the Sociedad Latinoamericana 

de Medicina del Viajero. 

SLAMVI is honored to co-chair this year’s congress with the 4th Regional Conference of the International 

Society of Travel Medicine (RCISTM4). The travel medicine track is included in the 14th International Congress 

of Infectious Diseases. 

SLAMVI is immensely grateful to both the ISTM and the ISID for this unique opportunity to help us promote 

the growth of Travel Medicine as a prominent specialty in our region as well as the membership of our 

young society. 

The scientific program of the 14th ICID includes a comprehensive Travel Medicine track with sessions 

that focus on almost all aspects of our rapidly developing discipline. There is particular emphasis on the major 

topics of concern in Latin America. We especially invite our colleagues to join the sessions on March 9th, 

which in recognition to our languages will be held, in part, in Spanish and Portuguese. 

We hope this conference presents to all attendees the opportunity of meeting colleagues and friends, enhancing 

their knowledge of Travel Medicine and enjoying the complete update in Infectious Diseases that the 

14th ICID presents to us all. 

Welcome to Miami, Bienvenidos a Miami, Bem-vindos a Miami! 

Mario Masana Wilson, MD 

President, Sociedad Latinoamericana de Medicina del Viajero (SLAMVI) 

SLAMVI 

Sociedad Latinoamericana 

de Medicina del Viajero 

Final Program ~ 5

Table of Contents 


Time Schedule . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . ii 

Welcome . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1 

Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 

Congress Committees and Organization . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7 

Congress Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 

Members of the ISID Council . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 

Membership in the ISID . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 

International Journal of Infectious Diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 9 

Awards . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .10 

Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .13 

General Information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .14 

ISID Business Meeting. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .16 

Speakers Center and Lounge . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .16 

Poster Presentations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .16 

Plenary Lectures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .18 

Meet-the-Expert . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .22 

CME Accreditation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .22 

Commercial Exhibition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .23 

Schedule-at-a-Glance . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .24 

Floorplans . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .26 

Opening Ceremony . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .38 

Scientific Program . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .29 

Tuesday, March 9, 2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .29 

Wednesday, March 10, 2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .39 

Thursday, March 11, 2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .97 

Friday, March 12, 2010 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 149 

Disclosures . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 210 

Index of Authors and Co-Authors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 212 

6 ~ Final Program

Congress Committees 

International Organizing Committee 

Timothy Brewer (Canada) 

Keryn Christiansen (Australia) 

Jonathan Cohen (UK) 

Raúl Istúriz (Venezuela), President 

Keith Klugman (USA) 

Daniel Lew (Switzerland) 

Carla Odio (Costa Rica) 

Heikki Peltola (Finland) 

Didier Raoult (France) 

Eric Summers (USA) 

Richard Wenzel (USA) 

Program Advisory Committee 

Guillermo Acuña (Chile) 

Deshratn Asthana (USA) 

NC Bodonaik (Jamaica) 

Lina Bofill (USA) 

Pedro Cahn (Argentina) 

Gordon Dickinson (USA) 

Gustavo Kouri (Cuba) 

Samuel Ponce de Leon (Mexico) 

Frederick Southwick (USA) 

Jaime Torres (Venezuela) 

Sergio Wey (Brazil) 


RCISTM4/SLAMVI Travel Medicine 

Program Committee 

Arlene Calvo (Panamá), Associate Chair 

Jessé Reis Alves (Brazil), Chair 

Cristián Biscayart (Argentina), Co-Chair 

Susana Lloveras (Argentina), Associate Chair 

Members 


Suni Boraston (Canada) 

Marcos Boulos (Brasil) 

Jeanette Dabanch Peña (Chile) 

Carlos Franco-Paredes (USA/Mexico) 

David Freedman (USA) 

Eduardo Gotuzzo (Peru) 

Sylvia Lemos Hinrichsen (Brasil) 

Alejandro Lepetic (Argentina) 

Alejandra Macchi (Argentina) 

Alan Magill (USA) 

Melissa Mascheretti (Brasil) 

Mario Masana Wilson (Argentina) 

Tomás Orduna (Argentina) 

Alejando Ortiz (Mexico) 

Cecilia Perret (Chile) 

Franklin Simões de Santana Filho (Brasil) 

Nestor Sosa (Panamá) 

Tânia Souza Chaves (Brasil) 


Collaborating Organizations 

Infectious Diseases Society of America (IDSA) 

International Society of Travel Medicine (ISTM) 

Latin American Society of Pediatric 

Infectious Diseases (SLIPE) 

Pan American Association for 

Infectious Diseases (API) 

Sociedad Latinoamericana de Medicina 

del Viajero (SLAMVI) 

Cooperating Organizations 

American Society for Microbiology (ASM) 

Argentinian Society of Infectious Diseases (SADI) 

Asociación Colombiana de Infectología (ACIN) 

Brazilian Society of Infectious Diseases (BSID) 

Costa Rican Society of Infectious Diseases 

European Society of Clinical Microbiology and 

Infectious Diseases (ESCMID) 

International Society for Anaerobic Bacteria (ISAB) 

Panamanian Society of Infectious Diseases 

Pan American Health Organization (PAHO) 

Paraguayan Society for Infections Diseases 

Venezuelan Society of Infectious Diseases (SVI) 

Final Program ~ 7

Congress Information 


Congress Site 

James L Knight International Center & 

Hyatt Regency Miami 

Miami, FL, USA 

Official Language 

The official language of the Congress is English. 

Some Spanish language sessions will be 

available on Tuesday, March 9, 2010 during 

the SLAMVI/ISTM program. 

International Society for 

Infectious Diseases (ISID) 

Norman R. Stein, Executive Director 

Eric Summers, Program Director 

International Society for Infectious Diseases 

1330 Beacon Street, Suite 228 

Brookline, MA 02446, USA 

Phone: (617) 277-0551 

Fax: (617) 278-9113 

E-mail: info@isid.org 

web site: http://www.isid.org 

14th ICID Congress Secretariat 

Registration 

B.P. SERVIMED, S.A. DE C.V. 

Barranca del Muerto No. 520, Col. Alpes, 

01010 México, D.F. 

Phone: +52 (55) 9171 9570 

Fax: +52 (55) 5660 1903 

E-mail: isid@servimed.com.mx 

Housing 

Greater Miami Convention & Visitors Bureau 

701 Brickell Ave., Ste. 2700 

Miami, FL 33131, USA 

Phone: (305) 539 2928 

(800) 476 9969 

Fax: (305) 539 3106 

E-mail: housing@gmcvb.com 

Exhibition Management 

Media Plan 

Ms. Bettina Kreiner 

Freyung 6 

1010 Vienna, Austria 

Phone: (+43 1) 536 63 0 

Fax: (+43 1) 535 60 16 

E-mail: maw@media.co.at 

Official Travel Agency 

Stewart International Travel is delighted to have 

been selected as the Official Travel Agent for the 

14th International Congress on Infectious Diseases. 

As such, we would be happy to assist with your 

air transportation to Miami. 

For further information please contact: 

Stewart International Travel 

50 Boylston Street 

Brookline, MA 02445 

Phone: (617) 738-1575 

(800) 738-1575 

E-mail: pilar@stewartintltravel.com 

web site: www.stewartintltravel.com 

8 ~ Final Program

International Society for Infectious Diseases (ISID) 


Members of the ISID Council 


John Bartlett (USA) 

Mohammed Benbachir (Morocco) 

Zulfiqar Bhutta (Pakistan) 

N.C. Bodonaik (Jamaica) 

Pedro Cahn (Argentina) 

Jun Cheng (China) 

Ron Dagan (Israel) 

Adriano Duse (South Africa) 

Le Dang Ha (Vietnam) 

Javier Ena (Spain) 

Barry Gilbert (Australia) 

Bart Gordts (Belgium) 

Nii Hanson-Nortey (Ghana) 

Waleria Hryniewicz (Poland) 

Abeeda Kamarulzaman (Malaysia) 

Moses Kamya (Kenya) 

Gustavo Kourí (Cuba) 

Vladimir Krčméry (Slovak Republic) 

Hsieh-Shong Leu (Taiwan) 

Chewe Luo (Zambia) 

Cristina Marino (Colombia) 

Ziad Memish (Saudi Arabia) 

Alaine Nyaruhirira (Ewanda)) 

Emanuele Nicastri (Italy) 

Nobuhiko Okabe (Japan) 

Franco Paradisi (Italy) 

Samuel Ponce de Leon (Mexico) 

Mahbubur Rahman (Bangladesh) 

RK Ratho (India) 

Marie-Christine Roy (Canada) 

Sally Roberts (New Zealand) 

Roberto Salvino (The Philippines) 

Atef Shibl (Egypt) 

Yupin Suputtamongkol (Thailand) 


Constanze Wendt (Germany) 

Sergio Wey (Brazil) 

Membership in the ISID 

Any individual interested in infectious diseases may become a Regular Member of the Society. 

Benefits include: 

• 1-year online subscription to the International Journal of Infectious Diseases 

• Discounts at the International Congress on Infecious Diseases (ICID) 

• Subscription to the Society’s newsletter (ISID News) 

• Subscription to ProMED-mail, an email network providing up-to-date, reliable reports 

on infectious diseases outbreaks around the world. 

Individuals who pay the full registration fee for the ICID become Regular Members and are entitled to all of the 

benefits of membership for a two-year term. 

You may also become a Regular Member by paying the membership fee of US$150. The term of membership 

is one year. Membership is available for individuals who work and reside in low-resource countries, or for 

students, for US$50 per year. 

Corresponding Membership in the Society is available without charge through application to the Society. 

This type of membership includes all of the benefits of Regular Membership, except for the Journal and the 

discounts at the ICID. 

For additional information or to apply for membership, please contact the ISID headquarters or visit the Society 

website at http://www.isid.org. 

International Journal of Infectious Diseases 

The International Journal of Infectious Diseases (IJID) is an English-language publication of the International 

Society for Infectious Diseases available in an on-line format. Because the Society is the only international organization 

dealing specifically with infectious diseases, its journal has a unique mission: to communicate and 

disseminate information to infectious disease researchers and clinicians throughout the world. The IJID is cited 

and indexed in MEDLINE. 

Final Program ~ 9

Awards 


More than 1,000 abstracts were considered for the Awards Program. The award-winning scientists 

were selected by the Program Committee and representatives from Sanofi Pasteur and Novartis 

Vaccines according to the criteria described in the preliminary program. 

Winners of the Novartis Vaccines Awards for Epidemiology of Infectious Diseases 

The Novartis Vaccines 

Awards will be officially 

presented during the 

Opening Ceremony on 

March 9 at 18:30hrs 

Phabiola M. Herrera Aldana ~ Peru is a medical research scientist working with The Johns Hopkins School of 

Public Health overseas research site in Lima, Peru. Her research focuses on gastrointestinal infectious diseases, 

specifically the Helicobacter pylori infection. Her training from Johns Hopkins was crucial in developing and 

coordinating epidemiologic projects in shantytowns and other underserved Peruvian communities. This work 

with diverse communities in Peru led to international collaboration with colleagues at Johns Hopkins, Washington 

University St Louis, Center for Disease Control (CDC) and Universidad Federal de Minais Gerais in Brazil. 

The National Institutes of Health (NIH) funded Helicobacter pylori infection research focused on three areas: 

Intrafamiliar transmission in Lima’s shantytowns, genetic characterization in Peruvian jungle villages, and 

genotypes of strains related to gastric cancer in hospital settings. 

In addition to several publications, Dr. Herrera has supervised foreign students, interacted with young US and 

developing country researchers and received the Fogarty/Ellison Global Overseas Fellowship from the NIH. 

Dr. Herrera has also been involved in other areas of infectious disease research including first episode of 

schizophrenia and childhood diarrheal and neglected mucosal enteric infection. In social research, her work 

has examined the link between drug and alcohol consumption with sexual behavior in young adults with a grant 

funded by Belgium Technical Cooperation. 

Currently, Dr. Herrera is focusing on improving her understanding of clinical environments to enhance and 

continue her gastroenterology infectious disease research. 

Mussaret Zaidi ~ Mexico is an investigator at the Hospital General O’Horan and the Hospital Regional de 

Alta Especialidad in Yucatan, Mexico. She is currently a member of the World Health Organization Advisory 

Group for Integrated Surveillance of Antimicrobial Resistance. Over the last decade, her research has focused on 

the epidemiology of antimicrobial resistance in foodborne and nosocomial pathogens and the transmission of 

foodborne pathogens from animals to humans. More recently, her studies have centered on the immune response 

to foodborne pathogens in highly endemic settings. 

With the support of a generous grant from the United States Food and Drug Administration, Dr. Zaidi coordinated 

the first multistate study on antimicrobial resistance in foodborne pathogens in Mexico. This study integrated 

active surveillance data from food-animals, raw retail meat and human fecal specimens to study transmission 

through the food chain. This integrated approach was subsequently used in a community-based cohort study to 

determine the frequency of transmission of antimicrobial resistant foodborne pathogens from food-animals to 

humans and its impact on human health. These studies provided the first data on antimicrobial-resistant foodborne 

pathogens throughout the food chain in Mexico. Using data from active epidemiological surveillance and pulsedfield 

gel electrophoresis analysis, public health risks were determined for the different foodborne pathogens and 

Salmonella serotypes. Multilocus sequence typing was used to identify recently emerging multidrug-resistant 

clones that are associated with specific resistance determinants and geographic distributions within Mexico. 

The Society gratefully acknowledges the support of 

NOVARTIS VACCINES, which made these awards possible. 

Winner of the ISID New Investigator Award 

Juan Carlos Quintero Vélez ~ Colombia is an investigator of the Veterinary Science “Centauro” group and DMV 

at the Universtiy of Antioquia and Animal Productions at the National University of Colombia. Msc Candidate 

of Animal Science at the University of Antioquia. His current research is on Rickettsial Disease and zoonoses in 

the Urabá area of Antioquia, Colombia. This research is carried out in collaboration with the National Institute of 

Health, Colombia; Gorgas Institute, Panama; University of Sao Paulo, Brazil; and the University of Texas, USA. 

The ISID New Investigator Award will be officially presented 

during the Opening Ceremony on March 9 at 18:30hrs 

10 ~ Final Program

Awards 


Winners of the Sanofi Pasteur Awards 

Beate Sander, RN, MBA, MEcDev ~ Canada is a PhD candidate in the Department of Health Policy, Management 

and Evaluation at the University of Toronto, Canada, a collaborator with THETA, the Toronto Health Economics 

and Technology Assessment Collaborative, and a research fellow in decision-analytic modeling in the 

Division of Clinical Decision Making at the University Health Network Research Institute. Her research interests 

include the use of advanced modeling techniques to evaluate new health technologies within the larger context 

of comprehensive health care programs to support health policy decision-making. Her doctoral research extends 

current modeling techniques used in economic evaluation to incorporate individual human behavior, important 

for simulating infectious disease transmission. She is interested in answering public health policy questions by 

using models to assess the impacts of vaccination and other control measures. Recent projects include an economic 

evaluation of Ontario’s Universal Influenza Immunization program and economic evaluations of influenza 

pandemic mitigation strategies in Canada and the US. Beate Sander works extensively with mathematicians, 

epidemiologists, and public health researchers on various interdisciplinary collaborations. 

Akira Suzuki, MD, PhD, MPH ~ Japan is an assistant professor in Department of Virology at Tohoku University 

Graduate School of Medicine, Japan. After eight years of practice as pediatrician in Japan, he earned his Master’s 

Degree in Public Health at University of Michigan on the Fulbright Scholarship. His main research topic is 

the epidemiology of respiratory viruses among children. Currently, Tohoku University and Research Institute 

for Tropical Medicine, the Philippines, have been conducting a series of collaborating studies on emerging and 

re-emerging infections, supported by Ministry of Education, Culture, Sports, Science, and Technology-Japan. The 

study covers not only respiratory viruses (influenza virus, human metapneumovirus, RS virus, and rhinovirus) but 

also enteric viruses (norovirus, rotavirus), polio-related viruses (enteroviruses), and zoonosis (ebola and rabies). 

The Sanofi Pasteur Awards will be officially presented during the Opening Ceremony on March 9 at 18:30hrs 

The Society gratefully acknowledges the support of 

SANOFI PASTEUR, which made these awards possible. 

Sanofi Pasteur Travel Grants for Latin American Women Physicians and Scientists 

Carmen Sarah Mota 

DOMINICAN REPUBLIC 

Mayra Ligia Raciny 

COLOMBIA 

Carina Ramos 

BRAZIL 

Silvina Ruvinsky 

ARGENTINA 

Yagahira Castro Sesquen 

PERU 

Kelly Salomão 

BRAZIL 

Carmona Sandoval 

CHILE 

Virgina Verdaguer 

ARGENTINA 

Gabriela Vidiella 

ARGENTINA 

Cecilia Vizcaya 

CHILE 

Maria Laura Yantorno 

ARGENTINA 

Final Program ~ 11

Awards 


CDC Awards for Epidemiology, Surveillance and Communications in Travelers’ Health 

José Roberto P. 

De Andrade-Lima 

BRAZIL 

Pablo Elmassian 

ARGENTINA 

Cristiano Gregis 

BRAZIL 

Cristiane Lamas 

BRAZIL 

Maria Ester Lázaro 

ARGENTINA 

Susana Lloveras 

ARGENTINA 

Manuel Loayza 

PERU 

Alejandra Macchi 

ARGENTINA 

Melissa Mascheretti 

BRAZIL 

Tomas Orduña 

ARGENTINA 

12 ~ Final Program

Acknowledgements 


The International Organizing Committee would like to take this opportunity 

to acknowledge the following sponsors: 

PREMIER SPONSORS 

Pfizer 

Sanofi Pasteur 

SPONSORS 

ASM (American Society for Microbiology) 

API (Associacion Panamericana de Infectiologia) 

Astellas Pharma Global Development Inc. 

Baxter 

CDC (U.S. Centers for Disease Control and Prevention) 

ESCMID (European Society of Clinical Microbiology and Infectious Diseases) 

GMCVB (Greater Miami Convention & Visitors Bureau) 

ISC (International Society of Chemotherapy) 

Merck 

Novartis Vaccines 

PAHO (Pan American Health Organization) 

Salix Pharmaceuticals, Inc. 

Final Program ~ 13

General Information 


Badges 

All registrants have been issued badges, which must be worn to gain admission to the convention 

facilities and social program. Badges are color-coded as follows: 

Participants – blue 

Staff – red 

Accompanying Persons – orange Exhibitors – yellow 

Press – grey 

A fee of USD 150 will be charged for the replacement of lost or forgotten badges. 

Only participants with blue and grey badges will be admitted to the scientific sessions. 

Congress Venue 

The 14th ICID takes place at the Hyatt Regency Miami. No smoking is allowed. Mobile phones must be switched 

off in the meeting rooms. Your cooperation will be appreciated. Unauthorized recording (video and/or audio) and 

photography are not allowed. 

Congress Language 

The official language of the Congress is English. Some Spanish language sessions will be available on Tuesday, 

March 9, 2010 during the SLAMVI / ISTM program. 

Lunch/Snack Bar and Restaurant 

A lunch and snack bar area will be available to Congress participants. This area is located in the Exhibit area in 

Riverfront Hall on the Lobby Level. Lunch is also available at the Riverwalk Cafe on the Lobby Level. 

Message & Info Center 

A message center for collection and distribution of messages is available on the Terrace Level near the meeting 

rooms. 

Internet Corner 

Congress participants are invited to the internet corner which is located in the exhibit area in Riverfront Hall on 

the Lobby Level. 

Dining 

Miami’s dining scene is truly exciting, one of varying tastes that can satisfy the most complete palate or craving. 

With so many different cultures migrating to Miami, local flavors tend to be much more exotic. The influence of 

flavors and culture here is almost overwhelming and has many positive effects on menu and recipe design. 

Entertainment 

Miami offers exciting nightlife. Besides local and international theatre shows and symphony orchestras, there 

is a wide variety of entertainment including live bands, jazz bands, strollers, dinner shows, cabaret, disco 

and karaoke lounges. Nightlife in the city also thrives with the many pubs, street cafés and bistros that offer 

visitors a guaranteed exciting night. 

Tipping 

Tipping is customary in Miami (15%–20%). 

14 ~ Final Program

General Information 


Credit Cards 

Major credit cards are accepted in most hotels, shops and restaurants. Travelers checks and currency can be 

changed at hotels or at a bank. Banking hours vary, but most banks are open weekdays from 9am to 3pm. Several 

stay open until 5pm or so at least 1 day during the week. 

Currency 

The US Dollar is the United States’ unit of currency. The dollar is divided into 100 cents (100¢) with coins of 

one cent (penny), five cents (nickel), 10 cents (dime), 25 cents (quarter) and relatively rare 50 cents (half dollar). 

Shopping 

As a general rule, shop hours are Monday through Saturday from 10am to 6pm, and Sunday from noon to 5pm. 

Many stores stay open late (until 9pm or so) 1 night of the week, usually Thursday. Shops in Coconut Grove are 

open until 9pm Sunday through Thursday, and even later on Friday and Saturday. South Beach’s stores also stay 

open later—as late as midnight. Department stores and shopping malls keep longer hours as well, with most staying 

open from 10am to 9 or 10pm Monday through Saturday, noon to 6pm on Sunday. 

Sales Tax 

A 7% state sales tax is added on at the register for all goods and services purchased in Florida. 

Electrical Current 

Type A & B sockets with 110 volts AC at 15A are used. 

Official Carrier 

American Airlines was appointed official carrier for the 14th International Congress on Infectious Diseases. 

Taxis and Public Transportation 

Taxis are always available and required to use meters when ferrying passengers. Fares do not include a tip, plan 

to give around 15%. Public transportation (‘People Mover’) is very convenient and free. 

Tours 

Tours can be booked through the Tours Counter in the registration area on the Lobby Level. 

Safety Precautions 

As in most places, it is advisable to take the following precautions while in Miami: 

•.Do not leave luggage or valuables unattended. 

•.Use the safety deposit boxes provided by most hotels. 

•.Carry only the cash, credit cards, and identification that you need. 

Insurance 

The Organizing Committee, ISID and Servimed accept no liability for personal injuries sustained by or for loss 

or damage to property belonging to Congress participants, either during or as a result of the Congress or during 

tours.It is therefore recommended that delegates and accompanying persons arrange for appropriate travel and 

health insurance before traveling. 

Emergencies 

For emergencies, dial tel. 911 from any phone. No coins are needed for this call. For other police matters, call 

tel. 305/595-6263. 

Final Program ~ 15

ISID Business Meeting 


The ICID, held every 2 years, is the only opportunity for the Society’s membership to come together. It is only 

then that members can actively exchange ideas concerning the ISID and its activities with representatives of the 

Executive Committee and Council. Your input is important and your contributions are appreciated. We would like 

to invite all members to participate in the Business Meeting, which will take place on Friday, March 12, 2010, 

at 12:30hrs in Room Orchid B/C/D on Terrace Level. During this meeting, Regular Members will vote on the 

composition of the Executive Committee and Council for the period 2010–2012. You will hear reports from various 

officers concerning the ongoing activities of the Society, and you will be able to voice your suggestions and 

concerns. A light lunch will be provided. We hope you will attend this important meeting. 

Speakers Center and Lounge 


An LCD projector and laptop for MS Powerpoint presentations are provided in all meeting rooms. All speakers 

are requested to take their presentations on CD/USB stick to the speakers center in Room Orchid A on Terrace 

Level at the Hyatt Regency Miami. All presentations must be received as early as possible but no later than two 

hours before the presentation. Please use the meeting room laptop computer rather than your personal computer 

for your presentation. 

A technician will be available to assist the speakers. Any questions regarding presentations should be directed to 

the speakers center located in room Orchid A on Terrace Level at the Hyatt Regency Miami. 

Poster Presentations 


Riverfront Hall 

Exhibition Area 

Lobby Level 

9.45 – 10:15hrs 

12:30 – 14:30hrs 

15:15 – 15:45hrs 

Posters are displayed in the exhibition area in Riverfront Hall on the Lobby Level of the Hyatt Regency Miami. 

Each poster board is marked with the number assigned to each abstract, which can be found in the abstract and/ 

or program book. Authors are requested to affix their posters at the number assigned to them (as listed in the 

program) on the morning of their designated date of presentation between 8:00 and 9:30hrs. At least one author 

of each poster should be present for discussion and questions during the official poster sessions each day from 

12:30 to 13:30hrs and, if possible, during the coffee breaks. 

All posters must be removed at the end of the day of the poster session, but no later than 17:45hrs. Posters not 

removed by this time will be dismantled by the Congress staff and may be claimed from the poster attendant. The 

Congress assumes no responsibilities for the condition of posters not removed by the presenter. All posters not 

collected by 17:45hrs on Friday, March 12, will be disposed of. 

Abstracts of poster presentations are published on the abstract CD-rom which is a supplement to the International 

Journal of Infectious Diseases (IJID). Abstracts accepted for “International Scientific Exchange” are not presented 

but published on a separate “International Scientific Exchange” CD-rom. 

16 ~ Final Program

Poster Presentations 



Exhibition Area 

Lobby Level 

9.45 – 10:15hrs 

12:30 – 14:30hrs 

15:15 – 15:45hrs 

Wednesday, March 10, 2010 Riverfront Hall Sessions 23–34 

Thursday, March 11, 2010 Riverfront Hall Sessions 48–59 

Friday, March 12, 2010 Riverfront Hall Sessions 73–84 

Wednesday, March 10, 2010 

23 Antibiotic Resistance: Gram-Negative 

24 Arboviruses 

25 Clinical Bacterial Infections 

26 Foodborne Diseases and Outbreaks 

27 HIV: Epidemiology and Prevention 

28 Influenza 

29 Malaria & Blood-borne Parasites 

30 Mycology, Fungal Infections and Antifungal Drugs 

31 Non-tuberculous Mycobacteria 

32 Travel Medicine and Travel Health 

33 Tuberculosis: Epidemiology, Prevention & Control 

34 Zoonoses and Infections in Animals 

Thursday, March 11, 2010 

48 Antibiotics: Mechanisms and Spectrum 

49 Antibiotics: Pharmacology and Clinical Studies 

50 Antibiotics: Usage and Stewardship 

51 Epidemiology of Pathogens 

52 Gram-negative Bacterial Infections 

53 Hepatitis 

54 HIV: Pathogenesis 

55 HIV: Therapeutics 

56 Infection Control, Nosocomial Infections and Critical Care 

57 Infectious Diseases Surveillance 

58 Parasites 

59 Tuberculosis: Diagnosis, Treatment & Drug Resistance 

Friday, March 12, 2010 

73 Animal Models, Pathogenesis & Host Defenses 

74 Antibiotic Resistance: Gram-Positive 

75 Diagnostics 

76 Emerging Infectious Diseases 

77 Gram-positives & Miscellaneous Pathogens 

78 HIV: Opportunistic Infections & Malignancies 

79 Obstetrical-Gynecological, Surgical and Sexually Transmitted Infections 

80 Pediatric and Perinatal Infections 

81 Mycobacterial Pathogenesis, Immunology and Vaccines 

82 Trypanosomiasis, Leishmaniasis & Schistosomiasis 

83 Vaccines and Vaccine Development 

84 Virology and Viral Infections (Non-HIV) 

Final Program ~ 17

Plenary Lectures 


Jarbas Barbosa da Silva, BRAZIL 

Emerging Infectious Diseases in Latin America 

Dr. Jarbas Barbosa da Silva Jr. has been Manager of the Health Surveillance, Disease Prevention and Control 

Area of the Pan American Health Organization (PAHO) since 10 January 2007. The HSD area is responsible 

for coordinating regional activities on surveillance, prevention and control of communicable and noncommunicable 

diseases; health information and analysis; and veterinarian public health. 

Dr. Barbosa received his degree in medicine from the Federal University of Pernambuco. He later received 

specialized credentials in public health and epidemiology from the National School of Public Health at the 

Oswaldo Cruz Foundation (FIOCRUZ), Brazil. He received a Master’s degree and later a Doctoral degree in 

public health from the State University of Campinas (Unicamp) in São Paulo state, Brazil. 

Dr. Barbosa began his professional career in the public health sector in 1982, working for the Secretariat of 

Health for the state of Pernambuco, Brazil. In 1987, he became Coordinator for the Program on Sexually 

Transmitted Diseases and HIV/AIDS in this state. In 1993, he was appointed Secretary of Health of the 

municipality of Olinda, and in 1995 Secretary of Health for the State of Pernambuco. In these positions he 

was the coordinator of the entire municipality health system and the state health system, respectively. 

From 1997 to 2003, Dr. Barbosa da Silva worked as Director of the National Center for Epidemiology 

(CENEPI) in Brasilia, Brazil, in the Ministry of Health. In this position he was the national coordinator of 

the epidemiological surveillance system. In 2003 he was nominated as the first Secretary of Public Health 

Surveillance, a new branch created in the Brazilian MoH that joined the areas of epidemiological surveillance 

and the prevention and control of diseases programmes. In the second semester of 2007 he was appointed 

as Executive Secretary (Vice Minister) of the Ministry of Health. 

Dr. Barbosa is author and co-author of articles, books and chapters on several public health and 

epidemiological matters. 

Edward H. Kass Lecture 

Françoise Barré-Sinoussi, FRANCE 

The Discovery of HIV: An Example of Translational Research on Response to an Emerging Epidemic 

Françoise Barre-Sinoussi, PhD, is the acting Director of the “Regulation of Retroviral Infections” Unit at the 

Institut Pasteur in Paris. She has been involved in retrovirology research since the early 1970’s and is recognized 

for her contributions to HIV/AIDS research, in particular as the first author of the publication that 

reported in 1983 the discovery of a retrovirus, later named HIV, in a patient at risk for AIDS. In 1988, she 

became responsible for her own laboratory at the Institut Pasteur and initiated research programs on viral and 

host determinants of HIV/AIDS pathogenesis. 

Between 1988 and 1998, Dr. Barré-Sinoussi has been involved in collaborative programs on HIV vaccine 

research using primate models. Today, the research programs of her team are focused on regulations of HIV/ 

SIV infection (intracellular restrictions of HIV-1infection and innate immunity, in particular regulations of 

T cell activation resulting from the NK-dendritic cell interplay). 

Dr. Barré-Sinoussi is author and co-author of more than 220 original publications and more than 120 articles 

and book reviews. She has been invited to speak at more than 250 International meetings and/or conferences. 

She has been (and is still) a member of a number of scientific committees in France and elsewhere, 

including scientific committees of several International AIDS Conferences. She has received 10 awards, both 

nationally and internationally for her contributions to HIV/AIDS research. Dr. Barré-Sinoussi shared the 2008 

Nobel Prize in Medicine with Dr. Luc Montagnier for their discovery of HIV. 

Along with her research activities, since the early 80’s Dr. Barré-Sinoussi has been strongly involved in 

promoting integration between HIV/AIDS research and actions in resource-limited countries, in particular 

through the Institut Pasteur International Network and the coordination of the ANRS research programs in 

Cambodia and Vietnam, in accordance with her strong commitment to building capacity, training and technology 

transfers on site in Africa and Asia. 

18 ~ Final Program



Martin Cetron, USA (SLAMVI/ISTM Plenary Speaker) 

The Changing Patterns of Global Migration and the Impact on Infectious Diseases 

Dr. Martin Cetron is the Director for the Division of Global Migration and Quarantine (DGMQ) at the 

U.S. Centers for Disease Control and Prevention (CDC). The DGMQ mission is to prevent introduction of 

infectious diseases in the U.S. and to prevent morbidity among immigrants, refugees, migrant workers, and 

international travelers. 

Dr. Cetron received his M.D. from Tufts University and trained in Infectious Diseases at the University of 

Washington before joining the CDC’s Epidemic Intelligence Service in 1992. 

His primary research interests are international health and global migration with a focus on emerging 

infections, tropical diseases, and vaccine-preventable diseases in mobile populations. He has been in this 

current leadership role at CDC during responses to the key emerging infectious disease outbreaks of the 21st 

century including the anthrax bio-terrorism incident, the smallpox threat, the global SARS epidemic, and the 

U.S. Monkeypox outbreak. He is part of the CDC Pandemic Influenza Planning and Preparedness Team and 

the WHO Influenza Pandemic Task Force. 

Richard K. Root Memorial Lecture 

Myron S. Cohen, USA 

Transmission and Prevention of Transmission of HIV: Clues from the Early 21st Century 

Myron S. Cohen is the J. Herbert Bate Distinguished Professor of Medicine, Microbiology and Immunology 

and Public Health at the University of North Carolina at Chapel Hill. He is Associate Vice Chancellor for 

Medical Affairs-Global Health. Dr. Cohen received his BS degree (Magna Cum Laude) from the University of 

Illinois, Champaign-Urbana, an MD degree from Rush Medical College, Chicago Illinois and he completed 

an Infectious Disease Fellowship at Yale University. 

Dr. Cohen serves as the Director of the UNC Division of Infectious Disease and the UNC Institute for Global 

Health and Infectious Disease, and he is Associate Director of the UNC Center for AIDS Research. Dr. Cohen 

serves on the Senior Leadership Group of the NIH Center for HIV Vaccine Immunology (CHAVI), and serves 

as part of the leadership group of the NIH HIV Prevention Trials Network (HPTN). Dr. Cohen serves as an 

Associate Editor of the journal, Sexually Transmitted Diseases, and the comprehensive textbook, Sexually 

Transmitted Diseases. 

Dr. Cohen received the Distinguished Alumnus Award from Rush Medical College in 2000. He received 

the Thomas Parran Award (2005) for lifetime achievement in STD research from the American Sexually 

Transmitted Diseases Association. In 2008 Dr. Cohen received the O. Max Gardner Award for “contributions 

to mankind,” the greatest honor in the University of North Carolina 16-campus system. Dr. Cohen has been 

repeatedly recognized as one of America’s “Top Doctors” and “Best Doctors.” 

Dr. Cohen’s research work focuses on the transmission and prevention of transmission of HIV, with emphasis 

on the role played by STD co-infections. He has conducted landmark studies related to the biology of HIV 

transmission and use of antiretroviral agents for prevention. In 2005, Dr. Cohen received an NIH MERIT 

Award for ongoing support of this work. Dr. Cohen is the author of more than 400 publications. Much of Dr. 

Cohen’s research has been conducted internationally, especially in the African country of Malawi and in the 

People’s Republic of China. 

Final Program ~ 19



Keith Klugman, USA 

Pneumococcal Infections in Children and their Impact on Adults 

Keith Klugman is the William H. Foege Chair of Global Health in the Hubert Department of Global Health at 

the Rollins School of Public Health, Emory University, in Atlanta, Georgia. He is a Professor of Medicine in 

the Division of Infectious Diseases of the School of Medicine at Emory University and a Visiting Researcher in 

the Respiratory Diseases Branch of the Centers for Disease Control and Prevention (CDC). He is also the Co- 

Director of the Respiratory and Meningeal Pathogens Research Unit of the University of the Witwatersrand, the 

Medical Research Council and the National Institute for Communicable Diseases in Johannesburg, South Africa. 

Professor Klugman is the Treasurer of the Executive Committee of the International Society for Infectious 

Diseases, and Chair of the International Board of the American Society for Microbiology. He has chaired expert 

committees for the World Health Organization in Geneva and the Wellcome Trust in London, and currently 

serves as an editor or member of the editorial board of 8 international journals on medicine, infectious diseases 

and antimicrobials. 

Professor Klugman’s research interests are in antibiotics, antimicrobial resistance and vaccines for bacterial 

pathogens—particularly the pneumococcus. He has published more than 375 papers on these subjects to date. 

Roberto Kolter, USA 

Microbial Chemical Ecology and the Future of Antibiotics 

Roberto Kolter has been a highly influential microbiologist for a period that spans four decades. Early in his 

career he made enduring advances in our understanding of the regulation of DNA replication as well as 

practical advances in the development of the most widely used “suicide delivery vectors” of today. 

Since establishing his own laboratory at Harvard Medical School in 1983, Dr. Kolter has made contributions 

in diverse areas of microbiology. Initially, he worked on peptide antibiotic synthesis and secretion, providing 

some of the earliest knowledge on “ABC exporters.” This was followed by an exploration of the starvation 

physiology of E. coli at a time when virtually no one else thought of investigating stationary phase cultures. In 

part as a result of those efforts, the control of gene expression in non-growing cells became an area of intense 

investigation by others that continues to this day. Dr. Kolter’s work on the population dynamics of stationary 

phase cultures, the so-called “GASP” (growth advantage in stationary phase) phenomenon, established such 

cultures as excellent model systems for experimental evolution studies. Since the mid-1990’s he has applied 

genetic approaches to study bacterial biofilms; Dr. Kolter’s laboratory developed the most widely used highthroughput 

assay for detection of biofilm development. His studies with Bacillus subtilis as a model system 

to understand biofilms continue to be at the leading edge of the field. Most recently, Dr. Kolter is investigating 

the chemistry of interspecies communication in bacteria. In this area he discovered that a bacterium’s 

quorum sensing signal can also act as a fungal morphogen. In addition, he has developed screens that have 

led to the discovery of novel secondary metabolites produced by one species that profoundly affect the 

developmental patterns of other species. 

Since 2002, Dr. Kolter has played a key role in the organizing and launching of the Microbial Sciences 

Initiative at Harvard (MSI) and is currently its co-director. The MSI (www.msi.harvard.edu) is an innovative 

University-wide interdisciplinary science program aimed at developing new approaches to explore the 

microbial world. MSI is playing a leadership role in microbial sciences worldwide by bringing together 

scientists from diverse backgrounds to think about and discuss key issues in microbiology. 

Dr. Kolter is the current President of the American Society for Microbiology. 

20 ~ Final Program



Louis Loutan, Switzerland 

The Challenges of Travel Medicine in the 21st Century 

Louis Loutan, MD, MPH is the head of the Division of International and Humanitarian Medicine since its 

creation in the Department of Community Medicine and Primary Care at the Geneva University Hospitals 

(HUG) in Geneva, Switzerland. He is also Associate Professor in International and Humanitarian Medicine 

at the University of Geneva. Dr. Loutan is a specialist in internal medicine and tropical medicine and has a 

Master’s in Public Health from Harvard SPH. 

Dr. Loutan has extensive field experience in international health projects in Africa, the Balkans, Nepal and 

Central Asia conducting research projects and organizing training programs. He has spent five years in 

the Republic of Niger running epidemiological surveys in nutrition and tropical medicine, and organizing 

programs in community health for nomadic populations. He spent two years in the Department of Community 

Health at Tufts University School of Medicine (Boston) organizing training courses in international health. He 

also served as technical advisor and coordinator of training and research programs in the family medicine 

reform in Bosnia & Herzegovina. 

Dr. Loutan has been the founder and head of the Geneva travel and migration medicine unit since 1991. 

He has conducted research in various aspects of travel medicine including immunogenicity and tolerance of 

vaccines, security and the health of humanitarian expatriates. 

His appointments included: president of the Swiss Society of Tropical Medicine and Parasitology; president 

of the International Society of Travel Medicine; board member of the Federation of European Societies for 

Tropical Medicine and International Health; chair of the organizing committee of the 5th International 

Conference on Travel Medicine (Geneva 1997); president of the HUG Committee of Humanitarian and 

International Cooperation Activities; president of the Geneva Forum: Towards Global Access to Health, held 

in Geneva in 2006, 2008 and in preparation for 2010. 

Christopher Plowe, USA 

Malaria Eradication 

Christopher Plowe is a Howard Hughes Medical Institute Investigator and Professor of Medicine, of 

Microbiology and Immunology, and of Epidemiology and Preventive Medicine at the University of Maryland 

School of Medicine, where he is Chief of the Malaria Section of the University’s Center for Vaccine 

Development. Plowe received his B.A. in Philosophy from Cornell University, an M.D. from Cornell University 

Medical College, and an M.P.H. in Tropical Medicine from Columbia University School of Public Health. 

He completed fellowships in Malaria Research at the National Institutes of Health, USA and in Infectious 

Diseases at Johns Hopkins University. He has received a Doris Duke Distinguished Clinical Scientist Award 

and the Bailey K. Ashford Medal for distinguished work in tropical medicine from the American Society of 

Tropical Medicine and Hygiene. 

Dr. Plowe leads a multidisciplinary clinical translational malaria research program with field sites in Mali, 

West Africa and Malawi, Central Africa. He is best known for his work on the molecular epidemiology of 

drug resistant malaria. Working with African colleagues, his group at the University of Maryland developed 

rapid molecular assays to detect drug resistant malaria using dried blood spots on paper. These tests have 

been used to understand the population genetics of malaria and to control malaria outbreaks and inform 

treatment policy decisions. Dr. Plowe’s work encompasses malaria drug resistance, molecular epidemiology, 

molecular evolution, rapid diagnostics, pathogenesis, immunology, international research ethics, interactions 

between HIV and malaria, and clinical trials of drugs and vaccines. His group is currently concentrating on 

understanding and mitigating the impact of genetic diversity on malaria vaccine efficacy and on developing 

strategies to deter the emergence and spread of drug resistant malaria. Dr. Plowe directs the Molecular 

Module of the Worldwide Antimalarial Resistance Network (WWARN). 

Dr. Plowe provides expert advice on malaria research and control to national and international agencies and 

has testified before Congress on tropical medicine research priorities and before a Presidential commission 

on international research ethics. 

Final Program ~ 21

Meet-the-Expert 


Meet-the-Expert Sessions are scheduled from Tuesday, March 9, to Friday, March 12, from 07:45 

to 08:45hrs. Delegates are invited to meet informally with leading scientists. Meet-the-Expert 

Sessions will be held at the Miami Hyatt Regency in rooms Jasmine and Orchid B/C/D on Terrace Level. 

Continental breakfast will be provided for participants in the Meet-the-Expert sessions. 

Tuesday, March 9, 2010 

Revisions of Yellow Fever Risk Mapping: Rationale and Recent Updates 

Emily Jentes, USA 

Travel Medicine Resources 

Gilles Poumerol, Switzerland 


Family Travel: Andes and Amazonia 

Eduardo Gotuzzo, Peru 

Issues of Antibiotic Usage in Pediatrics 

Carla Odio, Costa Rica 


Corporate Travel: A Returning Executive 

Gordon Dickinson, USA 

Choosing Between Second Line ARVs 

Pedro Cahn, Argentina 


Integration of Informal Information into Disease Surveillance 

Marjorie Pollack, USA 

Antiviral Prophylaxis in Transplant Recipients 

Sherif Mossad, USA 

Room Orchid B/C/D 

Room Jasmine 


Room Jasmine 


Room Jasmine 


Room Jasmine 

CME Accreditation 


The scientific program of 14th International Congress on Infectious Diseases has been reviewed by the 

American Medical Association and approved for a maximum of 22 AMA PRA Category 1 Credits. 

Physicians should only claim credit commensurate with the extent of their participation in the activity. 

One credit may be claimed for each hour of participation in approved sessions. 

All sessions approved for CME credit are designated CME . AMA PRA Category 1 Credit Claim 

Forms and information for US participants are available in the congress bags and at the CME counter 

in the registration area on the Lobby Level. Completed AMA PRA Category 1 Credit Claim Forms 

must be returned to the AMA CME counter by Friday, March 12, 2010 at 18:00hrs or submitted via fax 

to (312) 464-5830 by May 11, 2010. 

The American Medical Association (AMA) has an agreement of mutual recognition of continuing 

medical education (CME) with the European Union of Medical Spcialities (UEMS). International 

physicians interested in converting AMA PRA Category 1 Credits to EACCME credit should contact 

the UEMS. 

Opening hours / AMA Desk: Tuesday, March 9 to Thursday, March 11, 2010: 12:00–14:30hrs and 

Friday, March 12, 2010: 12:15–13:15hrs and 15:15–18:00hrs 

22 ~ Final Program

Commercial Exhibition 


The exhibits and coffee break areas are located on the Lobby Level in Riverfront Hall. 

All delegates are encouraged to visit the exhibits. 




09:00 – 17:30 hrs 

09:00 – 17:30 hrs 

09:00 – 17:30 hrs 

Exhibitors 

(as per printing date) 

Abbott Molecular, United States 

American Society for Microbiology, United States 

Ani Labsystems, Finland 

Applied Maths, United States 

Bioquell, United States 

Bridge PTS, United States 

CDC Travelers’ Health Branch, United States 

Elsevier, United States 

International Society for Infectious Diseases (ISID), United States 

International Society of Travel Medicine (ISTM), United States 

Inverness Medical, United Kingdom 

Merck & Co., United States 

National Institute of Allergy and Infectious Diseases, United States 

Novartis, United States 

Oxford Immunotec, United States 

Pfizer, United States 

QBC Diagnostics, United States 

Royal Society Publishing, United Kingdom 

Sage Products, United States 

Sanofi Pasteur, France 

Travis Medical Software, United States 

Exhibition Management 

Media Plan 

International Exhibitions and Advertising 

Helferstorferstr. 2 

1010 Vienna, Austria 

Phone: (43 1) 536 63-37 

Fax: (43 1) 535 60 16 

E-mail: mp@media.co.at 

Final Program ~ 23

Hyatt Regency Miami & James L. Knight Center 

General James L. Knight Center Ballroom 1 (Brickell) Ballroom 2 (Flagler & Monroe) Ballroom 3 (Tuttle) 

07:45–08:45hrs 

FRIDAY • March 12 THURSDAY • March 11 

WEDNESDAY • March 10 

TUESDAY • March 9 

09:00–09:45hrs 

09:45–10:15hrs 

10:15–12:15hrs 

12:15–14:30hrs 

12:30–14:15hrs 

14:30–15:15hrs 

15:15–15:45hrs 

15:45–17:45hrs 

18:30–20:00hrs 

20:00–21:30hrs 

07:45–08:45hrs 

09:00–09:45hrs 

09:45–10:15hrs 

10:15–12:15hrs 

12:15–14:30hrs 

12:30–14:15hrs 

14:30–15:15hrs 

15:15–15:45hrs 

15:45–17:45hrs 

07:45–08:45hrs 

09:00–09:45hrs 

09:45–10:15hrs 

10:15–12:15hrs 

12:15–14:30hrs 

12:30–14:15hrs 

14:30–15:15hrs 

15:15–15:45hrs 

15:45–17:45hrs 

07:45–08:45hrs 

09:00–09:45hrs 

09:45–10:15hrs 

10:15–12:15hrs 

12:15–14:30hrs 

12:45–13:45hrs 

14:30–15:15hrs 

15:15–15:45hrs 

Registration & Info ~ 08:00 – 18:30 

On Tuesday only: Some sessions will be in Spanish 

as marked, no translation into English provided. 




OPENING CEREMONY 

02 ~ Travel Medicine Symposium 

ABCs of Travel Medicine I (Spanish) 


ABCs of Travel Medicine II (Spanish) 

01 ~ PLENARY ~ Challenges of TM in the 

21st Century ~ L. Loutan (Switzerland) 

BREAK 


Epicenters of Major Diseases 

LUNCH BREAK (Optional) 

Lunch Satellite Symposium 

Meningococcal Disease in Travelers 

05 ~ PLENARY Lecture ~ Emerging ID in 

Latin America ~ J. Barbosa (Brazil) 

BREAK 


TM & Influenza Pandemic (Spanish) 

WELCOME RECEPTION — Terrace Level (Hyatt Regency Miami) 


The Ill Returned Traveler (Spanish) 


Rabies, Bites & Envenomations 

09 ~ PLENARY Lecture ~ The Discovery of HIV: An Example of Translational Research 

in Response to an Emerging Epidemic ~ F. Barre-Sinoussi (France) 

BREAK [Coffee Break— Exhibition & Poster Area (Riverfront Hall/Lobby Level] 

10 ~ Symposium 

MRSA: Mechanisms and Control 


Seasonal Influenza Vaccines 

LUNCH BREAK (Optional) — Exhibition & Poster Sessions 23–34 (12:30–13:30) 

12 ~ Travel Medicine Symp. 

Traveler’s Diarrhea & Enteric Dis. 

16 ~ PLENARY Lecture 

The Changing Patterns of Global Migration and the Impact on Infectious Diseases ~ Martin Cetron (USA) 



Will the Next Generation End AIDS? 


H1N1 Influenza Pandemic 


Malaria in the Americas 


Transmission and Prevention of Transmission of HIV: Clues from the Early 21st Century ~ M. Cohen (USA) 



Dengue and Pertussis 


ID and Vaccines Updates 



Malaria Eradication ~ C. Plowe (USA) 



Neonatal Sepsis 


Bacterial Infections Following Influenza 


The Ill Returnee from Latin America 


Travelers to Latin America 


Pneumococcal Infections in Children and their Impact on Adults ~ K. Klugman (USA) 



Antimictobial Stewardship 


Current Challenges in HIV Care 



Microbial Chemical Ecology and the Future of Antibiotics ~ R. Kolter (USA) 



Biomarkers in Infectious Diseases 

15:45–17:45hrs 


Tuberculosis: Tools for the Future 


Infections in Tranplant Patients 

70 ~ Symposium ~ International 

Perspectives on Infection Control 

24 ~ Final Program 

n ICID Scientific Sessions n Travel Medicine Sessions n Satellite Symposia

14th International Congress on Infectious Diseases ~ Schedule at-a-Glance 

General 

Room Jasmine Room Orchid B/C/D South Hall 


Travel Medicine Resources 


Yellow Fever Risk Mapping 

07:45–08:45hrs 


On Tuesday only: Some sessions will be in Spanish 

as marked, no translation into English provided. 

BREAK 

LUNCH BREAK (Optional) 

BREAK 

09:00–09:45hrs 

09:45–10:15hrs 

10:15–12:15hrs 

12:15–14:30hrs 

12:30–14:15hrs 

14:30–15:15hrs 

15:15–15:45hrs 

15:45–17:45hrs 

18:30–20:00hrs 

TUESDAY • March 9 

WELCOME RECEPTION — Terrace Level (Hyatt Regency Miami) 

20:00–21:30hrs 


Antibiotic Usage in Pediatrics 


Family Travel: Andes and Amazonia 

07:45–08:45hrs 





Viral Hepatitis 


Multi Drug-Resistant Gram-Negatives 


Choosing Between Second Line ARVs 


Neglected Tropical Diseases 


ID Surveillance Systems in Practice 


Antiviral Prophylaxis 


P.vivax Malaria in Latin America 

Cultural Lecture 

Death of Enrico Caruso 



ID Following Catastrophes 



21 ~ Oral Presentations 

Pathogens in Population 





Viral Diseases 




Advances from the Laboratory 


Disease Surveillance 



Influenza 


ISID Business Meeting 



Update on Fungal Infections 


A Decade of Experience with PCV7 


Short Course Rx for Childhood Pneumonia 


Carbapenemase-Producing Bacteria 


HPV Infection & Prevention 


MRSA: The Clinical Challenge 

09:00–09:45hrs 

09:45–10:15hrs 

10:15–12:15hrs 

12:15–14:30hrs 

12:30–14:15hrs 

14:30–15:15hrs 

15:15–15:45hrs 

15:45–17:45hrs 

07:45–08:45hrs 

09:00–09:45hrs 

09:45–10:15hrs 

10:15–12:15hrs 

12:15–14:30hrs 

12:30–14:15hrs 

14:30–15:15hrs 

15:15–15:45hrs 

15:45–17:45hrs 

07:45–08:45hrs 

09:00–09:45hrs 

09:45–10:15hrs 

10:15–12:15hrs 

12:15–14:30hrs 

12:45–13:45hrs 

14:30–15:15hrs 

15:15–15:45hrs 

WEDNESDAY • March 10 THURSDAY • March 11 FRIDAY • March 12 


Bacterial Meningitis: Prevention and Cure 


Parasitology 

15:45–17:45hrs 

n ICID Scientific Sessions n Travel Medicine Sessions n Satellite Symposia 

Final Program ~ 25

Floorplans 


Terrace Level 

Hyatt Regency Miami 

Azalea 

Elevators 

Ballroom 2 

(Flagler & Monroe) 

Ballroom 3 

(Tuttle) 

WC 

WC 

Jasmine 

Hibiscus A 

Hibiscus B 

Gardenia A 

ISID Office 

Gardenia B 

Gardenia C 

Ballroom 1 

(Brickell) 

PREFUNCTION 

PROMENADE LOWER 

PROMENADE UPPER 

RIVERWALK 

Orchid B/C/D 

Speakers Center 

Orchid A 

MIAMI RIVER 

Info Counter and Message Center 

26 ~ Final Program 

TERRACE LEVEL (HYATT REGENCY MIAMI) 

Ballroom 1 (Brickell) 

Ballroom 2 (Flagler & Monroe) 

Ballroom 3 (Tuttle) 

Speakers Center (Orchid A) 

ISID Office (Gardenia B) 

Info Counter & Message Center 

LOBBY LEVEL (JAMES L. KNIGHT CENTER) 

South Hall 

Riverfront Hall (Exhibition, Coffee, Posters, Snack Bar) 

Registration Area 

Congress Bag Counter (Cloak Room, Lost & Found) 

THIRD LEVEL (JAMES L. KNIGHT CENTER) 

Opening Ceremony

Lobby Level 

James L. Knight Center 


Exhibition 

Internet Corner 

Snack Bar 

Coffee 

Posters 

Registration Area & 

Congress Bags 

South Hall 

Third Level 

James L. Knight Center 

Opening 

Ceremony 

Final Program ~ 27

Save-the-Date 

Over 1 billion of the world’s poorest people suffer from one or more 

NTDs that profoundly affect their lives. These diseases are termed 

“neglected” because, in spite of the great suffering they cause, only 

limited resources have been available to prevent and treat them even 

though some of the most common NTDs can be treated effectively at 

very low cost. 

Awareness about the problem of NTDs has grown over recent years. 

Governments, foundations and nonprofit organizations are increasingly 

taking notice and taking action. ISID aims to bring this community 

of providers and investigators together by organizing the first 

ISID-NTD meeting to encourage cross-discipline sharing of information 

related to combating NTDs as well as provide an opportunity to 

raise public awareness of the importance of NTDs around the world. 

Partial List of NTDs: 

• Schistosomiasis 

• Lymphatic Filariasis 

• African Trypanosomiasis 

• Chagas Disease 

• Soil Transmitted 

Helminthiasis 

• Trachoma 

• Onchocerciasis 

• Leishmaniasis 

JULY 8–10, 2011 

Boston, Massachusetts • USA 

Planned Topics Include: 

• Documenting the global NTD burden 

• Development of diagnostics and drugs for NTDs 

• Current NTD treatment and control programs: 

Successes and challenges 

• Program integration: Sharing of infrastructure and operations 

• Achieving sustained control and elimination of NTDs 

• Improving access to clean water and sanitation to prevent NTDs 

• The role of human and animal health integration in the 

control of NTDs 

ISID-NTD Program Committee 

Alan Fenwick, Imperial College 

Christy Hanson, USAID 

Peter Hotez, Sabin Vaccine Institute 

Adrian Hopkins, Task Force for Global Health 

Julie Jacobson, Bill and Melinda Gates Foundation 

Daniel Lew, Geneva University Hospital and 


Adel Mahmoud, Princeton University 

David Molyneux, Liverpool School of Tropical Medicine 

Mary Moran, George Institute 

Mirta Roses Periago, Pan American Health Organization 

Lorenzo Savioli, World Health Organization 

Eric Summers, International Society for Infectious Diseases 

International Society for Infectious Diseases • 1330 Beacon Street, Suite 228 • Brookline, MA 02446 USA 

Phone: (617) 277-0551 • Fax: (617) 278-9113 • Email: info@isid.org • Web site: http://isid.org



Room Jasmine ~ Terrace Level Tuesday, March 9, 2010 Travel Medicine Track 

Hyatt Regency Miami 07:45–08:45 

MEET-THE-EXPERT 

Travel medicine resources 

G. Poumerol 

Geneva (Switzerland) 

TUESDAY • March 9, 2010 



Room Orchid B/C/D ~ Terrace Level Tuesday, March 9, 2010 Travel Medicine Track 



Revisions of yellow fever risk mapping: Rationale and recent updates 

E. Jentes 

Atlanta, GA (USA) 

Final Program ~ 29


Session 1 


Ballroom 2: Flagler/Monroe Tuesday, March 9, 2010 Plenary 

Terrace Level ~ Hyatt Regency Miami 09:00–09:45 Travel Medicine Track 

PLENARY LECTURE I 

Chair: David FREEDMAN, USA 

01.001 The Challenges of travel medicine in the 21st century 

L. Loutan 


CME 

30 ~ Final Program

Session 2 


Balloom 1: Brickell ~ Terrace Level Tuesday, March 9, 2010 Symposium 

Hyatt Regency Miami 10:15–12:15 Travel Medicine Track 

(In Spanish) 

ABCS OF TRAVEL MEDICINE (I) 

Co-Chairs: Mario MASANA WILSON, Argentina 

Sergio SOSA-ESTANI, Argentina 

02.001 Development of travel medicine in Latin America 

A. Lepetic 

Buenos Aires (Argentina) 


02.002 Approach to pre-travel consultation 

G. Acuña 

Santiago (Chile) 

02.003 Traveling with kids 

C. Perret 


02.004 The elderly traveler 

S. Lemos Hinrichsen 

São Paulo (Brazil) 

Final Program ~ 31


Session 3 


Ballroom 2: Flagler/Monroe Tuesday, March 9, 2010 Symposium 


EPICENTERS OF MAJOR DISEASES (I) 

Co-Chairs: Jesse ALVES, Brazil 

Edward RYAN, USA 

03.001 Central America and the Caribbean: Dengue and P.Vivax malaria 

J. Torres 

Caracas (Venezuela) 

CME 

03.002 Hantavirus and bartonellosis 

E. Gotuzzo 

Lima (Peru) 

03.003 Yellow fever transmission in Brazil 

M. Mascheretti 


03.004 The Amazon II: Leishmaniasis and Chagas disease 

S. Sosa-Estani 


32 ~ Final Program

Session 4 


Ballroom 3: Tuttle ~ Terrace Level Tuesday, March 9, 2010 Symposium 


(In Spanish) 

THE ILL-RETURNED TRAVELER 

Co-Chairs: Tania CHAVES, Brazil 

Cristian BISCAYART, Argentina 

04.001 Assessment in travelers coming from Latin America 

J. Dabanch Pena 



04.002 Fever and their etiologies 

T. Orduna 


04.003 After a trip: The souvenirs in the skin 

S. Lloveras 


04.004 Ten most common imported diseases in Florida 

J. Murillo 

Miami, FL (USA) 

Final Program ~ 33


Session 5 


Ballroom 2: Flagler/Monroe Tuesday, March 9, 2010 Plenary 


PLENARY LECTURE II 

Chair: Gilles POUMEROL, Switzerland 

05.001 Emerging infectious diseases in Latin America 

J. Barbosa da Silva Jr 

Washington, DC (USA) 

CME 

34 ~ Final Program

Session 6 


Ballroom 1: Brickell ~ Terrace Level Tuesday, March 9, 2010 Symposium 


(In Spanish) 

ABCS OF TRAVEL MEDICINE (II) 

Co-Chairs: Susana LLOVERAS, Argentina 

Sylvia LEMOS HINRICHSEN, Brazil 

06.001 Customizing immunization to travelers 

A. Macchi 



06.002 Routine immunization 

A. Rísquez Parra 


06.003 Vaccines recommended for global travelers 

T. S. Chaves 


06.004 Yellow fever vaccine 

C. Biscayart 


Final Program ~ 35


Session 7 


Ballroom 2: Flagler/Monroe Tuesday, March 9, 2010 Symposium 


(In Spanish) 

TRAVEL MEDICINE AND THE INFLUENZA PANDEMIC 

Co-Chairs: 

Cecilia PERRET, Chile 

Tomas ORDUNA, Argentina 

07.001 From the Americas to the world 

J. Sotelo Morales 

Mexico City (Mexico) 

07.002 Clinical spectrum of disease. Influenza AH1N1 2009 

J. Dabanch Peña 


07.003 Interim lessons from 2009 

J. Alves 


07.004 Prospects on influenza vaccines 

G. Baracco 


36 ~ Final Program

Session 8 


Ballroom 3: Tuttle ~ Terrace Level Tuesday, March 9, 2010 Symposium 


RABIES, BITES AND ENVENOMATIONS 

Co-Chairs: Marcos BOULOS, Brazil 

Miguel CABADA, Peru 

08.001 Rabies, the emerging challenge 

D. Warrell 

Oxford (United Kingdom) 

CME 


08.002 Envenomation by Latin American arthropods 

C. Malaque 


08.003 Diagnostic and treatment of snake bites 

F. Franca 


08.004 Immunobiologicals in South America 

J. Murillo 


Final Program ~ 37

Opening Ceremony 



James L. Knight Center / 3rd Floor Tuesday, March 9, 2010 

18:30–20:00 

18:15hrs 

18:30hrs 

All guests to be seated 

Welcome Remarks 

Raúl Istúriz 

President 


Alan J. Magill 

President 

International Society for Travel Medicine (ISTM) 

2009–2011 

Mario Masana Wilson 

President 

Sociedad Latinoamericana de Medicina del Viajero (SLAMVI) 

Mirta Roses Periago 

Director 


Award Presentation 

– Presentation of the Novartis Vaccines Awards for 

Epidemiology of Infectious Diseases 

– Presentation of the Sanofi Pasteur Awards for 

Communicable Disease Epidemiology 

– Presentation of the ISID New Investigator Award 

20:00hrs 

Welcome Reception at the Hyatt Regency Miami (Terrace Level) 

For all participants and registered accompanying persons 

Dress code: Business Attire 

38 ~ Final Program


Room Jasmine ~ Terrace Level Wednesday, March 10, 2010 




Issues of antibiotic usage in pediatrics 

C. Odio 

San Jose (Costa Rica) 


Room Orchid B/C/D ~ Terrace Level Wednesday, March 10, 2010 Travel Medicine Track 



Family travel: Andes and Amazonia 

E. Gotuzzo 

Lima (Peru) 


WEDNESDAY • March 10, 2010 

Final Program ~ 39

Session 9 


Ballroom 1/2/3 ~ Terrace Level Wednesday, March 10, 2010 Plenary 


CME 

PLENARY LECTURE III 

Chair: Daniel LEW, Switzerland 

EDWARD H. KASS LECTURE 

09.001 The discovery of HIV 

F. Barre-Sinoussi 

Paris (France) 


Final Program ~ 41

Session 10 


Ballroom 1: Brickell ~ Terrace Level Wednesday, March 10, 2010 Symposium 


CME 

MRSA: DISEASE MECHANISMS AND CONTROL 

Co-Chairs: Keryn CHRISTIANSEN, Australia 

Gonzalo BEARMAN, USA 

10.001 Inducible dormant MRSA 

G. Bearman 

Richmond, VA (USA) 


10.002 The role of PVL in severe disease—What is the evidence? 

K. Christiansen 

Perth (Australia) 

10.003 MRSA control programs in the UK: Impact on quality of care, 

nosocomial infection, and public perception 

I. Gould 

Aberdeen (Saudi Arabia) 

10.004 MRSA epidemiology and control in developing countries 

V. Rosenthal 


42 ~ Final Program

Session 11 


Ballroom 2: Flagler/Monroe ~ Terrace Level Wednesday, March 10, 2010 Symposium 


CME 

SEASONAL INFLUENZA VACCINES: CURRENT STATUS AND FUTURE DIRECTIONS 

Chair: Gregory POLAND, USA 

Introduction 

G.A. Poland 

Rochester, MN (USA) 

11.001 Influenza vaccination: Where do we stand? 

A. E. Fiore 


11.002 Overcoming limitations of seasonal vaccines 

A. S. Monto 

Ann Arbor, MI (USA) 

11.003 Emerging Trends: Vaccines in late development 

R. L. Atmar 

Houston, TX (USA) 

Conclusion and Question-and-Answer Session 


This CME program is sponsored by Albert Einstein College of Medicine 

and supported by an educational grant from Sanofi Pasteur 

Final Program ~ 43

Session 12 


Ballroom 3: Tuttle ~ Terrace Level Wednesday, March 10, 2010 Symposium 


CME 

TRAVELER’S DIARRHEA AND ENTERIC DISEASES OF LATIN AMERICA 

Co-Chairs: Frank VON SONNENBURG, Germany 

Robert STEFFEN, Switzerland 

12.001 Epidemiology of traveler’s diarrhea 

A. McCarthy 

Ottawa, ON (Canada) 


12.002 Traveler’s diarrhea: Prevention and treatment 

R. Steffen 

Zurich (Switzerland) 

12.003 Helminths of Latin America 

C. Coyle 

Bronx, NY (USA) 

12.004 Food-borne toxins 

V. Ansdell 

Honolulu, HI (USA) 

Supported in part by an educational grant from 

Salix Pharmaceuticals Inc. 

44 ~ Final Program

Session 13 


Room Jasmine ~ Terrace Level Wednesday, March 10, 2010 Symposium 


CME 

VIRAL HEPATITIS 

Co-Chairs: Sergio CIMERMAN, Brazil 

Jun CHENG, China 

13.001 Epidemiology of chronic viral Hepatitis in Latin America 

D. Diament 


13.002 Update on Hepatits B therapy 

E. Savio 

Montevideo (Uruguay) 

13.003 Hepatitis C treatment today and the future 

R. Sarmento e Castro 

Porto (Portugal) 

13.004 Management of HIV and Hepatitis C co-infection 

M. Brito 

Chicago, IL (USA) 


Organized in collaboration with the 

Pan American Association for Infectious Diseases (API) 

Final Program ~ 45

Session 14 


Room Orchid B/C/D ~ Terrace Level Wednesday, March 10, 2010 Symposium 


CME 

INFECTIOUS DISEASES FOLLOWING CATASTROPHES 

Co-Chairs: Vladimir KRČMÉRY, Slovak Republic 

Nabin BODONAIK, Jamaica 

14.001 Infectious diseases and infection control after natural disasters. 

J. Ambrosioni 



14.002 Infectious diseases and war conflicts in the Middle East 

A. Shibl 

Ryadh (Saudi Arabia) 

14.003 Infectious diseases and earthquakes in Peru 

E. Gotuzzo 

Lima (Peru) 

14.004 Disaster relief in Haiti 

V. Krčméry 

Bratislava (Slovak Republic) 

46 ~ Final Program

Session 15 


South Hall ~ Lobby Level Wednesday, March 10, 2010 Symposium 


CME 

UPDATE ON FUNGAL INFECTIONS 

Co-Chairs: Thomas PATTERSON, USA 

Jorge GABINO, Switzerland 

15.001 Treating resistant filamentous fungi infections 

R. Graybill 

San Antonio, TX (USA) 

15.002 The endemic systemic fungal infections in Latin America 

A. Restrepo 

Medellin (Colombia) 

15.003 Fungal skin infections in the tropics 

R. Hay 

London (United Kingdom) 

15.004 Prevention and treatment of nosocomial Candidiasis 

M. Nucci 

Rio de Janeiro (Brazil) 


Final Program ~ 47

Session 16 


Ballroom 1/2/3 ~ Terrace Level Wednesday, March 10, 2010 Plenary 


CME 

PLENARY LECTURE IV 

Chair: Alan MAGILL, USA 

16.001 The changing patterns of global migration and the 

impact on infectious diseases 

M. Cetron 



48 ~ Final Program

Session 17 


Ballroom 1: Brickell ~ Terrace Level Wednesday, March 10, 2010 Symposium 


CME 

WILL THE NEXT GENERATION END AIDS? 

Co-Chairs: Margaret JOHNSTON, USA 

Akichi IWAMOTO, Japan 

17.001 Role of innate immunity in the control of HIV infection 

G. Alter 

Boston, MA (USA) 

17.002 The role of T-cell immunity in the control of HIV infection 

N. Goonetilleke 


17.003 Understanding anti-HIV antibody targets 

P. Moore 

Johannesburg (South Africa) 

17.004 The hope and progress in microbicides and pre-exposure prophylaxis 

to prevent HIV 

P. Ndase 

Kampala (Uganda) 


Final Program ~ 49

Session 18 


CME 

Ballroom 2: Flagler/Monroe ~ Terrace Level Wednesday, March 10, 2010 Symposium 


THE H1N1 INFLUENZA PANDEMIC 

Co-Chairs: Richard WENZEL, USA 

Samuel PONCE DE LEON, Mexico 

18.001 Historical perspective: Lessons learned from past pandemics 

D. Morens 

Bethesda, MD (USA) 


18.002 The H1N1 outbreak in Mexico 

S. Ponce de Leon 

Mexico (Mexico) 

18.003 Global surveillance of the H1N1 pandemic 

A. W. Mounts 


18.004 International response to the H1N1 pandemic 

A. S. Monto 


50 ~ Final Program

Session 19 


Ballroom 3: Tuttle ~ Terrace Level Wednesday, March 10, 2010 Symposium 


CME 

MALARIA IN THE AMERICAS 

Co-Chairs: Melissa MASCHERETTI, Brazil 

Gary BRUNETTE, USA 

19.001 Epidemiology and intensity of transmission 

K. Carter 


19.002 Need for chemoprophylaxis for travelers to the Americas: Yes 

P. Arguin 


19.003 Need for continuous prophylaxis for travelers to the Americas: No 

M. Boulos 


19.004 Choice of drugs for the prophylaxis of malaria in the Americas 

A. Magill 

Silver Spring, MD (USA) 


Final Program ~ 51

Session 20 


Room Jasmine ~ Terrace Level Wednesday, March 10, 2010 Symposium 


CME 

CURRENT ISSUES IN MULTI DRUG-RESISTANT GRAM-NEGATIVES 

Co-Chairs: Giuseppe CORNAGLIA, Italy 

Manuel GUZMAN-BLANCO, Venezuela 

20.001 Escherichia coli 

M.-I. Morosini 

Madrid (Spain) 

20.002 Multidrug-resistance in Klebsiella pneumoniae 

P. Nordmann 

Paris (France) 

20.003 Pseudomonas aeruginosa 

G. Cornaglia 

Siena (Italy) 

20.004 Evolution of antimicrobial resistance in Acinetobacter baumannii: 

Factors affecting multiresistance 

J. Vila 

Barcelona (Spain) 



European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 

Final Program ~ 53

Session 21 


Room Orchid B/C/D ~ Terrace Level Wednesday, March 10, 2010 Oral Presentations 


PATHOGENS IN POPULATIONS 

Co-Chairs: Tam GARLAND, USA 

Stuart HANDYSIDES, United Kingdom 


21.001 Incidence and trends of imported malaria in the Netherlands: 2000–2007 

G. Van Rijckevorsel 1 , G. J. B. Sonder 1 , R. B. Geskus 1 , P. J. J. Van Genderen 2 , 

M. Keuter 3 , R. J. Ligthelm 2 , L. G. Visser 4 , J. C. F. M. Wetsteyn 1 , 

J. A. R. Van Den Hoek 1 

1 

Amsterdam (Netherlands), 2 Rotterdam (Netherlands), 3 Nijmegen (Netherlands), 

4 

Leiden (Netherlands) 

21.002 Predictors of primary multiple drug resistant tuberculosis (MDR-TB) transmission 

in Lima, Peru 

L. Shah 1 , H. Choi 2 , F. Krapp 3 , C. Zamudio 3 , C. Seas 3 , A. Ciampi 1 , T. Brewer 1 , 

E. Gotuzzo 3 

1 

Montreal, QC (Canada), 2 Baltimore, MD (USA), 3 Lima (Peru) 

21.003 Foodborne Campylobacter infections have a low impact on human health: 

A community-based cohort study in Yucatan, Mexico 

M. B. Zaidi 1 , F. D. Campos 1 , F. Martinez 1 , F. Gutierrez 1 , A. Polanco 1 , M. Leon 1 , 

S. Patzi-Vargas 2 , T. Estrada-Garcia 2 , J. J. Calva 2 

1 

Merida (Mexico), 2 Mexico City (Mexico) 

21.004 DNA-Level diversity and relatedness of Helicobacter pylori strains in Shantytown 

families in Peru and transmission in a developing-country setting 

P. Herrera Aldana 1 , M. Mendez 1 , B. Velapatiño 1 , L. Santivañez 1 , J. Balqui 1 , 

S. A. Finger 2 , J. Sherman 1 , M. Zimic 1 , L. Cabrera 1 , J. Watanabe 1 , C. Rodriguez 1 , 

R. H. Gilman 3 , D. E. Berg 2 

1 

Lima (Peru), 2 St Louis, MO (USA), 3 Baltimore, MD (USA) 

21.005 Etiology of childhood pneumonia in Tacloban, the Philippines 

A. Suzuki 1 , S. Lupisan 2 , N. Fuji 1 , A. Ohno 1 , Y. Furuse 1 , R. Tamaki 2 , M. Saito 2 , 

H. Oreste 2 , M. Mondoy 2 , L. Sombrero 2 , A. De Leon 3 , R. Olveda 2 , H. Oshitani 1 

1 

Sendai (Japan), 2 Manila (Philippines), 3 Tacloban (Philippines) 

54 ~ Final Program

Session 21 


Room Orchid B/C/D ~ Terrace Level Wednesday, March 10, 2010 Oral Presentations 


PATHOGENS IN POPULATIONS 

21.006 Population-based surveillance for pneumonia, sepsis and meningitis in all ages 

in The Gambia: Implications for pneumococcal vaccine introduction and 

surveillance in Africa 

G. Mackenzie 1 , E. Usuf 1 , M. Jasseh 1 , D. Nsekpong 2 , N. Ikumapayi 1 , H. Badji 1 , 

D. Saha 1 , D. Ameh 1 , U. Uchendu 1 , T. Corrah 1 , P. Hill 3 , S. Howie 1 , 

B. Greenwood 4 , R. A. Adegbola 5 

1 

Fajara (Gambia), 2 Banjul (Gambia), 3 Dunedin (New Zealand), 

4 

London (United Kingdom), 5 Seattle, WA (USA) 

21.007 Controlling persistent cholera outbreaks in Africa: Lessons from the recent 

Cholera Outbreak, West District Unguja Zanzibar, Tanzania, 2009 

S. Masauni 1 , M. Mohammed 1 , G. H. Leyna 1 , F. Mosha 1 , J. Mghamba 1 , 

K. Omar 2 , H. Ali 2 , F. Abdallah 2 , O. Oleribe 1 , P. Mmbuji 1 

1 

Dar Es Salaam (United Republic of Tanzania), 

2 

Zanzibar (United Republic of Tanzania) 

21.008 High-risk travelers in the Boston Area Travel Medicine Network: 

Demographics, trip plans and vaccinations 

N. S. Hochberg 1 , M. M. Sosa 1 , J. B. Trivedi 1 , M. Pfaff 1 , W. B. Macleod 1 , 

C. Benoit 1 , L. H. Chen 2 , L. Kogelman 1 , W. W. Ooi 3 , A. W. Karchmer 1 , 

M. E. Wilson 2 , D. H. Hamer 1 , E. D. Barnett 1 

1 

Boston, MA (USA), 2 Cambridge, MA (USA), 3 Burlington, MA (USA) 


21.009 Factors determining performance of integrated disease surveillance strategy 

cancelled in Kenya, 2008 

C. Njuguna, J. K. Onsongo, C. M. Nzioka, D. Mutonga 

Nairobi (Kenya) 

21.010 Molecular analysis of excised valves in the diagnosis of blood culture 

negative infective endocarditis (BCNE) in a Cardiac Surgery Referral Center 

in Rio de Janeiro, Brazil: 1998 to 2009 

C. Lamas 1 , R. G. Ramos 1 , G. Q. Lopes 2 , W. Golebiovski 1 , M. D. S. Santos 1 , 

C. Weksler 1 , G. D. Ferrauioli 1 , H. Lepidi 3 , P.-E. Fournier 3 , D. Raoult 3 

1 

Rio de Janeiro (Brazil), 2 Duque de Caxias (Brazil), 3 Marseilles (France) 

Final Program ~ 55

Session 22 


South Hall ~ Lobby Level Wednesday, March 10, 2010 Symposium 


CME 

SUCCESSFUL SHORT ANTIBIOTIC TREATMENT OF CHILDHOOD PNEUMONIA— 

MYTH OR REALITY? 

Co-Chairs: Ron DAGAN, Israel; 

Zulfiqar BHUTTA, Pakistan 

22.001 Determinants of Bacteriologic Eradication in Respiratory Tract Infections 

M. Jacobs 

Cleveland, OH (USA) 


22.002 What Are the Benefits of Short Antibiotic Treatment? 

H. Goossens 

Edegem-Antwerp (Belgium) 

22.003 Short Treatment and the WHO Pneumonia—What are We Treating? 

Z. Bhutta 

Karachi (Pakistan) 

22.004 Can Short Antibiotic Treatment be Widely Used in Developed Countries 

R. Dagan 

Beer-Sheva (Israel) 


Pfizer 

56 ~ Final Program

Session 23 


Riverfront Hall ~ Lobby Level Wednesday, March 10, 2010 Poster Presentations 


ANTIBIOTIC RESISTANCE: GRAM-NEGATIVE 

23.001 Clinico epidemiologic and molecular characterization of metallo 

beta lactamases (MBLs) producing nosocomial Pseudomonas aeruginosa (PSA) 

S. Chatterjee 1 , A. Kumar 2 , K. N. prasad 3 , D. Mathai 1 , A. Manoharan 1 

1 

Vellore, Tamil Nadu (India), 2 Kochi (India), 3 Lucknow (India) 

23.002 The resistance patterns of Pseudomonas aeruginosa in hospitals from Greece and 

Romania and its importance for the therapy of nosocomial infections and 

infection control practices 

L. M. Junie 1 , S. KASTANAKIS 2 , M. Petrascu 1 , C. Boboş 1 , A. Tsouri 2 , P. Karagianni 2 , 

E. Papadomanolaki 2 , G. Aleuraki 2 , M. Gatzima 2 , I. Varthalitis 2 

1 

Cluj Napoca (Romania), 2 Chania (Greece) 

23.003 Extended spectrum β-lactamase production at the Komfo Anokye Teaching 

Hospital, Kumasi, Ghana 

Y. Adu-Sarkodie 

Kumasi (Ghana) 

23.004 Antimicrobial susceptibility profile of Pseudomonas aeruginosa strains isolated at 

a tertiary-care University Hospital (S. Orsola Hospital, Bologna, Italy) 

R. Manfredi 

Bologna (Italy) 


23.005 Characterization of ertapenem resistance in Klebsiella pneumoniae from Croatia 

B. Bedenic, J. Vranes, Z. Bosnjak, A. Budimir, S. Kalenic 

Zagreb (Croatia) 

23.006 Changing trends in antimicrobial resistance among salmonella serotypes in 

Southern India 

S. Rao 1 , B. Kabir 2 

1 

Karnataka (India), 2 Madhav Nagar, Manipal (India) 

23.007 Molecular epidemiology of aminoglycosides resistance in Acinetobacter spp. 

with emergence of multidrug-resistant strains in hospitalized patients in Iran 

R. Moniri, R. Kheltabadi Farahani 

Kashan (Islamic Republic of Iran) 

23.008 Incidence of Carbapanemase Resistance Gene (KPC) among Klebsiella 

pneumoniae isolates and its Clinical Implications 

B. Yegneswaran, W. Numsuwan, D. Alcid 

New Brunswick, NJ (USA) 

Final Program ~ 57

Session 23 





23.009 In vitro activity of Tigecycline against molecularly defined Carbapenemase 

producing Acinetobacter baumannii 

M. Hackel 1 , P. Higgins 2 , H. Seifert 2 , S. Bouchillon 1 , B. Johnson 1 , R. Badal 1 , 

J. johnson 1 , D. Hoban 1 , S. Hawser 3 , M. Dowzicky 4 

1 

Schaumburg, IL (USA), 2 Cologne (Germany), 3 Epalinges (Switzerland), 

4 

Collegeville, PA (USA) 


23.010 Molecular typing of multi-drug resistant Acinetobacter baumannii from 

London hospitals 

D. Wareham, D. Bean 


23.011 Emerging multi drug-resistant Acinetobacter in Iran: Study of 800 cases 

F. Abbasi, D. Yadegarynia, M. Mardani, B. Frasinejad, T. Yaghubi, S. Gholamin 

Tehran (Islamic Republic of Iran) 

23.012 The prevalence of extended spectrum beta-lactamases at a tertiary hospital 

in South Africa 

N. Mbelle 


23.013 First characterization of blaIMP and blaVIM cassette-containing Novel Integron 

in metallo-β-lactamase producing Pseudomonas aeruginosa in Malaysia 

Y. Khosravi, S. T. Tay, V. Jamuna 

Kuala Lumpur (Malaysia) 

23.014 Carbapenem hydrolyzing multidrug resistant Acinetobacter baumannii 

J. Koirala 1 , I. Tyagi 1 , V. Sundareshan 1 , S. Bergman 2 , J. Lawhorn 1 , C. Drake 1 , 

C. Speil 1 

1 

Springfield, IL (USA), 2 Edwardsville, IL (USA) 

23.015 Antimicrobial resistance in non-typhoidal Salmonellae 

B. Harish 1 , M. Khan 2 , J. Hays 2 , G. Menezes 1 

1 

Pondicherry (India), 3 Rotterdam (Netherlands) 

23.016 First description of CTX-M extended-spectrum β-lactamase-producing clinical 

Escherichia coli strains from Macao, China 

Q. H. Ye, Y. Lau 

Macao (China) 

58 ~ Final Program

Session 23 





23.017 Utilizing hospital generated antibiograms to examine state trends in 

antibiotic resistance 

S. Onofrey, M. Morrison, M.-Y. Lin, B. Bolstorff, A. DeMaria 

Jamaica Plain, MA (USA) 

23.018 A Comparative study on gram-negative bacterial infections in Mansoura University 

Hospitals, Egypt 

W. El-Naggar, R. Ibrahim, E. Habib, S. Gerorge, E. Abd-Elmagid 

Mansoura (Egypt) 

23.019 Extended spectrum beta-lactamases in Escherichia coli and Klebsiella spp. from 

Eastern Romania 

E. Miftode 1 , , O. Dorneanu, D. Leca, A. Teodor, A. Badescu, G. Juganariu, 

A. Vita, C. Dorobat 

Iasi (Romania) 

23.020 Can we rely on automated VITEK2 system the detection of KPC and other class A 

carbapenemase producers enterobacteriaceae? 

F. Pasteran, C. Lucero, R. Soloaga, A. Corso 



23.021 Emergence of multi-drug-resistant gram-negative bacilli and enterococci from 

rectal swabs of newborn and their mothers from Central India 

S. Chitnis, V. Chitnis, D. Chitnis 

Indore (India) 

23.022 Patients with hematological malignancies who are prescribed quinolone 

prophylaxis post-chemotherapy in a hospital with high gram-negative quinolone 

resistance are at a higher risk for febrile neutropenia 

E. Ng, Y. X. Liew, Y. Ding, L. P. Koh, J. Jin, L. Y. Hsu 

Singapore (Singapore) 

23.023 Multidrug resistant and sensitive strains of Pseudomonas aeruginosa: 

Establishing clonal relationship by Pulsed Field Gel Electrophoresis and in vitro 

antibiotic synergy testing by E test 

S. F. A. Mohd Nawi 1 , R. Karunakaran 2 , K.-L. Thong 2 , M. Y. Yusof 2 , J. Vadivelu 2 

1 

Shah Alam, Selangor (Malaysia), 2 Kuala Lumpur (Malaysia) 

Final Program ~ 59

Session 23 





23.024 KPC Antibiogram in a large teaching Brazilian Hospital 

J. Almeida, A. P. Cury, M. Maffucci, H. Caiaffa, J. A. Duarte, F. Rossi 



23.025 Decreased susceptibility to polymyxins emerging during treatment for 

carbapenem-resistant Enterobacter aerogenes infection 

J. Almeida, H. Caiaffa, A. P. Cury, G. D. Almeida, D. O. Garcia, 

M. N. Burattini, F. Rossi 


23.026 Outbreak of (OXA-66 carbapenemase) multidrug-resistant 

Acinetobacter baumannii in a Spanish tertiary-care hospital: 

Epidemiology and study of patient movements 

F. Gonzalez, E. Culebras, J. Head, M. Gomez, G. Morales, J. Picazo 


23.027 Online games teaching children hygiene and antibiotic resistance: 

Evaluation of the e-Bug games 

D. Farrell 1 , P. Kostkova 1 , J. Weinberg 1 , D. Lecky 2 , C. McNulty 2 

1 

London (United Kingdom), 2 Gloucester (United Kingdom) 

23.028 Antimicrobial utilization and susceptibility patterns of a sentinel group of 

bacterial isolates prior and subsequent to the introduction of Ertapenem to 

the hospital formulary 

J. Araujo 1 , C. Rodriguez-Osorio 1 , E. Criollo-Mora 1 , A. Ramos-Hinojosa 1 , 

A. Macías Hernandez 2 , A. Ponce-de-Leon 1 , J. Sifuentes-Osornio 1 

1 

Tlalpan (Mexico), 2 Mexico City (Mexico) 

23.029 Clinical characterization of patients with carbapenem-resistant versus 

carbapenem-susceptible Acinetobacter baumannii infections 

I. Tyagi, J. Koirala 

Springfield, IL (USA) 

60 ~ Final Program

Session 24 




ARBOVIRUSES 

24.001 Doxycycline modify the cytokine storm in patients with dengue and dengue 

hemorrhagic fever 

J. Zavala Castro 1 , T. Fredeking 2 

1 

Merida, Yucatán (Mexico), 2 Hurst, TX (USA) 

24.002 Field hospital for fluid intake: The solution for the decrease mortality in 

dengue fever 

D. Borghi, M. D. Canetti, W. Braz, L. Cortes, R. C. Vasconcellos 


24.003 Utility of dengue antigen-capture ELISA in the diagnosis of dengue fever 

in the real world 

S. Kalimuddin, H. N. Leong, X. L. Bai, S. H. Lim, K. P. Chan 


24.004 Specific point mutations in the envelope protein of Tick-borne encephalitis 

virus enhance non-viraemic transmission efficiency in a tick vector. 

M. Khasnatinov 1 , K. Ustanikova 2 , T. V. Frolova 3 , V. V. Pogodina 3 , 

N. G. Bochkova 3 , L. S. Levina 3 , M. Slovak 2 , M. Kazimirova 2 , M. Labuda 2 , 

B. Klempa 2 , E. Eleckova 2 , E. A. Gould 4 , T. S. Gritsun 5 

1 

Irkutsk (Russian Federation), 2 Bratislava (Slovak Republic), 

3 

Moscow (Russian Federation), 4 Oxford (United Kingdom), 

5 

Reading (United Kingdom) 


24.005 A pre-exposure prophylactic for arenaviral hemorrhagic fever in the 

pirital virus—Syrian golden hamster model 

E. Vela, R. Stammen, J. Garver, S. Sarrazine 

Columbus, OH (USA) 

24.006 Characterization of a novel neutralizing monoclonal antibody that recognizes 

the fusion loop of Flavivirus envelope protein 

Y. Deng 1 , G. Ji 2 , Y. Kang 2 , T. Jiang 1 , J. Dai 2 , E. Qin 1 , Y. Guo 2 , C. Qin 1 

1 

Beijing (China), 2 Shanghai (China) 

24.007 Gene optimization for expression of Crimean-Congo haemorrhagic fever 

viral nucleoprotein 

R. Samudzi, F. J. Burt 

Bloemfontein (South Africa) 

24.008 Preparation of antigenically active recombinant yellow fever viral envelope 

domain III protein 

S. Smouse, F. J. Burt 


Final Program ~ 61

Session 24 




ARBOVIRUSES 

24.009 Development of a recombinant antigen and multiplex PCR for differentiation of 

tick-borne and mosquito-borne flaviviruses. 

L. Mathengtheng, F. J. Burt 



24.010 A novel cell encapsulation mode for delivery of therapeutic antibodies against 

West Nile Virus infections that maintains steady plasma antibody levels 

throughout therapy 

A. J. S. Chua, E. M. Brandtner, J. A. Dangerfield, B. Salmons, 

W. H. Gunzburg, M. L. Ng 


24.011 Association of tumor necrosis factor-alpha gene promoter regions polymorphism 

in Japanese encephalitis patients 

S. K. Pujhari, R. K. Ratho, S. Prabhakar, B. Mishra, M. Sharma, M. Modi 

Chandigarh (India) 

24.012 A novel antagonistic relationship between human Sec3 exocyst and flavivirus 

capsid protein 

B. Raghavan, K. L. Yeo, M. L. Ng 


24.013 Effect of dengue virus infection on the host signal transduction pathways 

M. K. Chong, A. J. S. Chua, M. L. M. Ng 


24.014 Jumping over the sharp edge of dengue shock syndrome 

V. Pinto 

Kandy (Sri Lanka) 

24.015 Japanese encephalitis virus and neuronal cell interaction: a study on cellular 

receptor and gene expression profile 

S. Das, R. Vasanthapuram 


24.016 Chikungunya virus (CHIKV) infection: Analytical performance of real-time 

NASBA assay 

G. Rossini, F. Cavrini, P. Gaibani, A. Pierro, M. P. Landini, V. Sambri 


24.017 Wild yellow fever cases in São Paulo state, Brazil, 2009 

M. Mascheretti 1 , A. Ribeiro 1 , C. Tengan 1 , H. K. Sato 1 , P. Opromolla 1 , A. Suzuki 1 , 

R. Brasil 1 , C. Fortaleza 2 , F. Chudk 1 , M. S. Carli 1 , R. Albernaz 1 , R. Souza 1 

1 

São Paulo (Brazil), 2 Botucatu (Brazil) 

62 ~ Final Program

Session 25 




CLINICAL BACTERIAL INFECTIONS 

25.001 Clinical significance of polymicrobial bacteremial as determined by the pattern 

of gram stain 

M. Norizuki, S. Yamamoto, N. Hosokawa 

Kamogawa (Japan) 

25.002 Infective endocarditis after dental surgery 

V. Krčméry, A. Demitrovicova, E. Kalavsky, P. Kisac, M. Karvaj, F. Bauer, 

R. Kovac, P. Mlkvy 


25.003 Efficacy of serum semi-quantitative procalcitonin measurement kit PCT-Q® 

for bacteremia 

T. Kodama, H. Wakatake, M. Yanai, S. Fujitani 

Kawasaki-City (Japan) 

25.004 Salivary IgA responses in newborn against pathogen of oral cavity. Influence of 

prematurity in this response 

R. D. Nogueira, M. L. T. Sesso, M. C. L. Borges, L. R. Roberti, V. P. L. Ferriani 

Ribeirao Preto, SP (Brazil) 


25.005 Infectious complications of venomous snakebite: 2 cases from Eastern Nepal 

S. K. Sharma, S. Shrestha, B. Badhu, C. S. Agrawal, B. Khanal 

Dharan (Nepal) 

25.006 Clinicomicrobiological profile of infective endocarditis in a tertiary care centre 

of Nepal 

M. Ghimire 


25.007 The relation of the contraction period and the bacteria of the otorrhea of 

chronic otitis media 

M. Shinogami, H. Iwamura, W. Nakanishi, C. Yamada 

Tokyo (Japan) 

25.008 Bone and joint infections in elderly and young adults patients: 

Comparison of clinical features and outcomes (1991–2007) 

F. Nacinovich, C. A. Pensotti, C. Vizzotti, P. Fernandez Oses, A. Ferraris, 

P. Luchetti, M. Marin, 

A. Sucari, J. Thierer, C. Di Stéfano, D. Stamboulian 


Final Program ~ 63

Session 25 





25.009 Prosthetic joint infections: A multidisciplinary approach (1992–2008) 

C. A. Pensotti, F. Nacinovich, P. Fernandez Oses, J. Thierer, A. Ferraris, 

C. Vizzotti, C. Di Stéfano, D. Stamboulian 



25.010 Cerebrospinal meningitis outbreak in Kano state, Nigeria 

O. Biya, O. Alabi, G. Tolough 

Abuja (Nigeria) 

25.011 A comparison of infective endocarditis related Sequelae incidence among 

population-based, multicenter, and hospital-based cohorts: Data trom a 

systematic review for the global burden of disease project 

A. Bin Abdulhak 1 , M. George 2 , L. M. Baddour 3 , E. Patricia 3 , V. Chu 4 , 

M. Ezzati 5 , B. Hoen 6 , I. M. Tleyjeh 1 

1 

Riyadh (Saudi Arabia), 2 Georgia, GA (USA), 3 Rochester, MN (USA), 

4 

North Carolina, NC (USA), 5 Boston, MA (USA), 6 Paris (France) 

25.012 The impact of a microbial sealant to reduce surgical site infection reduction in 

cardiac surgery 

P. Dohmen, T. Christ, J. Linneweber, W. Konertz 

Berlin (Germany) 

25.013 The global burden of infective endocarditis: Methodology for a systematic review 

to assess disease burden and trends in 21 world regions for 1990–2005 

I. M. Tleyjeh 1 , M. George 2 , A. Bin Abdulhak 1 , E. Patricia 3 , V. Chu 4 , M. Ezzati 5 , 

B. Hoen 6 , L. M. BADDOUR 3 

1 

Riyadh (Saudi Arabia), 2 Georgia, GA (USA), 3 Rochester, MN (USA), 

4 

North Carolina, NC (USA), 5 Boston, MA (USA), 6 Paris, Paris (France) 

25.014 Psoas abscess in Korea: Etiology, clinical features, treatment and outcome 

M. W. Kang, Y. J. Kim, K.-W. Hong, S. I. Kim, Y. R. Kim 

Seoul (Republic of Korea) 

25.015 Mortality and ICU-admission in community-acquired pneumonia: CURB-65 

score validation in Uruguay 

H. Albornoz 1 , D. Goleniuk 2 

1 

Montevideo (Uruguay), 2 Rivera (Uruguay) 

64 ~ Final Program

Session 25 





25.016 Encrusted Pyelitis: A kidney stone disease of infectious origin 

M. Lodigiani, C. Ottone, V. Bellesi, D. Cera, S. Rojas, A. Celentano, S. Ripoll 

Rosario (Argentina) 

25.017 Distant infection and the risk of Prosthetic Joint Infection (PJI): 

A case control study 

G. Tsaras, D. R. Osmon, A. D. Hanssen, L. M. Baddour, D. G. Greene, 

W. S. Harmsen, J. N. Mandrekar, J. M. Steckelberg, W. R. Wilson, E. F. Berbari 

Rochester, MN (USA) 

25.018 Infective endocarditis in children: Analysis of cases admitted to a cardiac surgery 

referral hospital from January 2006 to July 2009 

L. A. Pereira 1 , G. Q. Lopes 2 , M. R. G. Vasques 1 , P. R. Travancas 1 , W. Paiva 1 , 

L. C. Simões 1 , G. I. D. Ferraiuoli 1 , M. D. S. Santos 1 , C. Lamas 1 

1 

Rio de Janeiro (Brazil), 2 Duque de Caxias (Brazil) 

25.019 Anaerobic bacteria as etiological agents of intraabdominal infections from a 

Costa Rican hospital 

C. Quesada-Gómez, E. Rodríguez-Cavallini, M. D. M. Gamboa-Coronado 

San José (Costa Rica) 


25.020 Blood culture negative infective endocarditis (IE). Clinical features, long-term 

outcome and comparison with positive blood culture IE 

F. Nacinovich, E. Perez Carrega, M. Trivi, J. Thierer, D. Navia, F. Piccinini, 

M. Marin, A. Sucari, P. Fernandez Oses, D. Stamboulian 


25.021 Treatment of Chronic Osteomyelitis (COM): Rwanda experience of in situ sterile 

Plaster Of Paris (POP) pellets containing antibiotics 

I. Nyaruhirira, E. Nsengiyumva 

Kigali (Rwanda) 

Final Program ~ 65

Session 26 




FOODBORNE DISEASES AND OUTBREAKS 

26.001 Shiga-toxin producing Escherichia coli in fresh milk from small-holder dairy 

farms in Kaduna, Nigeria 

N. E. Waziri 1 , J. U. Umoh 2 , H. M. Kazeem 2 , I. Ajogi 2 

1 

Plateau (Nigeria), 2 Zaria (Nigeria) 


26.002 Investigation and control of a meningitis outbreak in Birbhum-Murshidabad 

border of West Bengal, India, March 2009 

G. Roy 

Kolkata (India) 

26.003 Burden of illness for food-borne Salmonella: a cohort study in an agricultural 

community in Yucatan, Mexico 

M. B. Zaidi 1 , F. D. Campos 1 , F. Martinez 1 , F. Gutierrez 1 , M. Leon 1 , A. Polanco 1 , 

T. Estrada-Garcia 2 , J. J. Calva 2 

1 

Merida (Mexico), 2 Mexico City (Mexico) 

26.004 Laboratory investigation for clonality of a foodborne outbreak due to Vibrio 

parahaemolyticus in Singapore, 2009 

M.-V. La, S. Zulaina, R. Jureen, R. Lin 


26.005 Detection waterborne diseases associated viruses in the river water Metro Manila 

and Bulacan, the Philippines 

T. Imagawa 1 , A. Suzuki 1 , M. Saito 2 , Y. Masago 1 , C. Okumura 1 , S. Lupisan 2 , 

R. Olveda 2 , T. Omura 1 , H. Oshitani 1 

1 

Sendai (Japan), 2 Manila (Philippines) 

26.006 Detection of human enteric viruses in shellfish, vegetables, waters and 

environmental samples: A preliminary study 

V. Cannella 1 , G. Purpari 1 , A. Ferrari 2 , A. Migliazzo 1 , P. Di Marco 1 , A. Guercio 1 

1 

Palermo (Italy), 2 Genoa (Italy) 

26.007 Gastroenteritis outbreak investigation in Adamawa State Nigeria, 2009 

M. Adamu Kida 1 , S. A. Idris 2 

1 

Abuja (Nigeria), 2 Zaria (Nigeria) 

66 ~ Final Program

Session 26 




FOODBORNE DISEASES AND OUTBREAKS 

26.008 Phenotypical profile against antibiotics of Lactobacillus sp isolated 

from artisanal cheeses 

G. Rozos 1 , A. Vatopoulos 2 , X. Voidarou 3 , D. Vassos 3 , A. Alexopoulos 4 , 

S. Plessas 4 , E. Bezirtzoglou 4 

1 

Syros (Greece), 2 Athens (Greece), 3 Arta (Greece), 4 Orestiada (Greece) 

26.009 An outbreak of Cerebrospinal meningitis in Jigawa state Nigeria 2009. 

M. O. Akhimien, H. Akpan H. 


26.010 Risk factors for repeated cholera outbreak in Arua municipal council, 

north-western Uganda 

M. Andrawa 1 , P. Anguzu 2 , A. Anguaku 2 , C. Nalwadda 1 , O. Namusisi 1 , 

R. Tweheyo 1 

1 

Kampala (Uganda), 2 Arua (Uganda) 

26.011 Top health concerns in rural Honduras following the introduction of 

clay water filters 

R. Hemrajani, B. Morehouse, K. Elam, D. Markley, L. F. Stevens, 

G. Bearman, M. P. Stevens 

Richmond, Va (USA) 


26.012 E.coli infectious complicated with HUS in Georgia 

E. Vashakidze, T. Megrelishvili, E. Pachkoria, P. Imnadze, S. Canava, 

L. Tevzadze, M. Lashkarashvili 

Tbilisi (Georgia) 

26.013 Epidemiology of alimentary toxiinfection in western Romania 

S.-M. Draghici, C. Laslau, A. Jarca 

Oradea (Romania) 

Final Program ~ 67

Session 27 




HIV: EPIDEMIOLOGY AND PREVENTION 

27.001 The vertical transmission of the HIV/AIDS. 22 years of experience in Cuba 

I. González Nuñez 

Ciudad De La Habana (Cuba) 

27.002 Community involvement in HIV/AIDS prevention 

C. Okonkwoh 

Lagos (Nigeria) 


27.003 Community awareness including male involvement in prevention of 

mother-to-child transmission of HIV infection is crucial 

K. A. Myint 

Yangon (Myanmar) 

27.004 Frequency of isolated antibody to hepatitis B core antigen in HIV-HCV 

coinfected individuals 

A. Ramezani, A. Aghakhani, A. Eslamifar, M. Mohraz, M. Banifazl 


27.005 HIV voluntary counseling and testing (VCT) in three sites in Nigeria 

M. L. Alkan 1 , O. A. Akinwande 2 , U. I. Gebi 2 , R. Owolabi 2 , P. S. Dakum 2 

1 

Beer Sheva (Israel), 2 Abuja, FCT (Nigeria) 

27.006 Does knowing someone who has died of AIDS affect condom use? 

An analysis from Ivory Coast 

A. Ngui Ngamini 

Montreal, QC (Canada) 

27.007 The features of HIV-infected patients at A. Wahab Sjahranie General Hospital 

Samarinda, Indonesia 

C. Gunawan 

Samarinda (Indonesia) 

27.008 Bile salt stimulated lipase genotype distribution in Ghanaian couples discordant 

for HIV-1 infection 

Y. Affram 

Accra (Ghana) 

27.009 Safety and immunogenicity of measles vaccine in HIV-infected children: 

Systematic review and meta-analysis 

P. Scott 1 , W. J. Moss 2 , Z. Gilani 2 , N. Low 1 

1 

Berne (Switzerland), 2 Baltimore, MD (USA) 

68 ~ Final Program

Session 27 





27.010 Metabolic changes in HIV-infected children and adolescents from 

São Paulo city, Brazil 

C. Zanin Palchetti, R. Vega Patin, A. D. F. Thomé Barbosa Gouvea, 

F. Bononi do Carmo, A. M. Rufino, V. L. Szejnfeld, R. C. de Menezes Succi, 

F. L. Ceragioli Oliveira 


27.011 Body composition measurements and fat redistribution in HIV-infected children 

and adolescents from São Paulo city, Brazil 

C. Zanin Palchetti, R. Vega Patin, D. M. Machado, S. Vasconcelos Beltrão, 

E. R. Paulino, V. L. Szejnfeld, R. C. de Menezes Succi, F. L. Ceragioli Oliveira 


27.012 Antioxidant nutritional status and superoxide dismutase (SOD) levels in 

school–aged children infected with human immunodeficiency virus 

R. Vega Patin, F. L. Ceragioli Oliveira, R. C. de Menezes Succi, 

O. M. Silvério Amâncio, A. D. F. Thomé Barbosa Gouvea, C. Zanin Palchetti, 

D. M. Machado, F. Ancona Lopez 



27.013 Lipodystrophy and antioxidants in school-aged children infected with 

human immunodeficiency virus 

R. Vega Patin, F. L. Ceragioli Oliveira, R. C. de Menezes Succi, D. M. Machado, 

C. Zanin Palchetti, S. Pessoa, O. M. Silvério Amâncio, F. Ancona Lopez 


27.014 Factors influencing pregnancy among HIV positive women receiving 

anti-retroviral therapy in Tororo district, Uganda 

M. Busuulwa 


27.015 Epidemiologic characteristics and transmitted drug resistance mutation patterns 

among newly diagnosed HIV infected individuals in a large tertiary care hospital 

in Detroit 

M. Huaman, J. Aguilar, N. Markowitz, D. Baxa, A. Golembieski, I. Brar 

Detroit, MI (USA) 

27.016 Occupational risk of HIV infection among Nigerian dentists 

C. Azodo 

Benin City (Nigeria) 

27.017 Outbreak investigation of HIV/AIDS in Jalalpur Jattan (JPJ), Pakistan—2008 

J. Ansari 1 , M. Salman 1 , R. M. Safdar 1 , N. Ikram 1 , T. Mahmood 1 , H. A. Zaheer 1 , 

B. M. Kazi 1 , H. Walke 2 , R. J. Asghar 1 

1 

Islamabad (Pakistan), 2 Atlanta, GA (USA) 

Final Program ~ 69

Session 27 





27.018 A randomized controlled field trial of HIV-STI risk reduction program among 

undergraduate students at a University in Northern Nigeria 

A. Saad 1 , L. Rampal 1 , K. Sabitu 2 , H. AbdulRahman 1 , B. AbuSamah 1 , 

A. Y. Ibrahim 3 , A. Awaisu 4 

1 

Serdang (Malaysia), 2 Zaria (Nigeria), 3 Kano (Nigeria), 4 Penang (Malaysia) 


27.019 Qualitative analysis of a new web-based system for monitoring and evaluation 

of HIV/AIDS, El Salvador 2009 

M. Mengel 1 , J. Armero 2 , F. Job 1 

1 

Madrid (Spain), 2 San Salvador (El Salvador) 

27.020 HIV infection in elderly (patients over 65 years) 

F. Almasi Nokiani 

Courbevoie (France) 

27.021 Primary human immunodeficiency virus-1 infection: Clinical, virological and 

immunological characteristics of a braziliam cohort 

D. Pellegrino, E. Boccardo, M. Eira, R. Silva, I. Moreira, M. Bocoli Rossi 


27.022 Prevalence of metabolic syndrome and estimated Framingham risk score among 

Brazilian HIV-infected patients 

E. Margareth, E. L. Dorea, I. M. Bensenor, I. R. S. Oliveira, G. A. Pinto, 

A. L. Sassaki, P. A. Lotufo 


27.023 Factors affecting acceptance of HIV testing among antenatal care attendees in 

Ethiopia: With emphasis on role of male partners 

T. Zewde 

Hawassa (Ethiopia) 

27.024 Attitudes towards neonatal male circumcision among Hispanic men and women 

in Miami, Florida 

J. G. Castro, D. Jones, I. Barradas, M. Lopez, S. Weiss 


27.025 Patients with newly-diagnosed HIV in 2004 versus 2008: 

No apparent difference in progression 

A. Brown, C. Ní Bhuachalla, C. de Gascun, R. Hagan, C. Bergin 

Dublin (Ireland) 

27.026 Effectiveness of “positive prevention”among people living with HIV/AIDS in 

Yunnan Province, China 

L. Li, Y. Guo 

Beijing (China 

70 ~ Final Program

Session 27 





27.027 Demographic and psychosocial factors associated with appointment attendance 

among HIV-positive outpatients 

L. Bofill 


27.028 The role of HIV Viral Load and CD4+ Cell Count in the prolongation of the QT 

interval in patients from an HIV outpatient clinic 

H. Shaaban, A. Qaqa, J. Slim, G. Perez 

Newark, NJ (USA) 

27.029 Modelling the between-host evolution of set-point viral load in HIV infection 

G. Shirreff, T. D. Hollingsworth, W. P. Hanage, C. Fraser 


27.030 Large scale HIV survey in Cameroon by mass HIV testing mobile units: Evidence 

of HIV epidemic hot spot areas and high HIV vulnerability of women over time 

F.-X. Mbopi-Keou 1 , G. C. M. Kalla 1 , R. Guiadem 1 , H. Tchouamani 1 , R. Mbele 1 , 

C. Nkada 1 , E. Voundi 1 , G. Ondobo Andze 1 , I. Takoungang 1 , L. Bélec 2 , 

P. Ndumbe 3 , F. Angwafo III 1 

1 

Yaounde (Cameroon), 2 Paris (France), 3 Buea (Cameroon) 


27.031 Potential impact of a customized peer-facilitators training program on sexual 

health intervention 

A. Saad 1 , L. Rampal 1 , K. Sabitu 2 , H. AbdulRahman 1 , B. AbuSamah 1 , 

A. Awaisu 3 , A. Y. Ibrahim 4 

1 

Serdang (Malaysia), 2 Zaria (Nigeria), 3 Penang (Malaysia), 4 Kano (Nigeria) 

27.032 Molecular epidemiology of HIV-1 in newly-diagnosed treatment-naïve patients 

in Singapore 

Y.-J. Sun, P. Kaur, Y. S. Leo 


27.033 Factors influencing access to HIV care services by clients referred from a district 

home-based HIV counseling and testing program in eastern Uganda, 2009 

D. Lubogo, H. Wamani, J. Ddamulira, R. Tweheyo 


27.034 Adherence to infant feeding practices among HIV positive women with infants 

aged less than six months in Rakai district, South-western Uganda 

V. Kawooya, B. T. Kirunda, W. G. Maina, R. Tweheyo 


Final Program ~ 71

Session 28 




INFLUENZA 

28.001 The new North American strain of influenza A virus (H1N1) may not be a novel 

variant of H1 subtype 

Y.-H. Lu, L.-W. Ju, C.-Y. Jiang, Y.-J. Zheng, Q.-W. Jiang 

Shanghai (China) 


28.002 NS1 protein of avian influenza A virus prevents activation of NF-κB through 

binding to IKKα and IKKβ 

S. Gao, H. Peng, W. Jiang, L. Song 

Beijing (China) 

28.003 H5N1 NS1 change the cell cytoskeleton and interferes with host cell motility 

through the GTPase 

W. Jiang, Q. Wang, S. Gao, L. Song, W. Huang 


28.004 Novel influenza A H1N1 infection among healthcare workers 

M. Querci, F. Herrera, E. Temporiti, W. Alcala, L. Figueras, F. Barberis, 

G. Carballal, M. Echavarria, M. Stryjewski, P. Bonvehi 


28.005 Demographic and epidemiological characteristics of influenza in HIMA, 

San Pablo Caguas Hospital, Puerto Rico 

M. Collado, L. Collado, C. Cortes 

Caguas, PR (USA) 

28.006 Influenza disease burden study on 2 sentinel sites of Mongolia, 2008/09 season 

N. Nukiwa 1 , A. Burmaa 2 , T. Naranzul 2 , T. Kamigaki 1 , B. Darmaa 2 , B. Gantsooj 2 , 

H. Oshitani 1 , P. Nymadawa 2 

1 

Sendai (Japan), 2 Ulaanbaatar (Mongolia) 

28.007 Clinical profile and outcome in 100 patients admitted with pandemic influenza 

in four intensive care units in Uruguay during the winter of 2009 

H. Bagnulo, A. Soca, M. Buroni, G. Limongi, E. Echavarria, S. Noveri, M. Godino 


28.008 Intravenous peramivir for treatment of influenza A and B infection in 

high-risk patients 

S. Kohno 1 , H. Kida 2 , M. Mizuguchi 3 , N. Hirotsu 4 , T. Ishida 5 , J. Kadota 6 , 

J. Shimada 4 

1 

Nagasaki (Japan), 2 Sapporo (Japan), 3 Tokyo (Japan), 4 Kawasaki (Japan), 

5 

Kurashiki (Japan), 6 Yufu (Japan) 

72 ~ Final Program

Session 28 




INFLUENZA 

28.009 Neuraminidase sub typing and drug resistance among influenza A viruses 

circulating in western India 

V. Potdar, M. Dakhave, M. Chadha, A. Mishra 

Pune (India) 

28.010 Influenza in the tropics—Epidemiology and burden 

L. Da Silva, M. H. Kyaw 

Cambridge, MA (USA) 

28.011 Novel influenza A H1N1 (NIA) infection in Argentinean Children—Experience at 

Hospital de Niños “Ricardo Gutiérrez” 

E. L. Lopez, A. FALLO, M. M. Contrini, A. Mistchenko, C. Molise, S. Neyro, 

N. Gonzalez, D. Lazzarini, G. Manonelles, J. Grichener, M. Dastugue, 

A. Teper, N. Study Group 


28.012 Assessing the risk of Influenza virus strains isolated from birds and 

mammals to humans 

G. Vdovichenko, A. Sergeev, O. K. Demina, A. Kabanov, A. S. Kudriavcev, 

A. V. Palcev, U. E. Narov, L. N. Shishkina, I. G. Drozdov 

Novosibirsk (Russian Federation) 


28.013 In vitro inactivation of avian influenza virus by Capryilic acids and its derivatives 

N. I. Hariastuti, S. Babapoor, Y. Huang, M. I. Khan 

Storrs, CT (USA) 

28.014 Development of new effective antiinfluenza drugs based on extracts 

of basidiomycetes 

A. Kabanov, A. O. Sementsova, M. O. Skarnovich, T. V. Teplyakova, 

L. N. Shishkina, A. N. Sergeev 


28.015 Multifocal cerebral hemorrhages in H1N1 SOIV influenza patients: 

Report of 2 cases 

E. Carvalho Siqueira, L. M. Carvalho valle, A. D. F. Borges, 

P. S. Gonçalves da Costa 

Juiz de Fora (Brazil) 

Final Program ~ 73

Session 28 




INFLUENZA 

28.016 Development of a consensus microarray method for identification of different 

influenza A viruses 

D. Barlic-Maganja 1 , A. Fratnik Steyer 2 , N. Toplak 2 , A. Zrimec 2 , O. Zorman Rojs 2 

1 

Izola (Slovenia), 2 Ljubljana (Slovenia) 


28.017 Clinic-epidemiologic identification of the first wave of AH1N1 in adults in Albania 

N. Como, D. Kraja, P. Pipero, S. Bino, E. Meta, N. Gjermeni, E. Muco, A. Kica, 

E. Erindi, V. Ostreni, R. Petrela, S. Cibuku 

Tirana, AL (Albania) 

28.018 Analysis of first cluster outbreak of the pandemic influenza (H1N1) in Georgia 

K. Zakhashvili, P. Imnadze, O. Tarkhan-Mouravi 


28.019 2009 Influenza A (H1N1) first outbreak in a Spanish military training center 

E. Ballester, E. Mayo-Montero, P. Santa Olalla, M. J. Sierra-Moros, A. Fe Marques 


28.020 Investigation of pandemic influenza A (H1N1) 2009 virus: 

Isolation and genetic analysis of brazilian strains 

T. Paiva 


28.021 An analysis of critically ill patients with the novel influenza A (H1N1) 

virus in Japan 

K. Wada 1 , H. Nishiura 2 , A. Kawana 2 

1 

Sagamihara (Japan), 2 Saitama (Japan) 

28.022 Clinical, radiological features and outcome in children with confirmed infection 

by 2009 influenza A H1N1, admitted to a reference hospital of Curitiba, 

Brazillian South region 

H. Giamberardino 1 , L. F. Bricks 2 , V. H. Costa Jr. 1 , P. F. A. Boze 1 , F. A. Motta 1 , 

A. P. P. Oliveira 1 , M. Guedes 1 

1 

Curitiba (Brazil), 2 São Paulo (Brazil) 

28.023 Novel influenza A 2009—A comparison of intensive care unit vs non-intensive 

care unit patients 

C. Boehringer 

Fresno, CA (USA) 

74 ~ Final Program

Session 28 




INFLUENZA 

28.024 Impact of educational measures about influenza A (H1N1) directed to 

healthcare workers and patients 

C. Freuler, C. Ezcurra, M. Mayer-Wolf, V. Rodríguez, R. Durlach 


28.025 How was the telephone consultation service perceived by the officers who 

provided it in Japan during swine-origin influenza A (H1N1) outbreak? 

A qualitative study 

K. Iwata, C. Shirai 

Kobe (Japan) 

28.026 Epidemiological profile of the A (H1N1) pandemic influenza in the state of 

São Paulo, Brazil, for the April–September 2009 timeframe 

T. R. M. P. Carvalhanas, A. L. F. Yu, G. D. Freitas, A. C. G. Pellini, 

A. F. Ribeiro, B. L. Liphaus 

São Paulo, SP (Brazil) 

28.027 H1N1 Pandemic: From imported cases in July 2009 to sustained transmission 

in school clusters in September, Uganda, 2009 

L. Lukwago 1 , J. Wamala 1 , B. Erima 1 , C. Okot 1 , B. Bakamutumaho 1 , 

I. Nabukenya 1 , J. J. Lutwama 2 

1 

Kampala (Uganda), 2 Entebbe (Uganda) 


28.028 Factors associated to death in patients with confirmed diagnosis for 

influenza A/H1N1. State of São Paulo, Brazil, April to October, 2009 

A. Ribeiro, A. C. G. Pellini, T. R. M. P. Carvalhanas, B. D. L. Liphaus, 

A. L. F. L. F. Yu, G. D. Freitas, M. D. C. S. T. Timenetsky 


28.029 H1N1 Epidemic: Our experience at PGIMER Delhi, India 

A. Yadav, T. Samra, M. Pawar 

New Delhi (India) 

28.030 Deaths in women during fertile years and pregnant women as confirmed for 

pandemic influenza A (H1N1) in the state of São Paulo 

A. Ribeiro, G. D. Freitas, A. C. G. Pellini, T. R. M. P. Carvalhanas, 

A. L. F. Yu, B. D. L. Liphaus, M. D. C. S. T. Timenetsky 


Final Program ~ 75

Session 28 




INFLUENZA 

28.031 The impact of the “novel” influenza A (N1H1) pandemic in Norway, as 

monitored by recorded fatal cases—end of October 2009 

V. Hasseltvedt 

Lillehammer (Norway) 


28.032 A survey in Taiwan 2009 for the public perception and the willingness to be 

vaccinated of pandemic influenza A (H1N1) 

W.-S. Jhao, T.-H. Wang, L.-L. Ho, H.-P. Huang, C.-M. Chen, Y.-P. Chou, 

M.-C. Peng 

Taipei (Taiwan, R.O.C.) 

28.033 The outcomes of H1N1 09 screening at the 17th World Transplant Games 

G. Thompson 1 , M. Schmittmann 2 , C. Hahne 2 

1 

Campbelltown, NSW (Australia), 2 Deakin, NSW (Australia) 

28.034 Epidemiology of severe pediatric patients with novel influenza A (H1N1) in Korea 

S. Soo Youn, J. H. Kim, H. S. Kim, Y. A. Kang, H. G. Lee, J. S. Kim, W. K. Kim 


28.035 Epidemiologic characteristics of deaths associated with 2009 pandemic 

influenza A (H1N1) virus infection in Korea 

H. S. Kim, J. H. Kim, S. Y. Shin, Y. A. Kang, H. G. Lee, J. S. Kim, B. Cho 


28.036 The effect of influenza-like illness symptoms and laboratory confirmed influenza A 

on hand hygiene and other health habits among US University students 

V. Perez, S. Galea, J. Kalbfleisch, A. S. Monto, A. E. Aiello 


28.037 The progressive expansion of the Novel A (H1N1) v epidemic in the EpiSouth 

region (Mediterranean and Balkans) 

F. Ait Belghiti 1 , N. El Omeiri 1 , J. Gueguen 1 , A. Rachas 1 , M. Gastellu-Etchegorry 1 , 

S. Declich 2 , M.-G. Dente 2 , P. Barboza 1 

1 

Saint Maurice (France), 2 Rome (Italy) 

28.038 An outbreak of influenza A pandemic (H1N1) 2009 in a residential home 

for the disabled in Hong Kong and detection of the first local case of 

oseltamivir-resistant infection 

W. H. A. Leung, L. T. T. LOH 

Hong Kong (China) 

76 ~ Final Program

Session 28 




INFLUENZA 

28.039 Evaluation of direct immunofluorescent assay (DFA) and rapid antigen test (RAT) 

for diagnosis of new pandemic influenza A H1N1 2009 (FLU AH1N1) during 

first wave in Santiago, Chile 

C. Vizcaya, M. Ferrés, C. Perret, C. Martinez, P. Godoy, A. M. Contreras, 

P. Ferrer, T. Azocar 


28.040 Influenza A (H1N1) pandemic in Argentina. Experience in two private general 

hospitals during the outbreak (June 2009) 

G. Vidiella, P. Titanti, V. Cruzat, E. Parino, H. Quinteros, G. Diaz Colodrero, 

M. Curone, I. Moine, G. Kohan, J. C. Gallo, A. Moreno, P. Gallego 


28.041 Epidemiologic and clinical finding of A H1N1 2009 pandemic influenza in the 

Dominican Republic 

M. Thormann, R. Pimentel, C. Then, C. Perez 

Santo Domingo (Dominican Republic) 


28.042 Prolonged prophylaxis for A H1N1 Influenza pandemic in Oncohematologic 

patients—Adherence, security and efficiency. 

S. J. Ramirez Borga 1 2 , A. S. Firpo 1 , L. Lopez 2 , J. J. Napal 2 , M. V. Prates 2 , 

S. Yantorno 2 , A. Enrico 2 , J. Milone 2 

1 

Buenos Aires (Argentina), 2 La Plata (Argentina) 

28.043 Homologous and heterologous immune responses to naturally-acquired 

influenza virus infection 

L. Lau, V. J. Fang, K. H. Chan, E. Ma, G. M. Leung, M. Peiris, B. J. Cowling 


28.044 The role of schools as social networks in transmission of Influenza A (H1N1 2009): 

The Mbulu District, Northern Tanzania, November 2009 experience 

E. Mwakapeje, J. Mghamba, E. Nyale, M. A. Mohamed, V. Makundi, 

O. Oleribe, P. Mmbuji 

Dar Es Salaam (United Republic of Tanzania) 

28.045 Co-infection between the pandemic influenza virus A H1N1 and seasonal 

influenza A virus in a patient presenting severe acute respiratory disease 

A. Feltrin, K. Augusto, V. Isper, J. Delamain, B. Kemp, A. R. R. Freitas, 

M. Pacola, R. Angerami 

Campinas, SP (Brazil) 

Final Program ~ 77

Session 28 




INFLUENZA 

28.046 Response to pandemic influenza in the English and Dutch Caribbean 

E. Boisson, B. Irons 

Port of Spain (Trinidad and Tobago) 

28.047 Enhanced influenza survey: Khartoum state survey in selected paediatric hospitals 

S. Mustafa, M. S. Karsani, A. A. Badri, M. Mangory, R. Elagib, A. S. Abd Elfadeel 

Khartoum (Sudan) 


28.048 Assessing H1N1 (2009) mitigation strategies under epidemiologic and 

programmatic uncertainty 

M. Zivkovic Gojovic 1 , B. Sander 1 , D. Fisman 1 , M. Krahn 1 , C. Bauch 2 

1 

Toronto, ON (Canada), 2 Guelph, ON (Canada) 

28.049 Providing guidance during the swine flu outbreak in 2009: 

An evaluation study of the National Resource for Infection Control (NRIC) 

S. Wiseman, P. Kostkova, E. de Quincey, G. Jawaheer 


28.050 Severe acute respiratory disease caused by pandemic influenza A H1N1 virus. 

A case series of hospitalized patients in Southeastern Brazil during the 

2009 epidemic 

A. Feltrin 1 , K. Augusto 1 , J. Carvalho 2 , J. Vitone 2 , A. Silva 1 , J. Morelli 3 , F. Toniatti 2 , 

M. Reis 3 , C. Silva 2 , B. Kemp 1 , A. R. R. Freitas 1 , M. Pacola 1 , 

R. Angerami 1 

1 

Campinas, SP (Brazil), 2 Valinhos, SP (Brazil), 3 Vinhedo, SP (Brazil) 

28.051 Is the 2009 influenza A (H1N1) virus uncovering health disparities in Miami? 

F. Leguen, A. LLau, G. Zhang, E. O’Connell 


28.052 Comparative evaluation of ARDS patients with and without H1N1 infection at 

a tertiary care referral center 

T. Samra, M. Pawar, A. Yadav 


28.053 Comparison between three not pharmacological strategies aimed to prevent the 

dissemination of the A/H1N1 influenza virus in Colombia 

C. Alvarez, J. A. Cortes, M. Sossa, G. Aristizabal, C. Rodriguez 

Bogotá (Colombia) 

78 ~ Final Program

Session 29 




MALARIA & BLOOD-BORNE PARASITES 

29.001 A study of acute myocardial infarction in a hospital cohort of malaria: 

4 years retrospective analysis 

K. Jain 1 , D. C. M. 2 

1 

Mysore (India), 2 Mangalore (India) 

29.002 Severe malaria in East Kalimantan, Indonesia 

C. Gunawan, P. D. Nasution, A. R. Magdaleni 

Samarinda (Indonesia) 

29.003 Performance of four rapid diagnostic tests for diagnosis of falciparum and 

non-falciparum malaria in endemic areas of Gondar region, Northern Ethiopia 

A. K. Gelaglie 

Addis Ababa (Ethiopia) 

29.004 Clinical presentation and outcome of severe falciparum malaria in Eastern Nepal 

S. K. Sharma 1 , B. Khanal 1 , D. Manandhar 2 , S. Rijal 1 

1 

Dharan (Nepal), 2 Kathmandu (Nepal) 

29.005 APACHE III score as a prognostic marker in severe malaria in a tertiary care 

hospital from south India 

K. Nataraj 1 , M. Prabhu 2 , M. Sangar 2 , B. Ramachandran 2 

1 

Kolkata (India), 2 Manipal (India) 


29.006 Poor impact of the primary health care (PHC) on malaria control in rural 

communities of Southeast Nigeria 

O. Odikamnoro 

Abakaliki (Nigeria) 

29.007 Malaria parasitemia in surgical patients in University of Calabar 

Teaching Hospital, Nigeria 

N. Usoro, E. E. Anwan, I. O. Uchejuru, O. J. Bam 

Calabar (Nigeria) 

29.008 Improving estimates of malaria intervention coverage from household surveys 

using GPS data 

C. Burgert 1 , S. E. Bradley 2 , F. Arnold 2 , E. Eckert 2 

1 

Arlington, VA (USA), 2 Calverton, MD (USA) 

29.009 Assessment of chloroquine resistance of Plasmodium in patients attending 

malaria clinic in a government general hospital, Kurnool; Strategies to prevent 

chloroquine resistance 

N. Mullaguri 

Kurnool (India) 

Final Program ~ 79

Session 29 




MALARIA & BLOOD-BORNE PARASITES 

29.010 Blood microfilarial-stage specific gene expression profile of Brugia malayi 

S. Nuchprayoon 1 , S. Sungpradit 1 , A. E. Jedlicka 2 , J. Bailey 2 , A. L. Scott 2 

1 

Bangkok (Thailand), 2 Baltimore, MD (USA) 


29.011 Nitric oxide synthase immunity in the malaria non-vector Anopheles culicifacies 

species B: a putative transmission blocking Plasmodium vivax immune 

responsive mechanism for refractoriness 

A. Sharma, S. Vijay, M. Rawat, K. Raghavendra 


29.012 Malaria vector studies in the Republic of Korea: Vector parasite rates and 

habitat distribution 

T. Klein 1 , H.-C. Kim 1 , L. M. Rueda 2 , D. H. Foley 2 , C. Li 2 , R. C. Wilkerson 2 

1 

Seoul (Republic of Korea), 2 Suitland, MD (USA) 

29.013 Cardiac function and haemodynamics in African children with severe malaria 

S. Yacoub 1 , H.-J. Lang 1 , M. Shebbe 2 , M. Twimba 2 , E. Ohuma 2 , R. Tulloh 3 , 

K. Maitland 2 

1 

London (United Kingdom), 2 Kilifi (Kenya), 3 Bristol (United Kingdom) 

29.014 Transfusion-associated Babesia infections: Reports received by the 

FDA 1997 to 2008 

D. Gubernot, K. C. Lee, G. B. Conley, L. G. Holness, S. O’Callaghan, 

S. Cannon, E. Cowan, H. Nakhasi, R. P. Wise 

Rockville, MD (USA) 

29.015 Clinical and epidemiological study of patients with malaria treated at the 

hospital central de Las Fuerzas Armadas in Dominican Republic 

C. Rodriguez-Taveras, L. C. Socias, C. Blanco, J. R. Reyes, J. M. Puello 


29.016 Artemisinin combination therapies: Public and private market and policy surveys 

in Burundi and Sierra Leone 

J. Amuasi 1 , Y. Karikari 1 , I. Boakye 1 , S. Blay 1 , L. Nsabiyumva 2 , A. Jambai 3 , G. Diap 4 

1 

Kumasi (Ghana), 2 Bujumbura (Burundi), 3 Freetown (Sierra Leone), 

4 


29.017 Role of ultrasonography in malaria pregnancy 

M. Brock, F. E. M. Espinosa, J. R. D. T. Leao 

Manaus (Brazil) 

29.018 Treatment failure of Artemether-lumefantrine in Falciparum Malaria in 

Brazilian Amazon area 

M. Quiroga 1 , A. Lara 1 , M. Mascheretti 2 , P. Abati 1 , M. Boulos 3 

1 

Santarem (Brazil), 2 São Paulo (Brazil) 

80 ~ Final Program

Session 30 




MYCOLOGY, FUNGAL INFECTIONS AND ANTIFUNGAL DRUGS 

30.001 Candida species in the lower respiratory tract of healthy individuals 

H. J. Salzer, R. B. Raggam, I. Zollner-Schwetz, M. Hoenigl, T. Valentin, R. Krause 

Graz (Austria) 

30.002 Influence of gender, age, previous hospitalization and hospital stay on 

Candida-colonization of patients in a non-surgical ICU 

A. Gloeckner, P. Abel 

Greifswald (Germany) 

30.003 Mixed fungal colonization in non-surgical intensive care patients 

A. Gloeckner, P. Abel, K. Zimmermann 

Greifswald (Germany) 

30.004 Recent trends of Candida epidemiology in cancer and non-cancer patients 

M. Karthaus 1 , R. Biedenkopf 1 , M. Hentrich 1 , X. Schiel 1 , I. Schuth 2 , 

G. Schwarzkopf-Steinhauser 1 

1 

Munich (Germany), 2 Coblenz (Germany) 

30.005 Anti-Saccharomyces cerevisiae (ASCA) antibody levels in a subgroup of patients 

with ulcerative colitis, Crohn’s disease, GI Behcet, and GI tuberculosis: 

Correlations with disease duration, activity, and extension 

M. Aslan, B. Kocazeybek, A. Celik, Y. Erzin, I. Hatemi, G. Hatemi, H. Yazici 

Istanbul (Turkey) 


30.006 Clinical utility of perinuclear antineutrophil cytoplasmic antibodies and 

anti-Saccharomyces Cerevisiae antibodies for discriminating specific 

intestinal inflammations 

B. Kocazeybek, M. Aslan, Y. Erzin, A. Celik, I. Hatemi, G. Hatemi, H. Yazici 


30.007 Comparative studies on the in-vitro activity of pentamycin against non-albicans 

Candida species and Saccharomyces cerevisiae in 161 clinical isolates 

C. Winnips 1 , W. Buzina 2 , B. Dupont 3 

1 

Basel (Switzerland), 2 Graz (Austria), 3 Paris (France) 

30.008 Mycotic keratitis in Mashhad, Iran: Predisposing factors, etiologic agents and 

clinical manifestation 

S. Fata 1 , A. Derakhshan 1 , A. Boloorian 1 , M. Sedaghat 1 , H. Khakshoor 1 , F. Berenji 1 , 

M. J. Najafzadeh 2 , M. Afzal Aghee 1 , M. Meshkat 1 , A. Fata 1 

1 

Mashhad (Islamic Republic of Iran), 2 Amsterdam (Netherlands) 

30.009 Assessment of a novel region of the 28S rRNA operon for identification of 

clinically significant Mucormycota 

U. Kesavachandran, S. Hurst, L. Gade, A. Balajee 


Final Program ~ 81

Session 30 





30.010 Recurrent/resistant fungal infections in females 

N. Como, D. Kraja, N. Gjermeni, M. Qato, A. Kica, K. Duraku 

Tirana (Albania) 

30.011 Recurrent vulvovaginal candidiasis—where does Candida albicans persist? 

F. Beikert, M. T. Le, A. Clad 

Freiburg (Germany) 


30.012 Delayed diagnosis of disseminated Histoplasmosis capsulatum var. capsulatum 

infection in AIDS patients in a tuberculosis high endemic country 

P. Soentjens 1 , I. Eshun-Wilson 2 , J. Taljaard 2 

1 

Brussels (Belgium), 2 CapeTown (South Africa) 

30.013 Breakthrough Rhizopus spp. in an immunocompromised patient receiving 

caspofungin. Case report and review 

N. Dunkel, J. Ambrosioni, Y. Chalandon, J. Passweg, J. Garbino 


30.014 Granulomatous lesions in experimental Paracoccidioides brasiliensis infection 

E. Burger, R. F. S. Molina, J. V. Alves, C. R. P. Pizzo, A. S. Nishikaku 


30.015 Fibrosis treatment in experimental Paracoccidioides brasiliensis infection 

E. Burger, A. S. Nishikaku, J. V. Alves, C. R. P. Pizzo, R. F. S. Molina 


30.016 Cost-effectiveness analysis of the therapy for the invasive Candidiasis 

in Colombia 

F. J. Molina 1 , J. A. Cortes 2 , H. A. Caceres 2 , R. Soto 3 , E. V. Lemos Luengas 2 

1 

Medellin (Colombia), 2 Bogotá (Colombia), 3 Cali (Colombia) 

30.017 Myocardial infarction caused by aspergillus embolization in a patient 

with cirrhosis 

A. Shahzad 1 , B. Nseir 2 

1 

Kenner, LA (USA), 2 New Orleans, LA (USA) 

30.018 Correlation between HIV-1 viral load and cryptococcal capsular polysaccharide 

concentration: Evaluation in a clinical setting 

D. Cecchini, A. M. Cañizal, H. ROJAS, A. Arechavala, R. Negroni, 

M. B. Bouzas, J. Benetucci 


82 ~ Final Program

Session 30 





30.019 Risk factors for candidemia-related mortality in a 

Neonatal Intensive Care Unit (NICU) 

C. I. Echave, M. L. PRAINO, M. L. Vozza, C. Manso, M. Russman, 

C. Enfedaque, A. Martinez Burkett, A. Procopio, N. Rivas, E. L. Lopez 


30.020 Analysis of candidemia epidemiological data and antifungigram by distinct 

methodologies in a large Brazilian teaching hospital 

A. Motta, G. D. Almeida, J. N. Almeida Jr., M. I. Pinto, M. N. Burattini, F. Rossi 


30.021 Prevalence of cryptococcal meningitis among HIV seropositive patients 

in Georgia 

L. Gatserelia, L. Sharvadze, M. Karchava, L. Dzigua, N. Dvali, N. Badridze, 

T. Tsertsvadze 


30.022 Clinical analysis of 92 patients with Fungaemia—data from national survey 

in Slovak Republic 

L. Drgona, J. Trupl, H. Hupkova 



30.023 Cryptococcus: Species distribution and susceptibility profile of isolates in a 

teaching hospital from São Paulo, Brazil 

A. Motta, G. D. Almeida, J. Almeida, M. I. Pinto, S. Onorio, F. Rossi 


30.024 Saccharomyces fungemia associated with esophageal disease identified 

by D1/D2 Ribosomal RNA gene sequence 

A. Cheema, J. Farrell, C. Kurtzman 

Peoria, IL (USA) 

30.025 Determination of antifungal susceptibility in immunocompromised patients 

L. Siegfried, V. Hrabovsky, M. Sabol 

Kosice (Slovak Republic) 

30.026 Candidemia in third level hospitals in Bogotá, Colombia 

J. Cortes, P. Reyes, C. H. Gomez, S. I. Cuervo, P. Rivas, R. Sanchez 


Final Program ~ 83

Session 31 




NON-TUBERCULOUS MYCOBACTERIA 

31.001 AIDS-associated atypical mycobacteriosis other than Mycobacterium aviumintracellulare: 

A 16-year survey of Mycobacterium xenopi, Mycobacterium 

kansasii, and Mycobacterium fortuitum infections in the setting of HIV disease 

R. Manfredi 



31.002 FOXO3a Transcription Factor mediates Apoptosis of Mycobacterium bovis 

BCG-Infected Macrophages 

M. Essafi 1 , M. Houas 1 , A. Mallavialle 2 , N. Laabidi 1 , M. Deckert 2 , 

M. R. Barbouche 1 

1 

Tunis (Tunisia), 2 Nice (France) 

31.003 Hansen’s disease in Northeast Brazil 

F. Pucci, C. R. Teófilo, T. S. Feitosa, S. G. A. Aragão, L. F. Távora 

Fortaleza (Brazil) 

31.004 Identification of immunogenic proteins of Mycobacterium avium with 

diagnostic potential 

E. Amador, L. Lloret, A. I. Castillo, Y. López 


31.005 Characterization of nontuberculous mycobacteria isolated of potable water 

distribution system and wastewater of Mexico City Metropolitan Area 

L. Lloret-Sanchez, A. I. Castillo, M. Mazari-Hiriart, M. Vargas, Y. López-Vidal 


84 ~ Final Program

Session 32 




TRAVEL MEDICINE AND TRAVEL HEALTH 

32.001 Mass screening for fever: A comparison of three infrared thermal dectection 

systems and self-reported fever 

A. Nguyen 1 , N. Cohen 2 , H. Lipman 1 , C. Brown 1 , D. Fishbein 1 

1 

Atlanta, GA (USA), 2 Chicago, IL (USA) 

32.002 Characteristics of travelers to developing countries: Findings from the 2008 

consumer styles survey 

X. Davis, E. Jentes, P. Han, W. Pollard, C. Marano 


32.003 Attitudes towards Avian influenza and sources of media information in travelers 

to developing countries 

P. Han, E. Yanni, E. Jentes, X. Davis, W. Pollard, C. Marano 


32.004 Demographics, medical conditions, and use of immunizations and 

chemoprophylaxis among international travelers within the Global TravEpiNet 

U.S. National Clinic Network 

LaRocque 1 , S. Rao 1 , E. Yanni 2 , N. Marano 2 , N. Gallagher 2 , C. Marano 2 , 

G. Brunette 2 , J. Lee 3 , V. Ansdell 4 , B. S. Schwartz 5 , M. Knouse 6 , J. Cahill 7 , 

S. Hagmann 8 , J. Vinetz 9 , R. Hoffman 10 , S. Alvarez 11 , J. Goad 10 , 

C. Franco-Paredes 2 , P. Kozarsky 2 , D. Schoenfeld 1 , E. Ryan 1 

1 

Boston, MA (USA), 2 Atlanta, GA (USA), 3 Chicago, IL (USA), 

4 

Honolulu, HI (USA), 5 San Francisco, CA (USA), 6 Allenton, PA (USA), 

7 

New York, NY (USA), 8 Bronx, NY (USA), 9 La Jolla, CA (USA), 

10 

Los Angeles, CA (USA), 11 Jacksonville, FL (USA) 


32.005 Use and sources of medical information among departing international 

travelers to low and middle income countries at Logan International Airport, 

Boston, MA, 2009 

R. LaRocque 1 , S. Rao 1 , T. Lawton 1 , A. Tsibris 1 , D. Schoenfeld 1 , A. Barry 1 , 

E. Yanni 2 , N. Marano 2 , N. Gallagher 2 , C. Marano 2 , G. Brunette 2 , E. Ryan 1 

1 

Boston, MA (USA), 2 Atlanta, GA (USA) 

32.006 Transporting a critically ill patient from the Canadian north—lessons learned 

from almost a decade of SkyService Medevac experience 

G. Samoukovic 1 , E. Farias 2 , T. Malas 2 , H. Petrie 2 , M. Churchill Smith 2 

1 

H3A 1A1, QC (Canada), 2 Montreal, QC (Canada) 

Final Program ~ 85

Session 32 





32.007 Incidence and impact of travelers diarrhea among foreign backpackers in 

Southeast Asia 

W. Piyaphanee, T. Kusolsuk, C. Kittitrakul, W. Suttithum, T. Ponam, P. Wilairatana 

Bangkok (Thailand) 


32.008 The health surveillance stations at points of entry in Brazil under the revised 

International Health Regulations—IHR/2005 

C. Gregis, F. V. Pascalicchio 

Brasilia, DF (Brazil) 

32.009 Varicella (Chickenpox) outbreak in Bhutanese refugee camps in Eastern Nepal 

A. K. MISHRA, O. Gorbacheva, M. M. T. Hasan, N. Rimal 

Jhapa (Nepal) 

32.010 Foreign travel associated with increased sexual risk: A cohort study 

R. Vivancos 1 , P. R. Hunter 2 , I. Abubakar 2 

1 

Liverpool (United Kingdom), 2 Norwich (United Kingdom) 

32.011 Management of an international outbreak of norovirus on board a cruise ship 

R. Vivancos 1 , A. Keenan 1 , W. Sopwith 2 , C. Quigley 1 , K. Mutton 2 , G. Nichols 4 , 

J. Harris 4 , Q. Syed 1 , J. Reid 1 

1 

Liverpool (United Kingdom), 2 Wirral (United Kingdom), 

3 

Manchester (United Kingdom), 4 London (United Kingdom) 

32.012 Medical tourism research: A systematic review 

V. Balaban, C. Marano 


32.013 Preventing enteric fevers in London VFR travellers 

Y. Knight, E. Dapaah, B. Walsh 


32.014 International traveler and prevention of diarrheal diseases characterization of 

the international traveller to whom has been prescribed cholera vaccine at the 

international vaccination center of Oporto during the years 2007 and 2008 

G. Saldanha 


32.015 Travelers’ diarrhea (TD) incidence in argentine travelers to high-risk destinations. 

A telephonic survey at a private ambulatory center for infectious diseases (ID) 

and travel medicine (TM) in Buenos Aires 

M.A. Botas, C. Biscayart, P. Elmassian, D. Stamboulian 


86 ~ Final Program

Session 32 





32.016 First tavel medicine center in a public hospital from Buenos Aires province, 

Argentina. The first 18 months of experience 

M. L. Yantorno, G. de la Parra, M. Lares, K. Aguilera, D. Lizaso, 

M. Correa, A. Esposto 

La Plata (Argentina) 

32.017 Trends in fatal snakebites in Venezuela, 2003–2007 

L. Parra, J. Peña, A. Rísquez Parra, L. Echezuria, A. Rodriguez-Morales 


32.018 Epidemiology of drowning deaths in Venezuela, 1996–2007 

C. Madrid, M. H. Maldonado, A. Rísquez Parra, A. Rodriguez-Morales 


32.019 Travellers´ Hantavirus Pulmonary Syndrome in Andean Patagonia. Argentina 

M. E. Lazaro 1 , G. Cantoni 1 , L. Calanni 2 , A. J. Resa 3 , E. Herrero 1 , M. Iacono 2 , 

L. de Wouters 4 

1 

Bariloche, Rio Negro (Argentina), 2 Neuquen, Neuquen (Argentina), 

3 

El Bolsón, Rio Negro (Argentina), 4 Mar del Plata, Buenos Aires (Argentina) 


32.020 Characterization of pre-travel consults at a travel medicine clinic in Buenos Aires 

in 2008: Experience with 1,439 Travelers 

P. Elmassian, A. Macchi, C. Biscayart, V. Verdaguer, M. P. Della Latta, 

D. Stamboulian 


32.021 Risk assessment of potential anthropozoonotic pathogen transmission from 

ecotourists to wildlife populations in Borneo 

M. Muehlenbein 1 , L. A. Martinez 1 , A. Lemke 2 , L. Ambu 3 , S. Nathan 3 , 

S. Alsisto 3 , R. Sakong 4 

1 

Bloomington, IN (USA), 2 Milwaukee, WI (USA), 3 Kota Kinabalu (Malaysia), 

4 

Sandakan (Malaysia) 

32.022 Malaria in a community hospital 

O. Mascaro, C. Socolich, A. Pedragosa, E. Reynaga, G. Lucchetti, X. Gimeno, 

J. Brugues 

Vic (Spain) 

Final Program ~ 87

Session 32 





32.023 Meningococcal disease in travelers: A problem more than a 100 years old 

L. De Tora, L. Da Silva 


32.024 Free living amoebae encephalitis infection in a child who travelled to Peru 

C. A. Mora, N. Orellana, A. Schteinschnaider, N. Arakaki, M. Del Castillo 



32.025 New world cutaneous Leishmaniasis in travelers (1994–2008) experience 

in Argentina 

T. Orduna, S. Lloveras, G. D. Gonzalez, C. C. Falcone, S. L. Garro, 

S. E. Echazarreta 


32.026 Imported malaria in travelers assisted in Buenos Aires 

S. Lloveras 1 , S. E. Echazarreta 2 , S. L. Garro 2 , C. C. Falcone 2 , G. D. Gonzalez 2 , 

T. Orduna 1 

1 

Corunna (Argentina), 2 Buenos Aires (Argentina) 

32.027 Travel medicine working group 

A. Macchi 1 , A. Lepetic 2 , C. Biscayart 1 , P. Elmassian 1 , V. Verdaguer 1 , 

M. P. Della Latta 1 , C. Torroija 1 , E. Sturba 1 , M. Arrestia 1 , D. Stamboulian 1 

1 

Buenos Aires (Argentina), 2 Corunna (Argentina) 

32.028 Profile of imported malaria in travelers from the north of Portugal 

A. Silva, A. R. Silva, T. Teixeira, H. Coelho, R. Sarmento e Castro 


32.029 Demographics and travel patterns of travelers to Central America, South America 

and the Caribbean seen in the Boston Area Travel Medicine Network (BATMN) 

J. B. Trivedi 1 , N. S. Hochberg 1 , W. B. Macleod 1 , M. Pfaff 1 , M. M. Sosa 1 , 

C. Benoit 1 , L. H. Chen 2 , M. E. Wilson 2 , L. Kogelman 1 , W. W. Ooi 3 , 

A. W. Karchmer 1 , E. D. Barnett 1 , D. H. Hamer 1 

1 

Boston, MA (USA), 2 Cambridge, MA (USA), 3 Burlington, MA (USA) 

88 ~ Final Program

Session 32 





32.030 Hookworm-related cutaneous Larva Migrans: An annoying souvenir of some trips 

S. Lloveras 1 , S. E. Echazarreta 2 , T. Orduna 1 

1 

Corunna (Argentina), 2 Buenos Aires (Argentina) 

32.031 Immunocompromised travellers in the pre-travel appointment: 

A report from Portugal 

R. Coelho, C. Abreu, F. Danina, J. Nuak, C. Caldas, E. Quintas, N. Darwich, 

A. Sarmento 


32.032 Triquinellosis in domestic travelers in Argentina: Which is the advice for 

intenational travelers? 

S. E. Echazarreta 1 , S. Lloveras 2 , T. Orduna 2 , S. L. Garro 1 , C. C. Falcone 1 , 

G. D. Gonzalez 1 

1 


32.033 Health surveillance of Brazilian military peacekeepers deployed in the 

United Nations Stabilization Mission in Haiti (MINUSTAH), 2007–2009 

J. R. P. De Andrade-Lima 1 , R. B. Batista 2 

1 

Salvador, Bahia (Brazil), 2 Curtiba, Paraná (Brazil) 


32.034 Immunizations in travelers attending a private center for infectious diseases 

and travel medicine in Buenos Aires, Argentina, 2005–2008 

C. Biscayart, P. Elmassian, A. Macchi, V. Verdaguer, M. P. Della Latta, 

C. Torroija, D. Stamboulian 


Final Program ~ 89

Session 33 




TUBERCULOSIS: EPIDEMIOLOGY, PREVENTION & CONTROL 

33.001 Clinical manifestations of tuberculosis among pediatric household contacts with 

active culture confirmed disease 

A. Ackerman 1 , C. Whalen 2 , S. Zalwango 3 , J. I. Shwartz 4 

1 

Worcester, MA (USA), 2 Athens, GA (USA), 3 Kampala (Uganda), 

4 

New Haven, CT (USA) 


33.002 A validated clinical practice guideline for community health nurses working in 

tuberculosis Out-patient Clinics 

A. Ahmed, S. Soliman, L. A. Awad 

Dakahlia (Egypt) 

33.003 Genetic diversity of Mycobacterium tuberculosis population in Bulgaria 

V. Valcheva 

Sofia (Bulgaria) 

33.004 Transmission of drug resistant tuberculosis and its implication for TB control 

in rural China 

Y. Hu, W. Jiang, W. Wang, B. Xu 


33.005 Evaluation of cost and methods for detecting latent tuberculosis infection among 

target individual groups in Trinidad & Tobago 

P. E. Akpaka 1 , S. Baboolal 2 , D. Ramoutar 3 

1 

Champ Fleurs (Trinidad and Tobago), 2 St. Augustine (Trinidad and Tobago), 

3 

Caura (Trinidad and Tobago) 

33.006 HIV prevalence and MDR TB among DOTS attendees in a rural area 

of Haryana, India 

R. Kumar, S. Rai, S. Kant, K. Anand, L. Dar, U. Singh 


33.007 The social representation of DOT-related tuberculosis by patients of Guarulhos 

at the metropolitan area of São Paulo, Brazil 

V. Souza Pinto, V. M. N. Galesi, M. I. P. S. Braz 


33.008 Prevalence of bacteriologically confirmed pulmonary tuberculosis in the 

Bhutanese refugees in Nepal. Results of active case finding 

O. Gorbacheva, A. K. Mishra, D. Shapovalov, S. Sudtasay 

Jhapa (Nepal) 

90 ~ Final Program

Session 33 




TUBERCULOSIS: EPIDEMIOLOGY, PREVENTION & CONTROL 

33.009 Newly diagnosed tuberculosis patients and tobacco use in North Malaysia: 

The prevalence of tobacco use, knowledge, and attitudes 

A. Awaisu 1 , M. H. Nik Mohamed 2 , N. Mohamad Noordin 3 , A. R. Muttalif 1 , 

A. Ahmad Mahayiddin 3 , A. Saad 4 , S. Muhammadu Gobir 5 

1 

Penang (Malaysia), 2 Kuantan (Malaysia), 3 Kuala Lumpur, (Malaysia), 

4 

Serdang (Malaysia), 5 Kubang Kerian (Malaysia) 

33.010 Frequency of tuberculosis in the biggest island of the Persian Gulf 

K. Hamdi 1 , A. Shoae Hassani 2 , A. Akhavan Sepahi 1 

1 

Tehran (Islamic Republic of Iran), 2 Fars (Islamic Republic of Iran) 

33.011 The clinical and epidemiological characteristics of Mycobacterium tuberculosis 

Beijing/W family strains in a major immigrant-receiving province of Canada 

D. Langlois-Klassen, D. Kunimoto, D. Saunders, J. Boffa, L. Chui, R. Long 

Edmonton, AB (Canada) 

33.012 Evaluation of the performance of TB Control in Apac District in 2008 using 

Direct Observed Therapy (DOTS) 

S. M. Nakaggwa 



33.013 Analysis of the decentralization of tuberculosis control program in the sanitary 

district of Cabula-Beirú (SDCB) Salvador-Bahia-Brazil, 2008 

S. Cerqueira, L. G. Almeida, B. A. Santos 

Salvador, Bahia (Brazil) 

33.014 A community based tuberculosis control project in children in urban and rural 

settings: A public-private mix approach 

B. Cabrera 1 , J. Aldaba 2 , R. Buzon 2 , A. Fernandez 2 , B. J. Sablan 2 , F. Valdes 3 

1 

Pasay City (Philippines), 2 Manila (Philippines), 3 Pasig City (Philippines) 

33.015 Patterns of tuberculosis health problem in India: A gender perspective 

S. Gupta 

Mumbai (India) 

33.016 Tuberculosis in health-care workers: Results of a surveillance program 

in Mexico City 

P. Leal Moran 1 , M. Huertas Jimenez 2 , C. Romero 2 , A. Chavez RIos 2 , 

A. Haro Osnaya, R. De Paz Garcia, A. De la Torre, A. Macías Hernandez, 

S. Ponce de León Rosales 


Final Program ~ 91

Session 34 




ZOONOSES AND INFECTIONS IN ANIMALS 

34.001 Prevalence and associated risk factors of mastitis in lactating dairy cows 

N. Sharma, V. Pandey, J. S. Joodan 

Jammu (India) 


34.002 The clinico-pathological features associated with experimental concurrent PPR 

virus and Mannheimia hemolytica A: 2 infections in the West African dwarf goats 

B. O. Emikpe 

Ibadan (Nigeria) 

34.003 Ancylostoma spp. in sand of beaches of Navolato, Sinaloa, México 

M. C. Rubio Robles, S. M. Gaxiola C., N. Castro C. 

Culiacan, Sinaloa (Mexico) 

34.004 Arconobacterium pyogenes associated with pulmonary and submandibular 

lymph node abscessation in white tailed deer (Odocoileus virginiaus) 

R. Afifi 1 , J. M. Sleeman 2 , G.K. Saunders 3 , T. Kaur 3 

1 

Ismilia (Egypt), 2 Madison, WI (USA), 3 Blacksburg, VA (USA) 

34.005 Phylogenetic analysis of sporadic hepatitis E virus in Eastern China 

Y.-G. Xia 1 , Y.-T. Li 1 , Y.-H. Lu 1 , H. Ren 1 , F.-D. Wang 2 , J.-H. Yao 2 , 

Q.-W. Jiang 1 , Y.-J. Zheng 1 

1 

Shanghai (China), 2 Deqing County, Zhejiang (China) 

34.006 Molecular characterization of VP1-3 and NSP1-3 genes of porcine group A 

rotavirus G12 strain RU172: Evidence for porcine origin of human G12 strains 

S. Ghosh 1 , N. Kobayashi 1 , M. Ishino 1 , T. Naik 2 

1 

Sapporo, Hokkaido (Japan), 2 Bhubaneshwar, Orissa (India) 

34.007 Veterinary practitioners and the spread of infectious diseases 

S. T. Olodo-Atitebi 


34.008 Trypanosome infections in dogs from Chagas disease endemic regions in 

Panama, Central America 

V. J. Pineda Segundo 1 , I. Monfante 2 , N. L. Gottdenker 2 , A. Saldaña 1 , 

A. M. Santamaria 1 , S. Puga 1 , J. E. Calzada L. 1 

1 

Panama City, PAN (Panama), 2 Atlanta, US (USA) 

34.009 Molecular evidence of genetic diversity of Borrelia burgdorferi sensu lato 

detected in Ixodes granulatus ticks removed from rodents in Taiwan 

L.-L. Chao, C.-M. Shih 


92 ~ Final Program

Session 34 





34.010 Occurrence of Ureaplasma diversum in cows with various 

reproductive disorders 

P. Chandra, Y. Singh, D. Nand Garg 

Hisar (India) 

34.011 One health: Collaboration, recent research and developments in the 

global effort to eliminate Rabies 

R. Dedmon 1 , D. Briggs 2 , T. Lembo 3 , S. Cleaveland 3 

1 

Milwaukee, WI (USA), 2 Manhattan, KS (USA), 3 Glasgow (United Kingdom) 

34.012 Epizootiology of foot and mouth disease in Nepal 

R. Giri, P. Parshin 

Moscow (Russian Federation) 

34.013 The micro-adenomatous lesions associated with Lawsonia intracellularis 

in the pig intestine 

M. Sueyoshi, R. Uemura, H. Nagatomo 

Miyazaki (Japan) 


34.014 Emerging and zoonotic disease risk mitigation: Rabies prevention as a template 

for best practices 

C. Hanlon 1 , S. Moore 1 , R. J. Rudd 2 , S. J. Wong 2 

1 

Manhattan, KS (USA), 2 Albany, NY (USA) 

34.015 Identification and characterization of Shiga toxin-producing Escherichia coli 

(STEC) isolated from cattle, sheep and meat samples in Tehran Province, Iran 

F. Jafari 1 , M. Tajbakhsh 1 , S. Morabito 2 , M. Azimi Rad 1 , P. Torabi 1 , 

M. Arabshahi 1 , M. R. Zali 1 

1 

Tehran (Islamic Republic of Iran), 2 Rome (Italy) 

34.016 Brucellosis—Emerging zoonosis in Bosnia and Herzegovina 

S. Krkic Dautovic 1 , M. Hadzovic Cengic 1 , S. Mehanic 1 , S. Ahmetagic 2 , 

N. Ibrahimpasic 3 , E. Hadzic 4 , I. Curic 5 , N. Derviskadic 5 , J. Bajic 6 , J. Bojanic 6 

1 

Sarajevo (Bosnia and Herzegovina), 2 Tuzla (Bosnia and Herzegovina), 

3 

Bihac (Bosnia and Herzegovina), 4 Zenica (Bosnia and Herzegovina), 

5 

Mostar (Bosnia and Herzegovina), 6 Banja Luka (Bosnia and Herzegovina) 

34.017 Prevalence ectoparasites in dogs of beaches and fields fishing of 

Navolato, Sinaloa, Mèxico 

M. C. Rubio Robles, S. M. Gaxiola Camacho, N. Castro del C., J. Gaxiola M. 

Culiacan (Mexico) 

Final Program ~ 93

Session 34 





34.018 Phenotypical and genotypical traits of Listeria monocytogens strains isolated 

from tonsils of wild boars hunted in Switzerland 

S. Wacheck 1 , N. Giezendanner 2 , M. König 3 , M. Fredriksson-Ahomaa 1 , 

R. Stephan 2 

1 

Oberschleißheim (Germany), 2 Zurich (Switzerland), 3 Geneva (Switzerland) 


34.019 The “One Health” Initiative: Using open source data for disease surveillance 

M. Greene 

McLean, VA (USA) 

34.020 Assessment of Brucella melitensis disease burden in lactating goats 

in Mizque, Bolivia 

J. A. Zambriski 1 , M. Saito 2 , D. V. Nydam 1 , H. A. Reyes-Garay 2 , R. Castillo 2 , 

D. Cepeda 2 , M. J. Cespedes-Zambrano 2 , P. Garcia-Vara 2 , R. C. Maves 2 , 

M. Solano 3 , F. Torrico 3 , R. H. Gilman 4 

1 

Ithaca, NY (USA), 2 Lima (Peru), 3 Cochabamba (Bolivia), 4 Baltimore, MD (USA) 

34.021 Analysis of circulation influenza virus A on the Chany Lake (Novosibirsk region, 

Russia) in 2008 

M. Sivay, S. Sayfutdinova, M. Kulak 

Koltsovo (Russian Federation) 

34.022 Epidemiological study on infectious bovine rhinotracheitis in cattle 

Y. Alomar, Y. AlYasino 

Hama (Syrian Arab Republic) 

34.023 Clinical manifestations of leptospirosis 

M. Fabri, I. fabri 

Novi Sad (Serbia) 

34.024 Epidemiology of avian influenza viruses in wild birds in Mongolia 

E.-O. Tseren-Ochir 1 , B. Damdinjav 1 , T. Sharkhuu 1 , H. M. Kang 2 , Y. Sakoda 3 , 

B. Purevsuren 1 , S. Ruuragchaa 1 , Y. J. Lee 2 , H. Kida 3 , B. Khishgee 1 , S. Sengee 1 

1 

Ulaanbaatar (Mongolia), 2 Anyang-city (Republic of Korea), 3 Sapporo (Japan) 

34.025 Virological studies on migratory penguins captured in Brazilian southeast coast 

L. A. Fornells Arentz 1 , I. BIANCHI 2 , C. E. P. F. Travassos 2 , M. H. T. Liberal 3 , 

C. D. M. Andrade 1 , J. N. S. S. Couceiro 1 

1 

Cidade Universitária (Brazil), 2 Campos dos Goytacazes (Brazil), 

3 

Niteroi (Brazil) 

94 ~ Final Program

Session 34 





34.026 Poultry farmers’ response to AI outbreak and its control in Indonesia 

E. Basuno, Y. Yusdja, N. Ilham 

West Java (Indonesia) 

34.027 Cluster of MRSA in cats and staff of a veterinary clinic: 

Follow-up and possible implications for control 

A. M. Tjon-A-Tsien 1 , M. C. Vos 1 , E. V. Duijkeren 2 , W. J. Wannet 3 , H. M. Gotz 1 , 

W. Schop 1 , J. H. Richardus 1 

1 

Rotterdam (Netherlands), 2 Utrecht (Netherlands), 3 Bilthoven (Netherlands) 

34.028 An exploration of the knowledge, attitudes and perceptions of the local, adult, 

non-medically trained Grenadian population about certain zoonotic diseases 

S. Bidaisee 

St. George’s (Grenada) 

34.029 Leishmaniasis in Albania 

S. Bino 



34.030 Prevalence of HPAI in live-bird markets in the Jabodatabek region of west Java, 

Indonesia in 2009 

C. Lockhart, E. Wuryaninggsih, E. Brum, P. R. Barrios 

Jakarta (Indonesia) 

34.031 Ancylostoma spp. on beaches of Elota, Sinaloa, México 

M. C. Rubio Robles, S. M. Gaxiola Camacho, N. Castro del Campo 

Culiacan (Mexico) 

34.032 Characterization of Venezuelan field strains of EEEV by RT-PCR and SSCP 

V. M. Bermudez G., M. C. Gonzalez, J. M. Ruíz, J. Rivero, F. Herrera 

Maracay (Venezuela) 

34.033 Discovery of reverse zoonotic transmission of pandemic H1N1 influenza virus 

infection in cats following the initiation of a real time sero-molecular 

epidemiological study 

J. Trujillo 1 , B. Sponseller 1 , A. Jergens 1 , T. Pearce 1 , E. Strait 1 , K. Harmon 1 , 

S. Ramamoorthy 1 , C. Prior 2 , A. West 3 , P. Nara 1 

1 

Ames, IA (USA), 2 Park City, UT (USA), 3 Park City, Ut (USA) 

Final Program ~ 95


Room Jasmine ~ Terrace Level Thursday, March 11, 2010 




Choosing between second line ARVs 

P. Cahn 




Room Orchid B/C/D ~ Terrace Level Thursday, March 11, 2010 Travel Medicine Track 




G. Dickinson 


THURSDAY • March 11, 2010 

Final Program ~ 97

Session 35 


Ballroom 1/2/3 ~ Terrace Level Thursday, March 11, 2010 Plenary 


CME 

PLENARY LECTURE V 

Chair: Raúl ISTÚRIZ, Venezuela 

RICHARD K. ROOT MEMORIAL LECTURE 

35.001 Transmission and prevention of transmission of HIV: 

Clues from the early 21st century 

M. Cohen 

Chapel Hill, NC (USA) 


98 ~ Final Program

Session 36 


Ballroom 1: Brickell ~ Terrace Level Thursday, March 11, 2010 Symposium 


STRATEGIES FOR EXPANDING GLOBAL IMPACT OF IMMUNIZATION PROGRAMS 

Chair: Roberto DEBBAG, Argentina 

Dengue sub-symposium: 

Dengue: The next vaccine preventable disease 

36.001 Growing burden of dengue in Latin America: A new public health challenge 

J. Mendez-Galvan 


36.002 Clinical development of a tetravalent dengue vaccine for endemic areas 

M. Saville 

Marcy L’Etoile (France) 

Pertussis sub-symposium: 

Measuring and preventing Pertussis: How good are your programs? 

36.003 Pertussis surveillance and testing: Recommendations from the GPI 

C. H. Wirsing von König 

Krefeld (Germany) 

36.004 Adolescent and adult Pertussis vaccination programs: 

Are they having an impact? 

T. Tan 


Supported by an educational grant from 



Final Program ~ 99

Session 37 


Ballroom 2: Flagler/Monroe ~ Terrace Level Thursday, March 11, 2010 Symposium 


INFECTIOUS DISEASE AND VACCINES DEVELOPMENT 

Chair: Stanley PLOTKIN, USA 

37.001 Meningococcal epidemiology in Latin America 

E. Berezin 


37.002 Tick-borne encephalitis: Clinical development of vaccines 

for children and adults 

E. M. Pöllabauer 

Vienna (Austria) 

37.003 Strategies for the development of new vaccines 

S. Plotkin 

Doylestown, PA (USA) 

37.004 New technology update: Cell culture derived seasonal and 

pandemic fluvaccine 

H. Ehrlich 

Vienna (Austria) 


Supported by an educational grant from 

Baxter 

100 ~ Final Program

Session 38 


Ballroom 3: Tuttle ~ Terrace Level Thursday, March 11, 2010 Symposium 


CME 

THE ILL RETURNEE FROM LATIN AMERICA 

Co-Chairs: Jeannette DABANCH PENA, Chile 

Patricia WALKER, USA 

38.001 Febrile illnesses 

I. Tellez 


38.002 Cutaneous diseases in returnee travelers from Latin America 

C. Perret 


38.003 Non-enteric helminths including cysticercosis 

R. Istúriz 


38.004 Risks of getting HIV infections and STIs when traveling to Latin America 

G. Lopardo 



Final Program ~ 101

Session 39 


Room Jasmine ~ Terrace Level Thursday, March 11, 2010 Symposium 


CME 

NEGLECTED TROPICAL DISEASES: PRESENT NEED AND PRESENT ACTION 

Co-Chairs: Mirta ROSES PERIAGO, USA 

Raúl ISTURIZ, Venezuela 

39.001 The WHO global plan to map and combat neglected tropical diseases 

L. Savioli 


39.002 Neglected tropical diseases in Latin America and the Caribbean: 

Prospects for control and elimination 

S. Ault 


39.003 Chagas disease research: Advances and needs 

Z. Yadon 

Washington DC, DC (USA) 

39.004 Integrated control of neglected tropical diseases in Africa 

M. J. Bockarie 

Liverpool (United Kingdom) 




102 ~ Final Program

Session 40 


Room Orchid B/C/D ~ Terrace Level Thursday, March 11, 2010 Oral Presentations 


VIRAL DISEASES 

Co-Chairs: Thomas YUILL, USA 

Radha Kanta RATHO, India 

40.001 Unusual clinical profile of Dengue infection in patients attending a 

tertiary care teaching hospital in north India 

J. Agarwal, G. Kapoor, S. Srivastava, K. P. Singh, R. Kumar, A. Jain 

Lucknow (India) 

40.002 An outbreak of pneumonia associated with emergent human adenovirus 

serotype 14—Southeast Alaska, 2008 

D. Esposito 1 , T. J. Gardner 2 , E. Schneider 1 , L. J. Stockman 1 , J. Tate 1 , 

C. A. Panozzo 1 , C. L. Robbins 1 , S. A. Jenkerson 2 , L. Thomas 3 , C. M. Watson 4 , 

A. Curns 1 , D. D. Erdman 1 , X. Lu 1 , T. Cromeans 1 , M. Westcott 5 , C. Humphries 5 , 

J. Ballantyne 5 , G. E. Fischer 1 , J. B. McLaughlin 2 , G. Armstrong 1 , L. J. Anderson 1 

1 

Atlanta, GA (USA), 2 Anchorage, AK (USA), 3 Klawock, AK (USA), 

4 

Craig, AK (USA), 5 Fairbanks, AK (USA) 

40.003 Uptake and impact of Rotavirus vaccines in US Children 

J. Cortes, D. Esposito, M. Cortese, D. Bartlett, J. Tate, D. Payne, M. Patel, 

A. Curns, J. Gentsch, U. Parashar 


40.004 The epidemiology of rotavirus disease among children

Session 40 




VIRAL DISEASES 

40.008 Risk of being seropositive for multiple HPV types among Finnish 

and Ugandan women 

P. B. Namujju 1 , H.-M. Surcel 1 , P. Koskela 1 , E. K. Mbidde 2 , M. Muwanga 2 , 

R. Byaruhanga 3 , C. Banura 3 , M. Kaasila 1 , R. Kirnbauer 4 , M. Lehtinen 5 

1 

Oulu (Finland), 2 Entebbe (Uganda), 3 Kampala (Uganda), 4 Vienna (Austria), 

5 

Tampere (Finland) 

40.009 A phase 3 study of a short, two dose regimen of an investigational 

Hepatitis B vaccine 

J. Martin 1 , S. Halperin 2 , F. Diaz-Mitoma 3 

1 

Berkeley, CA (USA), 2 Halifax, NS (Canada), 3 Ottowa, ON (Canada) 


104 ~ Final Program

Session 41 


South Hall ~ Lobby Level Thursday, March 11, 2010 Symposium 


CME 

CARBAPENEMASE-PRODUCING BACTERIA: THE THREAT OF ‘PANRESISTANCE’ 

Co-Chairs: Daniel LEW, Switzerland 

Po-Ren HSUEH, Taiwan 

41.001 Detecting carbapenemase producers in the clinic 

C. Giske 

Stockholm (Sweden) 

41.002 Clinical impact and current epidemiology of carbapenemase producers 

K. Thomson 

Omaha, NE (USA) 

41.003 Controlling the spread of carbapenemase-producing bacteria 

M. Schwaber 

Tel Aviv (Israel) 

41.004 Treatment options for carbapenenam-resistant infections 

G. Daikos 

Athens (Greece) 


International Society of Chemotherapy (ISC) 


Final Program ~ 105

Session 42 


Ballroom 1/2/3 ~ Terrace Level Thursday, March 11, 2010 Plenary 


CME 

PLENARY LECTURE VI 

Chair: Keryn CHRISTIANSEN, Austalia 

42.001 Malaria eradication 

C. V. Plowe 

Baltimore, MD (USA) 


106 ~ Final Program

Session 43 


Ballroom 1: Brickell ~ Terrace Level Thursday, March 11, 2010 Symposium 


CME 

A RATIONAL APPROACH FOR THE TREATMENT AND PREVENTION OF NEONATAL SEPSIS 

Co-Chairs: Carla ODIO, Costa Rica 

Pablo SANCHEZ, USA 

43.001 Understanding the immune system of the neonate 

M. de la Morena 

Dallas, TX (USA) 

43.002 Global burden of neonatal sepsis 

E. K. Mulholland 


43.003 Rational use of antibiotics in the critically ill neonate and the premature infant 

C. Odio 

San Jose (Costa Rica) 

43.004 Strategies to limit infections in the neonate and to reduce 

infection-related mortality 

P. Sanchez 

Dallas, TX (USA) 


Latin American Society of Pediatric Infectious Diseases (SLIPE) 


Final Program ~ 107

Session 44 


Ballroom 2: Flagler/Monroe ~ Terrace Level Thursday, March 11, 2010 Symposium 


CME 

BACTERIAL INFECTIONS FOLLOWING INFLUENZA 

Co-Chairs: Keith KLUGMAN, USA 

Tracy HUSSELL, United Kingdom 

44.001 Secondary bacterial infections—The other side of influenza pathogenesis 

J. McCullers 

Memphis, TN (USA) 

44.002 The role of mucosal antiviral immunity in bacterial secondary lung infections 

D. Metzger 

Albany, NY (USA) 

44.003 Alteration of the innate immune rheostat and susceptibility to secondary 

bacterial super-infections 

T. Hussell 


44.004 Lessons from 1918 and the current H1N1 pandemic on the role of 

bacterial infections during pandemic influenza 

K. Klugman 





108 ~ Final Program

Session 45 


Ballroom 3: Tuttle ~ Terrace Level Thursday, March 11, 2010 Symposium 


CME 

TRAVELERS TO LATIN AMERICA WITH SPECIAL RISKS 

Co-Chairs: Jaime TORRES, Venezuela 

Phyllis KOZARSKY, USA 

45.001 High altitude itineraries 

M. Cabada 

Lima (Peru) 

45.002 Risks on common cruise itineraries 

A. Rísquez Parra 


45.003 Immunocompromised travelers 

E. Jong 

Seattle, WA (USA) 

45.004 Pregnant travelers 

D. Carroll 

Spring Lake, MI (USA) 


Final Program ~ 109

Session 46 


Room Jasmine ~ Terrace Level Thursday, March 11, 2010 Symposium 


CME 

INFECTIOUS DISEASES SURVEILLANCE SYSTEMS IN PRACTICE 

Co-Chairs: Larry MADOFF, USA 

Arnon SHIMSHONY, Israel 

46.001 ProMED and HealthMap: Collaboration to improve 

emerging disease surveillance 

L. Madoff, J. Brownstein 


46.002 Google flu trends: Mapping influenza in near real time 

C. Conrad 

San Francisco (USA) 

46.003 CaribVET: A model for surveillance of zoonotic diseases 

T. Lefrancois 

Petit Bourg (Guadeloupe) 

46.004 GeoSentinel: Provider-based Surveillance of International Travelers 

D. Freedman 

Birmingham, AL (USA) 


110 ~ Final Program

Session 47 




ADVANCES FROM THE LABORATORY 

Co-Chairs: Eric SUMMERS, USA 

Larry LUTWICK, USA 

47.001 Epidemiological description of infection with agents of the Rickettsia genus in 

rodents, ectoparasites and humans in the northern coast of Antioquia, Colombia 

J. C. Quintero Vélez 1 , A. Londoño 1 , V. Quiroz 1 , F. Díaz 1 , P. Agudelo 2 , 

M. Arboleda 2 , J. Rodas 1 

1 

Medellin (Colombia), 1 Sabaneta (Colombia) 

47.002 Distinct pathological signatures after lethal avian H5N1 and swine H1N1 

influenza infections suggest variable pathogenesis 

M.-M. Garigliany 1 , A. Habyarimana 2 , B. Lambrecht 2 , E. Van de Paar 1 , 

A. Cornet 1 , T. Van den Berg 2 , D. Desmecht 1 

1 

Liege (Belgium), 2 Brussels (Belgium) 

47.003 A novel nervous-to-immune signalling mechanism mediating innate 

responses to infections 

M. Bakhiet 1 , S. Taha 2 

1 

Bahrain (Bahrain), 2 Manama (Bahrain) 


47.004 Variable expression of alpha haemolysin and Panton Valentine leucocidin in 

clinical isolates of Staphylococcus aureus are linked to agr-dependent 

quorum sensing 

T. Sloan, R. O. Jensen, A. Cockayne, L. G. Durrant, P. Williams, R. James 

Nottingham (United Kingdom) 

47.005 HBs mutations related with YMDD mutation induced the expression 

of hfgl2 gene 

M. Han 1 , W. Li 1 , Y. Li 1 , D. Chen 1 , W. Yan 1 , X. Wang 1 , X. Luo 1 , Q. Ning 2 

1 

Wuhan (China), 2 Wuhan, Hubei (China) 

112 ~ Final Program

Session 47 




ADVANCES FROM THE LABORATORY 

47.006 Enteric virus detection and identification with a universal virus discovery assay 

C. Uhlenhaut, S. D. McClenahan, S. Sosnovtsev, K. Bok, A. Z. Kapikian, 

K. Y. Green, P. R. Krause 


47.007 Gene expression profilling of mouse host response to 

Candida tropicalis infection 

P. P. Chong 1 , V.-C. P. Yong 1 , H. F. Seow 2 , R. Rosli 1 

1 

Selangor (Malaysia), 2 Melbourne (Australia) 

47.008 Cytokines in experimental leptospirosis: Association with severe disease and 

postimmunization immune response 

A. Chagas-Junior, D. Athanazio, J. Macedo, M. Menezes, M. Reis, 

F. McBride, A. McBride 

Salvador (Brazil) 

47.009 Prevalence of genes responsible for resistance to antimicrobials in 

surface water Escherichia coli isolates 

G. Singh, P. Vajpayee, R. Shanker 


47.010 E-gene variation with reference to neurovirulence in the Indian clinical 

isolates of Japanese encephalitis virus 

S. K. Pujhari, S. Prabhakar, R. K. Ratho, M. Modi, M. Sharma, B. Mishra 



Final Program ~ 113

Session 48 


Riverfront Hall ~ Lobby Level Thursday, March 11, 2010 Poster Presentations 


ANTIBIOTICS: MECHANISMS AND SPECTRUM 

48.001 Antimycobacterial activity of pyrimido[4,5-b]diazepine derivatives 

J. G. Bueno Sánchez 1 , A. Garcia 2 , B. Insuasty 2 , J. Quiroga 2 

1 

Bogotá (Colombia), 2 Cali (Colombia) 

48.002 Five-year trend of antimicrobial susceptibility rates and daptomycin activity 

among Staphylococcus aureus isolates collected in Latin American medical 

centers (2005–2009) 

D. J. Biedenbach, R. N. Jones, H. Sader 

North Liberty, IA (USA) 

48.003 In vitro activity of new compound YF-13-1 against gram-postive and 

gram-negative bacteria strains of clinical isolates in chain 

S. Zhang, Y. Liu 

Chengdu (China) 

48.004 10-hydroxy-2-decenoic acid induce dispersion of 

Streptococcus mutans biofilms 

A. Shoae Hassani, N. Ordouzadeh 

Fars (Islamic Republic of Iran) 


48.005 In vitro activity of biapenem against Burkholderia pseudomallei 

V. Thamlikitkul, S. Trakulsomboon 


48.006 Role of Efflux pumps in the development of quinolone-resistance in Peruvian 

Escherichia coli isolates 

S. Mosquito 1 , M. J. Pons 2 , T. J. Ochoa 1 , R. C. Maves 1 , J. Ruiz 2 

1 

Lima (Peru), 2 Barcelona (Spain) 

114 ~ Final Program

Session 49 




ANTIBIOTICS: PHARMACOLOGY AND CLINICAL STUDIES 

49.001 A murine gastritis model to study antibacterial effect of Camellia sinensis 

(Green Tea) against H.pylori infection 

S. Sherwani, F. Aziz, T. Siddiqui, S. Akhter, W. Ahmed, S. S. U. K. Kazmi 

Karachi (Pakistan) 

49.002 Various dosages of linezolid in treatment of difficult 

multidrug-resistant tuberculosis 

W. W. Yew 


49.003 Intravaginal pentamycin for the treatment of bacterial vaginosis 

C. Winnips 1 , J. A. Balmer 2 

1 

Basel (Switzerland), 2 Spiez (Switzerland) 

49.004 Intravenous colistin therapy for infections caused by multidrug-resistant 

gram-negative bacteria in critically ill patients 

M. Cusato 

Pavia (Italy) 

49.005 Pharmacodynamic profiling of intravenous antibiotics against gram-negative 

bacteria collected during the Tracking Resistance in the United States Today 

(TRUST) surveillance program 

P. Koomanachai, D. P. Nicolau, J. L. Kuti, C. C. Bulik 

Hartford, CT (USA) 

49.006 Oral Cefixime is beneficial in acute uncomplicated Salmonella gastroenteritis in 

children with mucoid or bloody diarrhea—Do indications of antibiotics therapy 

need reassessment? 

H.-Y. Lee 1 , T.-Y. Lin 2 , C.-T. Wu 1 , C.-H. Chiu 1 , Y.-C. Huang 1 

1 

Kweishan, Taoyuan (Taiwan, R.O.C.), 2 Linkou (Taiwan, R.O.C.) 

49.007 Evaluation of the pharmacodynamics of Daptomycin (DAP)-Rifampin (RIF) 

combinations with Staphylococcus aureus using various in vitro methods 

S. Zinner 1 , M. Smirnova 2 , E. Strukova 2 , A. Firsov 2 

1 

Boston, MA (USA), 2 Moscow (Russian Federation) 


49.008 The effectiveness of oral suppression in high risk prosthetic joint infections 

after total knee arthroplasty 

M. McBroom, D. J. Barbaro 

Fort Worth, TX (USA) 

49.009 Population pharmacokinetics of meropenem in pediatric patients: a concurrent 

analysis of the plasma and urine concentration data 

K. Ikawa, N. Morikawa, K. Ikeda, M. Miki, M. Kobayashi 

Hiroshima (Japan) 

Final Program ~ 115

Session 50 




ANTIBIOTICS: USAGE AND STEWARDSHIP 

50.001 Appropriate use of fluoroquinolones in a Lebanese tertiary medical center 

W. Kabbara, P. Rahbany, S. Al-Natour 

Byblos (Lebanon) 

50.002 Impact of restriction policy as part of an antimicrobial stewardship program in a 

university hospital of a developing country 

P. Titanti, V. Berdiñas, J. Ramos, L. Manevich, L. Barcelona, P. Rios, G. Lopardo 


50.003 Utilization of activated protein C (Xigris) in a large teaching hospital— 

Possible overuse and complications 

M. R. Wallace, C. Arinyedokiari, B. Dattani 

Orlando, FL (USA) 

50.004 Antimicrobial prophylaxis for transrectal ultrasound guided biopsy of prostate: 

A comparative study between single dose of Gentamicin vs. Ofloxacin 

B. Chazan, G. Zelichenko, Y. Shental, H. Edelstein, R. Raz 

Afula (Israel) 


50.005 Reducing inappropriate antibiotic usage and costs in an academic 

Hematology-Oncology unit via antimicrobial stewardship 

C. L. Yeo, T. S. Wu, R. Lim, P. A. Tambyah, L. Y. Hsu 


50.006 Tigecycline usage in osteomielitis caused by multidrug-resistent acinetobacter: 

A report of 10 cases from a single institution 

N. M. Ruiz, E. Gayoso, Y. Vasquez 

Caracas, DC (Venezuela) 

116 ~ Final Program

Session 51 




EPIDEMIOLOGY OF PATHOGENS 

51.001 Tetanus immunity among intravenous drug users in Uppsala County, Sweden 

S. Sylvan 

Uppsala (Sweden) 

51.002 Three-year surveillance of community-acquired and health care-associated 

Methicillin-Resistant staphylococcus aureus infections in Uppsala County, Sweden 

S. Sylvan, B. Christenson, B. Ardung 


51.003 One-year epidemiology of febrile diseases on the Emergency Department of a 

Caribbean island: The Curaçao-experience 

M. Limper 1 , I. Gerstenbluth 2 , A. Duits 2 , E. Van Gorp 1 

1 

Amsterdam (Netherlands), 2 Curacao (Netherlands) 

51.004 Transmission risk and predictability of invasive meningococcal disease 

V. Racloz 1 , L. Da Silva 2 

1 

Basel (Switzerland), 2 Cambridge, MA (USA) 

51.005 Hospitalizations due to pneumonia and case-fatality rates in Brazil 

between 2003 and 2007 

J. Cássio de Moraes 1 , E. Berezin 1 , J. Markowitz 2 , T. Hong 3 , P. Seljan 3 

1 

São Paulo SP (Brazil), 2 Princeton, NJ (USA), 3 Collegeville, PA (USA) 

51.006 Meningococcal meningitis epidemic in Arua district North West of Uganda 

M. Busuulwa 


51.007 The study of epidemiological data of the mumps and the effect of MMR vaccine 

in the Albanian children 

H. Hoxha, A. Simaku, E. Kallfa-Foto, G. Lito, R. Petrela, E. Thartori 



51.008 Pertussis in Brazil: An overview from 1988 to 2009 

D. Leite, L. C. V. Melo, T. M. I. Vaz, K. Irino 


51.009 Serogroup B epidemiology in the southern cone of South America. 

A literature review 

L. Da Silva, M. H. Kyaw 


Final Program ~ 117

Session 51 





51.010 Status of bloodborne pathogen education for injection drug users in Indiana 

hospital emergency departments 

M. Wenger 

Indianapolis, IN (USA) 

51.011 Neighborhood urban environmental quality conditions probably drive malaria 

and diarrhea mortality in Accra, Ghana 

J. Fobil 1 , J. Fobil 2 , A. Kraemer 3 , J. May 1 

1 

Hamburg (Germany), 2 Legon, Accra (Ghana), 3 Bielefeld (Germany) 

51.012 Incidence of hospital- and ICU-admitted community-acquired pneumonia: A 

population-based study in Uruguay 

D. Goleniuk 1 , H. Albornoz 2 

1 

Rivera (Uruguay), 2 Montevideo (Uruguay) 

51.013 The Survey of leptospirosis in Mazandaran province, north of Iran by 

Microscopic agglutination test, 2006–2007 

S. P. Ziapour 1 , B. Esfandiari 1 , G. Abdollahpour 2 , M. Assmar 3 , M. R. Youssefi 4 , 

G. Amirbozorgi 1 , B. Amini Navaie 1 , S. Sattari Tabrizi 2 , M. Alipour Espeh-kolaie 4 

1 

Amol (Islamic Republic of Iran), 2 Karaj (Islamic Republic of Iran), 

3 

Tehran (Islamic Republic of Iran), 4 Babol (Islamic Republic of Iran) 


51.014 Incidence of mycobacteria and fungi in clinically suspected urinary tract 

infection of immunocompromised patients—A tertiary care hospital study 

S. Jain, V. Nag, R. S. K. Marak, N. Prasad, T. Dhole 


51.015 Molecular analysis and risk factors for nasal colonization with 

methicillin-resistant Staphylococcus aureus among community individuals 

attending a Family Health Care Program in Rio de Janeiro, Brazil 

T. Miranda, T. Brust, N. H. T. Miyazaki, H. Kang, L. Isaias, O. Fernandes, 

F. Aguiar-Alves 


51.016 The prevalence of Staphylococcus aureus nasal colonization among Korean 

children attending day care centers 

J.-H. Lee 1 , Y. M. Kim 2 , E. Y. Cho 1 , K. B. Hong 1 , J. Lee 1 , E. H. Choi 1 , H. J. Lee 1 

1 

Seoul (Republic of Korea), 2 Ulsan (Republic of Korea) 

51.017 Leptospirosis: analysis of the notification records and investigation on the year 

of 2007, of the municipal district of Salvador-Bahia-Brazil, 2009 

S. Cerqueira, J. F. Silva 

Salvador, Bahia (Brazil) 

118 ~ Final Program

Session 51 





51.018 Lassa fever awareness and practices in a nigerian rural community 

D. Asogun 1 , P. Okokhere 1 , S. Okogbenin 1 , G. Akpede 1 , S. Gunther 2 , C. Happi 3 

1 

Irrua, Edo (Nigeria), 2 Hamburg (Germany), 3 Ibadan (Nigeria) 

51.019 Serological update of the Chikungunya epidemic outbreak in Italy 

P. Gaibani, A. Pierro, F. CAVRINI, G. Rossini, M. P. Landini, C. Manisera, 

V. Sambri 


51.020 Sero-prevalence of West Nile virus in north-eastern Italy 

A. Pierro 1 , P. Gaibani 1 , F. CAVRINI 2 , C. Manisera 1 , G. Rossini 1 , M. P. Landini, 

V. Sambri 


51.021 A retrospective laboratory analysis of clinically diagnosed Lassa fever cases in a 

tertiary hospital in Nigeria 

D. Ehichioya 1 , D. Asogun 2 , M. Hass 3 , B. Becker-Ziaja 3 , S. Gunther 3 , S. Omilabu 1 

1 

Lagos (Nigeria), 2 Irrua, Edo (Nigeria), 3 Hamburg (Germany) 

51.022 Syphilis among young women: a population based survey in central Brazil 

F. L. B. Garcia 1 , M. Turchi 2 , E. M. B. Guimaraes 2 , N. Carvalho 2 , C. T. Ribeiro 2 , 

M. N. G. Reis 2 , M. F. C. Alves 2 

1 

Brasilia (Brazil), 2 Goiania (Brazil) 

51.023 Clinical features of Plasmodium malariae in Venezuela 

L. Villegas 1 , M. E. Guevara 2 , N. Hernandez 2 , V. Pacheco 2 , C. Fuenmayor 2 , 

B. Salazar 2 , M. Giron 2 , M. Pacheco 2 , J. Moreno 2 

1 

Paramaribo (Suriname), 2 Tumeremo (Venezuela) 

51.024 Severe malaria surveillance and treatment delays in Canada 

C. Prematunga, A. McCarthy 



51.025 Leptospirosis in Mazandaran province, northern Iran, 2008–2009 

B. Esfandiari 1 , S. P. Ziapour 1 , M. Assmar 2 , M. R. Youssefi 3 , G. Amirbozorgi 1 , 

B. Amini Navaie 1 , Z. Farzaneh-nejad 2 , M. Alipour Espeh-Kolaie 3 

1 

Amol (Islamic Republic of Iran), 2 Tehran (Islamic Republic of Iran), 

3 

Babol (Islamic Republic of Iran) 

51.026 Epidemiologic comparison of Human Brucella suis and 

Brucella melitensis infections 

D. Stanek 1 , P. Nicoletti 2 , D. Harrell 2 , G. churchwell 3 , P. Lee 3 , C. Blackmore 1 

1 

Tallahassee, FL (USA), 2 Gainesville, FL (USA), 3 Jacksonville, FL (USA) 

Final Program ~ 119

Session 52 




GRAM-NEGATIVE BACTERIAL INFECTIONS 

52.001 Shigellosis in Central American countries 

R. Achí, K. Barrantes 


52.002 Detection and molecular characterization of verotoxin gene in non-O157 

diarrheagenic Escherichia coli isolated from Miri hospital, Sarawak, Malaysia 

M. N. H. Maziz 1 , S. ismail 2 , H. Jamal 2 , A. Ansary 2 

1 

Shah Alam (Malaysia), 2 Kuala Lumpur (Malaysia) 

52.003 Isolation and characteristic distribution pattern of cagA+ Helicobacter pylori in 

dental plaque of dyspeptic patients 

M. Karbalayi, S. Khodadad 


52.004 Multiresistant Acinetobacter spp in a burn unit in Argentina 

M. T. Rosanova, G. Mudryck, A. Monaco, H. Lopardo, M. Villasboas, G. Berberian 



52.005 Investigation of Helicobacter pylori in dyspeptic patients and its relationship 

with Iranian life style 

L. Shokrzadeh, K. Baghaei, D. Mirsattari, R. Mashayekhi, H. Zojaji, M. R. Zali 


52.006 Cytokine profile in patients with severe gram negative sepsis 

S. Jain, S. Agrawal, V. Dhawan, N. Sharma, S. Varma 


52.007 Burkholderia pseudomallei musculoskeletal infections (Melioidosis) in India: 

Are the orthopaedic surgeons aware? 

V. Pandey, S. Rao, K. K. V. Acharya 

Manipal (India) 

52.008 Spectrum of hepatic dysfunction in enteric fever 

S. Bhatia 1 , M. Prabhu 2 , K. Saravu 1 , M. Docherla 1 , B. Shastry 1 

1 

Karnataka (India), 2 Manipal (India) 

52.009 Verotoxin gene in non-O157 diarrheagenic Escherichia coli 

can be plasmid-mediated 

M. N. H. Maziz 

Shah Alam (Malaysia) 

120 ~ Final Program

Session 52 





52.010 Vertebral column damage due to brucellosis 

K. Leka 

Tirana, (Albania) 

52.011 Carbapenem-resistant Enterobacteriaceae in a tertiary care cancer hospital 

S. Biswas 

Mumbai (India) 

52.012 Infections due to Haemophilus influenzae encountered in Jamaica: 

Analysis of 286 cases at the University Hospital of the West Indies 

N. Bodonaik, R. Willis, L. Rainford 

Kingston (Jamaica) 

52.013 Incidence of human Brucellosis in Gevgelia region, Macedonia 

G. Petkov 1 , Z. MIlenkovic 2 , M. Toshev 3 

1 

Gevgelia (Macedonia), 2 Scopje (Macedonia), 3 Negotino (Macedonia) 

52.014 Risk factors for death amongst children of five years and younger, with invasive 

non-typhoidal Salmonella infection, 2004 – 2008, South Africa 

V. Dermaux, A. Sooka, S. Meiring, N. Govender, J. Moyes, C. Cohen, K. Keddy 

Sandringham (South Africa) 

52.015 Changes in the epidemiology of Haemophilus influenzae invasive disease, in 

Portugal, after the introduction of the Hib vaccine 

M. P. Bajanca-Lavado, C. Betencourt 

Lisbon (Portugal) 

52.016 Analysis of clinical outcome in patients with multidrug-resistant 

Acinetobacter baumannii bacteremia 

M. W. Kang, Y. J. Kim, K.-W. Hong, S. I. Kim, Y. R. Kim, Y.-J. park 



52.017 Clinical profile and antimicrobial resistance pattern of Enteroaggregative E.coli 

isolated from patients with diarrhoea, using a multiplex PCR assay in a tertiary 

care hospital in North India 

S. Pahil, N. Taneja, G. Singh, M. Sharma 


Final Program ~ 121

Session 52 





52.018 Phenotypic and molecular characterization of Pseudomonas aeruginosa 

isolates expressing high-level betalactamic resistance in cystic fibrosis patients 

M. D. C. Batlle, J. Ayala 

Havana (Cuba) 

52.019 Epigenetic regulation of lymphocytes response to LPS 

E. Melo, M. Camargo, R. Curi, I. Velasco, F. Soriano 


52.020 Clinical and phylogenetic characteristics of Escherichia coli urinary tract infections 

S. Y. Lee, J. H. Kim, J. K. Hur, J. H. Kang 


52.021 Serogroup W135 meningococcal invasive disease in Argentina 

M. R. Agosti 1 , C. Vescina 1 , J. C. Morales 1 , R. S. Oderiz 1 , M. M. Greco 1 , 

D. M. Cecchini 2 , S. E. González Ayala 1 

1 

La Plata (Argentina), 2 Buenos Aires (Argentina) 


52.022 Salmonella prosthetic joint infections: An uncommon entity 

R. GUPTA, S. M. Boger, L. R. Leddy, H. D. Schutte, C. E. Marculescu, 

H. A. Demos 

Charleston, SC (USA) 

52.023 Genetic analysis by pulsed-field gel electrophoresis of Enteropathogenic 

Escherichia coli (EPEC) strains isolated from Peruvian children 

C. A. Contreras 1 , J. Ruiz 2 , C. F. Lanata 1 , T. G. Cleary 3 , T. J. Ochoa 1 

1 

Lima (Peru), 2 Barcelona (Spain), 3 Houston, TX (USA) 

52.024 Antibody subclasses as a tool for Helicobacter pylori antigen characterization 

F. Martine, G. Castillo Rojas 2 , Y. López 


122 ~ Final Program

Session 53 




HEPATITIS 

53.001 Age-specific seroprevalence of hepatitis A in SARI (northern part of IRAN) 

R. Ghasemian, S. Alian 

Sari (Islamic Republic of Iran) 

53.002 Association of polymorphism of HLA-DRB1 13 and HLA-A 33 alleles with 

outcome of hepatitis B virus infection 

A. Ramezani, A. Aghakhani, E. Kalantar, A. Eslamifar, M. Banifazl 


53.003 Hepatitis A epidemiology in a Brazilian fire department 

D. Borghi, R. P. Igreja, M. D. Canetti, R. C. Vasconcellos, C. L. Vitral, 

D. R. L. Santos 


53.004 Association of exon 9 but not intron 8 VDR polymorphisms with occult 

HBV infection in south-eastern Iranian patients 

G. Hassanshahiraviz 

Rafsanjan (Islamic Republic of Iran) 

53.005 IL-12 +1188 and IFN-g +874 polymorphisms is not associated with these 

cytokines serum level in occult HBV infected patients 

H. Abousaidi 


53.006 Occult hepatitis B virus infection in ART-naive HIV-infected Indian patients 

S. Singh 


53.007 Treatment of chronic hepatitis C: The efficacy and predictors of response 

to therapy 

M. Bozic 

Belgrade (Serbia) 


53.008 Occult hepatitis C virus infection among chronic liver disease patients in the 

United Arab Emirates 

M. Al-Moslih 

Sharjah (United Arab Emirates) 

53.009 Clinical features of acute viral hepatitis A complicated with acute renal failure 

H. Choi, B. S. Chin, S. Y. Shin, S. J. Jin, Y. T. Chae, S. H. Han, J.-H. Baek, 

J. Y. Choi, C. O. Kim, J. M. Kim 


Final Program ~ 123

Session 53 




HEPATITIS 

53.010 Prevalence of isolated hepatitis B core antibody among injection drug users in 

Central Province of Iran 

M. Sofian 1 , A. Rostampour 1 , N. Izadi 1 , F. S. Mahdaviani 1 , A. A. Farazi 1 , 

A. Ramezani 2 , N. Zarinfar 1 , H. Sarmadian 1 , A. Aghakhani 2 , M. Banifazl 2 

1 

Arak (Islamic Republic of Iran), 2 Tehran (Islamic Republic of Iran) 

53.011 Persistence of protective antibodies against Hepatitis B virus among vaccinated 

health workers, Al-Hussein Hospital, Salt, Jordan, 2008 

S. Sheikh Ali, M. Jaghbir 

Amman (Jordan) 

53.012 Regional and ethnical aspects of viral hepatitis B in pregnant women in the 

Slovak Republic 

P. Kristian, I. Schreter, Z. Paralicova, P. Jarcuska, L. Siegfried, S. Porubcin 

Kosice (Slovak Republic) 


53.013 New approaches in in-vitro diagnosis of Hepatitis C infections: 

The diagnostic performance of new hepatitis C virus core antigen detection test 

B. Kocazeybek, P. Yuksel, S. Saribas, R. Caliskan, S. Ergin, M. Aslan, 

A. Yalcıner, M. M. Torun 


53.014 No detected hepatitis B virus-DNA in thalassemic patients infected by 

hepatitis C virus in Kerman province of Iran 

G. Hassanshahiraviz 


53.015 Genotypes and reverse transcriptase variability in asymptomatic chronic 

hepatitis B virus 

M. Basaras, E. Arrese, S. Blanco, P. Ruiz, R. Cisterna 

Bilbao (Spain) 

53.016 Antiviral treatment with interferon alpha and ribavirin influences serum markers 

of liver fibrosis in children with chronic hepatitis C 

A. Mania, W. Sluzewski, P. Kemnitz, M. Figlerowicz, A. Kowala-Piaskowska 

Poznan (Poland) 

53.017 Incidence of HBeAg/anti-HBe and HBs/anti-HBs seroconversion after antiviral 

treatment in children with chronic hepatitis B 

P. Kemnitz, W. Sluzewski, A. Mania, M. Figlerowicz, A. Kowala-Piaskowska, 

M. Michalak 

Poznan (Poland) 

124 ~ Final Program

Session 53 




HEPATITIS 

53.018 Seroprevalence and associated risk factors of hepatitis B virus among street 

children in Isfahan, Iran (2005–2007) 

B. Ataei, Z. Nokhodian, A. Babak, P. Shoaei, N. Kassaian, M. Ataie 

Isfahan (Islamic Republic of Iran) 

53.019 Prevalence of HBeAg positive cases and abnormal aminotransferase tests in HBV 

chronic carriers in Kashan, Iran 

M. Momen Heravi 


53.020 Positive association of high risk behaviors and Hepatitis B infection 

A. Nejatizadeh, F. Abedi, A. Madani 

Bandar Abbas (Islamic Republic of Iran) 

53.021 Biodynamics of HCV infection in haemodialysis patients in Pahang 

M. Mustafa, M. S. Abdul Majid, H. A. Binti Hamzah, M. H. bin Hasmaini 

Kuantan (Malaysia) 

53.022 Runs test and linear trend test of the time series of primary hepatocellular 

carcinoma mortality in Haimen City, 1969–2007 

P.-X. Huang, H.-B. Lu, W.-Y. Lin 

Haimen (China) 

53.023 Predictive factors for sustained virological response in the treatment of patients 

with chronic hepatitis C 

N. Svirtlih, D. Delic, J. Simonovic, A. Radovanovic, N. Mitrovic, L. Nikitovic, 

E. Gvozdenovic, S. Zerjav, I. Boricic 

Belgrade (Serbia) 

53.024 Is there any association between chronic Hepatitis C virus and celiac disease? 

M. Rostami Nejad 1 , S. R. Mohebbi 1 , K. Rostami 2 , K. Cheraghipour 3 , M. R. Zali 1 

1 

Tehran (Islamic Republic of Iran), 2 Birmingham (United Kingdom), 

3 

Hamedan (Islamic Republic of Iran) 


53.025 Prevailing HCV genotypes and subtypes among HIV infected patients in Georgia 

M. Karchava, L. Sharvadze, L. Gatserelia, L. Dzigua, N. Dvali, T. Tsertsvadze 


53.026 Hepatitis B Virus (HBV) mutations during long-term therapy in chronic 

hepatitis B patients 

E. Arrese 1 , M. Basaras 2 , S. Blanco 2 , P. Ruiz 2 , R. Cisterna 2 

1 

Vitoria-Gasteiz (Spain), 2 Bilbao (Spain) 

Final Program ~ 125

Session 53 




HEPATITIS 

53.027 Long term virological follow up of Hepatitis C (VHC) monoinfected patients who 

achieved end of treatment response (ETR) 

C. Vujacich, P. Rodriguez Iantorno, G. Vidiella, E. Poggi, P. Titanti, P. Canda, 

E. Sturba, D. Stamboulian 


53.028 Seroprevalence of hepatitis A among children and adolescent from south and 

southeast region of Brazil 

G. Figueiredo 1 , M. R. Cardoso 1 , R. Moreira 1 , L. Pereira 2 , U. Montarroyos 2 , 

C. Braga 2 , A. Stein 2 , G. Coral 2 , R. Ximenez 3 

1 

São Paulo (Brazil), 2 Recife (Brazil), 3 Porto Alegre (Brazil) 

53.029 Household survey of hepatitis B infection and risk factor assessment in the from 

South and Southeast region of Brazil 

G. Figueiredo 1 , R. Moreira 1 , L. Pereira 2 , M. R. Cardoso 1 , G. Coral 5 , A. Stein 5 , 

U. Montarroyos 1 , C. Braga 2 , R. Ximenez 2 

1 

São Paulo (Brazil), 2 Recife (Brazil), 3 Porto Alegre (Brazil) 


53.030 Age-dependent, differentiated prevalence of anti-HAV and anti-HBc antibodies 

among patients with chronic hepatits C (CHC): New aspect of future vaccination 

perspectives against hepatitis A Virus 

J. Bialkowska 1 , W. Mazur 2 , J. Slusarczyk 3 , M. Jablkowski 1 

1 

Lodz (Poland), 2 Katowice (Poland), 3 Warsaw (Poland) 

53.031 Ultrasonography changes of the liver of patients infected with hepatitis C met 

in the Foundation of Tropical Medicine of Amazonas 

J. R. D. T. Leao 1 , M. Brock 1 , R. A. C. Carvalho 1 , W. S. M. Braga 2 

1 

Manaus, AM (Brazil), 2 Amazonas (Brazil) 

53.032 Detection of acute HCV infection among different risk groups 

L. Gatserelia, L. Sharvadze, M. Karchava, N. Dvali, L. Dzigua, N. Badridze, 

T. Tsertsvadze 


53.033 Efficacy of 96 weeks adefovir dipivoxil treatment in HBeAg positive chronic 

hepatitis B patients with various baseline biochemical levels 

L. Zhuang, J. You, L. Kong, H. Lei, R.-D. Yang, X. Zhang, Q.-Q. Wang 

Kunming (China) 

126 ~ Final Program

Session 53 




HEPATITIS 

53.034 The relationship between HBV precore region mutation and the variation of 

T-lymphocyte subpopulations in chronic HBV-infected individuals with normal 

liver function tests 

J. You, Y.-H. Chen, H.-Y. Chen, H.-Q. Yang, R.-D. Yang, Y.-F. Zhang, J.-Y. Qu, 

L. Zhuang, Q.-Q. Wang, X. Zhang, B.-Z. Tang, J.-H. Huang 


53.035 Patterns of hepatitis A infection by Brazilian regions: 

Results of the national household survey 2004–2009 

R. Ximenes 1 , C.T. Martelli, E. Merchan-Hamman 2 , U. Montarroyos 1 , C. Braga 1 , 

R. Moreira 3 , G. M. Figueiredo 6 , M. R. Cardoso 3 , M. Turchi 4 , G. Coral 5 , A. Stein 5 , 

M. L. Lima 1 , M. Costa 2 , L. C. Arraes-Alencar 1 , D. Crespo 6 , A. Santos dos Santos 6 , 

L. Pereira 1 

1 

Recife (Brazil), 2 Brasilia (Brazil), 3 São Paulo, SP (Brazil), 4 Goiania (Brazil), 

5 

Porto Alegre (Brazil), 6 Belem (Brazil) 

53.036 Acute liver failure in the Colombian pediatric population: Retrospective and 

prospective studies 

A. Santamaria 1 , M. M. Contreras 1 , L. C. Rubiano 2 , R. Devivero 3 , 

F. Medina 4 , J. Mojica 5 

1 

Medellin (Colombia), 2 Cali (Colombia), 3 Cartagena (Colombia), 

4 

Bucaramanga (Colombia), 5 Bogotá (Colombia) 

53.037 Hepatitis B seroprevalence and associated factors in pregnant women and their 

couples in 6 Amazonian indigenous populations in Peru 2007–2008 

M. Ormaeche, A. Whittembury, L. Suarez-Ognio, M. Pun 

Lima (Peru) 

53.038 Performance of serologic assays specific to IgM antibodies against 

hepatitis E virus: Pan-genotypic evaluation 

J. Drobeniuc 1 , J. Meng 1 , G. Reuter 2 , N. Khudyakov 1 , N.-T. Le 1 , 

T. Greene-Montfort 1 , Z. Dimitrova 1 , S. Kamili 1 , C.-G. Teo 1 

1 

Atlanta, GA (USA), 2 Pecs (Hungary) 


Final Program ~ 127

Session 54 




HIV: PATHOGENESIS 

54.001 CC-chemokine Co-receptor R5 genotypes in Ghanaian couples discordant for 

human immunodeficiency type 1 infection 

Y. Affram 

Accra, NA (Ghana) 

54.002 Endothelial Progenitors Cells and Microparticles in HIV-infected patients 

E. F. R. Silva, F. A. H. Fonseca, C. N. Franca, P. R. Abrao, C. M. C. Monteiro, 

L. M. Camargo, R. Salomao, S. B. Tenore, D. S. Lewi 


54.003 Analysis of longitudinal nef sequence variation throughout HIV-2 infection 

M. Remedios, E. Paixao, H. Feliciano, A. Silva-Graca, E. Pádua 


54.004 Prediction of R5, X4 HIV-1 coreceptor usage based on physicochemical 

properties of envelope V3-loop using artificial neural network 

S. Falahi, M. Ravanshad, A. Kenarkoohi 



128 ~ Final Program

Session 55 




HIV: THERAPEUTICS 

55.001 Clinical and immunologic response of HIV patients on different ART regimens at 

Gondar University Hospital (GUH) 

D. Ergete 


55.002 Comparison of efavirenz and nevirapine based HAART regimens in 4187 

patients with up to 6 years of follow up, a prospective, open label 

observational study 

C. Cortes, C. Beltran, M. Wolff 


55.003 The economic impact of introducing HIV/AIDS guideline into Colombian 

National Drug Formulary. Cost-effectiveness analysis 

E. V. Lemos Luengas, B. C. Castañeda, E. Quevedo, C. Castillo, L. R. Lemos 


55.004 Prevalence of metabolic abnormalities and metabolic syndrome in a cohort of 

hispanic patients on HAART 

E. Bissio 1 , G. Lopardo 2 

1 


55.005 Medication errors in patients receiving antiretroviral therapy at an urban hospital 

T. Zangeneh, G. Dickinson 


55.006 Comparison of the effectiveness of low dose Indinavir/ritonavir (IDV/r) versus 

Atazanavir/ritonavir (ATV/r) based antiretroviral therapy in NNRTI experienced 

HIV-1 infected patients in India 

K. Patel 1 , A. K. Patel 1 , J. K. Patel 1 , E. Naik 2 , J. Duan 2 , R. Ranjan 1 , S. Hamisu 2 

1 

Ahmedabad (India), 2 Tampa, FL (USA) 


55.007 NRTI resistance profile of the subtype F HIV-1 strains from children and 

adolescents treated with multiple antiretroviral drugs 

G. Jugulete, M. L. Luminos, M. Mardarescu, D. Otelea, M. Merisescu 

Bucharest (Romania) 

55.008 Implementation of HLA-B*5701 genetic screening prior to abacavir 

prescription in Georgia 

N. Dvali, N. Chkhartishvili, L. Sharvadze, L. Dzigua, M. Karchava, 

L. Gatserelia, T. Tsertsvadze 


Final Program ~ 129

Session 55 




HIV: THERAPEUTICS 

55.009 Efficacy of multivitamins containing phosphatidyl choline in the mananegment 

of hepatotoxicity from antiretroviral and/or antituberculous drugs 

N. Ladep 1 , N. Shehu 2 , A. Muazu 2 , P. Ugoagwu 2 , F. Kakjing 2 , B. Badung 2 , 

C. Daniyan 2 , J. Idoko 3 

1 

St George’s (Grenada), 2 Jos, Plateau (Nigeria), 3 Abuja, FCT (Nigeria) 

55.010 Prevalence of minor populations of drug-resistant HIV-1 in newly-diagnosed 

treatment-naïve individuals in Singapore 

Y.-J. Sun, P. Kaur, Y. S. Leo 


55.011 Prevalence of HIV-1 primary resistance among HIV chronically infected patients 

in Brazil’s Southeast region 

C. M. P. M. Soares 1 , T. R. C. Vergara 1 , M. M. Caseiro 2 , R. Côrtes 1 , B. Scarpellini 1 , 

M. C. A. Sucupira 1 , R. S. Diaz 1 

1 

São Paulo (Brazil), 2 Santos (Brazil) 


55.012 Challenges of antiretroviral therapy among children aged 6 to 15 years in 

Kabarole district (Western Uganda) 

P. Isabirye, N. Kiwanuka, J. Kiguli 


55.013 Survival, clinical, immunological and hematological outcomes of antiretroviral 

therapy among HIV-infected children attending a public clinic in Kinshasa, 

Democratic Republic of Congo 

M. Yotebieng 1 , A. Van Rie 1 , J. Luisiama 2 , F. Kitetele 2 , A. Edmonds 1 , F. Behets 1 , 

G. the SARA team 2 

1 

Chapel Hill, NC (USA), 2 Kinshasa (Democratic Republic of Congo) 

55.014 Apparent virologic failures and blips in a suburban HIV Clinic caused by 

laboratory errors in a commercial HIV-1 RNA PCR assay 

P. Cariello, T. Treadwell 

Framingham, MA (USA) 

55.015 Antiretroviral resistance-associated mutations and genomic diversity in reverse 

transcriptase and protease gene among drug-naïve patients 

S. Saini, P. Bhalla, U. K. Baveja, S. T. Pasha, R. Dewan 


130 ~ Final Program

Session 56 




INFECTION CONTROL, NOSOCOMIAL INFECTIONS AND CRITICAL CARE 

56.001 Clinical, radiological and microbiological corroboration to assess the role of 

endotracheal aspirate in diagnosing ventilator-associated pneumonia in an 

intensive care unit of a tertiary care hospital, India 

C. Mukhopadhyay, S. Krishna, A. Shenoy, K. Prakashini 


56.002 Virucidal efficacy of topical antiseptics versus a novel strain of Influenza H1N1 

V. Dzyakanava 1 , K. Burningham 1 , J. Stahl 2 

1 

Bozeman, MT (USA), 2 Saint Paul, MN (USA) 

56.003 Risk factors and clinical outcomes of multidrug-resistant 

Acinetobacter baumannii bacteremia in a University Hospital, Thailand 

S. Anunnatsiri, P. Tonsawan 

Khon Kaen (Thailand) 

56.004 Assessment of health care workers occupational exposure to HIV and 

post-exposure prophylaxis (PEP) in health centers and hospitals of 

Addis Ababa, Ethiopia 

T. Alemayehu 


56.005 Healthcare workers compliance to infection control practices in the 

haemodialysis unit in Sungai Buloh Hospital Malaysia 

G. Chua 1 , A. Adnan 2 , Z. Abdul Wahab 1 

1 

Sungai Buloh (Malaysia), 2 Shah Alam (Malaysia) 

56.006 Prevalence of nosocomial sinusitis in ICUs admitted patients in 

Rasool Hospital, Tehran, Iran 

S. Noorbakhsh, M. Barati, J. Mousavi, A. Tabatabaei 



56.007 Aspects of needlestick injuries among medical students: Reported or not? 

H. J. Salzer 1 , H. Langmann 1 , F. Stigler 2 , M. Sprenger 1 , M. Hoenigl 1 

1 

Graz (Austria), 2 Ferney-Voltaire (France) 

56.008 Factors associated with septic shock in patients with hematological malignancies 

and Pseudomonas infections 

R. Jeddi, H. Ghédira, R. Ben Amor, A. Turki, L. Aissaoui, K. Kacem, W. Bouteraa, 

Y. Ben Abdennebi, R. Ben Lakhal, H. Ben Abid, Z. Bel Hadjali, B. Meddeb 

Tunis (Tunisia) 

Final Program ~ 131

Session 56 





56.009 Initiatives to decrease the incidence and transmission of Clostridium difficile 

(C. difficile) 

J. Murillo, V. Heitzer, M. Ruiz, F. Ordieres 


56.010 Initiatives to decrease the incidence of methicillin-resistant 

Staphylococcus aureus (MRSA) 

J. Murillo, V. Heitzer, M. Ruiz, F. Ordieres 


56.011 Failure of dry mist of hydrogen peroxide 5% to kill Mycobacterium tuberculosis 

B. M. Andersen, G. Syversen, H. Thoresen, M. Rasch, K. Hochlin, B. Seljordslia, 

I. Snevold, J. Berg 

Oslo (Norway) 

56.012 Outbreak of methicillin-sensitive Staphylococcus aureus joint infections 

associated with magnetic resonance arthrograms performed at a single outpatient 

radiology center, Los Angeles County, California, USA, 2009 

M. Kim, C. Tyson, L. Mascola 

Los Angeles, CA (USA) 


56.013 Predictors of mortality in neutropenic patients with septic shock 

R. Jeddi, H. Ghédira, R. Ben Amor, L. Aissaoui, W. Bouteraa, Y. Ben Abdennebi, 

K. Kacem, R. Ben Lakhal, A. Turki, H. Ben Abid, Z. belhadjali, B. Meddeb 

Tunis (Tunisia) 

56.014 Incidence of nosocomial respiratory tract infection in pediatric intensive care 

unit of University Hospital Center (UHC) of Tirana 

I. Kasmi, G. Kasmi, S. Sallabanda, E. Kola, F. Zavalani, R. Llukaj, I. Bakalli, 

A. Koja, E. Celaj, K. Marku 

Tirana, AL (Albania) 

56.015 Clinical chracteristics and prognostic factors in patients with 

Stenotrophomonas maltophilia bacteremia 

Y. Nukui, S. Hatakeyama, Y. Shintani, H. Yotsuyanagi, K. Moriya, K. Koike 

Tokyo (Japan) 

56.016 Prevalence of mecA, aap genes and slime layer formation and its association 

with antibiotic resistance in isolated Staphylococcus epidermidis of TUMS 

hospitals health care staffs 

M. R. Pourmand, Z. Abdossamadi, M. H. Salari 


132 ~ Final Program

Session 56 





56.017 Central line associated bloodstream infection rates in 166 intensive care units 

of 54 cities in 23 developing countries: findings of the International Nosocomial 

Infection Control Consortium (INICC) 

V. Rosenthal 1 , C. Álvarez Moreno 2 , A. Mehta 3 , H. Leblebicioglu 4 , 

E. A. Medeiros 5 , L. Raka 6 , B. Hu 7 , S. Jamulitrat 8 , I. A. Khader 9 , 

M. G. Miranda Novales 10 , Y. Hussain 11 , R. Fernández Hidalgo 12 , S. S. Kanj 13 , 

Á. Villacres 14 , J. A. Navoa-Ng 15 , T. Mapp 16 , H. Guanche Garcell 17 , A. Barkat 18 , 

V. Suljagic 19 , Z. Mitrev 20 , L. Dueñas 21 , L. Cuellar 22 , A. Hamdi 23 

1 

Buenos Aires (Argentina), 2 Bogotá (Colombia), 3 Mumbai (India), 4 Samsun (Turkey), 

5 

São Paulo (Brazil), 6 Prishtina (Kosovo, Republic of (under UNSCR 1244/1999)), 

7 

Shanghai (China), 8 Songkla (Thailand), 9 Amman (Jordan), 10 Mexico (Mexico), 

11 

Lahore (Pakistan), 12 San Jose (Costa Rica), 13 Beirut (Lebanon), 14 Quito (Ecuador), 

15 

Quezon City (Philippines), 16 Panama (Panama), 17 La Habana (Cuba), 

18 

Rabat (Morocco), 19 Belgrade (Serbia), 20 Skopje (Macedonia), 21 San Salvador 

(El Salvador), 22 Lima (Peru), 23 Tunis (Tunisia) 

56.018 Central line associated bloodstream infection rates, extra length of stay, extra 

mortality and microbiological profile in a German tertiary intensive care unit: 

findings of the International Nosocomial Infection Control Consortium. 

A. W. Friedrich 1 , R. Köck 1 , C. Goeters 1 , K. Becker 1 , K. Pohl 1 , V. Rosenthal 2 

1 

Munster (Germany), 2 Buenos Aires (Argentina) 

56.019 Impact of outcome surveillance on ventilator associated pneumonia rates in 

3 intensive care units from 2 Mexican cities: findings of the International 

Nosocomial Infection Control Consortium (INICC) 

M. Sobreyra Oropeza 1 , V. Rosenthal 2 , H. Torres Hernández 3 , A. Chávez Gómez 3 , 

J. Rivera Morales 3 , J. E. Valero Rodríguez 3 

1 

Mexico City (Mexico), 2 Buenos Aires (Argentina), 3 Irapuato (Mexico) 

56.020 Expectations and perceptions of Nigerian patients regarding infectious diseases 

in dentistry 

C. Azodo, A. Umoh, H. Oboro 

Benin City (Nigeria) 


56.021 Nosocomial infections in a pediatric hospital in Santo Domingo, 

Dominican Republic 

C. S. Mota 


56.022 Predominance of diarrhoeagenic E.coli in hospital acquired diarrhoea in a 

case-controlled study in a tertiary care hospital in North India 

N. Taneja, B. K. Chandra, G. Singh, S. pahil, M. Sharma, S. Singhi 


Final Program ~ 133

Session 56 





56.023 Nosocomial infections—5 years of prevalence studies in the Czech Republic 

B. Cecetkova 1 , M. Girod Schreinerova 2 , M. Kolarova 3 , Z. Kancelova 1 , 

R. Chlibek 4 , J. Jirous 5 , J. Kapek 1 , J. Kohoutova 6 , J. Kratochvilova 3 , V. Kurkova 7 , 

E. Mickova 4 , M. Podzimkova 1 , V. Ryantova 1 , I. Sipova 8 , P. Totusek 1 

1 

Prague (Czech Republic), 2 Carlsbad (Czech Republic), 3 Brno (Czech Republic), 

4 

Hradec Kralove (Czech Republic), 5 Plzen (Czech Republic), 6 Olomouc (Czech 

Republic), 7 Pisek (Czech Republic), 8 Ceske Budejovice (Czech Republic) 

56.024 Predicting health care associated infections (HAI) in a high incidence low cost 

intensive care unit 

G. George, S. Kumar, K. Sivagnanam, P. Srikanth 

Chennai (India) 

56.025 Gram negative bacillary catheter related blood stream infection in the era of 

increased resistance 

V. Kapoor, C. Engell, E. Bishburg 



56.026 Device-associated infection rates, extra length of stay, extra mortality, 

microorganism profile, and bacterial resistance in two ICUs from Cuba: 

Findings of the international nosocomial infection control consortium (INICC) 

V. Rosenthal 1 , H. Guanche Garcell 2 , O. Requejo Pino 3 , C. Morales Pérez 3 , 

O. Delgado González 3 , D. Fernández González 3 

1 

Buenos Aires (Argentina), 2 La Habana (Cuba), 3 Havana (Cuba) 

56.027 Characterization of hospital-acquired infections in a University Hospital in 

Colombia: January 2005–July 2009 

J. G. Jiménez, J. K. Balparda, D. M. Castrillón, S. Y. Díaz, J. A. Echeverri, 

C. Estrada, C. Lopera, M. M. Raigosa, L. V. Vásquez 

Medellín (Colombia) 

56.028 “Non Traditional” Extended Spectrum Beta-lactamase-producing Isolates at a 

Community Hospital 

R. Nog, K. Singaravelu, P. Dhaubhadel, A. Guddati, S. Upadhyay, 

S. Mannheimer, C. Badshah, V. Sivapalan 

New York, NY (USA) 

56.029 Ventilator-associated pneumonia in HIV-infected ICU patients 

L. Gino, H. Bagnulo 


134 ~ Final Program

Session 56 





56.030 Implementation of a central line bundle to reduce central line associated 

bacteremia at the intensive care unit 

C. Alvarez, J. Pisapia, C. Rosello, M. Lira, M. Curone, G. Vidiella 


56.031 Phenotipic and molecular characteristics of Clostridium difficile infections in a 

tertiary-care center 

R. Mendoza, A. Camacho, J. O. Herrera, J. E. Diaz, S. D. M. Aldrete, 

A. L. Martinez, A. Hernandez, M. Bobadilla, A. Ponce de Leon, J. Sifuentes 


56.032 Epidemiology of diarrhea due to Clostridium difficile in a tertiary general 

hospital in San José, Costa Rica, from January to October, 2009 

E. San-Gil, E. Avendano, N. Mora 


56.033 Impact of pretransplant nutritional status and supplement on postoperative sepsis 

in living donor liver transplantation 

T. Kaido, F. Oike, Y. Ogura, A. Mori, S. Uemoto 

Kyoto (Japan) 

56.034 Multidrug-resistant Acinetobacter spp. bloodstream infections in a University 

Hospital of Buenos Aires, Argentina: frequency and antimicrobial susceptibility 

M. Zárate, L. Contardi, D. Cecchini, J. Smayevsky 


56.035 Recovery rate of NTM from AFB smear-positive sputum specimens during the 

pseudo-outbreak of mycobacterium species at a long-term care facility 

Y.-W. Lee, K. A. Jun, S. Y. Shin 

Jeju (Republic of Korea) 


56.036 Clinical impact of Systemic Inflammatory Response Syndrome (SIRS) in patients 

with bloodstream infection 

K. A. Jun, S. Y. Shin 

Jeju (Republic of Korea) 

56.037 Risk factors for central venous catheter-related infections in cardiac unit of 

tertiary care hospital in northern India 

R. Kumar, B. KAJLA, D. kaur, G. S. wander 

Ludhiana (India) 

Final Program ~ 135

Session 56 





56.038 Success in stopping transmission of enterococci in a Brazilian public 

teaching hospital 

F. Rossini, R. Fagnani, M. Leichsenring, L. Cardoso, M. L. Moretti, P. Trabasso 

Campinas (Brazil) 

56.039 Pseudooutbreak of Cedecea lapagei bacteremia in emergency room 

W. S. Choi, Y. K. Youn, Y. M. Jo, J. Y. Kim, M. J. Kim, W. J. Kim, H. J. Cheong, 

J.-W. Sohn, J. Y. Song, D. W. Park 


56.040 Development of subsequent bloodstream infections in patients with 

positive catheter-drawn blood culture results and negative peripheral 

blood culture results 

K.-H. Park, S.-H. Kim, O.-H. Cho, Y. P. Chong, S.-O. Lee, S.-H. Choi, 

Y. S. Kim, J. H. Woo 


56.041 Prevalence and factors associated with hospital acquired infections in Kayunga 

district hospital, central Uganda 

R. Ankunda 1 , D. Musisi 2 , R. Tweheyo 1 , O. Namusisi 1 

1 

Kampala (Uganda), 2 Kayunga (Uganda) 


56.042 Vancomycin-resistant enterococci cross-transmission among patients admitted to 

public and private hospitals in central Brazil 

M. A. Souza, A. O. Guilarde, M. Turchi, M. C. D. P. B. André, J. L. Cardoso, 

S. A. S. Paiva, C. A. Kobayashi, C. X. Carvalho, G. S. Leal, A. Kipnis, 

J. D. G. Vieira, L. J. A. Batista, A. L. Andrade 

Goiania (Brazil) 

56.043 Determinants of good adherence to hand hygiene among surgical 

health care workers 

C. Masuet Aumatell, M. Banque Navarro, I. Roman Romera, D. López Gallego, 

A. J. Sanabria Uribe, A. Fité Gallego, J. M. Ramon Torrell 

L’Hospitalet de Llobregat (Spain) 

56.044 Effectiveness of copper contact surfaces in reducing the microbial burden (MB) 

in the intensive care unit (ICU) of hospital del Cobre, Calama, Chile 

V. Prado 1 , C. Durán 1 , M. Crestto 2 , A. Gutierrez 2 , P. Sapiain 2 , G. Flores 2 , 

H. Fabres 2 , M. Schmidt 3 

1 

Santiago (Chile), 2 Calama (Chile), 3 Charlestone, SC (USA) 

56.045 An intervention to reduce the rate of Acinetobacter Hospital Acquired Infections 

in an urban community teaching hospital 

R. B. Hulette 

Nashville, TN (USA) 

136 ~ Final Program

Session 57 




INFECTIOUS DISEASES SURVEILLANCE 

57.001 Cytomegaloviris antibodies amongst immunocompromised (HIV) patients at 

Lagos University Teaching Hospital (LUTH) Idi-Araba, Lagos 

A. Akinbami 


57.002 Evaluation of Tanzania National Measles Surveillance System with laboratory 

component, for 2006 and 2007 

D. M. Kadigi 

Dar Es Salaam (Tanzania, United Republic of) 

57.003 The first needle and syringe exchange program in Iranian prisons 

M. Shahbazi, M. Farnia, M. Keramati 


57.004 Prevalence of urinary schistosomiasis in Offinso-South Municipality 

in Ashanti Region-Ghana 

D. Adu-Gyasi 1 , K. Kye-Amoah 2 , E. Sorvor 2 

1 

Kintampo (Ghana), 2 Maase-Offinso (Ghana) 

57.005 Influenza-like illness among US pilgrims returning from the Hajj in the Kingdom 

of Saudi Arabia compared to other US-bound Travelers: Data from the CDC 

quarantine activity reporting system (QARS), 2006–2008 

E. Yanni, A. Berro, P. Han, C. LAwson, N. Gallagher, K. Liske, P. Houck, 

H. Lipman, G. Brunette, N. Marano, C. Brown 


57.006 Assessing burden and depth of hepatitis B infection within Asian Pacific islander 

families in San Francisco 

T. Vijayan, P. Zheng, C. Nguyen, M. Peters 

San Francisco, CA (USA) 


57.007 Serological typing improves the epidemiological surveillance of gonorrhoea 

among men who have sex with men 

S. Sylvan, J. Hedlund 


57.008 Surveillance of human infections with Avian influenza in Guangzhou 

during 1997–2006 

P. Z. Qin, W. Ming, Y. Liu 

GuangZhou (China) 

Final Program ~ 137

Session 57 





57.009 Rapid analysis of known and unknown pathogens using a pan-microbial 

detection microarray 

J. Thissen, S. Gardner, K. McLoughlin, T. Slezak, C. Jaing 

Livermore, CA (USA) 

57.010 Indexing infectious disease information into a relational database for useful 

queries on the World Wide Web 

J. Brown 

Tacoma, WA (USA) 

57.011 Respiratory disease surveillance aboard Peruvian Navy Ships: 

Detection of a pandemic influenza A (pH1N1) outbreak 

D. Vera 1 , R. A. Hora 1 , V. Gonzaga 1 , J. Quispe 1 , J. M. Neyra 1 , M. Ramos 1 , 

C. Loret de Mola 1 , P. Mote 2 , M. Fernández 1 , J. Montgomery 1 

1 

Lima (Peru), 2 Athens, GA (USA) 


57.012 Population-based seroprevalence of hepatitis C virus infection in the South and 

Southeast regions of Brazil 

R. Moreira 1 , G. M. Figueiredo 1 , R. Ximenez 2 , U. Montarroyos 2 , C. Braga 2 , 

M. R. Cardoso 1 , G. Coral 3 , F. Carrilho 1 , A. Stein 3 , Z. Marion 3 , A. Spina 1 , 

A. Cardoso 4 , Y. Moriya 5 , A. Alves 3 , E. B. D. Correa 4 , M. Theme-Filha 6 , 

D. Muzzillo 5 , A. C. Vidor 4 , C. V. Nogueira 7 , M. E. Pinto 3 , A. A. Barone 1 , 

L. Ferreira 5 , L. Pereira 2 

1 

São Paulo (Brazil), 2 Recife (Brazil), 3 Porto Alegre (Brazil), 4 Florianópolis (Brazil), 

5 

Curitiba (Brazil), 6 Rio de Janeiro (Brazil) 

57.013 The European Centre for Disease Prevention and Control strengthening MedISys 

as a tool to accelerate detection of threats to human health from communicable 

diseases in the EU 

J. Mantero 1 , A. Cox 1 , J. Linge 2 , E. van der Goot 2 , D. Coulombier 1 

1 

Stockholm (Sweden), 2 Ispra, Varese (Italy) 

57.014 Changing trend of measles and rubella in Nepal: Is it time to introduce 

rubella immunization? 

S. P. Dumre 1 , S. Malla 2 , G. Shakya 2 , K. KC 2 , P. Ghimire 2 

1 

Pathumthani (Thailand), 2 Kathmandu (Nepal) 

57.015 Influenza A activities in Shanghai, China during 2004 to 2009 

L. Jiang, L.-W. Ju, X. Lv, J. Yang, Q. Shi, Y. Tan, H. Shen, Q.-W. Jiang 


138 ~ Final Program

Session 57 





57.016 Serological survey on influenza A (H1, H3, H5 and H9) antibodies in human 

populations in Shanghai, China in 2008 and 2009 

L.-W. Ju, L. Jiang, Q. Shi, X. Lv, J. Yang, H. Shen, Y. Zhou, W. Zhu, Q.-W. Jiang 


57.017 A survey of lymphatic filariasis using ICT test in Attapeu Province, Lao PDR 

Y. Knight 1 , C. Chanthavisouk 2 , V. Nakhonesid-Fish 2 , K. Chindavongsa 2 , 

E. Michael 1 , P. Aratchige 2 

1 

London (United Kingdom), 2 Vientiane (People’s Democratic Republic of Lao) 

57.018 Evaluation of bacterial meningitis Sentinel Surveillance Program (BMSSP) 

introduced in 2007 in São Paulo state, Brazil 

T. R. M. P. Carvalhanas, B. L. Liphaus, A. C. G. Pellini, A. L. F. Yu, 

G. D. Freitas, A. F. Ribeiro 


57.019 The proportion of influenza infections from severe acute respiratory infection 

(SARI) cases in Indonesia 2008–2009 

R. Ramadhany 1 , V. Setiawaty 1 , H. A. Wibowo 1 , D. Lokida 2 

1 

Jakarta (Indonesia), 2 Tangerang (Indonesia) 

57.020 Ranking the burden of infectious diseases in Ontario, Canada 

S. Ratnasingham, J. Kwong, N. Daneman, M. Campitelli, N. Crowcroft 

Toronto, ON (Canada) 

57.021 Burden of new swine-origin H1N1 influenza virus in a subtropical 

region of Mexico 

G. Ayora-Talavera, M. Betancourt-Cravioto, A. Quijano-Vivas, 

M. R. Gonzalez-Losa 

Merida (Mexico) 


57.022 Measles, neonatal tetanus (NNT), pertussis, cerebrio-spinal meningitis 

(CSM) and polio trends in Nigeria, 1994 to 2007 

M. O. Akhimien 


57.023 A two year surveillance for influenza and RSV using Real-time PCR among 

children with acute respiratory infections in Kolkata reveals distinct seasonality 

of infection 

A. S. Agrawal, S. Chakrabarti, M. Chawla-Sarkar 


Final Program ~ 139

Session 57 





57.024 Sampling considerations for Flavivirus arthropod vectors in Western Canada— 

Making sense at a data collection level 

R. Waeckerlin, S. Cork 

Calgary, AB (Canada) 

57.025 Crossborder infectious disease surveillance in the Netherlands, 

Germany and Belgium 

C. Kara-Zaïtri 1 , H. ter Waarbeek 2 

1 

Bradford (United Kingdom), 2 Heerlen (Netherlands) 

57.026 Realtime intelligence for infectious disease prevention and control 

C. Kara-Zaïtri, R. Hamilton 

Bradford (United Kingdom) 

57.027 The implement of airport fever screening for dengue sentinel 

in Taiwan, 2003–2008 

M.-M. Kuan 



57.028 Comparison of three time series models for predicting campylobacteriosis 

risk in Georgia, Minnesota and Oregon 

J. Weisent 

Knoxville, TN (USA) 

57.029 Anticipating the species jump: Surveillance for emerging viral threats 

M. Flanagan 

State College, PA (USA) 

57.030 The making of a world atlas of infectious diseases 

H. F. Wertheim 1 , P. Horby 1 , T. L. Viet 1 , T. N. T. Tanh 1 , J. WOODALL 2 

1 

Hanoi (Viet Nam), 2 Brookline, MA (USA) 

57.031 Pertussis in Latin America: Developing the tools to face the challenge ahead 

F. Coronado 1 , M. Griffith 1 , M. L. Tondella 1 , M. Bonkosky 1 , M. Landaverde 2 , 

T. Clark 1 

1 

Atlanta, GA (USA), 2 Washington, DC (USA) 

57.032 Establishing the tuberculosis monitoring system at Brazil’s, Paraguay’s and 

Argentina’s frontier 

M. Lise 1 , J. R. P. D. Santos 1 , R. G. Abreu 1 , P. Colombana 2 , C. Martinez 3 , 

D. Barreira 1 

1 

Brasilia (Brazil), 2 Misiones (Argentina), 3 Asunción (Paraguay) 

140 ~ Final Program

Session 57 





57.033 Trends in pediatric bacterial meningitis in Sudan 2005–2006 

M. H. Mahmoud, M. E. M. Alkarsani 


57.034 Elimination of neglected diseases in Latin America and the Caribbean: 

A mapping of selected diseases 

M. C. Schneider 1 , X. P. Aguilera 1 , J. Barbosa da Silva Jr 1 , S. K. Ault 1 , P. Najera 1 , 

J. Martinez 1 , R. Requejo 1 , R. S. Nicholls 1 , Z. Yadon 1 , J. C. Silva 2 , L. F. Leanes 3 , 

M. Roses Periago 1 

1 

Washington DC, DC (USA), 2 Bogotá DC (Colombia), 3 Rio de Janeiro (Brazil) 

57.035 Warning System in Gaza Strip, post conflict 2009 

F. Riccardo 1 , A. El Jaish 2 , Y. Shahin 1 , M. Maqadma 2 , M. R. Malik 3 , A. Pinto 4 , 

G. Sabatinelli 1 

1 

Amman (Jordan), 2 Gaza City (Palestina), 3 Cairo (Egypt), 4 Bangkok (Thailand) 

57.036 Prevalescent infections post hurricanes Hanna & Ike 

S. Font 


57.037 Sentinel surveillance of pandemic influenza A H1N1 in Kenya in the period 

August–November 2009 

R. Achilla, J. Majanja, M. Wadegu, W. Bulimo, D. Schnabel 


57.038 Cholerae in the Americas region: An eradicated problem? 

P. Ramon-Pardo 1 , G. de Cosio 1 , M. Tato 2 , J. Mckenney 1 

1 

Washington, DC (USA), 2 Madrid (Spain) 

57.039 Evidence for influenza A virus infection among patients with respiratory tract 

infections in Nigeria 

D. Ehichioya 1 , R. Orenolu 1 , N. Gerloff 2 , S. De Landtsheer 2 , A. Nasidi 3 , 

T. Harry 3 , C. Muller 2 , S. Omilabu 1 

1 

Lagos (Nigeria), 2 Luxembourg (Luxembourg), 3 Abuja (Nigeria) 


57.040 Relevance of infectious diseases in nephrology patients: 

A retrospective single center review of twenty renal biopsies 

C. Nguyen 

Augusta, GA (USA) 

57.041 The impact of socioeconomic factors on risk and frequency of hospitalization 

for infectious diseases among teenagers in sub-sahara Africa 

O. Udorji, C. Ude 

Enugu (Nigeria) 

Final Program ~ 141

Session 58 




PARASITES 

58.001 Seroprevalence of Toxoplasma gondii antibodies amongst pregnant women at 

Lagos State University Teaching Hospital 

A. Akinbami 


58.002 Atypical neuroimaging of neurocystercercosis 

L. D. Wilke, J. Farrell 

Peoria, IL (USA) 

58.003 Detection of Toxoplasma gondii antibody for diagnosis of ocular toxoplasmosis 

F. Maleki, S. Sarafpoor 


58.004 Two-dimensional gel electrophoresis analysis of T. solium cysticerci lower 

molecular mass (10–30 kDa) antigens for the serodiagnosis of neurocysticercosis 

in children 

V. S. R. Atluri, P. D. Singhi, N. Khandelwal, N. Malla 



58.005 Prevalence of intestinal parasitic infections in the Ministry of Health Hospitals in 

Sharjah, UAE: 2-year retrospective study 

N. Dash, H. Al-Jesmi, M. AL-Zarouni, D. Panigrahi 

Sharjah (United Arab Emirates) 

58.006 A study of medically important fish—transmitted parasites in Alexandria 

R. M. G. Diab, M. M. El Temsahy, E. D. ElKerdany, M. Gaafar, M. A. Nasr 

Alexandria (Egypt) 

58.007 Study of the clinical efficiency of covariumtm10 on patients suffering from 

intestinal amoebiasis 

M. N. Emmanuel 

Yaoundé (Cameroon) 

58.008 Anisakis simplex from the Adriatic sea 

I. Zurak 


58.009 Evaluation of OSOM Trichomonas rapid test for diagnosis of Trichomonas 

vaginalis infection in females 

F. Shujatullah, H. M. Khan, R. Khatoon, T. Rabbani, M. Shahid, A. Raza 

Aligarh (India) 

142 ~ Final Program

Session 58 




PARASITES 

58.010 Giardia intestinalis: DNA extraction approaches to improve PCR results 

Z. Babaei, E. Razmjou, H. Oormazdi, S. Rezaie, M. Rezaeian 


58.011 Can cystic Echinococcosis trigger autoimmunity? 

M. Aslan, Y. A. Oner, S. Saribas, E. Polat 1 , H. Cakan, P. Yuksel, K. Zengin, 

S. Arikan, M. M. Torun, B. Kocazeybek 


58.012 Prevalence of intestinal parasitoses and factors related in the population infant of 

the community Santa Bárbara, Municipality Valley Guanape, State Anzoategui, 

Bolivarian Republic of Venezuela 

R. Martínez 

Ciudad Habana (Cuba) 

58.013 Efficacy and safety of ivermectin versus high dose albendazole for chronic 

strongyloidiasis in immunocompromised patients 

Y. Suputtamongkol, K. Bhumimuang, D. Waywa, S. Nilganuwong, 

N. Premasathian, A. Karuphong, T. Anekthananon, D. Wanachiwanawin, 

S. Silpasakorn 


58.014 Biochemical and immunological characterization of the EhCBP30 protein from 

Entamoeba histolytica 

C. González, A. Carabarin, L. Baylon-Pacheco, J. L. Rosales-Encina 

México (Mexico) 

58.015 Soil-transmitted helminthiasis in rural South West China: 

Prevalence, intensity and risk factor analysis 

L. Mofid, Q. Bickle 



58.016 Hymenolepiasis in institutionalized Romanian children 

T. R. Olariu, G. Darabus, I. Marincu, C. Balutescu, V. Dumitrascu, 

C. Petrescu, A. Koreck 

Timisoara (Romania) 

58.017 Computational characterization of molecular mechanism of surface receptor 

binding with alpha-enolase of Trichomonas vaginalis 

S. Dwivedi 1 , S. Mishra 2 , N. Husain 1 , N. Malla 3 

1 

Lucknow (India), 2 Moradabad, UP (India), 3 Chandigarh (India) 

Final Program ~ 143

Session 58 




PARASITES 

58.018 Prevalence of Dientamoeba fragilis among asymptomatic individuals from 

North Central Venezuela 

S. Jimenez 1 , J. Cortez 1 , M. Diaz 1 , C. Duran 2 , G. Hidalgo 2 , W. Aguilera 2 , 

S. Nakal 2 , C. Albano 2 , R. N. Incani 1 , A. Rodriguez-Morales 2 

1 

Valencia (Venezuela), 2 Caracas (Venezuela) 

58.019 Risk factors in patients with trichinellosis from Western Romania 

I. Marincu, L. Negrutiu, A. M. Neghina, I. Iacobiciu, R. Neghina 


58.020 The prevalence of giardiasis in patients with acute enterocolitis from 

Timis County, Romania 

I. Marincu, L. Negrutiu, I. Iacobiciu, A. M. Neghina, R. Neghina 


58.021 Immunological changes in children with giardiasis 

T. R. Olariu, V. Dumitrascu, I. Marincu, C. Petrescu, A. Koreck 



58.022 IgG antibodies relative avidity as a phase-specific diagnosis for toxocariasis in 

populations of Venezuela 

O. Delgado, J. Ortegoza, V. Coraspe, M. A. Rivas, S. Silvia, C. Duran, Y. Pascual, 

A. Rodriguez-Morales 


58.023 Characterization of proteins of excretion/secretion (ES) of nematode parasite 

Mammomonogamus laryngeus 

M. I. Giraldo, J. C. Castaño 

Armenia, Quindio (Colombia) 

58.024 Fibronectin increases the adherence of Taenia solium oncosphere in CHO–K1 

cells in vitro 

S. Palma 1 , N. Chile 1 , J. Evangelista 1 , Y. Arana 1 , M. Verastegui 1 , R. H. Gilman 2 

1 

Lima (Peru), 2 Baltimore, MD (USA) 

58.025 Ectopic knee tungiasis and historical aspects in Peru 

V. Maco, V. Maco C., E. Gotuzzo 

Lima (Peru) 

144 ~ Final Program

Session 58 




PARASITES 

58.026 Blastocystis hominis infection among patients with and without 

gastrointestinal disorders 

M. Rostami Nejad, E. Nazemalhosseini Mojarad, H. Dabiri, M. R. Zali 


58.027 A Portuguese couple with eosinophilia: From the diagnosis to the treatment 

C. Abreu, S. Xerinda, A. Sarmento 


58.028 Role of serology, neuroimaging and stool examination in diagnosis of 

neurocysticercosis 

K. Sapkota 1 , K. Sapkota 2 , S. P. Dumre 3 , K. Malla 4 , S. Singh 4 

1 

Myagdi (Nepal), 2 Las Cruces, NM (USA), 3 Pathumthani (Thailand), 

4 

Pokhara (Nepal) 

58.029 Ixodes persulcatus tick salivary gland extract (SGE) inhibits IL-4 and 

IFN-γ secretion and CD69 expression by mitogen-stimulated murine splenocytes 

V. Firstova 1 , S. Biketov 1 , E. Zyrina 1 , A. Shtannikov 1 , I. Vasiljeva 2 

1 

Obolensk (Russian Federation), 2 Moscow (Russian Federation) 

58.030 Seroprevalence of toxocariasis in hypereosinophilic individuals in Ahwaz city 

S. Maraghi 

Ahwaz (Islamic Republic of Iran) 

58.031 Immunogenicity of the recombinant ASP1r protein of A. caninum in a 

murine model 

M. I. Giraldo, J. C. Castaño Osorio 

Armenia, Quindio (Colombia) 

58.032 Prevalence of intestinal parasites in urban, rural and commercial farming 

communities in Zimbabwe 

S. Mtapuri-Zinyowera 

Harare (Zimbabwe) 


Final Program ~ 145

Session 59 




TUBERCULOSIS: DIAGNOSIS, TREATMENT & DRUG RESISTANCE 

59.001 Beijing genotype and other predominant Mycobacterium tuberculosis 

spoligotypes observed in Mashhad City, Iran 

M. Rohani 1 , P. Farnia 2 , M. Torfeh 1 

1 

Kashan (Islamic Republic of Iran), 2 Tehran (Islamic Republic of Iran) 

59.002 Integrating TB screening tool improved TB screening in HIV Patients in TASO 

S. Okoboi 

Tororo (Uganda) 

59.003 A case report: Cutaneous tuberculosis presenting as chronic thoracic 

chest wall fistula 

H. Afsali, M. Momen Heravi 


59.004 Use of Imunotest (tuberculin skin test) for early detection of pulmonary 

tuberculosis among health workers in a private hospital, 2008, Lima, Peru 

S. Manga 

Lima (Peru) 


59.005 Predictive value and cut off point of PPD in probable patients with 

pulmonary tuberculosis 

M. Sofian 1 , L. Moini 1 , S. Farahani 1 , A. Rostampour 1 , H. Khalili 1 , 

A. Aghakhani 2 , M. Banifazl 2 , A. Ramezani 2 

1 

Arak (Islamic Republic of Iran), 2 Tehran (Islamic Republic of Iran) 

59.006 Challenges in the case detection of sputum smear-positive tuberculosis 

in Rwanda: A low-resource setting 

C. Muvunyi 

Butare (Rwanda) 

59.007 Predictive factors for the indeterminate result on the QuantiFERON-TB Gold 

In-Tube test 

S. H. Han, B. S. Chin, H. Choi, S. Y. Shin, Y. T. Chae, S. J. Jin, J.-H. Baek, 

C. O. Kim, J. Y. Choi, Y. G. Song, J. M. Kim 


59.008 A retrospective study to assess treatment outcomes among TB patients taking 

DOTS treatment in South India 

P. Narasimhan 1 , R. Peter 2 , A. Manoharan 2 , J. Wood 1 , R. MacIntyre 1 , 

D. Mathai 2 , K. John 2 

1 

Sydney (Australia), 2 Vellore (India) 

59.009 Population-based investigation on molecular characterization of Fluoroquinolones 

resistance of Mycobacterium tuberculosis in rural area of eastern China 

B. Xu, Y. Hu, W. Jiang, W. Wang 


146 ~ Final Program

Session 59 





59.010 Usefulness of PCR in the differential diagnosis of tuberculosis in paraffin 

embedded tissues 

S. Montenegro, C. Delgado, S. Pineda, M. Pinilla, D. Guinez, M. Garrido, 

C. Cabezas, F. Mucientes 

Concepcion (Chile) 

59.011 Geneticdiversity and population structure of M.tuberculosis strains circulating 

in Central Russia 

I. Shemyakin, V. N. Stepanshina 

Obolensk (Russian Federation) 

59.012 Evaluation of IS6110 PCR, BACTEC and conventional methods in rapid 

diagnosis of extra pulmonary tuberculosis cases attending two tertiary care 

hospitals in North India 

A. K. Maurya, V. Nag, S. Kant, R. A. S. Kushwaha, M. K. Rana, 

W. Rahman, T. Dhole 


59.013 Diagnosis of latent tuberculosis infection by using the QuantiFERON-TB 

Gold in-tube test in children whose household contact has contagious 

pulmonary tuberculosis disease 

T. Lee, N. Kim, J. Kim 

Seongnam (Republic of Korea) 

59.014 Clinical and epidemiological features of tuberculous meningitis 

M. E. Ferreira, N. E. Frassone 

Córdoba (Argentina) 

59.015 Serum proteins in patients with pulmonary tuberculosis and controls in Nigeria 

M. Garbati 1 , A. Danburam 2 , H. Yusuph 3 , D. Mshelia 4 

1 

Riyadh, Riyadh (Saudi Arabia), 2 Yola (Nigeria), 3 Maiduguri (Peru), 

4 

Maidugiri (Nigeria) 


59.016 High ethionamide resistance in Mycobacterium tuberculosis strains 

isolated in Kenya 

V. Asiko 


59.017 Pulmonary TB among elderly patients: Higher rates, difficulties for diagnosis and 

poorer prognosis 

L. P. Cruz Hervert, R. A. Baez-Saldaña, L. D. Ferreyra-Reyes, 

E. E. Ferreira-Guerrero, B. Cano-Arellano, L. Juarez-Sandino, 

M. D. L. García-García 

Cuernavaca, Morelos (Mexico) 

Final Program ~ 147

Session 59 





59.018 Pleural effusion of patients with tuberculosis is characterized by accumulation 

of γδ T lymphocytes that expresses distinct surface markers 

L. H. Okamura, D. A. Oliveira, R. F. S. Moreira, F. Figueroa, J. B. Afiune, 

L. F. R. Medici, F. A. F. Melo, M. Rivero, D. Rodrigues 


59.019 Diagnostics of resistance mycobacterium tuberculosis (MR MT) to isoniazid (H) 

and rifampicin (R) by simultaneous identification of mutations in rpoB, katG, 

inhA and ahpC genes with use biological microchips (TB-biochip). 

V. Zhuravlev 

St.Petersburg (Russian Federation) 

59.020 Fast identification of Mycobacteria from positive Mb/Bact bottles using a 

multiplex PCR 

E. P. A. Bensi, C. E. Levy, M. Ramos, P. C. Panunto 

Campinas, SP (Brazil) 


59.021 Identification and treatment of latent tuberculosis infection in haemodialysis 

patients in New Zealand 

A. Verrall, M. Leikis, J. Hildreth, N. Raymond, T. Blackmore 

Wellington (New Zealand) 

59.022 The role of a whole blood interferon-γ releasing assay for the tracing of 

tuberculosis infection in bacilli Calmette Guerin vaccinated children 

J.-K. Chun, E. Soon, H. M. Kim 

Wonju (Republic of Korea) 

59.023 An unusual case of esophageal tuberculosis in immunocompetent female patient 

H. F. Brito, R. F. Arbex, C. M. S. Messina, M. H. Froes, J. B. Afiune, 

C. M. F. Paradela, F. A. F. Melo, D. Rodrigues 


59.024 Pott’s Spine in a 3-year-old child 

N. Bhumbra, R. Arrouk 

Toledo, OH (USA) 

59.025 Status of HIV/TB co-infection in Cuba and strategies followed in the 

health care of patients with active tuberculosis and AIDS in the Institute of 

Tropical Medicine “Pedro Kourí” 

M. Diaz Jidy 

La Lisa (Cuba) 

148 ~ Final Program


Room Jasmine ~ Terrace Level Friday, March 12, 2010 




Antiviral prophylaxis in transplant recipients 

S. Mossad 



Room Orchid B/C/D ~ Terrace Level Friday, March 12, 2010 




Integration of informal information into disease surveillance 

M. Pollack 


FRIDAY • March 12, 2010 

Final Program ~ 149

Session 60 


Ballroom 1/2/3 ~ Terrace Level Friday, March 12, 2010 Plenary 


CME 

PLENARY LECTURE VII 

Chair: Jonathan COHEN, United Kingdom 

60.001 Pneumococcal infection and colonization in children and its impact on 

pneumococcal disease in adults 

K. Klugman 



150 ~ Final Program

Session 61 


Ballroom 1: Brickell ~ Terrace Level Friday, March 12, 2010 Symposium 


CME 

ANTIMICROBIAL STEWARDSHIP: CHALLENGES AND STRATEGIES FOR THE 21ST CENTURY 

Co-Chairs: Daniel CURCIO, Argentina 

Memish ZIAD, Saudi Arabia 

61.001 Extreme drug resistance in nosocomial pathogens 

F. Pasteran 


61.002 Basic principles of implementing an antibiotic optimization program 

J. Cortes 


61.003 Infection control program as an additional tool to control bacterial resistance 

P. Cornejo 


61.004 New antibiotics: Which role in a antimicrobial stewardship program? 

D. Curcio 



Pfizer 


Final Program ~ 151

Session 62 


Ballroom 2: Flagler/Monroe ~ Terrace Level Friday, March 12, 2010 Symposium 


CME 

CURRENT CHALLENGES IN HIV CARE 

Co-Chairs: Pedro CAHN, Argentina 

Maximo BRITO, USA 

62.001 State of the art on ARV therapy: How many standards of care? 

P. Cahn 


62.002 Drug resistance and other laboratory monitoring assays in HIV infection 

M. Hirsch 


62.003 Opportunistic infections and IRIS in the era of HAART 

J. Miro 

Barcelona (Spain) 

62.004 Why are patients dying in the HAART era? 

E. Katabira 



152 ~ Final Program

Session 63 


Ballroom 3: Tuttle ~ Terrace Level Friday, March 12, 2010 Symposium 


CME 

BIOMARKERS IN INFECTIOUS DISEASES 

Co-Chairs: Jonathan COHEN, United Kingdom 

Timothy BREWER, Canada 

63.001 Clinical use of biomarkers in the diagnosis and management of CAP 

P. Ramirez 

Valencia (Spain) 

63.002 Biomarkers for sepsis 

S. LaRosa 

Providence, RI (USA) 

63.003 Biomarkers for the diagnosis of TB 

J. Friedland 


63.004 Clinical utility of biomarkers in fungal infection 

T. Patterson 

San Antonio, TX (USA) 


Final Program ~ 153

Session 64 


Room Jasmine ~ Terrace Level Friday, March 12, 2010 Symposium 


CME 

BURDEN OF PLASMODIUM VIVAX MALARIA IN LATIN AMERICA 

Co-Chairs: Jaime TORRES, Venezuela 

Keith CARTER, USA 

64.001 Epidemiology of P. vivax malaria in the world and Latin America 

A. J. Rodriguez-Morales 


64.002 Molecular epidemiology of P. vivax: tools for malaria control 

A. Escalante 

Tempe, AZ (USA) 

64.003 Severe and complicated Malaria due to P. vivax 

J. Murillo 


64.004 Treatment, prophylaxis and resistance in P. vivax malaria 

J. Torres 



154 ~ Final Program

Session 65 


Room Orchid B/C/D ~ Terrace Level Friday, March 12, 2010 Oral Presentations 


INFLUENZA 

Co-Chairs: 

Theodore TSAI, USA 

David MORENS, USA 

65.001 Mixed infection of influenza A viruses is common 

Y. Furuse, A. Suzuki, N. Nukiwa, N. Fuji, H. Oshitani 

Sendai (Japan) 

65.002 Influenza vaccine delivery to adolescents: Assessment of two 

multicomponent interventions 

L. M. Gargano 1 , K. Pazol 1 , J. E. Painter 1 , J. M. Sales 1 , D. Murray 2 , C. Morfaw 2 , 

L. M. Jones 1 , P. Weiss 1 , W. A. Orenstein 3 , R. J. DiClemente 1 , J. M. Hughes 1 

1 

Atlanta, GA (USA), 2 Augusta, GA (USA), 3 Seattle, WA (USA) 

65.003 A randomized intervention trial of mask use and hand hygiene to reduce 

seasonal influenza-like illness and influenza infections among young adults in a 

university setting 

A. E. Aiello 1 , R. M. Coulborn 1 , V. Perez 1 , B. M. Davis 1 , M. Uddin 1 , G. F. Murray 2 , 

D. K. Shay 3 , S. H. Waterman 3 , A. S. Monto 1 

1 

Ann Arbor, MI (USA), 2 Mobile, AL (USA), 3 Atlanta, GA (USA) 

65.004 Population-based surveillance for 2009 pandemic influenza A H1N1 Virus in 

Guatemala, 2009 

W. Arvelo 1 , L. Reyes 2 , A. Estevez 2 , J. Gray 2 , S. Lindstrom 1 , A. Fry 1 , S. Olsen 1 , 

F. Ardon 2 , G. Frenkel 2 , B. Gordillo 2 , K. Lindblade 1 

1 

Atlanta, GA (USA), 2 Guatemala City (Guatemala) 

65.005 Adjuvanted influenza vaccines and their potential role for vaccination 

of travelers 

T. Tsai 1 , N. Groth 2 , M. Pellegrini 2 , D. O’Hagan 1 , A. Hilbert 3 

1 

Cambridge, MA (USA), 2 Siena (Italy), 3 Marburg (Germany) 

65.006 Seasonal influenza vaccine may be associated with increased risk of 

illness due to the 2009 pandemic A/H1N1 virus 

D. M. Skowronski 1 , G. De Serres 2 , N. Crowcroft 3 , N. Janjua 1 , N. Boulianne 2 , 

T. S. Hottes 1 , L. C. Rosella 3 , J. A. Dickinson 4 , G. Rodica 2 , P. Sethi 3 , 

N. Ouhoummane 2 , D. J. Willison 3 , I. Rouleau 2 , K. Fonseca 5 , S. J. Drews 5 , 

A. Rebbapragada 3 , H. Charest 6 , M.-E. Hamelin 6 , G. Boivin 6 , J. Gardy 1 , Y. Li 7 , 

P. Martin 1 

1 

Vancouver, BC (Canada), 2 Québec, QC (Canada), 3 Toronto, ON (Canada), 

4 

Alberta, AB (Canada), 5 Calgary, AB (Canada), 6 Quebec, QC (Canada), 

7 

Winipeg, MB (Canada) 


Final Program ~ 155

Session 65 




INFLUENZA 

65.007 Monitoring for avian influenza in wild birds on the Far East in 2008 

S. Sayfutdinova 1 , J. Runstadler 2 , M. Kulak 1 , M. Sivay 1 

1 

Koltsovo (Russian Federation), 2 Fairbanks, AK (USA) 

65.008 Influenza surveillance contributions from South and Southeast Asia 

R. Jarman, K. S. A. Myint, S. Shrestha, J. Gaywee, J. M. Velasco, I.-K. Yoon, 

D. Saunders, A. Timmermans, K. Ungchusak, T. Wongstitwilairoong, 

C. J. Mason, R. V. Gibbons, J. A. Pavlin 


65.009 H1N1 experience at the Institute for Infectious Diseases Emilio Ribas, 

São Paulo, Brazil. The role of a travel clinic as sentinel for emerging diseases 

J. Alves, C. E. Guarnieri, T. S. Chaves 


65.010 Is a mass immunization program for pandemic (H1N1) 2009 good value for 

the money? Early evidence from the Canadian experience 

B. Sander 1 , C. Bauch 2 , R. A. Fowler 1 , D. Fisman 1 , J. Kwong 1 , A. McGeer 1 , 

M. Zivkovic Gojovic 1 , M. Krahn 1 

1 

Toronto, ON (Canada), 2 Guelph, ON (Canada) 

65.011 Rapid real-time surveillance and monitoring of pandemic influenza associated 

pneumonia and risk factors using primary care electronic medical records (EMR) 

T. Wong, J. G. Mercer, S. Mukhi, S. Totten, K. El Eman, G. Jayaraman, C. Babin, 

R. Saginur, R. Kropp, R. Rodin, G. Garber 



156 ~ Final Program

Session 66 


South Hall ~ Lobby Level Friday, March 12, 2010 Symposium 


CME 

MRSA: THE CLINICAL CHALLENGE 

Co-Chairs: Victor ROSENTHAL, Argentina 

AW KARCHMER, USA 

66.001 Systemic MRSA infections 

E. Rubinstein 

Winnipeg (Canada) 

66.002 Treatment of severe MRSA infections: Beyond vancomycin 

A. Karchmer 


66.003 The potential for a staphylococcal vaccine 

O. Schneewind 


66.004 MRSA in Latin America: Special considerations 

M. Guzman-Blanco 



Pfizer 


Final Program ~ 157

Cultural Lecture 


Room Jasmine ~ Terrace Level Friday, March 12, 2010 Cultural Lecture 


CULTURAL LECTURE 

Illness and death of Enrico Caruso, a Neapolitan tenor in the Americas 

G. Cornaglia 

Siena (Italy) 


158 ~ Final Program

Session 67 


Ballroom 1/2/3 ~ Terrace Level Friday, March 12, 2010 Plenary 


CME 

PLENARY LECTURE VIII 

Chair: Keith KLUGMAN, USA 

67.001 Microbial chemical ecology and the future of antibiotics 

R. Kolter 





Final Program ~ 159

Session 68 


Ballroom 1: Brickell ~ Terrace Level Friday, March 12, 2010 Symposium 


CME 

TUBERCULOSIS: TOOLS FOR THE FUTURE 

Co-Chairs: Timothy BREWER, Canada 

Rajesh GHOKALE, India 

68.001 Unlocking the mycobacterial cell wall: Insights into virulence, biosynthetic 

pathways and systems-based approach to drug discovery 

R. Gokhale 

Delhi (India) 

68.002 Diagnosing drug resistance in low-resource settings: Practical approaches 

A. Umubyeyi Nyaruhirira 

Corunna (Rwanda) 

68.003 Applicable insights from pharmacokinetic and pharmacodynamic modeling of 

antituberculosis chemotherapy 

E. Nuermberger 

Baltimore, MD (USA) 

68.004 Addressing latent tuberculosis in areas with high tuberculosis burden: 

Implications for control 

M. Conde 



160 ~ Final Program

Session 69 


Ballroom 2: Flagler/Monroe ~ Terrace Level Friday, March 12, 2010 Symposium 


CME 

UPDATE ON INFECTIONS IN TRANSPLANT RECIPIENTS 

Co-Chairs: Sherif MOSSAD, USA 

Hans HIRSCH, Switzerland 

69.001 Tropical infections in solid organ transplant recipients 

J. Cuellar 


69.002 Polyoma virus infection, replication, and disease after kidney transplantation 

H. Hirsch 

Basel (Switzerland) 

69.003 Respiratory viral infections in hematopoietic stem cell transplant recipients 

R. Chemaly 

Houston, TX (USA) 

69.004 Prevention of cytomegalovirus infection after hematopoietic stem cell 

transplantation: Preemptive therapy versus universal prophylaxis 

S. Mossad 



Final Program ~ 161

Session 70 


Ballroom 3: Tuttle ~ Terrace Level Friday, March 12, 2010 Symposium 


CME 

INTERNATIONAL PERSPECTIVES ON INFECTION CONTROL 

Co-Chairs: Richard WENZEL, USA 

Sergio WEY, Brazil 

70.001 Engaging nations in a commitment to infection control 

D. Pittet 


70.002 International controversies: Bare below the elbow and the incremental value 

of MRSA screening 

M. Edmond 


70.003 With limited resources: How to begin and how to sustain an 

infection control program 

S. Wey 


70.004 The future hospital epidemiologist’s portfolio for success 

R. Wenzel 



162 ~ Final Program

Session 71 


Room Jasmine ~ Terrace Level Friday, March 12, 2010 Symposium 


CME 

BACTERIAL MENINGITIS: PREVENTION AND CURE 

Co-Chairs: Heikki PELTOLA, Finland 

Andre LOMAR, Brazil 

71.001 The global impact of bacterial meningitis 

P. Heath 


71.002 Pathophysiology of bacterial meningitis 

R. Nau 

Göttingen (Germany) 

71.003 Vaccination against bacterial meningitis 

H. Peltola 

Helsinki (Finland) 

71.004 Effective adjuvant therapies for meningitis 

S. Singhi 



Final Program ~ 163

Session 72 




PARASITOLOGY 

Co-Chairs: Eskild PETERSEN, Denmark 

Ruben Santiago NICHOLLS, USA 

72.001 One year impact of a single dose of Praziquantel in five schistosomiasis endemic 

districts in Rwanda 

D. Mupfasoni 1 , E. Ruberanziza 1 , S. Jackson 1 , K. Blaise 1 , O. Mukabayire 1 , 

M. Kabera 1 , M. Kramer 1 , J. Ruxin 2 

1 

Kigali (Rwanda), 2 New York, NY (USA) 

72.002 A comparative study of Arco and Coartem in the treatment of uncomplicated 

malaria in patients aged 4 months to 16 years attending Mulago hospital, 

Kampala, Uganda 

J. Rujumba, E. A. Mworozi, A. K. Maganda, R. Kiguba, B. Rwakimali, S. Nsobya 


72.003 The effect of malaria on the outcome of Lassa Fever 

P. Okokhere, D. Asogun, S. A. Okogbenin 

Irrua (Nigeria) 

72.004 Clinical analysis and eco-epidemiology data of pediatric visceral leishmaniasis 

(VL) in Argentina 

S. Ruvinsky 1 , O. Salomon 1 , L. Arce 2 , D. Jozami 3 , J. Altcheh 1 , R. Cappellini 1 , 

S. Lopez Papucci 4 , A. Riarte 1 , S. Gomez 3 , L. Borchichi 2 , R. Bologna 1 , P. Paulin 1 , 

R. Pividori 3 , G. Moscatelli 1 , H. Freilij 1 , R. Chiabrando 1 , A. Gentile 1 , A. Aletti 4 , 

A. Gajo Gane 5 , T. Orduna 1 

1 

Buenos Aires (Argentina), 2 Posadas (Argentina), 3 Santiago del Estero (Argentina), 

4 

Rosario (Argentina), 5 Corrientes (Argentina) 

72.005 Novel molecular detection of drug resistance markers in Plasmodium falciparum 

from Papua New Guinean children with uncomplicated malaria 

R. Wong 1 , H. Karunajeewa 1 , I. Mueller 2 , P. Siba 2 , E. P. Carnevale 3 , 

P. Zimmerman 3 , T. M. E. Davis 1 

1 

Perth, WA (Australia), 2 Madang (Papua New Guinea), 3 Cleveland, OH (USA) 


72.006 Identification of intestinal parasites from naturally contaminated hands of people 

living in low socio-economic areas of Dhaka, Bangladesh 

M. K. Ijaz 1 , J. R. Rubino 1 , K. A. Talukder 2 , A. Nur-E-Kamal 3 

1 

Montvale, NJ (USA), 2 Mohakhali (Bangladesh), 3 Brooklyn, NY (USA) 

72.007 Training in fever case management and use of malaria rapid diagnostic testing 

kits improved fever case management in Uganda 

U. Ssekabira 


164 ~ Final Program

Session 73 


Riverfront Hall ~ Lobby Level Friday, March 12, 2010 Poster Presentations 


ANIMAL MODELS, PATHOGENESIS & HOST DEFENSES 

73.001 Antibacterial effects of Humulus lupulus L. extract on topical staphylococcal 

infection in BALB/c Mice cornea 

M. Hadipour Jahromy, S. Khakpour, M. Hadipour Jahromy, A. Najafi 


73.002 Up regulation of IRF-2 in West Nile Virus infection: Implications for 

establishment of viremia in the brain leading to encephalitis 

K. L. Yeo, M. L. Ng 


73.003 Crimean-Congo hemorrhagic fever virus infects human hepatocytes and 

induces IL-8 secretion 

R. Rodrigues, G. Paranhos-Baccala, C. Peyrefitte 

Lyons (France) 

73.004 The course of infection in respiratory infected chickens caused by avian 

influenza virus A/H5N1 

A. Sergeev, O. V. P’yankov, O. K. Demina, L. N. Shishkina, A. S. Safatov, 

A. N. Sergeev, 

I. G. Drozdov 


73.005 Role of leukotrienes in resistance and susceptibility to infection by 

Histoplasma capsulatum 

A. Secatto 1 , E. M. Soares 1 , A. I. Medeiros 2 , L. H. Faccioli 1 

1 

Ribeirão Preto, SP (Brazil), 2 Araraquara (Brazil) 

73.006 Different clinical isolates of Mycobacterium tuberculosis induced distinctive 

pulmonary inflammation in mice 

E. Soares 1 , C. M. Peres 2 , A. Secatto 3 , C. L. Silva 4 , L. H. Faccioli 5 

1 

Ribeirao Preto, SP (Brazil), 2 Bauru, SP (Brazil), 3 Ribeirão Preto, SP (Brazil), 

4 

Ribeirao Preto (Brazil), 5 Ribeirão Preto (Brazil) 

73.007 Evaluation of the ferret as a model for influenza A/Brisbane/10/07 H3N2 

J. Garver, K. Van Zandt, J. Rhone, G. Stark, J. Bigger 


73.008 Natural history study of a low dose HPAI (A/Vietnam/1203/04) infection in ferrets 

J. Long, J. Edwards, A. Wasko, M. Gainey, P. Herr-Calomeni, G. Stark, J. Bigger 



Final Program ~ 165

Session 73 




ANIMAL MODELS, PATHOGENESIS & HOST DEFENSES 

73.009 FcγR IIA polymorphism -131H/R and malaria severity in Ghanaian children 

D. Amoako-Sakyi 

Cape Coast (Ghana) 

73.010 An animal model to study antimicrobial effects on community-acquired 

methicillin-resistant Staphylococcus aureus infection 

M. Ip, E. T. Y. Leung, C. Wong, K. To 


73.011 Increased killing of liver NK cells by Fas/FasL and NKG2D/NKG2DL contributes 

to hepatocyte necrosis in virus-induced liver failure 

T. Chen, Y. Zou, M. Han, H. Wang, W. Yan, G. Song, Z. Wu, X. Wang, 

C. Zhu, X. Luo, Q. Ning 

Wuhan, Hubei (China) 

73.012 CMV infection causing Adult Onset Still’s Disease: A clinical case 

D. Bento, R. Leite, R. Tavares, A. MIranda, F. Ventura, C. Araújo, K. Mansinho 


73.013 Telbivudine preserves Th1 cytokine response and down regulates PD-L1 in 

MHV-3–induced viral hepatitis model 

Z. Wu, W. Yan, W. Guo, Y. Zou, H. Wang, X. Wang, X. Yang, Y. Lu, 

X. Luo, Q. Ning 

Wuhan, Hubei (China) 

73.014 Transcriptome profile of the human endothelial cell response to high- and 

low-density infections of Candida albicans 

P. P. Chong 1 , C. S. Y. Lim 1 , Y.-H. Tan 1 , H. F. Seow 2 , R. Rosli 1 

1 

Selangor (Malaysia), 2 Melbourne, Victoria (Australia) 


73.015 Levels of pro-inflammatory cytokines and soluble cell adhesion molecules serves 

as early markers for recognition of diseases severity in patients with dengue fever 

and dengue hemorrhagic fever 

M. Odreman, S. Vielma, C. Torres, L. Tellez, J. Mendoza, S. Perez, N. Mosqueda, 

M. Muñoz, J. Muñoz, J. Goyo 

Merida (Venezuela) 

73.016 Cavia porcellus as a model for experimental infection by Trypanosoma cruzi 

Y. Castro Sesquen 1 , R. H. Gilman 2 , M. Verastegui 1 , V. Yauri 1 , N. Angulo 1 , 

D. E. Velasquez Portocarrero 1 , C. Bern 3 

1 

Lima (Peru), 2 Baltimore, MD (USA), 3 Atlanta, AT (USA) 

166 ~ Final Program

Session 74 




ANTIBIOTIC RESISTANCE: GRAM-POSITIVE 

74.001 Prevalence of Vancomycin Intermediate Staphyloccus aureus (VISA) in a 

tertiary care hospital in Eastern Nepal 

B. Khanal, R. Baral, A. Acharya 


74.002 A worldwide surveillance program studying the In Vitro Activity of Tigecycline 

and 10 common therapeutic agents against methicillin-resistant Staphylococcus 

aureus and Vancomycin-resistant Enterococcus species from 2004–2009 

B. Johnson 1 , M. Renteria 1 , J. Johnson 1 , R. Badal 1 , S. Bouchillon 1 , 

D. Hoban 1 , M. Dowzicky 2 

1 

Schaumburg, IL (USA), 2 Collegeville, PA (USA) 

74.003 The survey of risk factors of multi drug resistant of E. faecalis isolated from 

clinical samples 

R. Moniri 


74.004 The relationship between macrolide resistance in Streptococcus pneumoniae 

and consumption of oral macrolides in Republic of Croatia and City of Zagreb 

J. Vranes, J. Knezevic, B. Bedenic, D. Stimac, N. Jarza-Davila, M. Anusic 


74.005 Blood culture isolates in a tertiary care hospital of Eastern Nepal: 

Trends in antimicrobial resistance 

B. Khanal, S. Shrestha, N. Gyawali 


74.006 Multicenter evaluation of tigecycline activity in Latin America: 

Report from the SENTRY antimicrobial surveillance program (2009) 

D. J. Farrell, H. Sader, S. D. Putnam, R. N. jones 

North Liberty, IA (USA) 

74.007 Genetic diversity of enterococci harboring high-level gentamicin resistance 

genes aac(6’)-Ie-aph(2”)-Ia or aph(2”)-Ie in a Japanese hospital 

N. Kobayashi 1 , S. Watanabe 1 , S. Nagashima 1 , D. Quinones 2 , N. Urushibara 1 

1 

Sapporo, Hokkaido (Japan), 2 Ciudad de La Habana (Cuba) 

74.008 The expansion of ST80-SCCmec-IV clone of community-acquired 

methicillin-resistant Staphylococcus aureus in Kuwait hospitals 

E. Udo, E. Sarkhoo 

Safat (Kuwait) 


Final Program ~ 167

Session 74 





74.009 A novel multiplex real-time PCR assay for CA-MRSA: Rapid typing of SCCmec 

type assignment with detection of the pathogenicity 

K. Yanagihara, M. Motoshima, Y. Yamada, S. Kamihira, S. Kohno 

Nagasaki (Japan) 

74.010 Trend of vancomycin MIC values among MRSA clinical isolates and 

association with patient outcome 

K. A. Kincaid, J. M. Koo, S. M. Borchardt, T. S. Lo 

Fargo, ND (USA) 

74.011 Prevalence of Methicillin Resistant Staphylococcus aureus (MRSA) in tertiary 

referral hospital in Nepal 

K. Sapkota 1 , S. R. Basnyat 1 , C. D. Shrestha 1 , J. Shrestha 1 , S. P. Dumre 2 , 

N. Adhikari 1 

1 

Kathmandu (Nepal), 2 Pathumthani (Thailand) 

74.012 Emergence of linezolid-resistant coagulase-negative staphylococci in an 

Intensive Care Unit 

O. Zarkotou, G. Chrysos, E. Magira, G. Altouvas, A. Prekates, K. Digalaki, 

A. Tsakris 


74.013 Inducible clindamycin-resistance in clinical staphylococcal isolates with 

reduced vancomycin susceptibility in a University Teaching Hospital 

B. Olayinka 1 , A. Olayinka 2 , A. Obajuluwa 1 , J. Onaolapo 1 , P. Olurinola 1 

1 

Zaria (Nigeria), 2 Shika-Zaria (Nigeria) 

74.014 Different antibiotic treatments in patients suffering from MRSA-mediastinitis 

after cardiac surgery 

P. Dohmen, J. Schaefer, W. Konertz 



74.015 Trends in Methicillin resistant staphylococcus aureus (MRSA) minimal 

inhibitory concentration (MIC) to Vancomycin over a 2 year period in a 

community-based hospital 

J. Murillo, C. Garcia, F. Ordieres 


168 ~ Final Program

Session 74 





74.016 Antimicrobial susceptibilities, and SCCmec and multi-locus VNTR analyses of 

polymorphism and genetic relationships of clinical isolates of MRSA 

P. Brown, S.-L. Peart, J.-A. Dookie 

Kingston (Jamaica) 

74.017 Resistance to antibiotics of acinetbacter strains isolated from 

hospital-associated infections 

L. M. Junie 1 , E. Papadomanolaki 2 , G. Aleuraki 2 , P. Karagianni 2 , A. Tsafaraki 2 , 

A. Tsouri 2 , D. Labousaki 2 , E. Volanis 2 , S. Kastanakis 2 

1 

Cluj Napoca (Romania), 2 Chania (Greece) 

74.018 Real time PCR resolution of community acquired MRSA reservoirs: 

A strategy for the reduction of time to detection of hospital acquired MRSA 

S. Connolly, S. N. Connolly, Y. Pasari 

Middlesbrough (United Kingdom) 

74.019 Study of Vancomycin (VA) and Trimethoprim/sulfamethoxazole (TMP-SMX) 

activity on community-associated Methicillin-Resistant Staphylococcus aureus 

(CA-MRSA) biofilms (Bf) in vitro 

A. Farinati 1 , M. V. Campana 1 , S. C. Lopez 1 , R. Notario 2 , J. M. Casellas 2 , 

G. Vazquez 1 

1 

Buenos Aires (Argentina), 2 Rosario, Santa Fe (Argentina) 

74.020 Disc diffusion methods versus PCR for mecA gene in detection of 

Methicillin-Resistant Staphylococcus aureus 

Z. Mohammadtaheri, M. Pourpaki, F. Mohammadi, S. Raeissi, 

M. A. Khodadoust, M. Masjedi 



Final Program ~ 169

Session 75 




DIAGNOSTICS 

75.001 Molecular diagnosis of Helicobacter pylori infection and risk factor of the 

presence of cagA and vacA genes 

A. Hassan 


75.002 Competitive ELISA for Toxoplasma gondii Zoonoses 

A. A. Entrena García 

La Habana (Cuba) 

75.003 Sensivity and specifity of ELISA test for diagnosis of brucellosis 

Z. Vakili, M. Momen Heravi, A. Sharif 

Kashan, Isfahan (Islamic Republic of Iran) 

75.004 Molecular epidemiology of selected sexually transmitted bacterial infections 

H. Jalal 

Cambridge (United Kingdom) 

75.005 Burden of infection with C. trachomatis, N. gonorrhoeae, T. vaginalis and 

HR-HPV in homeless youth determined by APTIMA testing 

M. Chernesky 1 , D. Jang 1 , M. Smieja 1 , E. Portillo 1 , J. Kapala 2 , J. Sumner 2 

1 

Hamilton, ON (Canada), 3 Brampton, ON (Canada) 

75.006 Evaluation of PCR versus EIA for diagnosis of Clostridium difficile infection 

M. T. Busowski, C. DeRyke, D. bohmer, J. D. Busowski, R. Franklin, A. F. Walsh, 

M. R. Wallace 


75.007 Serodiagnosis of tuberculosis using nine in silico predicted B-cell epitopes 

peptides derived from Mycobacterium tuberculosis proteins 

L. BaassIi 1 , K. Sadki 1 , F. Seghrouchni 1 , S. Contini 2 , W. Cherki 1 , N. Nagelkerke 3 , 

A. Benjouad 1 , C. Saltini 2 , V. Colizzi 2 , R. El aouad 1 , M. Amicosante 2 

1 

Rabat (Morocco), 2 Rome (Italy), 3 Al Ain (United Arab Emirates) 


75.008 Cerebrospinal and blood nitric oxide in tubercular meningitis 

S. Jain, R. Srinivas, N. Sharma, M. Khullar 


75.009 Combinatorial use of IgG antibodies to secreted mycobacterial proteins to create 

a screening test for childhood tuberculosis 

Z. Araujo 1 , F. Giampietro 1 , M. A. Patarroyo 2 , C. Fernandez de Larrea 3 

1 

Caracas (Venezuela), 2 Bogotá (Colombia), 3 Barcelona (Spain) 

170 ~ Final Program

Session 75 




DIAGNOSTICS 

75.010 Specificities of the APTIMA Combo 2 and ProbeTec for Chlamydia trachomatis 

and Neisseria gonorrhoeae in oropharyngeal and rectal specimens from MSM 

J. Schachter, J. Moncada, A. Roger, L. Rauch, S. Liska, C. Shayevich, 

J. D. Klausner 

San Francisco, CA (USA) 

75.011 Reverse transcritpase multiplex PCR for detection of viral agents in 

central nervous system infections 

V. Gopalakrishnan, H. Amar Singh, T. Sadanandan, G. Perkash Singh 

Ipoh (Malaysia) 

75.012 An improve dot enzyme immunoassay for serodiagnosis of melioidosis 

S. A. K. Zainoodin 1 , I. Asma 2 

1 

Kepala Batas (Malaysia), 2 Georgetown (Malaysia) 

75.013 Diagnostic value of Elisa serological test using synthetic peptides of 

Mycobacteriun tuberculosis antigens in childhood tuberculosis 

D. Lopez 1 , F. Giamprieto 1 , J. DE Waard 1 , M. A. Patarroyo 2 , 

C. Fernandez de Larrea 3 , Z. Araujo 1 

1 

Caracas (Venezuela), 2 Bogotá (Colombia), 3 Barcelona (Spain) 

75.014 Can the nucleic acid amplification test (NAT) be an alternative to the 

serologic tests? A prospective study results of 18,200 blood donors from 

Turkish Red Crescent 

B. Kocazeybek 1 , P. Yuksel 2 , H. Altunay 1 , E. Kosan 1 , M. Aymelek 1 , E. Alan 1 , 

S. Saribas 1 , M. Aslan 1 , O. S. Yenen 1 , I. Birinci 1 , K. Kirali 1 , A. Aksoy 2 

1 

Istanbul (Turkey), 2 Ankara (Turkey) 

75.015 Comparison of Bactec MGIT 960 and new culture system VersaTREK for 

isolation rate, time of detection and and contamination rate 

S. Saribas, P. Yuksel, Y. Bagdatli 


75.016 Development of genetic typing method to assign staphylocoagulase (SC) 

serotype I-X and two SC genotypes for Staphylococcus aureus 

N. Kobayashi 1 , S. Ghosh 1 , M. Hirose 2 , S. K. Paul 3 , N. Urushibara 1 , 

M. Kawaguchiya 1 

1 

Sapporo, Hokkaido (Japan), 2 Tobetsu (Japan), 3 Mymensingh (Bangladesh) 

75.017 Serological diagnosis of lyme disease in Valencia (Spain) 

M. T. Fraile Fariñas, J. L. Ramos Marti, N. Tormo Palop, C. Gimeno Cardona 



Final Program ~ 171

Session 75 




DIAGNOSTICS 

75.018 Multicenter evaluation of Ziehl-Neelsen bleach sedimentation method for 

diagnosis of smear-negative tuberculosis in Kenya 

S. Matu, L. Muita, E. Juma 


75.019 Multilocus PCR in real time for detection of highly dangerous and dangerous 

viral infections 

A. O. Sementsova, A. N. Shikov, V. A. Ternovoy, A. P. Agafonov, V. B. Loctev, 

I. G. Drozdov 


75.020 Expression of matrix metalloproteinases and tissue inhibitors in the serum and 

cerebrospinal fluid of patients with meningitis 

H.-C. Tsai, M.-H. Shi, S. S.-J. Lee, Y.-S. Chen 

Kaohsiung (Taiwan, R.O.C.) 

75.021 Combination of PCR and electrical microarray allows rapid and sensitive 

multiplex detection of mosquito-transmitted pathogens 

M. Kaiser 1 , M. Ulrich 1 , A. Löwa 1 , G. Piechotta 2 , R. Wörl 2 , H. Ellerbrok 1 

1 

Berlin (Germany), 2 Itzehoe (Germany) 

75.022 Detection and differentiation of Dengue infections with highly sensitive 

real-time PCRs 

M. Kaiser 1 , D. Bray 2 , K. Benlhassan-Chahour 2 , F. Bissuel 3 , P. Huc Anais 3 , 

W. Rozenbaum 4 , H. Ellerbrok 1 

1 

Berlin (Germany), 2 Buckinghamshire (United Kingdom), 

3 

Saint-Martin (France), 4 Paris (France) 

75.023 An automated workflow for high throughput MLVA using the BioNumerics® 

software, able to deal with varying experimental settings 

L. Del Rosario 1 , B. Pot 2 , J. Goris 2 , K. Janssens 2 , P. Vauterin 2 , L. Vauterin 2 

1 

Austin, TX (USA), 2 Sint-Martens-Latem (Belgium) 


75.024 Navigating Dante’s inferno: Creation of signatures for the rapid detection of 

heamorraghic fever agents 

K. Pitz, A. C. Carrillo, J. Thissen, J. Olivas, B. Harrel, S. Hall, M. El Sheikh, 

R. Lenhoff, P. Naraghi-Arani 

Livermore, CA (USA) 

172 ~ Final Program

Session 75 




DIAGNOSTICS 

75.025 Usefulness of Montenegro skin test for the diagnosis of Mucosal Leishmaniasis 

B. Valencia, P. Diaz, O. Ponce, A. Ramos, A. Llanos-Cuentas 

Lima (Peru) 

75.026 Study of the efficient treatment of the influenza (S-OIV, A/H1N1) 

H. Iwamura, W. Nakanishi, C. Yamada, M. Shinogami 

Tokyo (Japan) 

75.027 Design of improved polymerase chain reaction (PCR) method containing internal 

positive control (IPC) for molecular detection of Yersinia pestis 

F. Eini, M. Fallah Raoufi, M. Soleimani, F. Azarifard, E. Jamshidiyan, 

K. Majidzadeh 


75.028 Development of a multiplex PCR system with application of IPC (internal 

positive control) for detecting Bacillus anthracis from environmental samples 

M. Fallah Raoufi, F. Eini, F. Azarifard, M. Soleimani, E. Jamshidiyan, 

K. Majidzadeh 2 


75.029 TB test-kit for rapid drug susceptibility testing of M.tuberculosis 

L. Domotenko, M. Khramov 

Obolensk (Russian Federation) 

75.030 Production and standardization of Brucella national standard antiserum 

equivalent to OIEISS in Sudan 

M. F. E. M. Alawad, M. T. Musa 


75.031 Identification of novel microRNA biomarkers of viral infection 

P. Naraghi-Arani 1 , S. Bavari 2 , S. Gardner 1 , C. Jaing 1 , J. Thissen 1 

1 

Livermore, CA (USA), 2 Fredrick, MD (USA) 

75.032 Procalcitonin as a diagnostic marker in differentiating bacterial from 

abacterial meningitis 

H. El-Shamy, A. Abbass, Y. Omran, A. Amine 



Final Program ~ 173

Session 75 




DIAGNOSTICS 

75.033 Western blotting studies of IgG antibodies, IgG avidity and IgG subclasses during 

the follow up of patients with pulmonary tuberculosis, under treatment 

A. C. Felix, O. H. M. Leite, R. Arruda, A. W. Ferreira 


75.034 A multiplex real-time PCR method for presumptive identification of NAP1 clone 

of Clostridium difficile from stools 

P. Jayaratne, C. Lee, C. Rutherford 

Hamilton, ON (Canada) 

75.035 Accuracy of an ‘in-house’ sputum polymerase chain reaction assay for rapid 

diagnosis of sputum smear negative pulmonary tuberculosis at Mulago 

Hospital, Uganda 

L. Nakiyingi, P. Ocama, B. Asiimwe, F. Katabazi, A. Katamba, M. Joloba, 

H. Mayanja-Kizza 


75.036 Amplification of pre-membrane and non-structural region 5 for detection and 

typification of Dengue virus by real-time PCR using SYBR green I assay 

S. Vielma, M. Odreman, D. Atchley, J. McAvin, G. Comach, C. Torres, 

G. Aguilera, A. Chiarello, L. Tellez, M. Muñoz 

Merida (Venezuela) 

75.037 Cytokine response in severe sepsis—Predicting and modelling the 

course of illness 

J. Malaska, M. Kratochvil, M. Kyr, P. Jabandziev, F. Otevrel, K. Muriova, 

M. Fedora, V. Sramek, J. Michalek, P. Sevcik 

Brno (Czech Republic) 


75.038 Circulating antigens of Mycobacterium tuberculosis: Standardization of 

immunoenzymatic assay to detect circulating antigens related in the pathology 

of tuberculosis 

A. C. Felix, C. B. Tanganelli, K. Kanunfre, O. H. M. Leite, R. Arruda, 

A. W. Ferreira 


174 ~ Final Program

Session 75 




DIAGNOSTICS 

75.039 Variation in liver histopathology in chronic HBV-infected individuals with 

normal liver function tests correlates with HBV replication 

J. You, L. Zhuang, H.-Y. Chen, J.-H. Huang, B.-Z. Tang, M.-L. Huang 


75.040 Short primers for amplification of diverse virus strains 

C. Hara 1 , A. Hiddessen 2 , S. Gardner 1 , C. Bailey 2 

1 

Livermore, CA (USA), 2 Pleasanton, CA (USA) 

75.041 Evaluation of the C. difficile toxin A/B iitm, C. difficile check-60TM, and 

premier toxin A&BTM with the cytotoxin assay for the detection of 

Clostridium difficile GDH antigen and toxins A and B in feces 

W. Greene 

Hershey, PA (USA) 

75.042 A highly sensitive reverse transcription polymerase chain reaction method for 

yellow fever virus detection 

J. Méndez 1 , C. Mendez 1 , C. Domingo 2 , G. Rey 1 , A. Tenorio 3 

1 

Bogotá (Colombia), 3 Berlin (Germany), 4 Madrid (Spain) 

75.043 Molecular diagnosis of American tegumentary leishmaniasis with minimally 

invasive samples 

B. Valencia 1 , N. Veland 1 , J. Arevalo 1 , A. Llanos-Cuentas 1 , J.-C. Dujardin 2 

1 

Lima (Peru), 2 Antwerp (Belgium) 

75.044 Multiprobes real-time PCR direct detection of MDR-TB related genes in 

pulmonary samples 

W. Watcharasamphankul, S. Foongladda 



Final Program ~ 175

Session 76 




EMERGING INFECTIOUS DISEASES 

76.001 Successful containment of an avian influenza outbreak through public health 

intervention in district Howrah, West Bengal, India, January ‘08 

G. Roy 

Kolkata, West Bengal (India) 

76.002 How different is Chikungunya from Dengue? 

A. Chow, D. C. Lye, V. Lee, M. K. win, A. Tan, Y. S. Leo 


76.003 Community-acquired Staphylococcus aureus infection in previously 

healthy neonates 

G. Berberian, G. Castro, H. Lopardo, C. Hernandez, A. Mónaco, M. T. Rosanova 


76.004 Etiologic aspects of 341 cases of acute undifferentiated febrile syndrome (AUFS) 

in southeast Brazil 

P. S. Gonçalves da Costa, L. M. Carvalho Valle, M. E. Brigatte 

Juiz de Fora (Brazil) 

76.005 Tick-borne encephalitis virus in Mongolia 

M. Khasnatinov 1 , D. Tserennorov 2 , P. Nymadavaa 2 , E. A. Tchaporgina 1 , 

T. Glushenkova 1 , E. Arbatskaya 1 , J. Bataa 2 , D. Abmed 2 , G. A. Danchinova 1 , 

D. Otgonbaatar 2 

1 

Irkutsk (Russian Federation), 2 Ulaanbaatar (Mongolia) 

76.006 Bartonella spp infections diagnosed between 2005 and 2009 by the National 

Rickettsial Reference Laboratory in Rio de Janeiro, Brazil 

C. Lamas, K. Koppe, T. Azevedo, M. A. Mares-Guia, D. Almeida, A. Guterres, 

T. Rozental, A. Favacho, E. R. Lemos 



76.007 Multiplexed diagnostic assays for detection of high consequence foreign and 

emerging animal disease 

A. C. Carrillo 1 , J. Thissen 1 , J. Olivas 1 , K. Pitz 1 , M. El Sheikh 1 , B. Harrel 1 , S. Hall 1 , 

M. Rasmussen 2 , L. Bentley Tammero 1 , R. Lenhoff 1 , P. Naraghi arani 1 

1 

Livermore, CA (USA), 2 Green Port, NY (USA) 

76.008 Transmission of chikungunya in Singapore, 2008 

P. L. Ooi 


176 ~ Final Program

Session 76 





76.009 Escalation of Japanese encephalitis in India: Evidence from 2005 viral 

encephalitis outbreak and appraisal of niceties 

S. K. Saxena 1 , R. Saxena 1 , A. Mathur 2 

1 

Hyderabad (AP) (India), 2 Lucknow (India) 

76.010 What is the current situation with plague in North Africa? 

E. Bertherat 1 , K. England 2 

1 

Geneva (Switzerland), 2 Bethesda, MD (USA) 

76.011 Analysis and characterization of mouse monoclonal antibodies reactive to 

Chikungunya virus (CHIKV) 

G. Rossini, A. Pierro, P. Gaibani, F. Cavrini 2 , M. P. Landini 2 , V. Sambri 1 


76.012 Study of Hanta-viral hemorrhagic fever with renal syndrome (HFRS) in an 

endemic region of Bulgaria 

I. Baltadzhiev 

Plovdiv (Bulgaria) 

76.013 The complete genome sequence and analysis of the betaproteobacterium 

Laribacter hongkongensis 

K. L. Tsang, P. C. Y. Woo, S. K. P. Lau 


76.014 The 2008 dengue epidemic on Curaçao: Correlation with climatological factors 

M. Limper 1 , C. Van de Weg 2 , P. Koraka 2 , Y. Halabi 3 , I. Gerstenbluth 3 , 

J. Boekhoudt 3 , A. Martis 3 , B. Martina 2 , A. Duits 3 , A. Osterhaus 2 , E. Van Gorp 1 

1 

Amsterdam (Netherlands), 2 Rotterdam (Netherlands), 3 Curacao (Netherlands) 

76.015 Cross-reactive neutralizing antibody response to enterovirus 71 infection in 

Taiwanese young children 

M.-S. Lee 1 , P.-S. Chiang 1 , M.-L. Huang 1 , S.-C. Chen 1 , S.-T. Luo 1 , K.-C. Tsao 2 , 

G.-Y. Liou 1 , T.-Y. Lin 2 

1 

Zhunan (Taiwan, R.O.C.), 2 Linkou (Taiwan, R.O.C.) 

76.016 ‘One World One Health’ in practice: Integrating public health and veterinary 

curricula on emerging infectious diseases in Africa 

G. Mullins 1 , J. Jagne 1 , L. Stone 2 , E. Konings 2 , L. Howard-Grabman 3 , 

F. Hartman 2 , M. Fulton 4 

1 

Bethesda, MD (USA), 2 Cambridge, MA (USA), 3 Arlington, VA (USA), 

4 

Lansing, MI (USA) 


Final Program ~ 177

Session 76 





76.017 Vector-based metagenomics for animal virus surveillance 

T. F. F. Ng 1 , D. Willner 2 , C. Nilsson 3 , Y. W. Lim 2 , R. Schmieder 2 , B. Chau 2 , 

Y. Ruan 3 , F. Rohwer 2 , M. Breitbart 1 

1 

Saint Petersburg, FL (USA), 2 San Diego, CA (USA), 3 Singapore (Singapore) 

76.018 Epidemiological, clinical and zoonotic evidences for the existence of Lyme 

disease in Central of Mexico 

G. Gordillo 1 , F. Solorzano Santos 2 , J. Torres 3 , E. Velazquez 2 , G. Ramon 2 , 

R. Garcia 2 , M. Vargas 4 


76.019 Population incidence estimates for hepatitis C virus infection in Egypt 

F. D. Miller 

Honolulu, HI (USA) 

76.020 Prioritizing US Dengue fever interventions utilizing remote sensing and 

predictive modeling 

F. Grant 


76.021 Prevalence and presentation of Lassa fever in Nigerian children 

G. Akpede 1 , A. Odike 1 , P. Okokhere 1 , S. C. Olomu 1 , D. Asogun 1 , C. Happi 2 , 

S. Gunther 3 

1 

Irrua, Edo (Nigeria), 2 Ibadan (Nigeria), 3 Hamburg (Germany) 

76.022 New lessons from a case series review of Lassa fever in pregnancy 

S. A. Okogbenin 1 , D. Asogun 1 , G. Akpede 1 , P. Okokhere 1 , S. Gunther 2 , C. Happi 3 

1 

Irrua, Edo (Nigeria), 2 Hamburg (Germany), 3 Ibadan (Nigeria) 


76.023 Neuroimmunological findings from the first report of Angiostrongylus 

cantonensis outbreak in Ecuador 

A. J. Dorta-Contreras 1 , B. Padilla-Docal 1 , J. M. Moreira 2 , L. Martini Robles 3 , 

J. Muzzio Aroca 3 , F. Alarcon 2 , R. Bu Coifiu Fanego 1 

1 

Ciudad de la Habana (Cuba), 2 Quito (Ecuador), 3 Guayaquil (Ecuador) 

76.024 Pericarditis caused by spatype t011 MRSA in a butcher; an occupational hazard 

M. Schouten 

Tiel (Netherlands) 

178 ~ Final Program

Session 76 





76.025 Skin and soft-tissue infections caused by community-associated 

methicillin-resistant Staphylococccus aureus 

W. Cornistein, M. I. Lespada, C. Rodriguez 


76.026 The emergence of Clostridium difficile NAP1 hypervirulent strain in Latin America 

C. Quesada-Gómez 1 , T. Du 2 , M. D. M. Gamboa-Coronado 1 , C. Rodríguez 1 , 

M. R. Mulvey 2 , E. Rodríguez-Cavallini 1 

1 

San José (Costa Rica), 2 Winnipeg, MB (Canada) 

76.027 Differential patterns of tuberculosis disease between immigrant and native 

Spanish patients 

P. Merino, A. Vanegas, R. Cias, I. Gestoso, J. Picazo 


76.028 Imported cases of Chikungunya and Dengue fever in Emilia Romagna region, Italy 

F. Cavrini, P. Gaibani, C. Manisera, A. Pierro, G. Rossini, M. P. Landini, V. Sambri 


76.029 Importance of the animal/human interface in events of international concern for 

the Americas 

M. C. Schneider 1 , X. P. Aguilera 2 , R. M. Smith 3 , M. Moynihan 4 , 

J. Barbosa da Silva Jr 2 

1 

Washington, DC (USA), 2 Washington DC, DC (USA), 3 Pomona, CA (USA), 

4 

Charlottesville, VA (USA) 

76.030 Dengue fever in a Southeastern region of Brazil. Ten years period (1997–2007) 

clinical and epidemiological retrospective study. 

V. Ribeiro 1 , R. Angerami 1 , M. Resende 1 , M. H. Pavan 1 , E. Hoehne 1 , V. Souza 2 , 

C. Souza 2 , M. Souza 2 , M. Wonhrathi 2 , S. Cadogan 2 , F. Aoki 1 

1 

Campinas, SP (Brazil), 2 Sumaré, SP (Brazil) 

76.031 The potential of social networks for early warning nad outbreak detection 

systems: The swine flu Twitter study 

P. Kostkova, E. de Quincey, G. Jawaheer 


76.032 The meanings of resistance in a Brazilian dengue fever epidemic 

C. Alley 

Brooklyn, NY (USA) 


Final Program ~ 179

Session 77 




GRAM-POSITIVES & MISCELLANEOUS PATHOGENS 

77.001 Assessment of prognosis of tetanus and its related factors among Albanian adults 

A. Pilaca, A. Ndreu, G. Byrazeri, K. Shytaj 


77.002 Thrombocytopenia in murine typhus: A study of 161 cases 

S. Doukakis, M. Papadakis, M. Daoukakis, P. Stavroulakis, K. Bambili, 

G. Polymili, D. Triantafillidou, M. Junie, S. Kastanakis 

Chania (Greece) 

77.003 Prevalence of neonatal conjunctivitis due to Chlamydia trachomatis in two 

hospitals in Iran 

S. Rafiei Tabatabaei, S. A. Afjeiee, A. Karimi, F. Fallah, A. Tavakkoly Fard, 

N. Tahami Zanjani, R. Radmanesh Ahsani, A. R. Shamshiri 


77.004 Invasive Streptococcus pneumoniae serotypes associated with in-patient and 

out-patient isolates from the United States 

M. Hackel 1 , C. Lascols 1 , S. Bouchillon 1 , D. Hoban 1 , J. Johnson 1 , M. Dowzicky 2 

1 

Schaumburg, IL (USA), 2 Collegeville, PA (USA) 

77.005 Clinical and laboratory test follow up of patients with severe leptospirosis, after 

hospital discharge 

A. Spichler 1 , D. Athanazio 2 , A. C. Seguro 1 

1 

São Paulo (Brazil), 2 Salvador, BA (Brazil) 

77.006 The detection of antibodies directed against specific antigens of 

Borrelia burgdorferi sensu lato (B. burgdorferi s.s., B. afzelii, B. garinii, 

B. spielmanii) in patients with borreliosis in Eastern Poland 

M. Tokarska-Rodak 1 , H. Fota-Markowska 1 , M. Kozioł-Montewka 1 , 

F. Śmiechowicz 1 , B. Gajownik 2 , M. Prokop 1 , R. Modrzewska 1 

1 

Lublin (Poland), 2 Łuków (Poland) 


77.007 Enterococcal bone and joint infections: A working group experience 

along 17 years 

C. A. Pensotti, F. Nacinovich, C. Di Stéfano, J. Thierer, A. Ferraris, 



77.008 Bacillus cereus bacteremia in hospital setting 

G. Ohji, Y. Oba, K. Takimoto, H. Kagawa, D. Uchida, R. Suganaga, H. Oka, 

S. Kinoshita, M. Nakamura, H. Yoshida, K. Iwata 

Kobe (Japan) 

180 ~ Final Program

Session 77 





77.009 Prognostic markers and out comes in severe leptospirosis in a tertiary care 

hospital from south India 

M. Prabhu, R. Valsalan, N. KS, B. Ramachandran 

Manipal, Karnataka (India) 

77.010 Multilocus sequence typing of Enterococcus faecalis clinical isolates in Cuba 

D. Quinones 1 , N. Kobayashi 2 , S. Nagashima 2 , S. Watanabe 2 

1 

Ciudad de La Habana (Cuba), 2 Sapporo, Hokkaido (Japan) 

77.011 Analysis and correlates of atypical lymphocytosis in leptospirosis in the cohort of 

patients at an infectious diseases unit, University Hospital, from 1996 to 2009, 

in Rio de Janeiro, Brazil 

A. Barbosa, P. V. Damasco, C. A. L. Ávila, M. Ribeiro-Carvalho, 

E. R. S. Lemos, M. N. Bóia, M. M. Pereira 


77.012 Knowledge of Leptospirosis among community-based rural residents in Kandy, 

Sri Lanka: Implications for intervention 

C. Nwafor-Okoli 1 , S. Kularatne 2 , C. Gamage 1 , R. Rajapaske 2 , Y. Obayashi 1 , 

H. Tamashiro 1 

1 

Sapporo, Hokkaido (Japan), 2 Kandy (Sri Lanka) 

77.013 Bacillus cereus as a pathogen and retention of medical devices are risk factors 

for Bacillus bacteremia 

M. Kamimura, T. Kitazawa, Y. Yoshino, K. Tatsuno, K. Koike 

Tokyo (Japan) 

77.014 Concordance between Vir and protein M gene (emm) types of 

Streptococcus pyogenes strains isolated from patients with invasive and 

non-invasive infections of Mexico 

M. Carranza 1 , M. Quiñonez-Alvarado 1 , E. Martìnez-Lopez 1 , L. Perea-Mejia 2 , 

A. Inzunza-Montiel 2 , A. Villaseñor-Sierra 1 

1 

Guadalajara (Mexico), 2 Mexico (Mexico) 

77.015 Clinical aspects of neuroborreliosis in Bydgoszcz, Poland 

A. Olczak, E. Grabczewska 

Bydgoszcz (Poland) 

77.016 Diagnosis and treatment challenges in patients with chronic tick Associated 

Poly-organic Syndrome (TAPOS)—Case series 

A. Radulescu, M. Flonta, D. Tatulescu 

Cluj (Romania) 


Final Program ~ 181

Session 77 





77.017 Corynebacterium striatum: an under recognised cause of 

diabetic foot osteomyelitis. 

G. J. Boyd, N. Weightman, J. Martin 

Harrogate (United Kingdom) 

77.018 The rising concern of community-acquired methicillin-resistant 

Staphylococcus aureus central nervous system infections: 2 case reports 

R. Nog, H. Anyimadu, T. Schliep, O. Alao, V. Sivapalan, C. Badshah 


77.019 A scoring system for severity of disease associated with mortality for 

Clostridium difficile associated disease 

P. Ko, R. Jayasingam, C. Modi, R. Hallit, N. Nguyen, S. Daniel, T. Soleymani, 

J. Fallon, L. Booth, G. Perez, J. Slim, J. Sensakovic, J. Boghossian 


77.020 Disseminated nocardiosis 

A. R. Bastidas, M. Pérez, A. Piotrostanalzki, P. Reyes, M. Gonzáles, R. Rada 


77.021 Effectiveness of linezolid versus vancomycin treatment for MRSA skin and 

soft tissue infections 

M. Yim, J. Steingisser, R. Kan, A. Nshala, R. Larson 

Hanover, NH (USA) 

77.022 Follow-up of Gambian 9-valent pneumococcal conjugate vaccine trial 

participants who experienced acute lower respiratory infection aged less 

than 2.5 years 

G. Mackenzie 1 , B. Okoko 1 , A. Akinsola 1 , O. T. Idoko 1 , T. Corrah 1 , S. Howie 1 , 

E. K. Mulholland 2 , B. Greenwood 2 , R. A. Adegbola 3 

1 

Fajara (Gambia), 2 London (United Kingdom), 3 Seattle, WA (USA) 


77.023 Tetanus: Clinical and epidemiological characteristics. Review of 11 years 

R. Ilardo 1 , N. E. Frassone 2 

1 

Cordoba (Argentina), 2 Córdoba (Argentina) 

182 ~ Final Program

Session 77 





77.024 Characterization of community-acquired Staphylococcus aureus 

methicillin-resistant (CA-MRSA) vs methicillin-susceptible 

Staphylococcus aureus (CA-MSSA) infection (Inf) in Argentinean children 

G. A. Yerino, M. S. Vazquez, C. Magneres, G. Abalos, C. I. Cazes, M. L. Vozza, 

C. I. Echave, V. Valle, M. Langard, A. Procopio, M. M. Contrini, E. L. Lopez 


77.025 Diphtheria tox gene polymorphism in C. diphtheriae strains isolated in Russia 

during 2002–2009 

S. Kombarova, I. Mazurova, O. Borisova, N. Gadua, T. Kornienko 

Moscow (Russian Federation) 

77.026 Staphylococcus lentus: The troublemaker 

C. Mazal 1 , B. Sieger 2 

1 

Sanford, FL (USA), 2 Orlando, FL (USA) 

77.027 Staphylococcus lugdunensis—A wolf in sheep’s clothing 

A. Klotchko, M. Wallace, A. F. Walsh, B. Sieger, C. M. Licitra 


77.028 Association of breast milk Lactobacilli and Staphylococcus aureus in women 

with mastitis using quantitative PCR 

U. srinivasan, N. Shrivastwa, S. Ponnaluri, J. Debusscher, C. Barbossa-Cesnik, 

C. F. Marrs, B. Foxman 


77.029 Streptococcus pneumoniae treatment with catecholamines affects growth based 

on strain isolation site with a lack of effect on biofilm formation 

X. F. Gonzales, F. Quinones Falconi, G. Castillo Rojas, Y. Lopez Vidal 


77.030 Chronic pain: Crucial symptom in a case of neuroborreliosis analysis of 

three cases 

E. Marcinkowska, A. Horban, M. Malec-Milewska 

Warsaw (Poland) 


Final Program ~ 183

Session 78 




HIV: OPPORTUNISTIC INFECTIONS & MALIGNANCIES 

78.001 The emerging of non-AIDS related neoplasms in the era of combined 

antiretroviral therapy 

R. Manfredi 


78.002 The role of the tuberculosis in outcome and treatment failure in HIV-infected 

Cambodian children 

V. Krčméry, B. Irad, J. Vujcikova, E. Mitterpachova, A. Kalavska, P. Kisac 


78.003 AIDS-Associated mycobacterial infections in a large urban hospital during the 

HAART era (2003–2006) 

A. Sanche, M. Nguyen 

Los Angeles, CA (USA) 

78.004 A prospective cohort study of immunologic and virologic outcomes in patients 

with HIV/AIDS and hepatitis virus co-infection in Jos, Nigeria 

S. Isa 1 , L. N. Gwamzhi 2 , C. Akolo 3 , C. Ukoli 4 

1 

Abuja (Nigeria), 2 St Georges (Grenada), 3 Rockville, MD (USA), 4 Jos (Nigeria) 

78.005 Pulmonary microbiology of HIV positive subjects with community-acquired 

pneumonia (CAP) with special emphasis on Mycoplasma pneumoniae 

U. Rao, E. Shankar, N. Kumarasamy, P. Balakrishnan, S. Solomon 

Chennai (India) 

78.006 Kaposi’s sarcoma (KS) and AIDS. Survival study 

D. B. Lima, A. Barbosa, E. F. Cunha, R. G. Cunha, J. P. Almeida, V. R. Gomes 



78.007 Opportunistic infections in central nervous system and associated neurologic 

disorders in HIV-infected patients in a Western Hospital of Venezuela, 

2007–2009 

A. Herrera-Martínez, Y. Herrera, A. M. Pineda 

Barquisimeto (Venezuela) 

78.008 HIV and opportunistic infections in a western hospital of Venezuela, 2007–2009 

A. Herrera-Martínez, Y. Herrera, A. M. Pineda 

Barquisimeto, Lara (Venezuela) 

184 ~ Final Program

Session 78 





78.009 Prevalence of occult hepatitis B infection among HIV infected patients at an 

inner city clinic 

R. Nog, K. Singaravelu, A. Haider, V. Sivapalan, S. Mannheimer 


78.010 Predictors for hepatic carcinoma surveillance screening in a cohort of hepatitis B 

and HIV co-infected patients in a large urban HIV clinic 

A. Adejumo, Z. Oshikanlu, V. Sivapalan 


78.011 Virological and biochemical evolution of HIV-HBV co-infected patients treated 

with tenofovir 

G. Vidiella, P. Rios, C. Biscayart, S. Castillo, A. Botas, M. Christin, 

D. Stamboulian, P. Rodriguez Iantorno, C. Vujacich 


78.012 An assessment of the seroprevalence of hepatitis A antibody and vaccination 

among HIV patients in an inner city HIV clinic 

A. Adejumo, V. Sivapalan, S. Mannheimer 


78.013 Central nervous system opportunistic infections (CNS-OI) in HIV-infected 

children from Buenos Aires, Argentina 

A. Fallo, A. de Mena, L. Torrado, N. Sordelli, G. Manonelles, E. L. Lopez 


78.014 Parvovirus B 19 infection in immunodeficient patient 

A. V. Lombar, M. Segovia, C. M. Carranza, M. L. Chessari, A. I. Sanchez, 

A. M. Assetta 


78.015 Strategies to enhance Hepatitis B disease surveillance in Human 

Immunodeficiency Virus / Hepatitis B Virus co-infected patients 

C. Bannan, D. Gallagher, G. Farrell, S. Akin, C. Bergin 



Final Program ~ 185

Session 78 





78.016 Risk of an outbreak of Kaposi’s sarcoma associated with HIV/AIDS 

in Mozambique 

A. Caterino-de-Araujo 1 , R. C. R. Manuel 2 , R. Del Bianco 1 , E. Santos-Fortuna 1 , 

M. C. Magri 1 , J. M. K. Silva 1 , R. Bastos 2 

1 

São Paulo (Brazil), 2 Maputo (Mozambique) 

78.017 Severe febrile neutropenia (SFN) in HIV / AIDS 

D. Villalon, N. E. Frassone, L. Marianelli 

Cordoba (Argentina) 

78.018 Abnormal vaginal cytology and colpocytology in a group of HIV infected women 

at Fundação de Medicina Tropical do Amazonas 

M. Brock, J. R. D. T. Leao, C. M. O. Soeiro, L. C. D. L. Ferreira 

Manaus, AM (Brazil) 

78.019 Coinfection of tuberculososis and histoplasmosis in HIV patients from 

Medellin, Colombia 

A. Tobon, C. Agudelo, D. Molina, J. Marin, C. Restrepo, A. Restrepo 

Medellin, Antioquia (Colombia) 

78.020 Human Papillomavirus (HPV) detection in urine of HIV-infected women 

I. Rosa-Cunha, J. Prewitt, T. Guettouche, T. Hooton 



186 ~ Final Program

Session 79 




OBSTETRICAL-GYNECOLOGICAL, SURGICAL AND SEXUALLY TRANSMITTED INFECTIONS 

79.001 Prevalence of bacterial vaginosis amongst women of child bearing age 

E. O. Chima-Oduko, C.J. Uneke 


79.002 Syphilis and HIV co-infection in Thai Medical School Hospital 

N. Hiransuthikul 


79.003 Genotyping of Chlamydia trachomatis and human papillomavirus in clinical 

specimens from North-Eastern Croatia 

Z. Bosnjak, M. Peric, D. Pavlinic, S. Dzijan, I. Roksandic-Krizan, D. Vukovic, 

N. Ruzman, J. Burazin, G. Lauc, A. Antolovic-Pozgain 

Osijek (Croatia) 

79.004 Frequent infections in Mexican women experiencing spontaneous 

pregnancy loss 

L. Conde-Ferráez, R. Suarez-Allen, L. Manzano-Cabrera, M. R. Gonzalez-Losa, 

G. Koh-Tec, M. Perez-Tuyub, J. Camara-Mejia, J. Carrillo-Martinez, 

M. Puerto-Solis 

Merida, Yucatan (Mexico) 

79.005 Maternal group B Streptococcus colonization: Prevalence, risk factors, 

phenotypical and genotypical characteristics in a Brazilian population 

T. S. Pires, M. Turchi, M. C. D. P. B. André, J. L. Cardoso, L. E. P. R. Schmaltz, 

O. M. Peres, A. L. Andrade 

Goiania (Brazil) 

79.006 Puerperal group A streptococci (GAS) infection: 

Re-emergence of a dreaded disease—A case series 

M. T. Busowski, M. Lee, J. D. Busowski, K. Akhter, M. R. Wallace 


79.007 Potential impact of spouse’s circumcision on herpes simplex virus type 2 

prevalence among antenatal women in five northeastern states of India 

B. Borkakoty 1 , D. Biswas 1 , K. Walia 2 , J. Mahanta 1 

Dibrugarh, Assam (India), 2 Delhi (India) 

79.008 The “PREVEN” urban community randomised trial of a combined intervention 

for sexually transmitted disease prevention in Nepal 

R. P. Bhandari 1 , S. D. Joshi 2 

1 

Kathmandu (Nepal), 2 Kail (Nepal) 


Final Program ~ 187

Session 79 




OBSTETRICAL-GYNECOLOGICAL, SURGICAL AND SEXUALLY TRANSMITTED INFECTIONS 

79.009 HIV and syphilis seroprevalence and associated factors in pregnant 

women and their couples in 6 Amazonian indigenous populations 

in Peru 2007–2008 

M. Omaeche, A. Whittembury, M. Pun, L. Suarez-Ognio 

Lima (Peru) 

79.010 Superoxide anion in lesions of cervix associated or not papillomavirus-infection 

Y. Carrero, D. Callejas, R. Mindiola, L. Porto, F. Alana, M. E. castellanos, 

C. Silva, L. Costa 

Maracaibo, Zulia (Venezuela) 

79.011 Detection of human Papilloma virus DNA in cervical samples in 

Maracaibo-Venezuela 

D. Callejas, M. E. castellanos, R. Mindiola, Y. Carrero, F. Monsalve, 

L. Porto, R. Atencio 

Maracaibo, Zulia (Venezuela) 

79.012 Sexually transmitted disease recurrence in the department of defense 

A. McCabe, G. Nowak 

Portsmouth, VA (USA) 


188 ~ Final Program

Session 80 




PEDIATRIC AND PERINATAL INFECTIONS 

80.001 Effect of zinc supplementation on clinical course of acute diarrhea in patients 

admitted in Ali Asghar Children Hospital Medical Center Iran University of 

Medical SciencesTehran Iran 

K. Mahlouji 


80.002 Neonatal tetanus cases in a region in Ghana: Contributory factors and 

consequential outcomes 

E. Koomson 

Cape Coast (Ghana) 

80.003 Role of adjuvant zinc in the treatment of severe pneumonia in young children: 

A meta-analysis of benefits and risks 

R. Das, M. Singh, N. Gupta, N. Shafiq 


80.004 DNA amplification and sequence analysis of P1 adhesin gene fragments in 

M.pneumoniae from pediatric respiratory infections 

S. Kumar, S. R. Saigal, G. R. Sethi, R. Chaudhry 


80.005 Incidence and characterization of neonatal sepsis cases in a Colombian hospital 

during 2007–2008 

M. L. Raciny Aleman, A. M. Castro Cordero, L. R. Ramos Hernandez, 

A. B. Muñoz Delgado 

Monteria (Colombia) 

80.006 Epidemiological data of infectious disease for 10 years in PICU 

F. Zavalani, I. Bujari, A. Koja, I. Bakalli, E. Kola, E. Kallfa, S. Sallabanda, 

R. Petrela, R. Lluka, E. Celaj 


80.007 The feasibility of rectal artesunate as pre-referral treatment for severe malaria in 

under fives at community level in rural Uganda 

J. Rujumba, E. A. Mworozi, B. A. Mpeka, T. Lutalo, R. Azairwe 


80.008 Clinical features predicting mortality (M) in high risk febrile neutropenic 

cancer children (HR-NTPCH) at Hospital de Niños Ricardo Gutiérrez 

(HNRG), Argentina 

N. Rivas, A. Viña, G. Yerino, C. Ceccoli, F. Plat, C. Hascalovici, E. L. Lopez 



Final Program ~ 189

Session 80 





80.009 Non-typeable Haemophilus influenzae and Streptococcus pneumoniae: 

Primary causes of acute otitis media in Colombian children 

P. Lopez 1 , A. Sierra 1 , M. A. Zapata 1 , B. Vanegas 1 , R. De Antonio 2 , 

M. M. Castrejon 2 , W. Hausdorff 3 , R. Colindres 4 

1 

Cali (Colombia), 2 Panama City (Panama), 3 Wavre (Belgium), 

4 


80.010 Risk factors (RF) for necrotizing enterocolitis (NE) in Pediatric oncologic patients 

(POP) with neutropenia (NTP) 

N. Rivas, A. Viña, G. Yerino, M. L. Praino, C. Ceccoli, F. Plat, C. Hascalovici, 

A. Cane, E. L. Lopez 


80.011 Temporal variation of human rotavirus types circulating in Caracas 

during 2007–2008 

E. Vizzi, O. Piñeros, A. C. Alcala, M. D. Oropeza, L. Naranjo, J. A. Suarez, 

J. L. Zambrano, F. Liprandi 


80.012 Kawasaki disease in a children hospital at Dominican Republic, period 

January 2006–October 2009 

C. S. Mota 


80.013 Epidemiology, clinical and microbiology characteristic of multiresistant 

Acinetobacter spp. bacteremia in a pediatric hospital in Argentina 

S. Ruvinsky, G. Fiorilli, G. Perez, B. Juzielewski, L. Mannino, L. Casimir, 

M. T. Rosanova, H. Lopardo, R. Bologna 


80.014 Spectrum of infections in children with nephrotic syndrome 

D. Chopra, P. Kini, N. Bhaskaranand, S. Aroor 



80.015 Multicenter study of meningococcal disease in children in pediatric hospitals 

in Argentina 

H. Paganini, E. L. Lopez, A. Mónaco, M. L. Praino, C. Sarkis, L. Vozza, 

M. C. Ceinos, C. Echave, L. Inda, V. Vazquez, S. Neyro, A. Procopio, 

M. M. Contrini 


190 ~ Final Program

Session 80 





80.016 The association between vitamin D deficiency, folate deficiency and 

seropositivity to persistent pathogens among U.S. children 

A. Simanek 1 , J. Dowd 2 , A. Aiello 1 

1 

Ann Arbor, MI (USA), 2 New York, NY (USA) 

80.017 Pilot study to determine feasibility of development of an influenza clinical 

diagnostic tool 

R. Nipp, T. Bell, D. Ruhl, C. Lee, J. Kirkland 

Amarillo, TX (USA) 

80.018 Data management, design and analysis challenges in the prevention of perinatal 

sepsis (PoPS) randomized control trial, Soweto, South Africa 

L. Kuwanda, C. Cutland, S. Madhi 


80.019 RCT Methodology, population profile and pneumonia rates in socioeconomically 

deprived infants of Kabul: Data from a RCT investigating the 

effects of vitamin D supplementation on the incidence of infant pneumonia 

Z. Zabihullah 1 , S. Manaseki-Holland 2 , D. Chandramohan 1 , Z. Bhutta 3 , 

Z. Mughal 4 

1 

London (United Kingdom), 2 Birmingham (United Kingdom), 3 Karachi (Pakistan), 

4 

Manchester (United Kingdom) 

80.020 Morbility and mortality for neonatal sepsis in a Hospital in 

Havana City, 1998–2008 

M. Cristia Pacheco 

Ciudad de la Habana (Cuba) 

80.021 Age and sex specific pattern of urban malaria and diarrhea mortalities in Accra 

J. Fobil 1 2 , A. Kraemer 3 , J. May 1 

1 

Hamburg (Germany), 2 Legon, Accra (Ghana), 3 Bielefeld (Germany) 

80.022 Paediatric rotavirus disease in The Gambia: A hospital based sentinel study 

R. C. Ideh 1 , O. Rodrigues 2 , G. E. Armah 3 , A. S. Batchilly 1 

1 

Banjul (Gambia), 2 Accra (Ghana), 3 Legon (Ghana) 


Final Program ~ 191

Session 80 





80.023 The role of viruses in the aetiology of IRA in Peruvian children 

J. del Valle 1 , A. Cornejo 1 , L. del Valle 2 , T. Pumarola 2 , E. Verne 1 , V. Helasvuo 1 , 

R. Nazario 1 , D. Champin 1 

1 

Lima (Peru), 2 Barcelona (Spain) 

80.024 Clinical and epidemiology characterization of children hospitalized with 

influenza A H1N1 (FLU AH1N1) during the first wave of 2009 outbreak, 

Santiago, Chile 

C. Sandoval, C. Vizcaya, C. Perret, M. Ferrés, C. Martinez, P. Godoy, 

P. Ferrer, M. Monge, K. Abarca, A. Castillo, M. Potin, J. C. Lopez 


80.025 Rapid diagnostic tests for neonatal malaria: How reliable? 

A. A. Orogade 1 , S. Aminu 2 

1 

Kaduna (Nigeria), 2 Zaria (Nigeria) 

80.026 Detection of rotavirus antigen in stools samples collected from children 

in parts of Nigeria 

D. Ehichioya 1 , C. Bode 1 , C. J. Elikwu 1 , I. Ossai 2 , R. Orenolu 1 , S. Omilabu 1 

1 

Lagos (Nigeria), 2 Benin (Nigeria) 


192 ~ Final Program

Session 81 




PUBLIC HEALTH INTERVENTIONS, MODELING & TRAINING 

81.001 Bed net coverage, usage and condition in fishing villages of Suba district, 

Western Kenya 

D. Gabriel 

Kisumu (Kenya) 

81.002 Quantitatively estimated the global burden of disease of chronic 

and infectious diseases interface in 2002 

Y. Yan 1 , B. Choi 2 , H. Morrison 2 , T. Wong 2 , J. Wu 2 

1 

Xi’an (China), 2 Ottawa, ON (Canada) 

81.003 Application of international health regulations in the Singapore pandemic 

influenza experience 

P. L. Ooi 


81.004 Models and data for determining transmission routes 

J. Koopman 


81.005 Epidemiological transition in Venezuela: Relationships between infectious 

diarrheas, ischemic heart diseases and transportation accidents mortalities and 

the human development index (HDI) in Venezuela, 2005–2007 

A. Rísquez Parra, L. Echezuria, A. Rodriguez-Morales 


81.006 Medical needs assessment and infectious diseases concerns in rural Honduras— 

Implications for medical relief planning 

M. P. Stevens, K. Elam, L. F. Stevens, S. Shodhan, D. Markley, R. Hemrajani, 

K. Sanogo, G. Bearman 


81.007 Redevelopment and evaluation of EpiData: A practical software tool for use in 

the public health field 

A. Arthur 1 , J. Garay 2 , B. Guarda 3 , L. Sieswerda 4 , A. Stevens 5 

1 

Toronto, ON (Canada), 2 Newmarket, ON (Canada), 3 Ottawa, ON (Canada), 

4 

Thunder Bay, ON (Canada), 5 Brantford, ON (Canada) 

81.008 Similarities and differences between persons of higher and lower income in 

Argentina, concerning their knowledge on vertically transmitted diseases 

M. Mayer Wolf, A. V. Sanchez, C. Ezcurra, V. Rodríguez, C. Freuler 



Final Program ~ 193

Session 81 





81.009 Socioeconomical aspects of malaria morbidity and mortality in Venezuela: 

An analysis of their correlations with the Human Development Index 

and its components 

A. Rodriguez-Morales 1 , J. Benitez 2 , R. Harter-Griep 3 , M. A. Lopez-Zambrano 4 

1 

Trujillo (Venezuela), 2 Maracay (Venezuela), 3 Rio de Janeiro (Brazil), 

4 


81.010 FluZone: A national decision support system for the H1N1 flu pandemic 

in England 

C. Kara-Zaïtri 1 , M. Schweiger 2 , R. Hamilton 1 

1 

Bradford (United Kingdom), 2 Leeds (United Kingdom) 

81.011 Economic burden of health care at household level: Examination of 

out-of-pocket expenditure on sexual and reproductive health care 

T. Akalu 


81.012 Testing the effectiveness of dengue vector control interventions 

L. Sanchez 1 , J. Maringwa 2 , Z. Shkedy 3 , M. Castro 1 , N. Carbonell 4 , 

P. Van der Stuyft 5 

1 

Havana City (Cuba), 2 Brussels (Belgium), 3 Hasselt (Belgium), 

4 

Sancti Spiritus (Cuba), 5 Antwerp (Belgium) 

81.013 Age at sexual initiation and its determinants among youths in NE Ethiopia 

F. Mazengia 

Gondar (Ethiopia) 

81.014 World Rabies Day Campaign: Evaluating a global initiative 

P. Costa 1 , P. Orlosky 2 , J. Blanton 2 , D. Briggs 1 , C. Williams 1 , A. Tumpey 2 

1 

Manhattan, KS (USA), 2 Atlanta, GA (USA) 


81.015 From strategy to action: The vital roles of trained field epidemiologists and 

laboratory management professionals in epidemic control and prevention 

in Tanzania 

O. Oleribe 1 , F. Mosha 1 , M. Mohammed 1 , J. Mghamba 1 , P. Mmbuji 1 , 

P. Nsubuga 2 , D. Mukanga 3 

1 

Dar Es Salaam (Tanzania, United Republic of), 2 Atlanta, GA (USA), 

3 


81.016 Continuous medical education: Teaching infectology using the internet 

T. Zitto, A. Melamud, M. L. Arcidiacono, H. Lopez 


194 ~ Final Program

Session 81 





81.017 Measles epidemy with complications in Bosnian children during 2008— 

Prevention strategy 

A. Bajraktarevic 

Sarajevo (Bosnia and Herzegovina) 

81.018 GLaDMap: Global Laboratory Directory Map 

S. Mukhi 1 , L.-K. Ng 1 , M. Chu 2 , B. Swaminathan 3 

1 

Winnipeg, MN (Canada), 2 Geneva (Switzerland), 3 Atlanta, GA (USA) 

81.019 Comprehensive community hygiene promotion in peri-urban Cape Town: 

gastrointestinal and respiratory disease reduction in families 

E. Cole 1 , M. Hawkley 1 , J. R. Rubino 2 , K. McCue 2 , B. Crookston 3 , J. Dixon 1 , 

T. Maqelana 4 , J. Cwayi 4 , C. Adams 4 

1 

Provo, UT (USA), 2 Montvale, NJ (USA), 3 Salt Lake City, UT (USA), 

4 

Cape Town (South Africa) 

81.020 An alternative standard for radiological pneumonia in children 

G. Mackenzie, U. Uchendu, D. Ameh, O. Adeyemi, D. Saha 

Basse (Gambia) 

81.021 Field evaluation of ZeroVector Durable Lining as an alternative to indoor 

residual spraying (IRS) for the control Anopheles vectors of malaria in rural 

villages of Obuasi, Ghana 

J. Stiles-Ocran 1 , S. Knowles 1 , D. A. Boakye 2 

1 

Obuasi (Ghana), 2 Accra (Ghana) 

81.022 Mass screening and treatment for malaria among gold miners in Suriname 

L. Villegas, H. Cairo, A. Huur, H. Vinisi, H. Pereira, N. Jozuazoon, F. Refos, 

S. Summerville, L. Hardjopawiro, M. Jordaan, S. Mitro, H. Hiwat, C. Alensi, 

P. Malaria Technical Committee 

Paramaribo (Suriname) 

81.023 Almost 10.000 second opinion consultations in infectious diseases. 

A telemedicine program in Argentina 

C. Sarkis, C. Vujacich, F. García, L. Carniglia, S. Enrique, R. Debbag, 



81.024 7 Years’ experience in a telemedicine program in infectious diseases in Argentina 

R. Debbag, S. Enrique, F. García, C. Sarkis, C. Vujacich, E. Andión, L. Carniglia, 



81.025 Sustained malaria control in Suriname after 3 years of effective interventions 

L. Villegas, H. Hiwat, H. Cairo, L. Hardjopawiro, S. National Malaria Board 

Paramaribo (Suriname) 


Final Program ~ 195

Session 82 




TRYPANOSOMIASIS, LEISHMANIASIS & SCHISTOSOMIASIS 

82.001 Inhibition of entry and survival of Leishmania donovani by down regulation of 

TACO gene on human macrophages using Vitamin D3 & Retinoic Acid 

V. Reddy 


82.002 A diagnostic approach to detect murine Shistosoma mansoni infection using a 

polymerase chain reaction 

A. Hassan 

Gizan (Saudi Arabia) 

82.003 Leishmania aethiopica: The unusual etiologic agent of cutaneous leishmaniasis 

in Ho District of the Volta region of Ghana 

G. Kwakye-Nuako 

Accra (Ghana) 

82.004 The role of colonoscapy and squash preparations in diagnosis and follow-up of 

stool negative enteric schistosomiasis: A case report of double infection with 

S. mansoni and S. intercalatum 

M. Astriti, K. Tzanetou, K. Sarri, K. Ntinos, G. Adamis, V. Delis, G. Moustakas, 

M. Choreftaki, P. Gargalianos 


82.005 Trypanocidal activity of novel alkanediamide-linked bisbenzamidines and 

bisbenzamidoximes 

T. Huang 1 , N. Kode 1 , C. Bacchi 2 , D. Rattendi 2 , J. J. Vanden Eynde 1 , A. Mayence 1 , 

N. Yarlett 2 , I. Londono 2 

1 

New Orleans, LA (USA), 2 New York, NY (USA) 

82.006 A critical role of CD2 as an immunoprophylactic agent to combat 

visceral leishmaniasis 

S. Sinha 1 , S. Bimal 2 , S. Sundaram 1 

1 

Allahabad (India), 2 Patna (India) 


82.007 Patients with suspected visceral leishmaniasis in Istanbul 

H. Cakan, S. Saribas, V. Oz, E. Polat, M. Aslan, B. Kocazeybek 


196 ~ Final Program

Session 82 




TRYPANOSOMIASIS, LEISHMANIASIS & SCHISTOSOMIASIS 

82.008 Immunological profile of CD18-deficient mice during 

Schistosoma mansoni infection 

M. S. Espíndola, F. G. Frantz, L. H. Faccioli 

Ribeirão Preto, SP (Brazil) 

82.009 Control of Chagas disease patients whith chronic form of its treatment after 

Benznidazole treatment 

M. T. Fraile Fariñas, C. Parada Barba, J. L. Ramos Marti, M. Chanza Avino, 

M. Garcia Rodriguez, C. Gimeno Cardona 


82.010 Population structure of Leishmania infantum from Morocco 

H. Salsabil 1 , A. Amro 2 , G. Schönian 3 , L. Meryem 1 

1 

Casablanca (Morocco), 2 Jerusalem (Palestina), 3 Berlin (Germany) 

82.011 Propolis and derivatives of megazol: In vitro and in vivo activity on 

Trypanosoma cruzi, mechanism of action and selectivity 

K. Salomão 1 , E. M. De Souza 2 , H. S. Barbosa 1 , S. L. de Castro 2 

1 

Rio de Janeiro, Rio de Janeiro (Brazil), 2 Rio de Janeiro (Brazil) 

82.012 Alanine 163 in loop C of Leishmania major aquaglyceroporin LmAQP1 

resides near the pore mouth of the channel 

Y. Zhou 1 , G. Mandal 1 , V. S. R. Atluri 1 , E. Beitz 2 , R. Mukhopadhyay 1 

1 

Miami, FL (USA), 2 Kiel (Germany) 

82.013 Chagas disease: Mother to child transmission (MTCT). 

A single experience in a public hospital from Buenos Aires 

M. T. Rodriguez Brieschke, M. Seoane, C. Nieto, V. Loggia, E. Bottaro, 

M. Giacco, J. C. Gonzalez, P. G. Scapellato 


82.014 Trypanosoma cruzi expressing luciferase for drug screening using a 

Bolivian strain 

S. Nunez 1 , H. Mayta 1 , M. Verastegui 1 , C. Lafuente 2 , C. Bern 3 , R. Gilman 4 

1 

Lima (Peru), 3 Santa Cruz (Bolivia), 3 Atlanta, GA (USA), 4 Baltimore, MD (USA) 


Final Program ~ 197

Session 83 




VACCINES AND VACCINE DEVELOPMENT 

83.001 The effectiveness of one dose of varicella vaccine 

Z. Kurugol 

Izmir (Turkey) 

83.002 Production and characterization of a chimeric recombinant protein from 

synthetic genes consisting antigenic domain of EspA, Intimin and Tir of 

Escherichia coli O157 and evaluation as a candidate vaccine antigen 

in animal model 

J. Amani, S. L. Mousavi, S. Rafati, A. H. Salmanian 


83.003 Variability of PspC (Pneumococcal surface protein C) in strains isolated in the 

University Hospital of the University of São Paulo (Brazil) 

A. T. Moreno 1 , D. M. Ferreira 1 , F. C. Pimenta 2 , S. R. Santos 1 , 

M. B. Martinez 1 , E. Miyaji 1 

1 

São Paulo (Brazil), 2 Atlanta, GA (USA) 

83.004 Combination of whole cell pertussis vaccine and the pneumococcal surface 

protein A (PspA) antigen: proposal of a combined vaccine against pertussis and 

pneumococcal diseases 

M. L. Sarno de Oliveira, D. M. Ferreira, A. T. Moreno, P. C. D. Ferreira, 

E. Miyaji, P. Ho 


83.005 Protection against pneumococcal nasopharyngeal colonization in mice 

immunized with PspC (“Pneumococcal Surface Protein C”)-based vaccines 

formulated with whole bacteria as carriers or adjuvants 

M. De Lúcia Hernani, D. M. Ferreira, P. C. D. Ferreira, A. T. Moreno, E. Miyaji, 

P. Ho, M. L. Sarno de Oliveira 



83.006 Immunogenicity of interleukin 12 and DNA vaccine prime-BCG boost against 

Mycobacterium tuberculosis 

L. Bao, L. Gao, Y. Bao 

Chengdu (China) 

83.007 The role of inactivated polio vaccine (IPV) in achieving polio eradication in India 

A. Bhatti 

Delhi (India) 

198 ~ Final Program

Session 83 





83.008 Antibody persistence 22 months after vaccination of adolescents with the 

Novartis investigational meningococcal ACWY-CRM197 conjugate vaccine 

or Menactra® 

C. Gill 1 , A. Anemoma 2 , G. Ciavarro 1 , A. Kleinschmidt 3 , P. Dull 1 

1 

Cambridge, MA (USA), 2 Siena (Italy), 3 Marburg (Germany) 

83.009 Know essentials—A novel algorithm for informed vaccine-related 

decision-making in developing countries. 

J. L. Mathew 


83.010 vax-SPIRAL®: Cuban antileptospirosis vaccines for humans: Clinical and field 

assays and impact of the vaccine on the disease after 11 years of application 

in Cuba 

R. Martínez 

Ciudad Habana (Cuba) 

83.011 Immunization with surface protein 2 (TcSP2) protects mice from acute 

experimental Trypanosoma cruzi infection: A potential candidate for 

vaccine development 

A. Carabarin, C. González, L. Baylon-Pacheco, J. L. Rosales-Encina 

México (Mexico) 

83.012 Long term immunogenicity following a booster dose of the inactivated Japanese 

encephalitis vaccine IXIARO®, IC51 

K. L. Dubischar-Kastner 1 , S. Eder 1 , T. Jelinek 2 , B. Jilma 1 , A. Kaltenboeck 1 , 

H. Kollaritsch 1 , E. Schuller 1 , C. Klade 1 

1 

Vienna (Austria), 2 Berlin (Germany) 

83.013 Cost effectiveness of Pneumovax® 23 stockpile to prevent secondary 

pneumococcal infections among a high-risk population in the United States 

during an influenza pandemic 

P. Dhankhar 1 , J. Grabenstein 2 , M. O’Brien 2 , E. J. Dasbach 1 

1 

North Wales, PA (USA), 2 West Point, PA (USA) 

83.014 Cost-effectiveness of the use 23-valent pneumococcal polysaccharide vaccine to 

prevent secondary bacterial infections related to pandemic influenza in Brazil 

M. O’Brien 1 , P. Dhankhar 2 , J. Grabenstein 1 , E. J. Dasbach 2 

1 

West Point, PA (USA), 2 North Wales, PA (USA) 


Final Program ~ 199

Session 83 





83.015 Impact study of hepatitis B vaccination in Sikkim—A north eastern state of India 

A. Verma, V. Gupta 

Gangtok (India) 

83.016 A vaccine derived poliovirus case in an immunocompromised argentinian child 

M. E. Burgos, S. Elkik, P. Barbosa, M. Oleastro, C. Freire, A. Parra, M. Caparelli, 

C. Sarkis 


83.017 Influenza vaccine: Immunization rates, knowledge, attitudes and practice of 

health care workers in Iran in 2008/09 

Z. Khazaeipour, N. Ranjbar Novin, N. Hoseini 


83.018 Variable serological response to PPV in HIV-positive patients—A need to review 

pneumococcal boost-prime strategies? 

A. Brown, C. Rock, C. Ní Bhuachalla, T. Coulter, C. Dowling, C. Bergin 


83.019 The generation of immortalized human B-lymphocytes secreting neutralizing 

monoclonal antibodies against Dengue virus 

E. Teoh 


83.020 Factors Contributing to Uptake of the Publicly-funded HPV vaccine in Toronto 

H. Meghani, V. Dubey, O. Kadri, A. Mathur, J. Cameron, K. Beckermann 

Toronto, ON (Canada) 

83.021 Effectiveness of influenza vaccine in elderly people with chronic pulmonary and 

cardiovasculardiseases in Argentina 

F. Nacinovich, P. Bonvehi, R. Ruttimann, D. Stamboulian 



83.022 Development and immunogenicity of a novel polyetherimine (PETIM) 

endrimer-based nanoformulated DNA rabies vaccine 

M. Shampur, U. Padinjarenmattathil, A. Desai, J. Narayanaswamy 

Bangalore (India) 

200 ~ Final Program

Session 83 





83.023 Factors associated with DPT 1–3 vaccine dropout in Kabarole district, 

western Uganda 

M.-S. Opollo, F. Makumbi, D. Mukanga, O. Namusisi, N. Ayebazibwe, 

R. Tweheyo 


83.024 Antibody persistence 10 years after 1st and 2nd doses of 23-valent 

pneumococcal polysaccharide vaccine (PN23), and immunogenicity and safety 

of 2nd and 3rd doses in older adults 

S. Manoff 1 , R. McFetridge 1 , C. Liss 1 , R. Marchese 1 , J. Rabb 2 , A. Rueda 3 , 

D. Musher 3 

1 

North Wales, PA (USA), 2 Wayne, PA (USA), 3 Houston, TX (USA) 

83.025 Public health approach after detection of an iVDPV case in Argentina 

M. C. Freire, M. Caparelli, S. Garcia Jimenez, D. Cisterna, C. Vizzotti, 

C. Lema, A. Gentile 


83.026 Yellow fever vaccine (YFV) and events supposedly attributable to 

vaccination or immunization (ESAVIs): Argentina’s experience 

C. Vizzotti, C.Biscayart, D. Stecher, E. Perez Carrega, M. A. Morales, C. Digiglio, 

D. Enria, T. Orduña, S. Garcia Jimenez, A. Gentile, S. Betancourt, M. Diosque 


83.027 Genetic characterization of Mycobacterium bovis BCG Mexico 1931 

P. Orduña 1 , Y. López 1 , M. A. Cevallos 2 , S. Ponce de León 1 

1 

Mexico City (Mexico), 2 Cuernavaca (Mexico) 

83.028 Pneumococcal vaccination—Is hyporesponsiveness a problem? 

H. Lode 



Final Program ~ 201

Session 84 




VIROLOGY AND VIRAL INFECTIONS (NON-HIV) 

84.001 Intravenous immunoglobulin manufactured from selected Chinese donors 

protects mice from lethal Enterovirus 71 infection 

R. Cao, J. Han, E. Qin, C. Qin 


84.002 Polio controling Nigeria and other developing countries: A systematic review/ 

meta-analysis of literature on the use of combined OPV & IPV measure as 

against OPV only 

S. I. Ezikeanyi 


84.003 Factors associated with outbreaks of measles in the highly immunized hilly areas 

of district Kangra, Himachal Pradesh, India, 2007 

S. N. Gupta 1 , V. ramachandran 2 , N. N. Gupta 1 , M. D. Gupte 2 

1 

Kangra (India), 2 Chennai (India) 

84.004 Outbreak investigations of double measles in a two highly immunized hilly areas 

of district Kangra, Himachal Pradesh, India, 2007 

S. N. Gupta 1 , V. ramachandran 2 , N. N. Gupta 1 , M. D. Gupte 2 

1 

Kangra (India), 2 Chennai (India) 

84.005 Higher prevalence of norovirus than rotavirus as cause of acute gastroenteritis in 

hospitalized infants of Concepcion, Chile 

S. Montenegro, S. Pineda, I. Enriquez, N. Enriquez, M. Pinilla, 

N. Rivera, C. Delgado 

Concepcion (Chile) 

84.006 Lessons that human virology can acquire from studies on avian circoand 

tumor viruses 

I. Davidson 

Bet Dagan (Israel) 


84.007 Optimization of IgG-ELISA and molecular analysis of Reston-ebolavirus among 

swine in Northern Luzon, the Philippines 

S. Yusuke 1 , F. Shuetsu 2 , S. Mariko 1 , C. Demetria 3 , I. Itoe 2 , M. Tetsuya 2 , 

S. Masayuki 2 , O. Momoko 2 , S. Akira 1 , S. Lupisan 3 , K. Ichiro 2 , R. Olveda 3 , 

O. Hitoshi 1 , M. Shigeru 2 

1 

Sendai (Japan), 2 Tokyo (Japan), 3 Manila (Philippines) 

84.008 A newly discovered viral enzyme capable of alteration of nucleic acid structure 

via phospho-triester and phosphodiester bonding complex: An event leading to a 

new frontier of research and development for viral diseases 

D. Pan 

Madison, WI (USA) 

202 ~ Final Program

Session 84 





84.009 Infectious mononucleosis in Albanian children 

R. Petrela, E. Kallfa, G. Lito, H. Hoxha, G. Mullalli, N. Como 


84.010 Symptomatic, long-term Parvovirus B19 infection in otherwise healthy adults 

R. Manfredi 


84.011 Detection of Sudan ebolavirus (strain Gulu) epitopes that are targets of the 

humoral immune response in survivors 

A. Sobarzo 1 , A. Groseth 2 , O. Dolnik 2 , S. Becker 2 , J. J. Lutwama 3 , V. Yavelsky 1 , 

R. S. Marks 1 , L. Lobel 1 

1 

Beer Sheva (Israel), 2 Marburg (Germany), 3 Entebbe (Uganda) 

84.012 Full genome sequence analysis of Group B human rotaviruses 

D. Yamamoto 1 , N. Kobayashi 1 , S. Ghosh 1 , S. Nagashima 2 , T. Krishnan 3 , 

M. Chawla-Sarkar 3 , S. K. Paul 4 , T. S. Aung 5 

1 

Sapporo (Japan), 2 Tochigi (Japan), 3 Kolkata (India), 4 Mymensingh (Bangladesh), 

5 

Yangon (Myanmar) 

84.013 Diagnostic criteria for Herpes simplex encephalitis: 5 year analysis in 

Mofid Children’s Hospital 

A. Karimi, M. Hadipour Jahromy, S. Tabatabaei 


84.014 Problems Associated with Community-Based Parenteral Anti-Infective Therapy 

with Intravenous Ganciclovir for Cytomegalovirus Prophylaxis in Allogeneic 

Hematopoietic Stem Cell Transplant Recipients 

S. Mossad, N. Shrestha, S. Rehm, R. Avery, B. Bolwell 


84.015 A description of the pathogenesis associated with pirital virus (an arenavirus) 

infection in the Syrian golden hamster 

R. Stammen, J. Garver, S. Sarrazine, E. Vela 


84.016 Modification of the type I interferon and proinflammatory cytokine responses 

by enterovirus 71 

Y.-P. Lee, S.-W. Huang, Y.-F. Wang, C.-K. Yu 

Tainan City (Taiwan, R.O.C.) 

84.017 The study of epidemiological data of varicella and its complications in 

Albanian children 

H. Hoxha, E. Kallfa-Foto, G. Lito, R. Petrela, A. Simaku 



Final Program ~ 203

Session 84 





84.018 Latent manifestations in the US Congenital Rubella Syndrome (CRS) Population 

N. Armstrong 

Rockville Centre, ny (USA) 

84.019 Inhibition of high risk HPV-31 in human cervical epithelial cells in vitro by the 

PC-PLC inhibitor LMV-601 

E. Amtmann 1 , F. Mayer 2 , H. Pink 1 , W. Baader 1 

1 

Heidelberg (Germany), 2 Basel (Switzerland) 

84.020 The pain topography caused by misdiagnosed zoster 

K. Duraku, N. Como, E. Meta, D. Kraja, A. Kica 

Tirane (Albania) 

84.021 Study on the prevalence of human bocavirus among children with acute 

respiratory tract infection in Guangdong, China 

X. Lu 

ShenZhen (China) 

84.022 Deciphering the infectious entry process of human entrovirus 71 

K. Mohamed Hussain, K. L. J. Leong, M. L. Ng, J. J. H. Chu 


84.023 The clinical severity of Puumala hantavirus-induced nephropathia epidemica 

and partial complement protein C4 deficiencies 

J. Sane 1 , S. Mäkelä 2 , S. Meri 1 , A. Vaheri 1 , O. Vapalahti 1 , J. Mustonen 2 

1 

Helsinki (Finland), 2 Tampere (Finland) 

84.024 Diagnosis of congenital cytomegalovirus infection by detection of viral DNA in 

urine of neonates in Honduras—Advances 

A. Ferrera Boza, M. Rivera, A. Mena, J. Ortiz 

Tegucigalpa (Honduras) 


84.025 Epidemiology of human rhinovirus C (HRV-C) in Hong Kong reveals a potential 

HRV-C subgroup 

C. Y. Yip, S. K. P. Lau, K. H. Chan, P. C. Y. Woo, K. Y. Yuen 


84.026 The role of human papillomavirus Infection in prostate carcinoma 

A. Aghakhani, R. Hamkar, M. Parvin, M. Banifazl, A. Eslamifar, A. Ramezani 


204 ~ Final Program

Session 84 





84.027 Rotavirus diarrhea in Kashmir: Detection of genotype G12P[6] strains 

I. Ahmad 

Kashmir (India) 

84.028 Surveillance of rotavirus strains reveals evidence of emerging G12 and unusual 

human-animal reassortant strains in Manipur, North-eastern India 

A. Mukherjee, M. Chawla-Sarkar 


84.029 The nucleocapsid protein of measles virus and other morbillivirus blocks host 

interferon signaling pathway 

I. Takayama, H. Sato, C. Kai 

Tokyo (Japan) 

84.030 Analysis of phosphorylation residues on Nipah virus nucleoprotein and role 

of the phosphorylation 

M. Huang, H. Sato, K. Hagiwara, A. Watanabe, F. Ikeda, M. Oyama, 

M. Yoneda, C. Kai 

Tokyo (Japan) 

84.031 Regulation of poly(A) binding protein during herpes simplex virus infection 

O. G. Larralde-Diaz 1 , R. W. P. Smith 1 , P. Malik 1 , S. V. Graham 2 , N. K. Gray 1 

1 

Edinburgh (United Kingdom), 2 Glasgow (United Kingdom) 

84.032 Complications of varicella in healthy children in Izmir, Turkey 

Z. Kurugol, O. Halicioglu, I. Devrim, G. Koturoglu, F. Vardar, C. Dizdarer, 

M. Helvacı 

Izmir (Turkey) 

84.033 Para influenza type 3 epidemic in intermediate care nursery 

K. AlTawil, S. Al Saif, I. Ali, H. Tawakol, A. Shafei 

Riyadh (Saudi Arabia) 

84.034 Introduction of a new lineage VP7 of rotavirus G1 in the Venezuelan population 

E. Vizzi, O. Piñeros, A. C. Alcala, L. Naranjo, J. A. Suarez, F. Liprandi 


84.035 The nucleocapsid protein of SARS CoV interacts with PIAS1 and affects 

the NFkappaB pathway 

N. Satija, R. Ahmed, S. Lal 

Delhi (India) 


Final Program ~ 205

Session 84 





84.036 Molecular epidemiology of rhinoviruses among children diagnosed as 

severe pneumonia in the Philippines 

N. Fuji 1 , A. Suzuki 1 , S. Lupisan 2 , R. Tamaki 2 , M. Saito 2 , A. De Leon 3 , 

R. Olveda 2 , H. Oshitani 1 

1 

Sendai (Japan), 2 Manila (Philippines), 3 Tacloban (Philippines) 

84.037 Ferrovir in treatment of viral infectious diseases 

E. Kaplina 1 , E. Nazarova 2 , V. Ignatiev 3 , I. Evstaphieva 1 , N. Nosik 1 , D. Nosik 1 

1 

Moscow (Russian Federation), 2 Kirov (Russian Federation), 

3 

Saransk (Russian Federation) 

84.038 Initial poor prognostic factors of echovirus 6 and 9 infections in children 

H.-Y. Lee 1 , Y.-C. Huang 1 , C.-T. Wu 1 , C.-H. Chiu 1 , T.-Y. Lin 2 

1 

Taoyuan (China), 2 Linkou (Taiwan, R.O.C.) 

84.039 Detection and clinical characterization of WU polyomavirus with acute 

respiratory tract infection in children, Guangdong of China 

X. Lu 1 , Q. Wang 1 , W. L. Zhuang 2 , G. Y. Lin 2 

1 

ShenZhen (China), 2 ShanTou (China) 

84.040 Amplification of early genes of Human Papilloma Virus targeting nine virus 

genotypes. Z Mérida, Venezuela 

E. Michelli 1 , L. Tellez 1 , J. Mendoza 1 , C. Jurgensen 1 , W. Botello 1 , M. Correnti 2 , 

M. Cavazza 2 , S. Vielma 1 

1 

Merida (Venezuela), 2 Caracas (Venezuela) 

84.041 Development of a new genotyping system for predicting TTV genotype using 

evolutionary restriction map and artificial neural network 

A. Kenarkoohi 1 , M. Ravanshad 1 , S. Falahi 1 , M. Rasouli 2 

1 

Tehran (Islamic Republic of Iran), 2 Shiraz (Islamic Republic of Iran) 


84.042 Seroprevalence of human cytomegalovirus infection in Singapore 

H. N. Leong, B. H. Tan, S. H. Lim, K. P. Chan 


206 ~ Final Program

Session 84 





84.043 Viral load and genome integration detection: Two molecular markers for 

HPV persistent infection 

C. Jurgensen 1 , S. Vielma 1 , E. Michelli 1 , L. Tellez 1 , J. Mendoza 1 , M. Muñoz 1 , 

M. Correnti 2 , M. Cavazza 2 

1 

Merida (Venezuela), 2 Caracas (Venezuela) 

84.044 Rabies cases in dog markets in Kaduna state, northern Nigeria 

A. Ehimiyein 1 , M. Niezgoda 1 , L. Orciari 1 , I. Kuzmin 1 , M. Osinubi 1 , | 

I. O. Ehimiyein 2 , D. Adawa 2 , S. Abdullahi 2 , A. Ogunkoya 2 , C. E. Rupprecht 1 

1 

Atlanta, GA (USA), 2 Zaria (Nigeria) 

84.045 Clinical and epidemiological aspects of mumps virus infection 

L. Maninska, M. Arapova 

Strumica (Macedonia) 

84.046 Spatial and temporal trends of the Lassa fever epidemic in Nigeria 2001–2009, 

with particular reference to the Edo State experience 

G. Akpede 1 , D. Asogun 1 , P. Okokhere 1 , S. Okogbenin 1 , H. Akpan H. 2 , 

J. Ehiemuan 1 , C. Happi 3 , S. Gunther 4 

1 

Irrua (Nigeria), 2 Abuja (Nigeria), 3 Ibadan (Nigeria), 4 Hamburg (Germany) 

84.047 Immunocompromised patients with shingles—Therapeutic approach 

L. Zabaznoska, L. Ilieva, V. Markovski, V. Semenakova-Cvetkovska 

Skopje (Macedonia) 

84.048 Peculiar case of herpetic viral encephalitis 

S.-M. Draghici, N. Negrut, A. Csep, I. Zaporojan, M. Petric 

Oradea (Romania) 


Final Program ~ 207

Faculty Disclosures 


In order to assure the highest quality programming, individuals in a position to control conference content are 

required to disclose relevant financial relationships with any commercial or proprietary entity producing health care 

goods or services relevant to the content being presented. The following speakers have no disclosures. 

SPEAKER NAME 

ACUNA Guillermo (Chile) 

ALTER Galit (USA) 

AMBROSIONI Juan (Argentina) 

ANSDELL Vernon (USA)* 

ARGUIN Paul (USA)* 

AULT Steven (USA) 

BARBOSA Jarbas (Brazil)* 

BARACCO Gio (USA)* 

BARRE-SINOUSSI Francoise (France) 

BHUTTA Zulfiqar (Pakistan) 

BISCAYART Cristian (Argentina)* 

BOCKARIE Moses (UK) 

BOULOS Marcos (Brazil)* 

BRITO Maximo (USA) 

CABADA Miguel (PERU)* 

CARROLL Dale (USA)* 

CARTER Keith (USA) 

CETRON Martin (USA)* 

CHAVES Tania (Brazil)* 

CHRISTIANSEN Keryn (Australia) 

CONDE Marcus (Brazil) 

CORTES Jorge (Colombia) 

COYLE Christina (USA) 

CUELLAR-RODRIGUEZ Jennifer (El Salvador) 

DABANCH Jeanette (Chile) * 

De la MORENA, Maite (USA) 

ESCALANTE Ananias (USA) 

FRANCA Francisco (Brazil)* 

FRANCO-PAREDES Carlos (USA) 

FREEDMAN David (USA)* 

FRIEDLAND Jonathan (United Kingdom) 

GOKHALE Rajesh (India) 

GOONETILLRKE Nilu (United Kingdom) 

GOOSSENS Herman (Belgium) 

HIRSCH Martin (USA) 

HUSSELL Tracy (United Kingdom) 

JENTES Emily (USA)* 

KOLTER Roberto (USA) 

LaROSA Steven (USA) 

LEFRANCOIS Thierry (Guadeloupe) 

LEMOS HINRICHSEN Sylvia (Brazil)* 

LEPETIC Alejandro (Argentina)* 

SPEAKER NAME 

LLOVERAS Susan (Argentina)* 

LOPARDO Gustavo (Argentina)* 

LOUTAN Louis (Switzerland)* 

MACCHI Alejandra (Argentina)* 

MADOFF Larry (USA) 

MAGILL Alan (USA)* 

MALAQUE Ceila (Brazil) 

MASCHERETTI Melissa (Brasil) 

McCULLERS Jonathan (USA) 

METZGER Dennis (USA) 

MOORE Penny (USA) 

MORENS David (USA) 

MOROSINI Maria Isabel (Spain) 

MOSSAD Sherif (USA) 

MOUNTS Anthony (Switzerland) 

MULHOLLAND E.K. (United Kingdom) 

NDASE Patrick (Uganda) 

NORDMANN Patrice (France) 

NYARUHIRIRA Alaine (Rwanda) 

ODIO Carla (Costa Rica) 

PASTERAN Fernando (Argentina) 

PATTERSON, Thomas (USA) 

PERRET Cecilia (Chile)* 

PITTET Didier (Switzerland) 

RAMIREZ Paula (Spain) 

RESTREPO Angela (Colombia) 

RODRIGUEZ-MORALES Alfonso (Venezuela) 

SANCHEZ Pablo (USA) 

ROSENTHAL Victor (Argentina) 

SAEZ-LLORENS Xavier (Panama) 

SAVIO Eduardo (Uruguay)* 

SCHWABER Mitchell (Israel) 

SHIBL Atef (Saudi Arabia) 

SINGHI Sunit (India) 

SOSA-ESTANI, Sergio (Argentina) 

SOTELO Julio (Mexico)* 

TELLEZ Ildedonso (USA) 

TORRES Jaime (Venezuela) 

VILA Jordi (Spain) 

WARRELL David (United Kingdom)* 

WENZEL Richard (USA) 

WEY Sergio (Brazil) 

YADON Zaida (Brazil) 

208 ~ Final Program



In order to assure the highest quality programming, individuals in a position to control conference content are 

required to disclose relevant financial relationships with any commercial or proprietary entity producing health care 

goods or services relevant to the content being presented. The following disclosures are provided: 

SPEAKER NAME COMPANY NAME RELATIONSHIP 

BEARMAN Gonzalo (USA) Cardinal Health Investigator Initiated Research Grant 

Pfizer 

Investigator Initiated Research Grant 

Vestagen 


BioVigil LLC 


CAHN Pedro (Argentina) Boehringer-Ingelheim Investigator 

BMS 

Investigator, Speaker’s Bureau 

Abbott 

Investigator 

Pharmasset 

Investigator 

Merck 

Investigator, Scientific Advisor 

Pfizer 

Scientific Advisor 

Glaxo 


Avexa 


Tibotec 

Investigator, Scientific Advisor, Speaker’s Bureau 

Schering-Plough 

Investigator, Scientific Advisor, Consultant 

CHEMALY Roy (USA) ADMABiologies Grant Support 

Valeant Pharmaceuticals 

Grant Support 

Roche 

Grant Support 

GSK 

Grant Support 

COHEN Myron (USA) Merck Consultant 

CONRAD Corrie (USA) Google Employee 

CORNEJO Patricia (Mexico) Astra-Zeneca Scientific Advisor 

Merck Sharp & Dohme 

Scientific Advisor & Research Grant 

Wyeth 

Research Grant 

Janssen 


CURCIO Daniel (Argentina) Pfizer Consultant 

DABANCH Jeanette (Chile) * 

DAGAN Ron (Israel) Berna/CRucell Research Grant, Scientific Consultant, Speaker 

GSK 

Scientific Consultant, Speaker 

MSD 

Research Grant, Scientific Consultant 

Novartis 

Scientific Consultant 

Protea 

Scientific Consultant, Shareholder 

Pfizer (Wyeth) 

Research Grant, Scientific Consultant, Speaker 

DAIKOS George (Greece) Novartis Research Grant 

Bayer 

Travel Grant 

DIAMENT Decio (Brazil) Tibotec/Janssen Research Grant 

Pharmasset 


Schering-Plough 


EDMOND Michael (USA) Bio Vigil Research Grant 

Cardinal Health 


GISKE Christian (Sweden) Calixa Conference Support 

GOTUZZO Eduardo (Peru)* Pfizer Advisory Board 

MSD 

Grant for 

Tibotec 

Grant for 

GOULD Ian (Scotland) Amoeba Consultancy 

Astellas 

Consultancy / Sponsorship for meetings 

Becton Dickinson 

Consultancy 

Biomerieux 

Sponsorship for meetings 

Cubist 

Consultancy / Lecture fees / Sponsorship for meetings 

GSK 

Shares / Consultancy 

Johnson & Johnson 

Consultancy 

Lab 901 

Consultancy 

Lilly 

Shares 

MSD 

Consultancy / Lecture fees 

Novartis 

Consultancy / Sponsorship for meetings / Lecture fees 

Pfizer 


Phico 

Research funding / Consultancy 

Wyeth 


Zeneca 

Research funding / Sponsorship for meetings / Lecture fee 

Final Program ~ 209




GRAYBILL Richard (USA) Merck Speaker with honorarium 

Pfizer 

Speaker with honorarium, Advisory Board 

GUZMAN-BLANCO Manuel Pfizer Advisory Board Member 

(Venezuela) 

HAY Roy (United Kingdom) Celtic Pharma International Advisory Board 

Bayer Consumer Health 

Consultant 

HEATH Paul (United Kingdom) Novartis Research Grant 



Wyeth 


HIRSCH Hans (Switzerland) Biogen Idec Consultant 

Chimerix Inc 


Novartis Pharma 


Wyeth 

Consultant 

ISTURIZ Raul (Venezuela)* Pfizer Advisory Board Committee 


IDMC Membership 

JACOBS Michael (USA) Abbott Pharmaceuticals Research Grants, Consultant 

ARPIDA Pharmaceuticals Research Grants 

Aventis Pharmaceuticals 

Research Grants, Consultant 

Basilea Pharmaceuticals 

Research Grants 

Bayer Pharmaceuticals 

Research Grants, Consultant, Speakers Bureau 

BMS Pharmaceuticals 


Cerexa Pharmaceuticals 


Daiichi Pharmaceuticals 


Dr. Reddy’s Laboratory 


Eli Lilly & Co 


GeneSoft Pharmaceuticals Consultant 

GSK Pharmaceuticals 

Research Grants, Consultant, Speakers Bureau 

Lupin Pharmaceuticals 

Consultant 

Meiji Pharmaceuticals 


Ortho-McNeil Pharmaceuticals Research Grants, Consultant, Speakers Bureau 

Pfizer, Inc. 


Rambaxy Laboratories 


Roche Pharmaceuticals 


Sanofi-Pasteur Pharmaceuticals Consultant 

TAP Pharmaceuticals 


Warner-Lambert Pharmaceuticals Research Grants 

Wockhardt Pharmaceuticals Research Grants, Consultant 

Wyeth Ayerst/ 


Lederle Pharamaceuticals 

JONG Elaine (USA) Berna-Crucell Speakers Bureau 

GlaxoSmithKline 

Medical Advisory Board 

Novartis 

Medical Advisory Board 

KLUGMAN Keith (USA) Pfizer Vaccines Research Support & Consultancy 

Merck Vaccines 

Consultancy 

GSK Vaccines 

Consultancy 

Sanofi Vaccines 

Consultancy 


Consultancy 

KRCMERY Vladimir (Slovakia) Targanta Advisory Board 2008 

Pfizer Research Grants 2000–2009 

GSK Speaker 2001 

Pfizer Speaker 2009 

Pliva Speaker 2007 

MACCHI Alejandra (Argentina)* 

McCARTHY Anne (Canada)* Shorelands, Inc, Consultant 

MIRO Jose (Spain) Abbot Consultant, Speakers honoraria 

Boehringer-Ingelheim 


Bristol-Myers Squibb 

Consultant, Research Grant, Speakers honoraria 

Cubist 

Research Grant, Speakers honoraria 

Gilead Sciences 

Consultant, Speakers honoraria 

Glaxo Smith Kline 


Merck 


Novartis 

Consultant, Research Grant, Speakers honoraria 

Pfizer 


Theravance 

Research Grant, Speakers honoraria 

210 ~ Final Program




MONTO Arnold (USA) CSL DSmB 

GSK 

Consultant 

Novartis 

DSmB member 

Roche 

Consultant 


Grant 

MURILLO, Jorge (USA) Cubist Speaker 

Ortho-McNeil 

Speaker 

Pfizer 

Speaker 

NAU Roland (Germany) Vasopharm Research Grant 

NUCCI Marcio (Brazil) Astellas Consultant 

Merck 

Research Grant, Speaker, Consultant 

Pfizer 

Research Grant, Speaker, Consultant 

NUERMBERGER Eric (USA) Pfizer Research Grant, Patent 

Otsuka 


ORDUNA Tomas (Argentina)* Novartis Argentina Advisor 

PATTERSON, Thomas (USA) 

PELTOLA Heikki (Finland) Serum Institute of India Consultant 


Monitor 

PONCE de LEON Samuel Laboratoris de Biologicos y General Director 

(Mexico) 

Reactivos de Mexico, (BIRMEX) 

a state owned company 

RAMIREZ Paula (Spain) 

RISQUEZ PARRA Alejandro Sanofi Aventis Vaccine Venezuela Speaker, Research Grant 

(Venezuela)* Wyeth/Pfizer Venezuela Speaker, Research Grant, Consultant 

GSK Venezuela 

Speaker 

RUBINSTEIN Ethan (Canada) Astellas Consultant 

Bayer 

Consultant 

Cubist 

Consultant 

Pfizer 

Consultant 

Theravance 

Consultant 

SARMENTO e CASTRO Rui Janssen Cilag Participation in Advisory Board 

(Portugal) Roche Participation in Advisory Board 

Schering Plough 

Participation in Advisory Board 

Boehringer 

Participation in Advisory Board 

STEFFEN Robert (Switzerland)* Dr Falk Pharma Principal Investigator 

Intercell 

Consultant 

Janssen-Cilag 

Sponsored Lectures 

Johnson & Johnson 

Consultant 

Optimer 

Principal Investigator, Sponsored Poster Presentation 

Salix 

Research Grant, Sponsored Lecture 

Santarus 

Consultant 

THOMSON, Kenneth (USA) Merck Speaker, Research Grants 

Becton Dickinson 

Speaker, Patent Holder, Research Grant 

Biomerieux 


Ortho-McNeil 


Final Program ~ 211

Authors Index 


Abalos G. 77.024 

Abarca K. 80.024 

Abati P. 29.018 

Abbasi F. 23.011 

Abbass A. 75.032 

Abd Elfadeel A. S. 28.047 

Abd-Elmagid E. 23.018 

Abdallah F. 21.007 

Abdollahpour G. 51.013 

Abdool Karim S. 17.003 

Abdossamadi Z. 56.016 

Abdul Majid M. S. 53.021 

Abdul Wahab Z. 56.005 

Abdullahi S. 84.044 

Abdul Rahman H. 27.031, 

27.018 

Abedi F. 53.020 

Abel P. 30.003, 30.002 

Abousaidi H. 53.005 

Abrahams M.-R. 17.003 

Abrao P. R. 54.002 

Abreu C. 58.027, 32.031 

Abreu R. G. 57.032 

Abubakar I. 32.010 

AbuSamah B. 27.018, 27.031 

Acharya A. 74.001 

Acharya K. K. V. 52.007 

Achí R. 52.001 

Achilla R. 57.037 

Ackerman A. 33.001 

Acuña G. 02.002 

Adamis G. 82.004 

Adams C. 81.019 

Adamu Kida M. 26.007 

Adawa D. 84.044 

Adegbola R. A. 21.006, 77.022 

Adejumo A. 78.012, 78.010 

Adeyemi O. 81.020 

Adhikari N. 74.011 

Adnan A. 56.005 

Adu-Gyasi D. 57.004 

Adu-Sarkodie Y. 23.003 

Affram Y. 27.008, 54.001 

Afifi R. 34.004 

Afiune J. B. 59.023, 59.018 

Afjeiee S. A. 77.003 

Afsali H. 59.003 

Afzal Aghee M. 30.008 

Agafonov A. P. 75.019 

Agarwal J. 40.001 

Aghakhani A. 27.004, 53.002, 

59.005, 84.026, 53.010 

Agosti M. R. 52.021 

Agrawal A. S. 57.023 

Agrawal C. S. 25.005 

Agrawal S. 52.006 

Agudelo C. 78.019 

Agudelo P. 47.001 

Aguiar-Alves F. 51.015 

Aguilar J. 27.015 

Aguilera G. 75.036 

Aguilera K. 32.016 

Aguilera W. 58.018 

Aguilera X. P. 76.029, 57.034 

Ahmad I. 84.027 

Ahmad Mahayiddin A. 33.009 

Ahmed A. 33.002 

Ahmed R. 84.035 

Ahmed W. 49.001 

Ahmetagic S. 34.016 

Aiello A. 80.016 

Aiello A. E. 65.003, 28.036 

Aissaoui L. 56.013, 56.008 

Ait Belghiti F. 28.037 

Ajogi I. 26.001 

Akalu T. 81.011 

Akhavan Sepahi A. 33.010 

Akhimien M. O. 26.009, 57.022 

Akhter K. 79.006 

Akhter S. 49.001 

Akin S. 78.015 

Akinbami A. 58.001, 57.001 

Akinsola A. 77.022 

Akinwande O. A. 27.005 

Akira S. 84.007 

Akolo C. 78.004 

Akpaka P. E. 33.005 

Akpan H. H. 84.046, 26.009 

Akpede G. 51.018 

Akpede G. 76.021, 76.022, 

84.046 

Aksoy A. 75.014 

Al Saif S. 84.033 

Al-Jesmi H. 58.005 

Al-Moslih M. 53.008 

Al-Natour S. 50.001 

Al-Zarouni M. 58.005 

Alabi O. 25.010 

Alan E. 75.014 

Alana F. 79.010 

Alao O. 77.018 

Alarcon F. 76.023 

Alawad M. F. E. M. 75.030 

Albano C. 58.018 

Albernaz R. 24.017 

Albornoz H. 51.012, 25.015 

Alcala A. C. 80.011, 84.034 

Alcala W. 28.004 

Alcid D. 23.008 

Aldaba J. 33.014 

Aldrete S. D. M. 56.031 

Alemayehu T. 56.004 

Alensi C. 81.022 

Aletti A. 72.004 

Aleuraki G. 23.002, 74.017 

Alexopoulos A. 26.008 

Ali H. 21.007 

Ali I. 84.033 

Alian S. 53.001 

Alipour Espeh-kolaie M. 51.025, 

51.013 

Alkan M. L. 27.005 

Alkarsani M. E. M. 57.033 

Alley C. 76.032 

Almasi Nokiani F. 27.020 

Almeida D. 76.006 

Almeida G. D. 30.020, 23.025, 

30.023 

Almeida J. 23.025, 30.023, 

23.024 

Almeida J. P. 78.006 

Almeida L. G. 33.013 

Almeida JR J. N. 30.020 

Alomar Y. 34.022 

Alsisto S. 32.021 

AlTawil K. 84.033 

Altcheh J. 72.004 

Alter G. 17.001 

Altouvas G. 74.012 

Altunay H. 75.014 

Alvarez C. 28.053 

Alvarez C. 56.030 

Alvarez S. 32.004 

Álvarez Moreno C. 56.017 

Alves A. 57.012 

Alves J. 07.003, 65.009 

Alves J. V. 30.015, 30.014 

Alves M. F. C. 51.022 

AlYasino Y. 34.022 

Amador E. 31.004 

Amani J. 83.002 

Amar Singh H. 75.011 

Ambrosioni J. 30.013, 14.001 

Ambu L. 32.021 

Ameh D. 81.020, 21.006 

Amicosante M. 75.007 

Amine A. 75.032 

Amini Navaie B. 51.013, 51.025 

Aminu S. 80.025 

Amirbozorgi G. 51.013, 51.025 

Amoako-Sakyi D. 73.009 

Amro A. 82.010 

Amtmann E. 84.019 

Amuasi J. 29.016 

Anand K. 33.006 

Ancona Lopez F. 27.012, 27.013 

Andersen B. M. 56.011 

Anderson L. J. 40.002 

Andión E. 81.024 

Andrade A. L. 79.005, 56.042 

Andrade C. D. M. 34.025 

Andrawa M. 26.010 

André M. C. D. P. B. 56.042, 

79.005 

Anekthananon T. 58.013 

Anemoma A. 83.008 

Angerami R. 76.030, 28.050, 

28.045 

Anguaku A. 26.010 

Angulo N. 73.016 

Anguzu P. 26.010 

Angwafo III F. 27.030 

Ankunda R. 56.041 

Ansari J. 27.017 

Ansary A. 52.002 

Ansdell V. 32.004, 12.004 

Antolovic-Pozgain A. 79.003 

Anunnatsiri S. 56.003 

Anusic M. 74.004 

Anwan E. E. 29.007 

Anyimadu H. 77.018 

Aoki F. 76.030 

Arabshahi M. 34.015 

Aragão S. G. A. 31.003 

Arakaki N. 32.024 

Arana Y. 58.024 

Arapova M. 84.045 

Aratchige P. 57.017 

Araújo C. 73.012 

Araujo J. 23.028 

Araujo Z. 75.013, 75.009 

Arbatskaya E. 76.005 

Arbex R. F. 59.023 

Arboleda M. 47.001 

Arce L. 72.004 

Arcidiacono M. L. 81.016 

Ardon F. 65.004 

Ardung B. 51.002 

Arechavala A. 30.018 

Arevalo J. 75.043 

Arguin P. 19.002 

Arikan S. 58.011 

Arinyedokiari C. 50.003 

Aristizabal G. 28.053 

Armah G. E. 80.022 

Armero J. 27.019 

Armstrong G. 40.002 

Armstrong N. 84.018 

Arnold F. 29.008 

Aroor S. 80.014 

Arraes-Alencar L. C. 53.035 

Arrese E. 53.026 

Arrese E. 53.015 

Arrestia M. 32.027 

Arrouk R. 59.024 

Arruda R. 75.033, 75.038 

Arthur A. 81.007 

Arvelo W. 40.004, 65.004 

Asghar R. J. 27.017 

Asiimwe B. 75.035 

Asiko V. 59.016 

Aslan M. 30.005, 58.011, 

53.013, 82.007, 30.006, 

75.014 

Asma I. 75.012 

Asogun D. 51.021, 51.018, 

84.046, 76.021, 76.022, 

72.003 

Assetta A. M. 78.014 

Assmar M. 51.025, 51.013 

Astriti M. 82.004 

Ataei B. 53.018 

Ataie M. 53.018 

Atchley D. 75.036 

Atencio R. 79.011 

Athanazio D. 77.005, 47.008 

Atluri V. S. R. 82.012 

Atluri V. S. R. 58.004 

Atmar R. L. 11.003 

Augusto K. 28.045, 28.050 

Ault S. 39.002 

Ault S. K. 57.034 

212 ~ Final Program

Authors Index 


Aung T. S. 84.012 

Avendano E. 56.032 

Avery R. 84.014 

Ávila C. A. L. 77.011 

Awad L. A. 33.002 

Awaisu A. 27.018, 27.031, 

33.009 

Ayala J. 52.018 

Ayebazibwe N. 83.023 

Aymelek M. 75.014 

Ayora-Talavera G. 57.021 

Azairwe R. 80.007 

Azarifard F. 75.027, 75.028 

Azevedo T. 76.006 

Azimi Rad M. 34.015 

Aziz F. 49.001 

Azocar T. 28.039 

Azodo C. 56.020, 27.016 

Baader W. 84.019 

Baassli L. 75.007 

Babaei Z. 58.010 

Babak A. 53.018 

Babapoor S. 28.013 

Babin C. 65.011 

Baboolal S. 33.005 

Bacchi C. 82.005 

Badal R. 74.002, 23.009 

Baddour L. M. 25.017, 25.011, 

25.013 

Badescu A. 23.019 

Badhu B. 25.005 

Badji H. 21.006 

Badri A. A. 28.047 

Badridze N. 30.021, 53.032 

Badshah C. 56.028, 77.018 

Badung B. 55.009 

Baek J.-H. 53.009, 59.007 

Baez-Saldaña R. A. 59.017 

Bagdatli Y. 75.015 

Baghaei K. 52.005 

Bagnulo H. 56.029, 28.007 

Bai X. L. 24.003 

Bailey C. 75.040 

Bailey J. 29.010 

Bajanca-Lavado M. P. 52.015 

Bajic J. 34.016 

Bajraktarevic A. 81.017 

Bakalli I. 80.006, 56.014 

Bakamutumaho B. 28.027 

Bakhiet M. 47.003 

Balaban V. 32.012 

Balajee A. 30.009 

Balakrishnan P. 78.005 

Ballantyne J. 40.002 

Ballester E. 28.019 

Balmer J. A. 49.003 

Balparda J. K. 56.027 

Balqui J. 21.004 

Baltadzhiev I. 76.012 

Balutescu C. 58.016 

Bam O. J. 29.007 

Bambili K. 77.002 

Bandawe G. 17.003 

Banifazl M. 59.005, 53.002, 

53.010, 27.004, 84.026 

Bannan C. 78.015 

Banque Navarro M. 56.043 

Banura C. 40.008 

Bao L. 83.006 

Bao Y. 83.006 

Baracco G. 07.004 

Baral R. 74.001 

Barati M. 56.006 

Barbaro D. J. 49.008 

Barberis F. 28.004 

Barbosa A. 78.006, 77.011 

Barbosa H. S. 82.011 

Barbosa P. 83.016 

Barbosa da Silva Jr J. 05.001, 

57.034, 76.029 

Barbossa-Cesnik C. 77.028 

Barbouche M. R. 31.002 

Barboza P. 28.037 

Barcelona L. 50.002 

Barkat A. 56.017 

Barlic - Maganja D. 28.016 

Barnett E. D. 21.008, 32.029 

Barone A. A. 57.012 

Barradas I. 27.024 

Barrantes K. 52.001 

Barre-Sinoussi F. 09.001 

Barreira D. 57.032 

Barrios P. R. 34.030 

Barry A. 32.005 

Bartlett D. 40.003 

Basaras M. 53.026 

Basaras M. 53.015 

Basnyat S. R. 74.011 

Bastidas A. R. 77.020 

Bastos R. 78.016 

Basuno E. 34.026 

Bataa J. 76.005 

Batchilly A. S. 80.022 

Batista L. J. A. 56.042 

Batista R. B. 32.033 

Batlle M. D. C. 52.018 

Bauch C. 28.048, 65.010 

Bauer F. 25.002 

Bavari S. 75.031 

Baveja U. K. 55.015 

Baxa D. 27.015 

Baylon-Pacheco L. 58.014, 

83.011 

Bean D. 23.010 

Bearman G. 26.011, 81.006, 

10.001 

Becker K. 56.018 

Becker S. 84.011 

Becker-Ziaja B. 51.021 

Beckermann K. 83.020 

Bedenic B. 74.004, 23.005 

Behets F. 55.013 

Beikert F. 30.011 

Beitz E. 82.012 

Bel Hadjali Z. 56.008 

Bélec L. 27.030 

Belhadjali Z. 56.013 

Bell T. 80.017 

Bellesi V. 25.016 

Beltran C. 55.002 

Ben Abdennebi Y. 56.008, 

56.013 

Ben Abid H. 56.008, 56.013 

Ben Amor R. 56.008, 56.013 

Ben Lakhal R. 56.013, 56.008 

Benetucci J. 30.018 

Benitez J. 81.009 

Benjouad A. 75.007 

Benlhassan-Chahour K. 75.022 

Benoit C. 21.008, 32.029 

Bensenor I. M. 27.022 

Bensi E. P. A. 59.020 

Bentley Tammero L. 76.007 

Bento D. 73.012 

Berbari E. F. 25.017 

Berberian G. 76.003 

Berberian G. 52.004 

Berdiñas V. 50.002 

Berenji F. 30.008 

Berezin E. 51.005, 37.001 

Berg D. E. 21.004 

Berg J. 56.011 

Bergin C. 27.025, 83.018, 

78.015 

Bergman S. 23.014 

Bermudez G. V. M. 34.032 

Bern C. 73.016, 82.014 

Berro A. 57.005 

Bertherat E. 76.010 

Betancourt S. 83.026 

Betancourt-Cravioto M. 57.021 

Betencourt C. 52.015 

Bezirtzoglou E. 26.008 

Bhalla P. 55.015 

Bhandari R. P. 79.008 

Bhaskaranand N. 80.014 

Bhatia S. 52.008 

Bhatti A. 83.007 

Bhumbra N. 59.024 

Bhumimuang K. 58.013 

Bhutta Z. 22.003, 80.019 

Bialkowska J. 53.030 

Bianchi I. 34.025 

Bickle Q. 58.015 

Bidaisee S. 34.028 

Biedenbach D. J. 48.002 

Biedenkopf R. 30.004 

Bigger J. 73.008, 73.007 

Biketov S. 58.029 

Bimal S. 82.006 

Bin Abdulhak A. 25.013, 25.011 

bin Hasmaini M. H. 53.021 

Bino S. 28.017 

Bino S. 34.029 

Binti Hamzah H. A. 53.021 

Birinci I. 75.014 

Biscayart C. 78.011, 32.015, 

32.034, 32.027, 83.026, 

32.020, 06.004 

Bishburg E. 56.025 

Bissio E. 55.004 

Bissuel F. 75.022 

Biswas D. 79.007 

Biswas S. 52.011 

Biya O. 25.010 

Blackmore C. 51.026 

Blackmore T. 59.021 

Blaise K. 72.001 

Blanco C. 29.015 

Blanco S. 53.015 

Blanco S. 53.026 

Blanton J. 81.014 

Blay S. 29.016 

Boakye D. A. 81.021 

Boakye I. 29.016 

Bobadilla M. 56.031 

Boboş C. 23.002 

Boccardo E. 27.021 

Bochkova N. G. 24.004 

Bockarie M. J. 39.004 

Bocoli Rossi M. 27.021 

Bode C. 80.026 

Bodonaik N. 52.012 

Boehringer C. 28.023 

Boekhoudt J. 76.014 

Boffa J. 33.011 

Bofill L. 27.027 

Boger S. M. 52.022 

Boghossian J. 77.019 

Bohmer D. 75.006 

Bóia M. N. 77.011 

Boisson E. 28.046 

Boivin G. 65.006 

Bojanic J. 34.016 

Bok K. 47.006 

Bologna R. 80.013, 72.004 

Boloorian A. 30.008 

Bolstorff B. 23.017 

Bolwell B. 84.014 

Bonkosky M. 57.031 

Bononi do Carmo F. 27.010 

Bonvehi P. 83.021, 28.004 

Booth L. 77.019 

Borchardt S. M. 74.010 

Borchichi L. 72.004 

Borges A. D. F. 28.015 

Borges M. C. L. 25.004 

Borghi D. 53.003, 24.002 

Boricic I. 53.023 

Borisova O. 77.025 

Borkakoty B. 79.007 

Borrow P. 17.002 

Bosnjak Z. 79.003 

Bosnjak Z. 23.005 

Botas A. 78.011 

Botas M. A. 32.015 

Botello W. 84.040 

Bottaro E. 82.013 

Bouchillon S. 77.004, 74.002, 

23.009 

Boulianne N. 65.006 

Boulos M. 19.003, 29.018 

Final Program ~ 213

Authors Index 


Bourne V. 17.002 

Bouteraa W. 56.008, 56.013 

Bouzas M. B. 30.018 

Boyd G. J. 77.017 

Boze P. F. A. 28.022 

Bozic M. 53.007 

Bradley S. E. 29.008 

Braga C. 53.029, 53.035, 53.028 

Braga C. 57.012 

Braga W. S. M. 53.031 

Brandtner E. M. 24.010 

Brar I. 27.015 

Brasil R. 24.017 

Bray D. 75.022 

Braz M. I. P. S. 33.007 

Braz W. 24.002 

Breitbart M. 76.017 

Brewer T. 21.002 

Bricks L. F. 28.022 

Brigatte M. E. 76.004 

Briggs D. 81.014, 34.011 

Brito H. F. 59.023 

Brito M. 13.004 

Brock M. 29.017, 53.031, 

78.018 

Brown A. 27.025, 83.018 

Brown C. 32.001, 57.005 

Brown J. 57.010 

Brown P. 74.016 

Brownstein J. 46.001 

Brugues J. 32.022 

Brum E. 34.030 

Brunette G. 32.005, 32.004, 

57.005 

Brust T. 51.015 

Bu Coifiu Fanego R. 76.023 

Budimir A. 23.005 

Bueno Sánchez J. G. 48.001 

Bujari I. 80.006 

Bulik C. C. 49.005 

Bulimo W. 57.037 

Burattini M. N. 23.025, 30.020 

Burazin J. 79.003 

Burger E. 30.015, 30.014 

Burgert C. 29.008 

Burgos M. E. 83.016 

Burmaa A. 28.006 

Burningham K. 56.002 

Buroni M. 28.007 

Burt F. J. 24.007, 24.009, 24.008 

Busowski J. D. 75.006, 79.006 

Busowski M. T. 75.006, 79.006 

Busuulwa M. 27.014, 51.006 

Buzina W. 30.007 

Buzon R. 33.014 

Byaruhanga R. 40.008 

Byrazeri G. 77.001 

Cabada M. 45.001 

Cabezas C. 59.010 

Cabrera B. 33.014 

Cabrera L. 21.004 

Caceres H. A. 30.016 

Cadogan S. 76.030 

Cahill J. 32.004 

Cahn P. 62.001 

Caiaffa H. 23.024, 23.025 

Cairo H. 81.022, 81.025 

Cakan H. 82.007, 58.011 

Calanni L. 32.019 

Caldas C. 32.031 

Caliskan R. 53.013 

Callejas D. 79.011 

Callejas D. 79.010 

Calva J. J. 26.003, 21.003 

Calzada L. J. E. 34.008 

Camacho A. 56.031 

Camara-Mejia J. 79.004 

Camargo L. M. 54.002 

Camargo M. 52.019 

Cameron J. 83.020 

Campana M. V. 74.019 

Campitelli M. 57.020 

Campos F. D. 21.003, 26.003 

Canava S. 26.012 

Canda P. 53.027 

Cane A. 80.010 

Canetti M. D. 24.002, 53.003 

Cañizal A. M. 30.018 

Cannella V. 26.006 

Cannon S. 29.014 

Cano-Arellano B. 59.017 

Cantoni G. 32.019 

Cao R. 84.001 

Caparelli M. 83.016 

Caparelli M. 83.025 

Cappellini R. 72.004 

Carabarin A. 83.011, 58.014 

Carballal G. 28.004 

Carbonell N. 81.012 

Cardoso A. 57.012 

Cardoso J. L. 79.005, 56.042 

Cardoso L. 56.038 

Cardoso M. R. 57.012, 53.028, 

53.035, 53.029 

Cariello P. 55.014 

Carli M. S. 24.017 

Carnevale E. P. 72.005 

Carniglia L. 81.024, 81.023 

Carranza C. M. 78.014 

Carranza M. 77.014 

Carrero Y. 79.010, 79.011 

Carrilho F. 57.012 

Carrillo A. C. 75.024, 76.007 

Carrillo-Martinez J. 79.004 

Carroll D. 45.004 

Carter K. 19.001 

Carvalhanas T. R. M. P. 28.030, 

28.026, 28.028, 57.018 

Carvalho C. X. 56.042 

Carvalho J. 28.050 

Carvalho N. 51.022 

Carvalho R. A. C. 53.031 

Carvalho Siqueira E. 28.015 

Carvalho valle L. M. 76.004, 

28.015 

Caseiro M. M. 55.011 

Casellas J. M. 74.019 

Casimir L. 80.013 

Cássio de Moraes J. 51.005 

Castañeda B. C. 55.003 

Castaño J. C. 58.023 

Castaño Osorio J. C. 58.031 

Castellanos M. E. 79.011, 

79.010 

Castillo A. 80.024 

Castillo A. I. 31.005, 31.004 

Castillo C. 55.003 

Castillo R. 34.020 

Castillo S. 78.011 

Castillo Rojas G. 52.024, 77.029 

Castrejon M. M. 80.009 

Castrillón D. M. 56.027 

Castro G. 76.003 

Castro J. G. 27.024 

Castro M. 81.012 

Castro C. N. 34.003 

Castro Cordero A. M. 80.005 

Castro del C. N. 34.017 

Castro del Campo N. 34.031 

Castro Sesquen Y. 73.016 

Caterino-de-Araujo A. 78.016 

Cavazza M. 84.043, 84.040 

Cavrini F. 76.011, 51.019, 

24.016, 76.028, 51.020 

Cazes C. I. 77.024 

Cecchini D. 30.018, 56.034 

Cecchini D. M. 52.021 

Ceccoli C. 80.010, 80.008 

Cecetkova B. 56.023 

Ceinos M. C. 80.015 

Celaj E. 80.006, 56.014 

Celentano A. 25.016 

Celik A. 30.005, 30.006 

Celum C. 17.004 

Cepeda D. 34.020 

Cera D. 25.016 

Ceragioli Oliveira F. L. 27.013, 

27.010, 27.011, 27.012 

Cerqueira S. 33.013, 51.017 

Cespedes-Zambrano M. J. 

34.020 

Cetron M. 16.001 

Cevallos M. A. 83.027 

Chadha M. 28.009 

Chae Y. T. 53.009, 59.007 

Chagas-Junior A. 47.008 

Chakrabarti S. 57.023 

Chalandon Y. 30.013 

Champin D. 80.023 

Chan K. P. 24.003, 84.042 

Chan K. H. 28.043, 84.025 

Chandra B. K. 56.022 

Chandra C. 40.006 

Chandra P. 34.010 

Chandramohan D. 80.019 

Chang H.-L. 40.005 

Chanthavisouk C. 57.017 

Chanza avino M. 82.009 

Chao L.-L. 34.009 

Charest H. 65.006 

Chatterjee S. 23.001 

Chau B. 76.017 

Chaudhry R. 80.004 

Chaves T. S. 65.009, 06.003 

Chávez Gómez A. 56.019 

Chavez RIos A. 33.016 

Chawla-Sarkar M. 84.012, 

84.028, 57.023 

Chazan B. 50.004 

Cheema A. 30.024 

Chemaly R. 69.003 

Chen C.-M. 28.032 

Chen D. 47.005 

Chen H.-Y. 53.034, 75.039 

Chen L. H. 21.008, 32.029 

Chen S.-C. 76.015 

Chen T. 73.011 

Chen Y.-S. 75.020 

Chen Y.-H. 53.034 

Cheong H. J. 56.039 

Cheraghipour K. 53.024 

Cherki W. 75.007 

Chernesky M. 75.005 

Chessari M. L. 78.014 

Chiabrando R. 72.004 

Chiang P.-S. 76.015 

Chiarello A. 75.036 

Chile N. 58.024 

Chima-Oduko E. O. 79.001 

Chin B. S. 53.009, 59.007 

Chindavongsa K. 57.017 

Chitnis D. 23.021 

Chitnis S. 23.021 

Chitnis V. 23.021 

Chiu C.-H. 49.006, 84.038 

Chkhartishvili N. 55.008 

Chlibek R. 56.023 

Cho B. 28.035 

Cho E. Y. 51.016 

Cho O.-H. 56.040 

Choi B. 81.002 

Choi E. H. 51.016 

Choi H. 53.009, 59.007 

Choi H. 21.002 

Choi J. Y. 59.007, 53.009 

Choi S.-H. 56.040 

Choi W. S. 56.039 

Chong M. K. 24.013 

Chong P. P. 47.007, 73.014 

Chong Y. P. 56.040 

Chopra D. 80.014 

Choreftaki M. 82.004 

Chou Y.-P. 28.032 

Chow A. 76.002 

Christ T. 25.012 

Christenson B. 51.002 

Christiansen K. 10.002 

Christin M. 78.011 

Chrysos G. 74.012 

Chu J. J. H. 84.022 

Chu M. 81.018 

Chu V. 25.013, 25.011 

214 ~ Final Program

Authors Index 


Chua A. J. S. 24.010, 24.013 

Chua G. 56.005 

Chuang J.-H. 40.005 

Chudk F. 24.017 

Chui L. 33.011 

Chun J.-K. 59.022 

Churchill Smith M. 32.006 

Churchwell G. 51.026 

Ciampi A. 21.002 

Cias R. 76.027 

Ciavarro G. 83.008 

Cibuku S. 28.017 

Cisneros G. A. 40.007 

Cisterna D. 83.025 

Cisterna R. 53.015 

Cisterna R. 53.026 

Clad A. 30.011 

Clark T. 57.031 

Cleary T. G. 52.023 

Cleaveland S. 34.011 

Cockayne A. 47.004 

Coelho H. 32.028 

Coelho R. 32.031 

Cohen C. 52.014 

Cohen M. 35.001, 17.002 

Cohen N. 32.001 

Cole E. 81.019 

Colindres R. 80.009 

Colizzi V. 75.007 

Collado L. 28.005 

Collado M. 28.005 

Colombana P. 57.032 

Comach G. 75.036 

Como N. 84.020, 84.009, 

30.010, 28.017 

Conde M. 68.004 

Conde-Ferráez L. 79.004 

Conley G. B. 29.014 

Connolly S. 74.018 

Connolly S. N. 74.018 

Conrad C. 46.002 

Contardi L. 56.034 

Contini S. 75.007 

Contreras A. M. 28.039 

Contreras C. A. 52.023 

Contreras M. M. 53.036 

Contrini M. M. 80.015, 28.011 

Contrini M. M. 77.024 

Coral G. 53.028, 57.012, 

53.035, 53.029 

Coraspe V. 58.022 

Cork S. 57.024 

Cornaglia G. 20.003 

Cornejo A. 80.023 

Cornejo P. 61.003 

Cornet A. 47.002 

Cornistein W. 76.025 

Coronado F. 57.031 

Corrah T. 21.006, 77.022 

Correa E. B. D. 57.012 

Correa M. 32.016 

Correnti M. 84.043, 84.040 

Corso A. 23.020 

Cortes C. 28.005 

Cortes C. 55.002 

Cortes J. 40.003, 40.004 

Cortes J. A. 30.016, 28.053 

Cortes J. 30.026, 61.002 

Cortes L. 24.002 

Côrtes R. 55.011 

Cortese M. 40.003 

Cortez J. 58.018 

Costa L. 79.010 

Costa M. 53.035 

Costa P. 81.014 

Costa Jr. V. H. 28.022 

Couceiro J. N. S. S. 34.025 

Coulborn R. M. 65.003 

Coulombier D. 57.013 

Coulter T. 83.018 

Cowan E. 29.014 

Cowling B. J. 28.043 

Cox A. 57.013 

Coyle C. 12.003 

Crespo D. 53.035 

Crestto M. 56.044 

Criollo-Mora E. 23.028 

Cristia Pacheco M. 80.020 

Cromeans T. 40.002 

Crookston B. 81.019 

Crowcroft N. 65.006, 57.020 

Cruz Hervert L. P. 59.017 

Cruzat V. 28.040 

Csep A. 84.048 

Cuellar J. 69.001 

Cuellar L. 56.017 

Cuervo S. I. 30.026 

Culebras E. 23.026 

Cunha E. F. 78.006 

Cunha R. G. 78.006 

Curcio D. 61.004 

Curi R. 52.019 

Curic I. 34.016 

Curns A. 40.002, 40.003 

Curone M. 56.030, 28.040 

Cury A. P. 23.024, 23.025 

Cusato M. 49.004 

Cutland C. 80.018 

Cwayi J. 81.019 

Da Silva L. 51.009, 28.010, 

51.004, 32.023 

Dabanch Pena J. 04.001, 07.002 

Dabiri H. 58.026 

Dagan R. 22.004 

Dai J. 24.006 

Daikos G. 41.004 

Dakhave M. 28.009 

Dakum P. S. 27.005 

Damasco P. V. 77.011 

Damdinjav B. 34.024 

Danburam A. 59.015 

Danchinova G. A. 76.005 

Daneman N. 57.020 

Dangerfield J. A. 24.010 

Daniel S. 77.019 

Danina F. 32.031 

Daniyan C. 55.009 

Daoukakis M. 77.002 

Dapaah E. 32.013 

Dar L. 33.006 

Darabus G. 58.016 

Darmaa B. 28.006 

Darwich N. 32.031 

Das R. 80.003 

Das S. 24.015 

Dasbach E. J. 83.014, 83.013 

Dash N. 58.005 

Dastugue M. 28.011 

Dattani B. 50.003 

Davidson I. 84.006 

Davis B. M. 65.003 

Davis T. M. E. 72.005 

Davis X. 32.002, 32.003 

Ddamulira J. 27.033 

De Andrade-Lima J. R. P. 32.033 

De Antonio R. 80.009 

de Castro S. L. 82.011 

de Cosio G. 57.038 

de Gascun C. 27.025 

de la Morena M. 43.001 

de la Parra G. 32.016 

De la Torre A. 33.016 

De Landtsheer S. 57.039 

De Leon A. 21.005, 84.036 

De Lúcia Hernani M. 83.005 

de Mena A. 78.013 

de Menezes Succi R. C. 27.011, 

27.010, 27.013, 27.012 

De Paz Garcia R. 33.016 

de Quincey E. 76.031, 28.049 

De Serres G. 65.006 

De Souza E. M. 82.011 

De Tora L. 32.023 

De Waard J. 75.013 

De Wouters L. 32.019 

Debbag R. 81.023, 81.024 

Debusscher J. 77.028 

Deckert M. 31.002 

Declich S. 28.037 

Dedmon R. 34.011 

Del Bianco R. 78.016 

Del Castillo M. 32.024 

Del Rosario L. 75.023 

del Valle J. 80.023 

del Valle L. 80.023 

Delamain J. 28.045 

Delgado C. 59.010, 84.005 

Delgado O. 58.022 

Delgado González O. 56.026 

Delic D. 53.023 

Delis V. 82.004 

Della Latta M. P. 32.027, 

32.034, 32.020 

DeMaria A. 23.017 

Demetria C. 84.007 

Demina O. K. 73.004, 28.012 

Demitrovicova A. 25.002 

Demos H. A. 52.022 

Deng Y. 24.006 

Dente M.-G. 28.037 

Derakhshan A. 30.008 

Dermaux V. 52.014 

Derviskadic N. 34.016 

DeRyke C. 75.006 

Desai A. 24.015 

Desai A. 83.022 

Desmecht D. 47.002 

Devivero R. 53.036 

Devrim I. 84.032 

Dewan R. 55.015 

Dhankhar P. 83.014, 83.013 

Dhaubhadel P. 56.028 

Dhawan V. 52.006 

Dhole T. 51.014, 59.012 

Di Marco P. 26.006 

Di Stéfano C. 25.008, 77.007, 

25.009 

Diab R. M. G. 58.006 

Diament D. 13.001 

Diap G. 29.016 

Díaz F. 47.001 

Diaz J. E. 56.031 

Diaz M. 58.018 

Diaz P. 75.025 

Diaz R. S. 55.011 

Díaz S. Y. 56.027 

Diaz Colodrero G. 28.040 

Diaz Jidy M. 59.025 

Diaz-Mitoma F. 40.009 

Dickinson G. 55.005, 

Dickinson J. A. 65.006 

DiClemente R. J. 65.002 

Digalaki K. 74.012 

Digiglio C. 83.026 

Dimitrova Z. 53.038 

Ding Y. 23.022 

Diosque M. 83.026 

Dixon J. 81.019 

Dizdarer C. 84.032 

Docherla M. 52.008 

Dohmen P. 74.014, 25.012 

Dolnik O. 84.011 

Domingo C. 75.042 

Domotenko L. 75.029 

Dookie J.-A. 74.016 

Dorea E. L. 27.022 

Dorneanu O. 23.019 

Dorobat C. 23.019 

Dorta-Contreras A. J. 76.023 

Doukakis S. 77.002 

Dowd J. 80.016 

Dowling C. 83.018 

Dowzicky M. 74.002, 23.009, 

77.004 

Draghici S.-M. 26.013, 84.048 

Drake C. 23.014 

Drews S. J. 65.006 

Drgona L. 30.022 

Drobeniuc J. 53.038 

Drozdov I. G. 75.019, 28.012, 

73.004 

Du T. 76.026 

Final Program ~ 215

Authors Index 


Duan J. 55.006 

Duarte J. A. 23.024 

Dubey V. 83.020 

Dubischar-Kastner K. L. 83.012 

Dueñas L. 56.017 

Duijkeren E. V. 34.027 

Duits A. 76.014, 51.003 

Dujardin J.-C. 75.043 

Dull P. 83.008 

Dumitrascu V. 58.021, 58.016 

Dumre S. P. 57.014, 74.011, 

58.028 

Dunkel N. 30.013 

Dupont B. 30.007 

Duraku K. 30.010, 84.020 

Durán C. 56.044 

Duran C. 58.022, 58.018 

Durlach R. 28.024 

Durrant L. G. 47.004 

Dvali N. 55.008, 53.025, 

30.021, 53.032 

Dwivedi S. 58.017 

Dzigua L. 53.025, 30.021, 

53.032, 55.008 

Dzijan S. 79.003 

Dzyakanava V. 56.002 

Echavarria E. 28.007 

Echavarria M. 28.004 

Echave C. I. 30.019, 77.024 

Echave C. 80.015 

Echazarreta S. E. 32.025, 

32.030, 32.026, 32.032 

Echeverri J. A. 56.027 

Echezuria L. 32.017, 81.005 

Eckert E. 29.008 

Edelstein H. 50.004 

Eder S. 83.012 

Edmond M. 70.002, 10.001 

Edmonds A. 55.013 

Edwards J. 73.008 

Ehichioya D. 80.026, 51.021, 

57.039 

Ehiemuan J. 84.046 

Ehimiyein A. 84.044 

Ehimiyein I. O. 84.044 

Ehrlich H. 37.004 

Eini F. 75.027, 75.028 

Eira M. 27.021 

El aouad R. 75.007 

El Eman K. 65.011 

El Jaish A. 57.035 

El Omeiri N. 28.037 

El Sheikh M. 75.024, 76.007 

El-Naggar W. 23.018 

El-Shamy H. 75.032 

Elagib R. 28.047 

Elam K. 81.006, 10.001, 26.011 

Eleckova E. 24.004 

Elikwu C. J. 80.026 

ElKerdany E. D. 58.006 

Elkik S. 83.016 

Ellerbrok H. 75.022, 75.021 

Elmassian P. 32.027, 32.015, 

32.020, 32.034 

ElTemsahy M. M. 58.006 

Emikpe B. O. 34.002 

Emmanuel M. N. 58.007 

Enfedaque C. 30.019 

Engell C. 56.025 

England K. 76.010 

Enria D. 83.026 

Enrico A. 28.042 

Enrique S. 81.024, 81.023 

Enriquez I. 84.005 

Enriquez N. 84.005 

Entrena García A. A. 75.002 

Erdman D. D. 40.002 

Ergete 55.001 

Ergin S. 53.013 

Erima B. 28.027 

Erindi E. 28.017 

Erzin Y. 30.006, 30.005 

Escalante A. 64.002 

Esfandiari B. 51.025, 51.013 

Eshun-Wilson I. 30.012 

Eslamifar A. 27.004, 84.026, 

53.002 

Espíndola M. S. 82.008 

Espinosa F. E. M. 29.017 

Esposito D. 40.003, 40.002 

Esposto A. 32.016 

Essafi M. 31.002 

Estevez A. 65.004 

Estrada C. 56.027 

Estrada-Garcia T. 21.003 

Estrada-Garcia T. 26.003 

Eugene R. 72.001 

Evangelista J. 58.024 

Evstaphieva I. 84.037 

Ezcurra C. 81.008, 28.024 

Ezikeanyi S. I. 84.002 

Ezzati M. 25.011, 25.013 

Fabres H. 56.044 

Fabri I. 34.023 

Fabri M. 34.023 

Faccioli L. H. 73.005, 82.008, 

73.006 

Fagnani R. 56.038 

Falahi S. 54.004, 84.041 

Falcone C. C. 32.026, 32.032, 

32.025 

Fallah F. 77.003 

Fallah Raoufi M. 75.027, 75.028 

Fallo A. 28.011, 78.013 

Fallon J. 77.019 

Fang V. J. 28.043 

Farahani S. 59.005 

Farazi A. A. 53.010 

Farias E. 32.006 

Farinati A. 74.019 

Farnia M. 57.003 

Farnia P. 59.001 

Farrell D. 23.027 

Farrell D. J. 74.006 

Farrell G. 78.015 

Farrell J. 58.002, 30.024 

Farzaneh-nejad Z. 51.025 

Fata A. 30.008 

Fata S. 30.008 

Favacho A. 76.006 

Fe Marques A. 28.019 

Fedora M. 75.037 

Feitosa T. S. 31.003 

Feliciano H. 54.003 

Felix A. C. 75.033, 75.038 

Feltrin A. 28.050, 28.045 

Fenn E. 43.002 

Fernandes O. 51.015 

Fernandez A. 33.014 

Fernández M. 57.011 

Fernandez de Larrea C. 75.009, 

75.013 

Fernández González D. 56.026 

Fernández Hidalgo R. 56.017 

Fernandez Oses P. 25.020, 

25.009, 25.008 

Ferraiuoli G. I. D. 25.018 

Ferrari A. 26.006 

Ferraris A. 77.007, 25.009, 

25.008 

Ferrauioli G. D. 21.010 

Ferreira A. W. 75.038, 75.033 

Ferreira D. M. 83.005, 83.004, 

83.003 

Ferreira L. 57.012 

Ferreira L. C. D. L. 78.018 

Ferreira M. E. 59.014 

Ferreira P. C. D. 83.005, 83.004 

Ferreira-Guerrero E. E. 59.017 

Ferrer P. 28.039, 80.024 

Ferrera Boza A. 84.024 

Ferrés M. 28.039, 80.024 

Ferreyra-Reyes L. D. 59.017 

Ferriani V. P. L. 25.004 

Figlerowicz M. 53.016, 53.017 

Figueiredo G. 53.029 

Figueiredo G. M. 57.012 

Figueiredo G. 53.028 

Figueiredo G. M. 53.035 

Figueras L. 28.004 

Figueroa F. 59.018 

Finger S. A. 21.004 

Fiore A. E. 11.001 

Fiorilli G. 80.013 

Firpo A. S. 28.042 

Firsov A. 49.007 

Firstova V. 58.029 

Fischer G. E. 40.002 

Fishbein D. 40.006, 32.001 

Fisman D. 28.048, 65.010 

Fité Gallego A. 56.043 

Flanagan M. 57.029 

Flonta M. 77.016 

Flores G. 56.044 

Fobil J. 51.011 

Fobil J. 80.021, 51.011 

Fobil J. 80.021 

Foley D. H. 29.012 

Fonseca F. A. H. 54.002 

Fonseca K. 65.006 

Font S. 57.036 

Foongladda S. 75.044 

Fornells Arentz L. A. 34.025 

Fortaleza C. 24.017 

Fota-Markowska H. 77.006 

Fournier P.-E. 21.010 

Fowler R. A. 65.010 

Foxman B. 77.028 

Fraile Fariñas M. T. 75.017, 

82.009 

Franca C. N. 54.002 

Franca F. 08.003 

Franco-Paredes C. 32.004 

Franklin R. 75.006 

Frantz F. G. 82.008 

Fraser C. 27.029 

Frasinejad B. 23.011 

Frassone N. E. 78.017, 59.014, 

77.023 

Fratnik Steyer A. 28.016 

Fredeking T. 24.001 

Fredriksson-Ahomaa M. 34.018 

Freedman D. 46.004 

Freilij H. 72.004 

Freire C. 83.016 

Freire M. C. 83.025 

Freitas A. R. R. 28.045, 28.050 

Freitas G. D. 28.028, 28.026, 

28.030, 57.018 

Frenkel G. 65.004 

Freuler C. 81.008, 28.024 

Friedland J. 63.003 

Friedrich A. W. 56.018 

Froes M. H. 59.023 

Frolova T. V. 24.004 

Fry A. 65.004 

Fuenmayor C. 51.023 

Fuji N. 21.005 

Fuji N. 84.036 

Fuji N. 65.001 

Fujitani S. 25.003 

Fulton M. 76.016 

Furuse Y. 21.005, 65.001 

Gaafar M. 58.006 

Gabriel O D. 81.001 

Gade L. 30.009 

Gadua N. 77.025 

Gaibani P. 24.016 



Gaibani P. 76.011, 51.020 

Gainey M. 73.008 

Gajo Gane A. 72.004 

Gajownik B. 77.006 

Galea S. 28.036 

Galesi V. M. N. 33.007 

Gallagher D. 78.015 

Gallagher N. 57.005, 32.004, 

32.005 

Gallego P. 28.040 

216 ~ Final Program

Authors Index 


Gallo J. C. 28.040 

Gamage C. 77.012 

Gamboa-Coronado M. D. M. 

76.026, 25.019 

Gantsooj B. 28.006 

Ganusov V. 17.002 

Gao F. 17.002 

Gao L. 83.006 

Gao S. 28.002, 28.003 

Garay J. 81.007 

Garbati M. 59.015 

Garber G. 65.011 

Garbino J. 30.013 

Garcia A. 48.001 

Garcia C. 74.015 

Garcia D. O. 23.025 

García F. 81.024, 81.023 

Garcia F. L. B. 51.022 

Garcia R. 76.018 

Garcia Jimenez S. 83.025, 

83.026 

Garcia Rodriguez M. 82.009 

García-García M. D. L. 59.017 

Garcia-Vara P. 34.020 

Gardner S. 57.009, 75.040, 

75.031 

Gardner T. J. 40.002 

Gardy J. 65.006 

Gargalianos P. 82.004 

Gargano L. M. 65.002 

Garigliany M.-M. 47.002 

Garrido M. 59.010 

Garro S. L. 32.025, 32.032, 

32.026 

Garver J. 73.007, 84.015, 

24.005 

Gastellu-Etchegorry M. 28.037 

Gatserelia L. 53.032, 55.008, 

53.025, 30.021 

Gatzima M. 23.002 

Gaxiola C. S. M. 34.003 

Gaxiola Camacho S. M. 34.031, 

34.017 

Gaxiola M. J. 34.017 

Gayoso E. 50.006 

Gaywee J. 65.008 

Gebi U. I. 27.005 

Gelaglie A. K. 29.003 

Gentile A. 83.025 



Gentsch J. 40.003 

George G. 56.024 

George M. 25.013, 25.011 

Gerloff N. 57.039 

Gerorge S. 23.018 

Gerstenbluth I. 51.003, 76.014 

Geskus R. B. 21.001 

Gestoso I. 76.027 

Ghasemian R. 53.001 

Ghédira H. 56.008, 56.013 

Ghimire M. 25.006 

Ghimire P. 57.014 

Gholamin S. 23.011 

Ghosh S. 34.006, 75.016, 

84.012 

Giacco M. 82.013 

Giamberardino H. 28.022 

Giampietro F. 75.009 

Giamprieto F. 75.013 

Gibbons R. V. 65.008 

Giezendanner N. 34.018 

Gilani Z. 27.009 

Gill C. 83.008 

Gilman R. 82.014 

Gilman R. H. 34.020, 21.004, 

58.024, 73.016 

Gimeno X. 32.022 

Gimeno Cardona C. 82.009, 

75.017 

Gino L. 56.029 

Giorgi E. 17.002 

Giraldo M. I. 58.023, 58.031 

Giri R. 34.012 

Girod Schreinerova M. 56.023 

Giron M. 51.023 

Giske C. 41.001 

Gjermeni N. 28.017, 30.010 

Gloeckner A. 30.002, 30.003 

Glushenkova T. 76.005 

Goad J. 32.004 

Godino M. 28.007 

Godoy P. 80.024, 28.039 

Goeters C. 56.018 

Gokhale R. 68.001 

Golebiovski W. 21.010 

Golembieski A. 27.015 

Goleniuk D. 51.012, 25.015 

Gomes V. R. 78.006 

Gomez C. H. 30.026 

Gomez M. 23.026 

Gomez S. 72.004 

Gonçalves da Costa P. S. 76.004, 

28.015 

Gongora V. 46.003 

Gonzaga V. 57.011 

Gonzáles M. 77.020 

Gonzales X. F. 77.029 

González C. 58.014, 83.011 

Gonzalez F. 23.026 

Gonzalez G. D. 32.026, 32.025, 

32.032 

Gonzalez J. C. 82.013 

Gonzalez M. C. 34.032 

Gonzalez N. 28.011 

González Ayala S. E. 52.021 

González Nuñez I. 27.001 

Gonzalez-Losa M. R. 79.004, 

57.021 

Goonetilleke N. 17.002 

Goossens H. 22.002 

Gopalakrishnan V. 75.011 

Gorbacheva O. 32.009, 33.008 

Gordillo B. 65.004, 40.004 

Gordillo G. 76.018 

Goris J. 75.023 

Gottdenker N. L. 34.008 

Gotuzzo E. 21.002, 14.003, 

58.025, 03.002 

Gotz H. M. 34.027 

Gould E. A. 24.004 

Gould I. 10.003 

Govender N. 52.014 

Goyal A. 68.001 

Goyo J. 73.015 

Grabczewska E. 77.015 

Grabenstein J. 83.014, 83.013 

Graham S. V. 84.031 

Grant F. 76.020 

Gray E. 17.003 

Gray J. 65.004 

Gray N. K. 84.031 

Graybill R. 15.001 

Greco M. M. 52.021 

Green K. Y. 47.006 

Greene D. G. 25.017 

Greene M. 34.019 

Greene W. 75.041 

Greene-Montfort T. 53.038 

Greenwood B. 21.006, 77.022 

Greet V. 68.002 

Gregis C. 32.008 

Grichener J. 28.011 

Griffith M. 57.031 

Gritsun T. S. 24.004 

Groseth A. 84.011 

Groth N. 65.005 

Guanche Garcell H. 56.026, 

56.017 

Guarda B. 81.007 

Guarnieri C. E. 65.009 

Gubernot D. 29.014 

Guddati A. 56.028 

Guedes M. 28.022 

Gueguen J. 28.037 

Guercio A. 26.006 

Guettouche T. 78.020 

Guevara M. E. 51.023 

Guiadem R. 27.030 

Guilarde A. O. 56.042 

Guimaraes E. M. B. 51.022 

Guinez D. 59.010 

Gunawan C. 29.002, 27.007 

Gunther S. 51.021, 76.022, 

51.018, 76.021, 84.046 

Gunzburg W. H. 24.010 

Guo W. 73.013 

Guo Y. 24.006 

Guo Y. 27.026 

Gupta N. N. 84.003, 84.004 

Gupta N. 80.003 

Gupta R. 52.022 

Gupta S. 33.015 

Gupta S. N. 84.003, 84.004 

Gupta V. 83.015 

Gupte M. D. 84.004, 84.003 

Guterres A. 76.006 

Gutierrez A. 56.044 

Gutierrez F. 26.003, 21.003 

Guzman-Blanco M. 66.004 

Gvozdenovic E. 53.023 

Gwamzhi L. N. 78.004 

Gyawali N. 74.005 

Habib E. 23.018 

Habyarimana A. 47.002 

Hackel M. 23.009, 77.004 

Hadipour Jahromy M. 73.001 

Hadipour jahromy M. 84.013, 

73.001 

Hadzic E. 34.016 

Hadzovic Cengic M. 34.016 

Hagan R. 27.025 

Hagiwara K. 84.030 

Hagmann S. 32.004 

Hahn B. 17.002 

Hahne C. 28.033 

Haider A. 78.009 

Halabi Y. 76.014 

Halicioglu O. 84.032 

Hall S. 75.024, 76.007 

Hallit R. 77.019 

Halperin S. 40.009 

Hamdi A. 56.017 

Hamdi K. 33.010 

Hamelin M.-E. 65.006 

Hamer D. H. 32.029, 21.008 

Hamilton R. 57.026, 81.010 

Hamisu S. 55.006 

Hamkar R. 84.026 

Han J. 84.001 

Han M. 47.005, 73.011 

Han P. 32.003, 57.005, 32.002 

Han S. H. 59.007, 53.009 

Hanage W. P. 27.029 

Hanlon C. 34.014 

Hanssen A. D. 25.017 

Happi C. 76.021, 84.046, 

76.022, 51.018 

Hara C. 75.040 

Hardjopawiro L. 81.022, 81.025 

Hariastuti N. I. 28.013 

Harish B. 23.015 

Harmon K. 34.033 

Harmsen W. S. 25.017 

Haro Osnaya A. 33.016 

Harrel B. 76.007, 75.024 

Harrell D. 51.026 

Harris J. 32.011 

Harry T. 57.039 

Harter-Griep R. 81.009 

Hartman F. 76.016 

Hasan M. M. T. 32.009 

Hascalovici C. 80.010, 80.008 

Hass M. 51.021 

Hassan A. 82.002, 75.001 

Hassanshahiraviz G. 53.014, 

53.004 

Hasseltvedt V. 28.031 

Hatakeyama S. 56.015 

Hatemi G. 30.005, 30.006 

Hatemi I. 30.006, 30.005 

Hausdorff W. 80.009 

Final Program ~ 217

Authors Index 


Hawkley M. 81.019 

Hawser S. 23.009 

Hay R. 15.003 

Hays J. 23.015 

Head J. 23.026 

Heath P. 71.001 

Hedlund J. 57.007 

Heitzer V. 56.009, 56.010 

Helasvuo V. 80.023 

Helvacı M. 84.032 

Hemrajani R. 26.011, 81.006 

Hentrich M. 30.004 

Herbert-Hackshaw K. 46.003 

Hernandez A. 56.031 

Hernandez C. 76.003 

Hernandez N. 51.023 

Herr-Calomeni P. 73.008 

Herrera F. 28.004 

Herrera F. 34.032 

Herrera J. O. 56.031 

Herrera Y. 78.007, 78.008 

Herrera Aldana P. 21.004 

Herrera-Martínez A. 78.008, 

78.007 

Herrero E. 32.019 

Hidalgo G. 58.018 

Hiddessen A. 75.040 

Higgins P. 23.009 

Hilbert A. 65.005 

Hildreth J. 59.021 

Hill P. 21.006 

Hillier S. 17.004 

Hiransuthikul N. 79.002 

Hirose M. 75.016 

Hirotsu N. 28.008 

Hirsch H. 69.002 

Hirsch M. 62.002 

Hitoshi O. 84.007 

Hiwat H. 81.025, 81.022 

Ho L.-L. 28.032 

Ho P. 83.005, 83.004 

Hoban D. 74.002, 23.009, 

77.004 

Hochberg N. S. 21.008, 32.029 

Hochlin K. 56.011 

Hoehne E. 76.030 

Hoen B. 25.013, 25.011 

Hoenigl M. 30.001, 56.007 

Hoffman R. 32.004 

Hollingsworth T. D. 27.029 

Holness L. G. 29.014 

Hong K. B. 51.016 

Hong K.-W. 52.016, 25.014 

Hong T. 51.005 

Hooton T. 78.020 

Hora R. A. 57.011 

Horban A. 77.030 

Horby P. 57.030 

Hoseini N. 83.017 

Hosokawa N. 25.001 

Hottes T. S. 65.006 

Houck P. 57.005 

Howard-Grabman L. 76.016 

Howie S. 77.022, 21.006 

Houas M. 31.002 

Hoxha H. 

Hoxha H. 84.009 84.017, 

51.007 

Hrabovsky V. 30.025 

Hsu L. Y. 23.022, 50.005 

Hu B. 56.017 

Hu Y. 33.004, 59.009 

Huaman M. 27.015 

Huang C.-C. 40.005 

Huang H.-P. 28.032 

Huang J.-H. 53.034, 75.039 

Huang M.-L. 76.015 

Huang M.-L. 75.039 

Huang M. 84.030 

Huang P.-X. 53.022 

Huang S.-W. 84.016 

Huang T. 82.005 

Huang W. 28.003, 28.002 

Huang Y. 28.013 

Huang Y.-C. 49.006, 84.038 

Huc Anais P. 75.022 

Huertas Jimenez M. 33.016 

Hughes J. M. 65.002 

Hulette R. B. 56.045 

Humphries C. 40.002 

Hunter P. R. 32.010 

Hupkova H. 30.022 

Hur J. K. 52.020 

Hurst S. 30.009 

Husain N. 58.017 

Hussain Y. 56.017 

Hussell T. 44.003 

Huur A. 81.022 

Iacobiciu I. 58.019 

Iacobiciu I. 58.020 

Iacono M. 32.019 

Ibrahim A. Y. 27.018, 27.031 

Ibrahim R. 23.018 

Ibrahimpasic N. 34.016 

Ichiro K. 84.007 

Ideh R. C. 80.022 

Idoko J. 55.009 

Idoko O. T. 77.022 

Idris S. A. 26.007 

Ignatiev V. 84.037 

Igreja R. P. 53.003 

Ijaz M. K. 72.006 

Ikawa K. 49.009 

Ikeda F. 84.030 

Ikeda K. 49.009 

Ikram N. 27.017 

Ikumapayi N. 21.006 

Ilardo R. 77.023 

Ilham N. 34.026 

Ilieva L. 84.047 

Imagawa T. 26.005 

Imnadze P. 26.012, 28.018 

Incani R. N. 58.018 

Inda L. 80.015 

Insuasty B. 48.001 

Inzunza-Montiel A. 77.014 

Ip M. 73.010 

Irad B. 78.002 

Irino K. 51.008 

Irons B. 28.046 

Isa S. 78.004 

Isabirye P. 55.012 

Isaias L. 51.015 

Ishida T. 28.008 

Ishino M. 34.006 

Ismail S. 52.002 

Isper V. 28.045 

Isturiz R. 38.003 

Itoe I. 84.007 

Iwamura H. 75.026 

Iwamura H. 25.007 

Iwata K. 28.025 

Iwata K. 77.008 

Izadi N. 53.010 

Jabandziev P. 75.037 

Jablkowski M. 53.030 

Jackson S. 72.001 

Jacobs M. 22.001 

Jafari F. 34.015 

Jaghbir M. 53.011 

Jagne J. 76.016 

Jain A. 40.001 

Jain K. 29.001 

Jain S. 52.006, 75.008 

Jain S. 51.014 

Jaing C. 57.009, 75.031 

Jalal H. 75.004 

Jamal H. 52.002 

Jambai A. 29.016 

James R. 47.004 

Jamshidiyan E. 75.027, 75.028 

Jamulitrat S. 56.017 

Jamuna V. 23.013 

Jang D. 75.005 

Janjua N. 65.006 

Janssens K. 75.023 

Jarca A. 26.013 

Jarcuska P. 53.012 

Jarman R. 65.008 

Jarza-Davila N. 74.004 

Jasseh M. 21.006 

Jawaheer G. 28.049, 76.031 

Jayaraman G. 65.011 

Jayaratne P. 75.034 

Jayasingam R. 77.019 

Jeddi R. 56.008, 56.013 

Jedlicka A. E. 29.010 

Jelinek T. 83.012 

Jenkerson S. A. 40.002 

Jensen R. O. 47.004 

Jentes E. 32.002, 32.003 

Jergens A. 34.033 

Jhao W.-S. 28.032 

Ji G. 24.006 

Jiang C.-Y. 28.001 

Jiang C.-H. 40.005 

Jiang L. 57.015, 57.016 

Jiang Q.-W. 57.016, 34.005, 

57.015, 28.001 

Jiang T. 24.006 

Jiang W. 28.003 

Jiang W. 28.002 

Jiang W. 33.004, 59.009 

Jilma B. 83.012 

Jiménez J. G. 56.027 

Jimenez S. 58.018 

Jin J. 23.022 

Jin S. J. 59.007, 53.009 

Jirous J. 56.023 

Jo Y. M. 56.039 

Job F. 27.019 

John K. 59.008 

Johnson B. 23.009, 74.002 

Johnson J. 23.009, 77.004, 

74.002 

Joloba M. 75.035 

Jones D. 27.024 

Jones L. M. 65.002 

Jones R. N. 74.006, 48.002 

Jong E. 45.003 

Joodan J. S. 34.001 

Jordaan M. 81.022 

Josh R. 72.001 

Joshi S. D. 79.008 

Jozami D. 72.004 

Jozuazoon N. 81.022 

Ju L.-W. 57.016, 57.015, 28.001 

Juarez-Sandino L. 59.017 

Juganariu G. 23.019 

Jugulete G. 55.007 

Juma E. 75.018 

Jun K. A. 56.035, 56.036 

Junie L. M. 74.017, 23.002 

Junie M. 77.002 

Jureen R. 26.004 

Jurgensen C. 84.043, 84.040 

Juzielewski B. 80.013 

Kaasila M. 40.008 

Kabanov A. 28.014, 28.012 

Kabbara W. 50.001 

Kabir B. 23.006 

Kacem K. 56.008, 56.013 

Kadigi D. M. 57.002 

Kadota J. 28.008 

Kadri O. 83.020 

Kagawa H. 77.008 

Kai C. 84.030, 84.029 

Kaido T. 56.033 

Kaiser M. 75.021, 75.022 

Kajla B. 56.037 

Kakjing F. 55.009 

Kalantar E. 53.002 

Kalavska A. 78.002 

Kalavsky E. 25.002 

Kalbfleisch J. 28.036 

Kalenic S. 23.005 

Kalimuddin S. 24.003 

Kalla G. C. M. 27.030 

Kallfa E. 80.006, 84.009 

Kallfa-Foto E. 84.017, 51.007 

Kalloo M. 46.003 

Kaltenboeck A. 83.012 

218 ~ Final Program

Authors Index 


Kamigaki T. 28.006 

Kamihira S. 74.009 

Kamili S. 53.038 

Kamimura M. 77.013 

Kan R. 77.021 

Kancelova Z. 56.023 

Kang H. 51.015 

Kang H. M. 34.024 

Kang J. H. 52.020 

Kang M. W. 52.016, 25.014 

Kang Y. 24.006 

Kang Y. A. 28.035, 28.034 

Kanj S. S. 56.017 

Kant S. 59.012 

Kant S. 33.006 

Kanunfre K. 75.038 

Kapala J. 75.005 

Kapek J. 56.023 

Kapikian A. Z. 47.006 

Kaplina E. 84.037 

Kapoor G. 40.001 

Kapoor V. 56.025 

Kara-Zaïtri C. 57.025, 81.010, 

57.026 

Karagianni P. 74.017, 23.002 

Karbalayi M. 52.003 

Karchava M. 53.032, 53.025, 

55.008, 30.021 

Karchmer A. W. 32.029, 21.008 

Karchmer A. 66.002 

Karikari Y. 29.016 

Karimi A. 77.003, 84.013 

Karsani M. S. 28.047 

Karthaus M. 30.004 

Karunajeewa H. 72.005 

Karunakaran R. 23.023 

Karuphong A. 58.013 

Karvaj M. 25.002 

Kasmi G. 56.014 

Kasmi I. 56.014 

Kassaian N. 53.018 

Kastanakis S. 77.002, 23.002, 

74.017 

Katabazi F. 75.035 

Katabira E. 62.004 

Katamba A. 75.035 

Kaur D. 56.037 

Kaur P. 55.010, 27.032 

Kawaguchiya M. 75.016 

Kawana A. 28.021 

Kawooya V. 27.034 

Kazeem H. M. 26.001 

Kazi B. M. 27.017 

Kazimirova M. 24.004 

Kazmi S. S. U. K. 49.001 

KC K. 57.014 

Keddy K. 52.014 

Keele B. 17.002 

Keenan A. 32.011 

Kemnitz P. 53.017, 53.016 

Kemp B. 28.045, 28.050 

Kenarkoohi A. 54.004, 84.041 

Keramati M. 57.003 

Kesavachandran U. 30.009 

Keuter M. 21.001 

Khader I. A. 56.017 

Khakpour S. 73.001 

Khakshoor H. 30.008 

Khalili H. 59.005 

Khan H. M. 58.009 

Khan M. I. 28.013 

Khan M. 23.015 

Khanal B. 25.005 

Khanal B. 74.005, 74.001 

Khanal B. 29.004 

Khandelwal N. 58.004 

Khasnatinov M. 76.005, 24.004 

Khatoon R. 58.009 

Khazaeipour Z. 83.017 

Kheltabadi Farahani R. 23.007 

Khishgee B. 34.024 

Khodadad S. 52.003 

Khodadoust M. A. 74.020 

Khosravi Y. 23.013 

Khramov M. 75.029 

Khudyakov N. 53.038 

Khullar M. 75.008 

Kica A. 28.017, 84.020, 30.010 

Kida H. 34.024, 28.008 

Kiguba R. 72.002 

Kiguli J. 55.012 

Kim C. O. 53.009, 59.007 

Kim H.-C. 29.012 

Kim H. M. 59.022 

Kim H. S. 28.034, 28.035 

Kim J. Y. 56.039 

Kim J. 59.013 

Kim J. S. 28.034, 28.035 

Kim J. H. 52.020 

Kim J. H. 28.034, 28.035 

Kim J. M. 59.007, 53.009 

Kim M. J. 56.039 

Kim M. 56.012 

Kim N. 59.013 

Kim S. I. 25.014, 52.016 

Kim S.-H. 56.040 

Kim W. J. 56.039 

Kim W. K. 28.034 

Kim Y. R. 52.016, 25.014 

Kim Y. S. 56.040 

Kim Y. J. 25.014, 52.016 

Kim Y. M. 51.016 

Kincaid K. A. 74.010 

Kini P. 80.014 

Kinoshita S. 77.008 

Kipnis A. 56.042 

Kirali K. 75.014 

Kirchner J. 17.002 

Kirkland J. 80.017 

Kirnbauer R. 40.008 

Kirunda B. T. 27.034 

Kisac P. 78.002 , 25.002 

Kitazawa T. 77.013 

Kitetele F. 55.013 

Kittitrakul C. 32.007 

Kiwanuka N. 55.012 

Klade C. 83.012 

Klausner J. D. 75.010 

Klein T. 29.012 

Kleinschmidt A. 83.008 

Klempa B. 24.004 

Klotchko A. 77.027 

Klugman K. 60.001, 44.004 

Knezevic J. 74.004 

Knight Y. 57.017, 32.013 

Knouse M. 32.004 

Knowles S. 81.021 

Ko P. 77.019 

Kobayashi C. A. 56.042 

Kobayashi M. 49.009 

Kobayashi N. 77.010, 34.006, 

75.016, 74.007, 84.012 

Kocazeybek B. 75.014, 53.013, 

30.005, 30.006, 58.011, 

82.007 

Köck R. 56.018 

Kodama T. 25.003 

Kode N. 82.005 

Kogelman L. 32.029, 21.008 

Koh L. P. 23.022 

Koh-Tec G. 79.004 

Kohan G. 28.040 

Kohno S. 74.009, 28.008 

Kohoutova J. 56.023 

Koike K. 56.015 

Koike K. 77.013 

Koirala J. 23.014, 23.029 

Koja A. 56.014, 80.006 

Kola E. 80.006, 56.014 

Kolarova M. 56.023 

Kollaritsch H. 83.012 

Kolter R. 67.001 

Kombarova S. 77.025 

Konertz W. 25.012, 74.014 

Kong L. 53.033 

König M. 34.018 

Konings E. 76.016 

Koo J. M. 74.010 

Koomanachai P. 49.005 

Koomson E. 80.002 

Koopman J. 81.004 

Koppe K. 76.006 

Koraka P. 76.014 

Korber B. T. 17.002 

Koreck A. 58.021, 58.016 

Kornienko T. 77.025 

Kosan E. 75.014 

Koskela P. 40.008 

Kostkova P. 28.049, 76.031, 

23.027 

Koturoglu G. 84.032 

Kovac R. 25.002 

Kowala-Piaskowska A. 53.017, 

53.016 

Kozarsky P. 32.004 

Kozioł-Montewka M. 77.006 

Kraemer A. 80.021, 51.011 

Krahn M. 28.048, 65.010 

Kraja D. 84.020, 30.010, 28.017 

Krapp F. 21.002 

Kratochvil M. 75.037 

Kratochvilova J. 56.023 

Krause P. R. 47.006 

Krause R. 30.001 

Krčméry V. 14.004, 25.002, 

78.002 

Krishna S. 56.001 

Krishnan T. 84.012 

Kristian P. 53.012 

Krkic Dautovic S. 34.016 

Kropp R. 65.011 

Ks N. 77.009 

Kuan M.-M. 57.027 

Kudriavcev A. S. 28.012 

Kulak M. 34.021, 65.007 

Kularatne S. 77.012 

Kumar A. 23.001 

Kumar R. 56.037 

Kumar R. 40.001 

Kumar R. 33.006 

Kumar S. 56.024 

Kumar S. 80.004 

Kumarasamy N. 78.005 

Kunimoto D. 33.011 

Kurkova V. 56.023 

Kurtzman C. 30.024 

Kurugol Z. 83.001, 84.032 

Kushwaha R. A. S. 59.012 

Kusolsuk T. 32.007 

Kuti J. L. 49.005 

Kuwanda L. 80.018 

Kuzmin I. 84.044 

Kwakye-Nuako G. 82.003 

Kwong J. 57.020, 65.010 

Kyaw M. H. 51.009, 28.010 

Kye-Amoah K. 57.004 

Kyr M. 75.037 

La M.-V. 26.004 

Laabidi N. 31.002 

Labousaki D. 74.017 

Labuda M. 24.004 

Ladep N. 55.009 

Lafuente C. 82.014 

Lai S.-K. 40.005 

Lal S. 84.035 

Lamas C. 25.018, 21.010, 

76.006 

Lambrecht B. 47.002 

Lambson B. 17.003 

Lanata C. F. 52.023 

Landaverde M. 57.031 

Landini M. P. 76.028, 51.020, 

24.016, 51.019, 76.011 

Lang H.-J. 29.013 

Langard M. 77.024 

Langlois-Klassen D. 33.011 

Langmann H. 56.007 

Lara A. 29.018 

Lares M. 32.016 

LaRocque R. 32.005, 32.004 

LaRosa S. 63.002 

Larralde-Diaz O. G. 84.031 

Final Program ~ 219

Authors Index 


Larson R. 77.021 

Lascols C. 77.004 

Lashkarashvili M. 26.012 

Laslau C. 26.013 

Lau L. 28.043 

Lau S. K. P. 76.013, 84.025 

Lau Y. 23.016 

Lauc G. 79.003 

Lawhorn J. 23.014 

Lawson C. 57.005 

Lawton T. 32.005 

Lazaro M. E. 32.019 

Lazzarini D. 28.011 

Le M. T. 30.011 

Le N.-T. 53.038 

Leal G. S. 56.042 

Leal Moran P. 33.016 

Leanes L. F. 57.034 

Leao J. R. D. T. 53.031, 29.017, 

78.018 

Leblebicioglu H. 56.017 

Leca D. 23.019 

Lecky D. 23.027 

Leddy L. R. 52.022 

Lee C. 80.017 

Lee C. 75.034 

Lee H. G. 28.034, 28.035 

Lee H.-Y. 84.038, 49.006 

Lee H. J. 51.016 

Lee J. 32.004 

Lee J. 51.016 

Lee J.-H. 51.016 

Lee K. C. 29.014 

Lee M. 79.006 

Lee M.-S. 76.015 

Lee P. 51.026 

Lee S.-O. 56.040 

Lee S. Y. 52.020 

Lee S. S.-J. 75.020 

Lee T. 59.013 

Lee V. 76.002 

Lee Y.-P. 84.016 

Lee Y. J. 34.024 

Lee Y.-W. 56.035 

Lefrancois T. 46.003 

Leguen F. 28.051 

Lehtinen M. 40.008 

Lei H. 53.033 

Leichsenring M. 56.038 

Leikis M. 59.021 

Leite D. 51.008 

Leite O. H. M. 75.038, 75.033 

Leite R. 73.012 

Leka K. 52.010 

Lema C. 83.025 

Lembo T. 34.011 

Lemke A. 32.021 

Lemos E. R. 76.006, 77.011 

Lemos L. R. 55.003 

Lemos Hinrichsen S. 02.004 

Lemos Luengas E. V. 55.003, 

30.016 

Lenhoff R. 75.024, 76.007 

Leo Y. S. 55.010, 27.032, 76.002 

Leon M. 21.003, 26.003 

Leong H. N. 24.003, 84.042 

Leong K. L. J. 84.022 

Lepetic A. 02.001, 32.027 

Lepidi H. 21.010 

Lespada M. I. 76.025 

Leung E. T. Y. 73.010 

Leung G. M. 28.043 

Leung W. H. A. 28.038 

Levina L. S. 24.004 

Levy C. E. 59.020 

Lew D. 14.001 

Lewi D. S. 54.002 

Leyna G. H. 21.007 

Li C. 29.012 

Li H. 17.002 

Li L. 27.026 

Li W. 47.005 

Li Y. 65.006 

Li Y.-T. 34.005 

Li Y. 47.005 

Liberal M. H. T. 34.025 

Licitra C. M. 77.027 

Liew Y. X. 23.022 

Ligthelm R. J. 21.001 

Lim C. S. Y. 73.014 

Lim R. 50.005 

Lim S. H. 24.003, 84.042 

Lim Y. W. 76.017 

Lima D. B. 78.006 

Lima M. L. 53.035 

Limongi G. 28.007 

Limper M. 51.003, 76.014 

Lin G. Y. 84.039 

Lin M.-Y. 23.017 

Lin R. 26.004 

Lin T.-Y. 49.006, 76.015, 84.038 

Lin W.-Y. 53.022 

Lindblade K. 40.004, 65.004 

Lindstrom S. 65.004 

Linge J. 57.013 

Linneweber J. 25.012 

Liou G.-Y. 76.015 

Liphaus B. D. L. 28.030 

Liphaus B. L. 28.026 

Liphaus B. D. L. 28.028 

Liphaus B. L. 57.018 

Lipman H. 40.006, 32.001, 

57.005 

Liprandi F. 84.034, 80.011 

Lira M. 56.030 

Lise M. 57.032 

Liska S. 75.010 

Liske K. 57.005 

Liss C. 83.024 

Lito G. 84.009 

Lito G. 51.007, 84.017 

Liu M. K. 17.002 

Liu Y. 48.003 

Liu Y. 57.008 

Lizaso D. 32.016 

Llanos-Cuentas A. 75.043, 

75.025 

LLau A. 28.051 

Lloret L. 31.004 

Lloret-Sanchez L. 31.005 

Lloveras S. 32.032, 32.025, 

32.030, 04.003, 32.026 

Lluka R. 80.006 

Llukaj R. 56.014 

Lo T. S. 74.010 

Loayza M. 40.007 

Lobel L. 84.011 

Lockhart C. 34.030 

Loctev V. B. 75.019 

Lode H. 83.028 

Lodigiani M. 25.016 

Loggia V. 82.013 

Loh L. T. T. 28.038 

Lokida D. 57.019 

Lombar A. V. 78.014 

Londoño A. 47.001 

Londono I. 82.005 

Long J. 73.008 

Long R. 33.011 

Lopardo G. 50.002, 55.004, 

38.004 

Lopardo H. 76.003, 80.013, 

52.004 

Lopera C. 56.027 

Lopes G. Q. 25.018, 21.010 

Lopez B. 40.004 

Lopez D. 75.013 

Lopez E. L. 28.011, 78.013, 

80.010, 80.008, 30.019, 

80.015, 77.024 

Lopez H. 81.016 

Lopez J. C. 80.024 

Lopez L. 28.042 

Lopez M. 27.024 

Lopez P. 80.009 

Lopez S. C. 74.019 

López Y. 31.004, 83.027, 52.024 

López Gallego D. 56.043 

Lopez Papucci S. 72.004 

Lopez Vidal Y. 77.029 

López-Vidal Y. 31.005 

Lopez-Zambrano M. A. 81.009 

Loret de Mola C. 57.011 

Loro L. 40.007 

Lotufo P. A. 27.022 

Loutan L. 01.001 

Low N. 27.009 

Löwa A. 75.021 

Lu H.-B. 53.022 

Lu X. 40.002 

Lu X. 84.039, 84.021 

Lu Y.-H. 28.001, 34.005 

Lu Y. 73.013 

Lubogo D. 27.033 

Lucchetti G. 32.022 

Lucero C. 23.020 

Luchetti P. 25.008 

Luisiama J. 55.013 

Lukwago L. 28.027 

Luminos M. L. 55.007 

Luo S.-T. 76.015 

Luo X. 47.005, 73.013, 73.011 

Lupisan S. 26.005, 84.007, 

84.036, 21.005 

Lutalo T. 80.007 

Lutwama J. J. 84.011, 28.027 

Lv X. 57.016, 57.015 

Lye D. C. 76.002 

M. D. C. 29.001 

Ma E. 28.043 

Macchi A. 06.001, 32.027, 

32.034, 32.020 

Macedo J. 47.008 

Machado D. M. 27.013, 27.012, 

27.011 

Macías Hernandez A. 23.028, 

33.016 

MacIntyre R. 59.008 

Mackenzie G. 81.020, 21.006, 

77.022 

Macleod W. B. 21.008, 32.029 

Maco V. 58.025 

Maco C. V. 58.025 

Madani A. 53.020 

Madhi S. 80.018 

Madiga M. 17.003 

Madoff L. 46.001 

Madrid C. 32.018 

Maffucci M. 23.024 

Maganda A. K. 72.002 

Magdaleni A. R. 29.002 

Magill A. 19.004 

Magira E. 74.012 

Magneres C. 77.024 

Magri M. C. 78.016 

Mahanta J. 79.007 

Mahdaviani F. S. 53.010 

Mahlouji K. 80.001 

Mahmood T. 27.017 

Mahmoud M. H. 57.033 

Maina W. G. 27.034 

Maitland K. 29.013 

Majanja J. 57.037 

Majidzadeh K. 75.027, 75.028 

Mäkelä S. 84.023 

Makumbi F. 83.023 

Makundi V. 28.044 

Malaque C. 08.002 

Malaria Technical Committee P. 

81.022 

Malas T. 32.006 

Malaska J. 75.037 

Maldonado M. H. 32.018 

Malec-Milewska M. 77.030 

Maleki F. 58.003 

Malik M. R. 57.035 

Malik P. 84.031 

Malla K. 58.028 

220 ~ Final Program

Authors Index 


Malla N. 58.017, 58.004 

Malla S. 57.014 

Mallavialle A. 31.002 

Manandhar D. 29.004 

Manaseki-Holland S. 80.019 

Mandal G. 82.012 

Mandrekar J. N. 25.017 

Manevich L. 50.002 

Manfredi R. 23.004, 31.001, 

84.010, 78.001 

Manga S. 59.004 

Mangory M. 28.047 

Mania A. 53.017, 53.016 

Maninska L. 84.045 

Manisera C. 51.019 



Mannheimer S. 78.009, 56.028, 

78.012 

Mannino L. 80.013 

Manoff S. 83.024 

Manoharan A. 59.008, 23.001 

Manonelles G. 28.011, 78.013 

Mansinho K. 73.012 

Manso C. 30.019 

Mantero J. 57.013 

Manuel R. C. R. 78.016 

Manzano-Cabrera L. 79.004 

Mapp T. 56.017 

Maqadma M. 57.035 

Maqelana T. 81.019 

Maraghi S. 58.030 

Marak R. S. K. 51.014 

Marano C. 32.003, 32.004, 

32.005, 32.012, 32.002 

Marano N. 32.004, 32.005, 

57.005 

Marchese R. 83.024 

Marcinkowska E. 77.030 

Marculescu C. E. 52.022 

Mardani M. 23.011 

Mardarescu M. 55.007 

Mares-Guia M. A. 76.006 

Margareth E. 27.022 

Marianelli L. 78.017 

Mariko S. 84.007 

Marin J. 78.019 

Marin M. 25.020, 25.008 

Marincu I. 58.021, 58.016, 

58.020, 58.019 

Maringwa J. 81.012 

Marion Z. 57.012 

Markley D. 26.011, 81.006 

Markovski V. 84.047 

Markowitz J. 51.005 

Markowitz N. 27.015 

Marks R. S. 84.011 

Marku K. 56.014 

Marrs C. F. 77.028 

Martelli C. T. 53.035 

Martin J. 40.009 

Martin J. 77.017 

Martin P. 65.006 

Martina B. 76.014 

Martine T. 68.002 

Martinez A. L. 56.031 

Martinez C. 57.032 

Martinez C. 80.024, 28.039 

Martinez F. 21.003, 26.003 

Martinez F. 52.024 

Martinez J. 57.034 

Martinez L. A. 32.021 

Martinez M. B. 83.003 

Martínez R. 83.010, 58.012 

Martinez Burkett A. 30.019 

Martìnez-Lopez E. 77.014 

Martini Robles L. 76.023 

Martis A. 76.014 

Masago Y. 26.005 

Masauni S. 21.007 

Masayuki S. 84.007 

Mascaro O. 32.022 

Mascheretti M. 29.018, 24.017, 

03.003 

Mascola L. 56.012 

Mashayekhi R. 52.005 

Masjedi M. 74.020 

Mason C. J. 65.008 

Masuet Aumatell C. 56.043 

Mathai D. 59.008, 23.001 

Mathengtheng L. 24.009 

Mathew J. L. 83.009 

Mathur A. 83.020 

Mathur A. 76.009 

Matu S. 75.018 

Maurya A. K. 59.012 

Maves R. C. 48.006, 34.020 

May J. 51.011, 80.021 

Mayanja-Kizza H. 75.035 

Mayence A. 82.005 

Mayer F. 84.019 

Mayer Wolf M. 81.008 

Mayer-Wolf M. 28.024 

Mayo-Montero E. 28.019 

Mayta H. 82.014 

Mazal C. 77.026 

Mazari-Hiriart M. 31.005 

Mazengia F. 81.013 

Maziz M. N. H. 52.002, 52.009 

Mazur W. 53.030 

Mazurova I. 77.025 

Mbele R. 27.030 

Mbelle N. 23.012 

Mbidde E. K. 40.008 

Mbopi-Keou F.-X. 27.030 

McAvin J. 75.036 

McBride A. 47.008 

McBride F. 47.008 

McBroom M. 49.008 

McCabe A. 79.012 

McCarthy A. 12.001, 51.024 

McClenahan S. D. 47.006 

McCue K. 81.019 

McCullers J. 44.001 

McFetridge R. 83.024 

McGeer A. 65.010 

Mckenney J. 57.038 

McLaughlin J. B. 40.002 

McLoughlin K. 57.009 

McMichael A. J. 17.002 

McNulty C. 23.027 

Meddeb B. 56.013, 56.008 

Medeiros A. I. 73.005 

Medeiros E. A. 56.017 

Medici L. F. R. 59.018 

Medina F. 53.036 

Meghani H. 83.020 

Megrelishvili T. 26.012 

Mehanic S. 34.016 

Mehta A. 56.017 

Meiring S. 52.014 

Melamud A. 81.016 

Melo E. 52.019 

Melo F. A. F. 59.023, 59.018 

Melo L. C. V. 51.008 

Mena A. 84.024 

Mendez C. 75.042 

Méndez J. 75.042 

Mendez M. 21.004 

Mendez-Galvan J. 36.001 

Mendoza J. 84.040, 73.015, 

84.043 

Mendoza R. 56.031 

Menezes G. 23.015 

Menezes M. 47.008 

Meng J. 53.038 

Mengel M. 27.019 

Mercer J. G. 65.011 

Merchan-Hamman E. 53.035 

Meri S. 84.023 

Merino P. 76.027 

Merisescu M. 55.007 

Meryem L. 82.010 

Meshkat M. 30.008 

Messina C. M. S. 59.023 

Meta E. 84.020, 28.017 

Metzger D. 44.002 

Mghamba J. 28.044, 21.007, 

81.015 

Michael E. 57.017 

Michael K. 72.001 

Michalak M. 53.017 

Michalek J. 75.037 

Michee K. 72.001 

Michelli E. 84.043, 84.040 

Mickova E. 56.023 

Miftode E. 23.019 

Migliazzo A. 26.006 

Miki M. 49.009 

MIlenkovic Z. 52.013 

Miller F. D. 76.019 

Milone J. 28.042 

Mindiola R. 79.010, 79.011 

Ming W. 57.008 

Mlranda A. 73.012 

Miranda T. 51.015 

Miranda Novales M. G. 56.017 

Miro J. 62.003 

Mirsattari D. 52.005 

Mishra A. 28.009 

Mishra A. K. 32.009, 33.008 

Mishra B. 47.010, 24.011 

Mishra S. 58.017 

Mistchenko A. 28.011 

Mitrev Z. 56.017 

Mitro S. 81.022 

Mitrovic N. 53.023 

Mitterpachova E. 78.002 

Miyaji E. 83.004, 83.003, 

83.005 

Miyazaki N. H. T. 51.015 

Mizuguchi M. 28.008 

Mlisana K. 17.003 

Mlkvy P. 25.002 

Mmbuji P. 21.007, 28.044, 

81.015 

Modi C. 77.019 

Modi M. 47.010, 24.011 

Modrzewska R. 77.006 

Mofid L. 58.015 

Mohamad Noordin N. 33.009 

Mohamed M. A. 28.044 

Mohamed Hussain K. 84.022 

Mohammadi F. 74.020 

Mohammadtaheri Z. 74.020 

Mohammed M. 21.007, 81.015 

Mohd Nawi S. F. A. 23.023 

Mohebbi S. R. 53.024 

Mohraz M. 27.004 

Moine I. 28.040 

Moini L. 59.005 

Mojica J. 53.036 

Molina D. 78.019 

Molina F. J. 30.016 

Molina R. F. S. 30.015, 30.014 

Molise C. 28.011 

Momen Heravi M. 59.003, 

75.003, 53.019 

Momoko O. 84.007 

Monaco A. 52.004 

Mónaco A. 80.015, 76.003 

Moncada J. 75.010 

Mondoy M. 21.005 

Monfante I. 34.008 

Monge M. 80.024 

Moniri R. 23.007, 74.003 

Monsalve F. 79.011 

Montarroyos U. 57.012, 53.035, 

53.029, 53.028 

Monteiro C. M. C. 54.002 

Montenegro S. 59.010, 84.005 

Montgomery J. 57.011 

Monto A. S. 28.036, 11.002, 

65.003, 18.004 

Moore P. 17.003 

Moore S. 17.002 

Moore S. 34.014 

Mora C. A. 32.024 

Mora N. 56.032 

Morabito S. 34.015 

Morales G. 23.026 

Morales J. C. 52.021 

Final Program ~ 221

Authors Index 


Morales M. A. 83.026 

Morales Pérez C. 56.026 

Morehouse B. 26.011 

Moreira I. 27.021 

Moreira J. M. 76.023 

Moreira R. 53.028, 53.029, 

53.035, 57.012 

Moreira R. F. S. 59.018 

Morelli J. 28.050 

Moreno A. T. 83.005, 83.004, 

83.003 

Moreno A. 28.040 

Moreno J. 51.023 

Morens D. 18.001 

Moretti M. L. 56.038 

Morfaw C. 65.002 

Mori A. 56.033 

Morikawa N. 49.009 

Moriya K. 56.015 

Moriya Y. 57.012 

Morosini M.-I. 20.001 

Morris L. 17.003 

Morrison H. 81.002 

Morrison M. 23.017 

Moscatelli G. 72.004 

Mosha F. 81.015, 21.007 

Mosqueda N. 73.015 

Mosquito S. 48.006 

Moss W. J. 27.009 

Mossad S. 84.014, 69.004 

Mota C. S. 56.021, 80.012 

Mote P. 57.011 

Motoshima M. 74.009 

Motta A. 30.020, 30.023 

Motta F. A. 28.022 

Mounts A. W. 18.003 

Mousavi J. 56.006 

Mousavi S. L. 83.002 

Moustakas G. 82.004 

Moyes J. 52.014 

Moynihan M. 76.029 

Mpeka B. A. 80.007 

Mshelia D. 59.015 

Mtapuri-Zinyowera S. 58.032 

Muazu A. 55.009 

Mucientes F. 59.010 

Muco E. 28.017 

Mudryck G. 52.004 

Muehlenbein M. 32.021 

Mueller I. 72.005 

Mughal Z. 80.019 

Muhammadu Gobir S. 33.009 

Muita L. 75.018 

Mukanga D. 81.015, 83.023 

Mukherjee A. 84.028 

Mukhi S. 65.011, 81.018 

Mukhopadhyay C. 56.001 

Mukhopadhyay R. 82.012 

Mulholland E. K. 43.002, 77.022 

Mullaguri N. 29.009 

Mullalli G. 84.009 

Muller C. 57.039 

Mullins G. 76.016 

Mulvey M. R. 76.026 

Muñoz J. 73.015 

Muñoz M. 73.015, 84.043, 

75.036 

Muñoz Delgado A. B. 80.005 

Mupfasoni D. 72.001 

Murillo J. 56.009, 74.015, 

56.010, 08.004, 04.004, 

64.003 

Muriova K. 75.037 

Murray D. 65.002 

Murray G. F. 65.003 

Musa M. T. 75.030 

Musher D. 83.024 

Musisi D. 56.041 

Mustafa M. 53.021 

Mustafa S. 28.047 

Mustonen J. 84.023 

Mutonga D. 21.009 

Muttalif A. R. 33.009 

Mutton K. 32.011 

Muvunyi C. 59.006 

Muwanga M. 40.008 

Muzzillo D. 57.012 

Muzzio Aroca J. 76.023 

Mwakapeje E. 28.044 

Mworozi E. A. 80.007, 72.002 

Myint K. S. A. 65.008 

Myint K. A. 27.003 

Nabukenya I. 28.027 

Nacinovich F. 25.008, 25.020, 

83.021, 77.007, 25.009 

Nag V. 59.012, 51.014 

Nagashima S. 84.012 

Nagashima S. 74.007, 77.010 

Nagatomo H. 34.013 

Nagelkerke N. 75.007 

Naik E. 55.006 

Naik T. 34.006 

Najafi A. 73.001 

Najafzadeh M. J. 30.008 

Najera P. 57.034 

Nakaggwa S. M. 33.012 

Nakal S. 58.018 

Nakamura M. 77.008 

Nakanishi W. 75.026, 25.007 

Nakhasi H. 29.014 

Nakhonesid-Fish V. 57.017 

Nakiyingi L. 75.035 

Nalwadda C. 26.010 

Namujju P. B. 40.008 

Namusisi O. 56.041, 26.010, 

83.023 

Nand Garg D. 34.010 

Napal J. J. 28.042 

Nara P. 34.033 

Naraghi arani P. 76.007 

Naraghi-Arani P. 75.031, 75.024 

Naranjo L. 84.034, 80.011 

Naranzul T. 28.006 

Narasimhan P. 59.008 

Narayanaswamy J. 83.022 

Narov U. E. 28.012 

Nasidi A. 57.039 

Nasr M. A. 58.006 

Nasution P. D. 29.002 

Nataraj K. 29.005 

Nathan S. 32.021 

National Malaria Board S. 

81.025 

Nau R. 71.002 

Navia D. 25.020 

Navoa-Ng J. A. 56.017 

Nazario R. 80.023 

Nazarova E. 84.037 

Nazemalhosseini Mojarad E. 

58.026 

Ndase P. 17.004 

Ndreu A. 77.001 

Ndumbe P. 27.030 

Neghina A. M. 58.020, 58.019 

Neghina R. 58.020, 58.019 

Negroni R. 30.018 

Negrut N. 84.048 

Negrutiu L. 58.020 

Negrutiu L. 58.019 

Nejatizadeh A. 53.020 

Neyra J. M. 57.011 

Neyro S. 28.011, 80.015 

Ng E. 23.022 

Ng L.-K. 81.018 

Ng M. L. 73.002, 24.010, 

84.022, 24.012 

Ng M. L. M. 24.013 

Ng T. F. F. 76.017 

Ngui Ngamini A. 27.006 

Nguyen A. 32.001 

Nguyen C. 57.040 

Nguyen C. 57.006 

Nguyen M. 78.003 

Nguyen N. 77.019 

Ní Bhuachalla C. 83.018, 

27.025 

Nicholls R. S. 57.034 

Nichols G. 32.011 

Nicolau D. P. 49.005 

Nicoletti P. 51.026 

Nieto C. 82.013 

Niezgoda M. 84.044 

Nik Mohamed M. H. 33.009 

Nikitovic L. 53.023 

Nilganuwong S. 58.013 

Nilsson C. 76.017 

Ning Q. 73.011, 73.013, 47.005 

Nipp R. 80.017 

Nishikaku A. S. 30.014, 30.015 

Nishiura H. 28.021 

Njuguna C. 21.009 

Nkada C. 27.030 

Nog R. 56.028, 78.009, 77.018 

Nogueira C. V. 57.012 

Nogueira R. D. 25.004 

Nokhodian Z. 53.018 

Noorbakhsh S. 56.006 

Nordmann P. 20.002 

Norizuki M. 25.001 

Nosik D. 84.037 

Nosik N. 84.037 

Notario R. 74.019 

Noveri S. 28.007 

Nowak G. 79.012 

Nsabiyumva L. 29.016 

Nseir B. 30.017 

Nsekpong D. 21.006 

Nsengiyumva E. 25.021 

Nshala A. 77.021 

Nsobya S. 72.002 

Nsubuga P. 81.015 

Ntinos K. 82.004 

Nuak J. 32.031 

Nucci M. 15.004 

Nuchprayoon S. 29.010 

Nuermberger E. 68.003 

Nukiwa N. 65.001, 28.006 

Nukui Y. 56.015 

Numsuwan W. 23.008 

Nunez S. 82.014 

Nur-E-Kamal A. 72.006 

Nwafor-Okoli C. 77.012 

Nyale E. 28.044 

Nyaruhirira I. 25.021 

Nydam D. V. 34.020 

Nymadavaa P. 76.005 

Nymadawa P. 28.006 

Nzioka C. M. 21.009 

O’Brien M. 83.014, 83.013 

O’Callaghan S. 29.014 

O’Connell E. 28.051 

O’Hagan D. 65.005 

Oba Y. 77.008 

Obajuluwa A. 74.013 

Obayashi Y. 77.012 

Oboro H. 56.020 

Ocama P. 75.035 

Ochoa T. J. 52.023, 48.006 

Oderiz R. S. 52.021 

Odette M. 72.001 

Odikamnoro O. 29.006 

Odike A. 76.021 

Odio C. 43.003 

Odreman M. 75.036, 73.015 

Ogunkoya A. 84.044 

Ogura Y. 56.033 

Ohji G. 77.008 

Ohno A. 21.005 

Ohuma E. 29.013 

Oike F. 56.033 

Oka H. 77.008 

Okamura L. H. 59.018 

Okoboi S. 59.002 

Okogbenin S. 51.018 

Okogbenin S. A. 72.003 

Okogbenin S. 84.046 

Okogbenin S. A. 76.022 

Okokhere P. 51.018 

Okokhere P. 76.021, 76.022 



Okoko B. 77.022 

222 ~ Final Program

Authors Index 


Okonkwoh C. 27.002 

Okot C. 28.027 

Okumura C. 26.005 

Olariu T. R. 58.021, 58.016 

Olayinka A. 74.013 

Olayinka B. 74.013 

Olczak A. 77.015 

Oleastro M. 83.016 

Oleribe O. 21.007, 28.044, 

81.015 

Olivas J. 75.024 

Olivas J. 76.007 

Oliveira A. P. P. 28.022 

Oliveira D. A. 59.018 

Oliveira I. R. S. 27.022 

Olodo-Atitebi S. T. 34.007 

Olomu S. C. 76.021 

Olsen S. 65.004 

Olurinola P. 74.013 

Olveda R. 21.005, 26.005, 

84.007, 84.036 

Omaeche M. 79.009 

Omar K. 21.007 

Omilabu S. 51.021, 80.026, 

57.039 

Omran Y. 75.032 

Omura T. 26.005 

Onaolapo J. 74.013 

Ondobo Andze G. 27.030 

Oner Y. A. 58.011 

Onofrey S. 23.017 

Onorio S. 30.023 

Onsongo J. K. 21.009 

Ooi P. L. 76.008, 81.003 

Ooi W. W. 21.008, 32.029 

Oormazdi H. 58.010 

Opollo M.-S. 83.023 

Opromolla P. 24.017 

Orciari L. 84.044 

Ordieres F. 56.010, 74.015, 

56.009 

Ordouzadeh N. 48.004 

Orduña P. 83.027 

Orduna T. 04.002, 32.026, 

72.004, 32.030, 83.026, 

32.032, 32.025 

Orellana N. 32.024 

Orenolu R. 57.039, 80.026 

Orenstein W. A. 65.002 

Oreste H. 21.005 

Orlosky P. 81.014 

Ormaeche M. 53.037 

Orogade A. A. 80.025 

Oropeza M. D. 80.011 

Ortegoza J. 58.022 

Ortiz J. 84.024 

Oshikanlu Z. 78.010 

Oshitani H. 28.006, 84.036, 

65.001, 21.005, 26.005 

Osinubi M. 84.044 

Osmon D. R. 25.017 

Ossai I. 80.026 

Osterhaus A. 76.014 

Ostreni V. 28.017 

Otelea D. 55.007 

Otevrel F. 75.037 

Otgonbaatar D. 76.005 

Ottone C. 25.016 

Ouhoummane N. 65.006 

Owolabi R. 27.005 

Oyama M. 84.030 

Oz V. 82.007 

P’yankov O. V. 73.004 

Pacheco M. 51.023 

Pacheco V. 51.023 

Pachkoria E. 26.012 

Pacola M. 28.050, 28.045 

Padilla-Docal B. 76.023 

Padinjarenmattathil U. 83.022 

Pádua E. 54.003 

Paganini H. 80.015 

Pahil S. 52.017, 56.022 

Painter J. E. 65.002 

Paiva S. A. S. 56.042 

Paiva T. 28.020 

Paiva W. 25.018 

Paixao E. 54.003 

Pal’cev A. V. 28.012 

Palma S. 58.024 

Pan D. 84.008 

Pandey V. 34.001 

Pandey V. 52.007 

Panigrahi D. 58.005 

Panozzo C. A. 40.002 

Panunto P. C. 59.020 

Papadakis M. 77.002 

Papadomanolaki E. 23.002, 

74.017 

Parada Barba C. 82.009 

Paradela C. M. F. 59.023 

Paralicova Z. 53.012 

Paranhos-Baccala G. 73.003 

Parashar U. 40.003, 40.004 

Parino E. 28.040 

Park D. W. 56.039 

Park K.-H. 56.040 

Park Y.-J. 52.016 

Parra A. 83.016 

Parra L. 32.017 

Parshin P. 34.012 

Parvin M. 84.026 

Pasari Y. 74.018 

Pascalicchio F. V. 32.008 

Pascual Y. 58.022 

Pasha S. T. 55.015 

Passweg J. 30.013 

Pasteran F. 23.020, 61.001 

Patarroyo M. A. 75.013, 75.009 

Patel A. K. 55.006 

Patel J. K. 55.006 

Patel K. 55.006 

Patel M. 40.003 

Patricia E. 25.011, 25.013 

Patterson T. 63.004 

Patzi-Vargas S. 21.003 

Paul S. K. 84.012, 75.016 

Paulin P. 72.004 

Paulino E. R. 27.011 

Pavan M. H. 76.030 

Pavlin J. A. 65.008 

Pavlinic D. 79.003 

Pawar M. 28.052, 28.029 

Payne D. 40.003 

Pazol K. 65.002 

Pearce T. 34.033 

Peart S.-L. 74.016 

Pedragosa A. 32.022 

Peiris M. 28.043 

Pellegrini M. 65.005 

Pellegrino D. 27.021 

Pellini A. C. G. 28.028, 28.026, 

57.018, 28.030 

Peltola H. 71.003 

Peña J. 32.017 

Peng H. 28.002 

Peng M.-C. 28.032 

Pensotti C. A. 77.007, 25.009, 

25.008 

Perea-Mejia L. 77.014 

Pereira H. 81.022 

Pereira L. 53.029, 57.012, 

53.035, 53.028 

Pereira L. A. 25.018 

Pereira M. M. 77.011 

Perelson A. 17.002 

Peres C. M. 73.006 

Peres O. M. 79.005 

Perez C. 28.041 

Perez G. 77.019, 27.028 

Perez G. 80.013 

Pérez M. 77.020 

Perez S. 73.015 

Perez V. 28.036, 65.003 

Perez Carrega E. 83.026, 25.020 

Perez-Tuyub M. 79.004 

Peric M. 79.003 

Perkash Singh G. 75.011 

Perret C. 80.024, 28.039, 

02.003, 38.002 

Pessoa S. 27.013 

Peter R. 59.008 

Peters M. 57.006 

Petit-Sinturel M. 46.003 

Petkov G. 52.013 

Petrascu M. 23.002 

Petrela R. 28.017, 84.009, 

80.006 

Petrela R. 51.007, 84.017 

Petrescu C. 58.021, 58.016 

Petric M. 84.048 

Petrie H. 32.006 

Peyrefitte C. 73.003 

Pfaff M. 21.008, 32.029 

Philippe M. 14.004 

Picazo J. 76.027, 23.026 

Piccinini F. 25.020 

Piechotta G. 75.021 

Pierro A. 51.020, 24.016, 

76.028, 51.019, 76.011 

Pilaca A. 77.001 

Pimenta F. C. 83.003 

Pimentel R. 28.041 

Pineda A. M. 78.007, 78.008 

Pineda S. 84.005, 59.010 

Pineda Segundo V. J. 34.008 

Piñeros O. 80.011, 84.034 

Pinilla M. 84.005, 59.010 

Pink H. 84.019 

Pinto A. 57.035 

Pinto G. A. 27.022 

Pinto M. E. 57.012 

Pinto M. I. 30.023, 30.020 

Pinto V. 24.014 

Piotrostanalzki A. 77.020 

Pipero P. 28.017 

Pires T. S. 79.005 

Pisapia J. 56.030 

Pittet D. 70.001 

Pitz K. 75.024, 76.007 

Pividori R. 72.004 

Piyaphanee W. 32.007 

Pizzo C. R. P. 30.014, 30.015 

Plat F. 80.008, 80.010 

Plessas S. 26.008 

Plotkin S. 37.003 

Plowe C. V. 42.001 

Podzimkova M. 56.023 

Poggi E. 53.027 

Pogodina V. V. 24.004 

Pohl K. 56.018 

Polanco A. 26.003, 21.003 

Polat E. 82.007, 58.011 

Pöllabauer E. M. 37.002 

Pollard W. 32.002, 32.003 

Polymili G. 77.002 

Ponam T. 32.007 

Ponce O. 75.025 

Ponce de Leon A. 56.031 

Ponce de León S. 83.027 

Ponce de Leon S. 18.002 

Ponce de León Rosales S. 33.016 

Ponce-de-Leon A. 23.028 

Ponnaluri S. 77.028 

Pons M. J. 48.006 

Portaels F. 68.002 

Portillo E. 75.005 

Porto L. 79.011, 79.010 

Porubcin S. 53.012 

Pot B. 75.023 

Potdar V. 28.009 

Potin M. 80.024 

Pourmand M. R. 56.016 

Pourpaki M. 74.020 

Prabhakar S. 24.011, 47.010 

Prabhu M. 29.005, 52.008, 

77.009 

Prado V. 56.044 

Praino M. L. 80.010, 30.019, 

80.015 

Prakashini K. 56.001 

Prasad K. N. 23.001 

Prasad N. 51.014 

Final Program ~ 223

Authors Index 


Prates M. V. 28.042 

Prekates A. 74.012 

Premasathian N. 58.013 

Prematunga C. 51.024 

Prewitt J. 78.020 

Prior C. 34.033 

Procopio A. 80.015, 77.024 

Procopio A. 30.019 

Profapi 2009/160 34.031 

Prokop M. 77.006 

Pucci F. 31.003 

Puello J. M. 29.015 

Puerto-Solis M. 79.004 

Puga S. 34.008 

Pujhari S. K. 24.011, 47.010 

Pumarola T. 80.023 

Pun M. 79.009, 53.037 

Purevsuren B. 34.024 

Purpari G. 26.006 

Putnam S. D. 74.006 

Qaqa A. 27.028 

Qato M. 30.010 

Qin C. 84.001, 24.006 

Qin E. 84.001, 24.006 

Qin P. Z. 57.008 

Qu J.-Y. 53.034 

Querci M. 28.004 

Quesada-Gómez C. 76.026, 

25.019 

Quevedo E. 55.003 

Quigley C. 32.011 

Quijano-Vivas A. 57.021 

Quinones D. 74.007, 77.010 

Quinones Falconi F. 77.029 

Quiñonez-Alvarado M. 77.014 

Quintas E. 32.031 

Quintero Vélez J. C. 47.001 

Quinteros H. 28.040 

Quiroga J. 48.001 

Quiroga M. 29.018 

Quiroz V. 47.001 

Quispe J. 57.011 

Rabb J. 83.024 

Rabbani T. 58.009 

Rachas A. 28.037 

Raciny Aleman M. L. 80.005 

Racloz V. 51.004 

Rada R. 77.020 

Radmanesh ahsani R. 77.003 

Radovanovic A. 53.023 

Radulescu A. 77.016 

Raeissi S. 74.020 

Rafati S. 83.002 

Rafiei tabatabaei S. 77.003 

Raggam R. B. 30.001 

Raghavan B. 24.012 

Raghavendra K. 29.011 

Rahbany P. 50.001 

Rahman W. 59.012 

Rai S. 33.006 

Raigosa M. M. 56.027 

Rainford L. 52.012 

Rajapaske R. 77.012 

Raka L. 56.017 

Ramachandran B. 29.005, 

77.009 

Ramachandran V. 84.004, 

84.003 

Ramadhany R. 57.019 

Ramamoorthy S. 34.033 

Ramezani A. 53.010, 84.026, 

59.005, 27.004, 53.002 

Ramirez P. 63.001 

Ramirez Borga S. J. 28.042 

Ramon G. 76.018 

Ramon Torrell J. M. 56.043 

Ramon-Pardo P. 57.038 

Ramos A. 75.025 

Ramos J. 50.002 

Ramos M. 59.020 

Ramos M. 57.011 

Ramos R. G. 21.010 

Ramos Hernandez L. R. 80.005 

Ramos Marti J. L. 75.017, 82.009 

Ramos-Hinojosa A. 23.028 

Ramoutar D. 33.005 

Rampal L. 27.018, 27.031 

Rana M. K. 59.012 

Ranchobe N. 17.003 

Ranjan R. 55.006 

Ranjbar novin N. 83.017 

Rao S. 32.004, 32.005 

Rao S. 52.007 

Rao S. 23.006, 52.007 

Rao U. 78.005 

Raoult D. 21.010 

Rasch M. 56.011 

Rasmussen M. 76.007 

Rasouli M. 84.041 

Ratho R. K. 47.010 

Ratho R. K. 24.011 

Ratnasingham S. 57.020 

Rattendi D. 82.005 

Rauch L. 75.010 

Ravanshad M. 54.004, 84.041 

Rawat M. 29.011 

Raymond N. 59.021 

Raz R. 50.004 

Raza A. 58.009 

Razmjou E. 58.010 

Rebbapragada A. 65.006 

Reddy V. 82.001 

Refos F. 81.022 

Rehm S. 84.014 

Reid J. 32.011 

Reis M. 28.050 

Reis M. 47.008 

Reis M. N. G. 51.022 

Remedios M. 54.003 

Ren H. 34.005 

Renteria M. 74.002 

Requejo R. 57.034 

Requejo Pino O. 56.026 

Resa A. J. 32.019 

Resende M. 76.030 

Restrepo A. 15.002, 78.019 

Restrepo C. 78.019 

Reuter G. 53.038 

Rey G. 75.042 

Reyes J. R. 29.015 

Reyes L. 40.004, 65.004 

Reyes P. 30.026, 77.020 

Reyes-Garay H. A. 34.020 

Reynaga E. 32.022 

Rezaeian M. 58.010 

Rezaie S. 58.010 

Rhone J. 73.007 

Riarte A. 72.004 

Ribeiro A. F. 28.026 

Ribeiro A. 24.017 


Ribeiro A. F. 57.018 


Ribeiro C. T. 51.022 

Ribeiro V. 76.030 

Ribeiro-Carvalho M. 77.011 

Riccardo F. 57.035 

Richardus J. H. 34.027 

Rijal S. 29.004 

Rimal N. 32.009 

Rios P. 78.011, 50.002 

Ripoll S. 25.016 

Rísquez Parra A. 81.005, 32.018, 

06.002, 32.017, 45.002 

Rivas M. A. 58.022 

Rivas N. 80.010, 80.008, 30.019 

Rivas P. 30.026 

Rivera M. 84.024 

Rivera N. 84.005 

Rivera Morales J. 56.019 

Rivero J. 34.032 

Rivero M. 59.018 

Robbins C. L. 40.002 

Roberti L. R. 25.004 

Rock C. 83.018 

Rodas J. 47.001 

Rodica G. 65.006 

Rodin R. 65.011 

Rodrguez-Osorio C. 23.028 

Rodrigues D. 59.018, 59.023 

Rodrigues O. 80.022 

Rodrigues R. 73.003 

Rodriguez C. 28.053 


Rodríguez C. 76.026 


Rodríguez V. 81.008, 28.024 

Rodriguez Brieschke M. T. 

82.013 

Rodriguez Iantorno P. 53.027, 

78.011 

Rodríguez-Cavallini E. 25.019, 

76.026 

Rodriguez-Morales A. 58.018, 

81.009, 32.018, 32.017, 

81.005, 58.022 

Rodriguez-Morales A. J. 64.001 

Rodriguez-Taveras C. 29.015 

Roger A. 75.010 

Rohani M. 59.001 

Rohwer F. 76.017 

Rojas H. 30.018 

Rojas S. 25.016 

Roksandic-Krizan I. 79.003 

Roman Romera I. 56.043 

Romero C. 33.016 

Rosa-Cunha I. 78.020 

Rosales-Encina J. L. 58.014, 

83.011 

Rosanova M. T. 76.003, 80.013, 

52.004 

Rosato A. 10.001 

Rosella L. C. 65.006 

Rosello C. 56.030 

Rosenthal V. 56.018, 10.004, 

56.017, 56.026, 56.019 

Roses Periago M. 57.034 

Rosli R. 47.007, 73.014 

Rossi F. 23.025, 23.024, 30.020, 

30.023 

Rossini F. 56.038 

Rossini G. 76.028 

Rossini G. 24.016, 51.020 



Rostami K. 53.024 

Rostami Nejad M. 53.024, 

58.026 

Rostampour A. 59.005, 53.010 

Rouleau I. 65.006 

Roy G. 26.002, 76.001 

Rozenbaum W. 75.022 

Rozental T. 76.006 

Rozos G. 26.008 

Ruan Y. 76.017 

Rubiano L. C. 53.036 

Rubino J. R. 81.019, 72.006 

Rubinstein E. 66.001 

Rubio Robles M. C. 34.003, 

34.031, 34.017 

Rudd R. J. 34.014 

Rueda A. 83.024 

Rueda L. M. 29.012 

Rufino A. M. 27.010 

Ruhl D. 80.017 

Ruiz J. 52.023, 48.006 

Ruíz J. M. 34.032 

Ruiz M. 56.010, 56.009 

Ruiz N. M. 50.006 

Ruiz P. 53.015 

Ruiz P. 53.026 

Rujumba J. 80.007, 72.002 

Runstadler J. 65.007 

Rupprecht C. E. 84.044 

Russman M. 30.019 

Rutherford C. 75.034 

Ruttimann R. 83.021 

Ruuragchaa S. 34.024 

Ruvinsky S. 80.013, 72.004 

Ruzman N. 79.003 

Rwakimali B. 72.002 

Ryan E. 32.004, 32.005 

224 ~ Final Program

Authors Index 


Ryantova V. 56.023 

Saad A. 27.031, 27.018, 33.009 

Sabatinelli G. 57.035 

Sabitu K. 27.018, 27.031 

Sablan B. J. 33.014 

Sabol M. 30.025 

Sadanandan T. 75.011 

Sader H. 48.002, 74.006 

Sadki K. 75.007 

Safatov A. S. 73.004 

Safdar R. M. 27.017 

Saginur R. 65.011 

Saha D. 21.006, 81.020 

Saigal S. R. 80.004 

Saini S. 55.015 

Saito M. 84.036, 26.005, 21.005 

Saito M. 34.020 

Sakoda Y. 34.024 

Sakong R. 32.021 

Salari M. H. 56.016 

Salazar B. 51.023 

Salazar J. 17.002 

Saldaña A. 34.008 

Saldanha G. 32.014 

Sales J. M. 65.002 

Sallabanda S. 56.014, 80.006 

Salman M. 27.017 

Salmanian A. H. 83.002 

Salmons B. 24.010 

Salomão K. 82.011 

Salomao R. 54.002 

Salomon O. 72.004 

Salsabil H. 82.010 

Saltini C. 75.007 

Salzer H. J. 56.007, 30.001 

Sambri V. 24.016, 51.019, 

76.028, 76.011, 51.020 

Samoukovic G. 32.006 

samra T. 28.052, 28.029 

Samudzi R. 24.007 

San-Gil E. 56.032 

Sanabria Uribe A. J. 56.043 

Sanche A. 78.003 

Sanchez A. I. 78.014 

Sanchez A. V. 81.008 

Sanchez L. 81.012 

Sanchez P. 43.004 

Sanchez R. 30.026 

Sander B. 28.048, 65.010 

Sandoval C. 80.024 

Sane J. 84.023 

Sangar M. 29.005 

Sankaranarayanan R. 68.001 

Sanogo K. 81.006 

Santa Olalla P. 28.019 

Santamaria A. 53.036 

Santamaria A. M. 34.008 

Santivañez L. 21.004 

Santos B. A. 33.013 

Santos D. R. L. 53.003 

Santos J. R. P. D. 57.032 

Santos M. D. S. 25.018, 21.010 

Santos S. R. 83.003 

Santos dos Santos A. 53.035 

Santos-Fortuna E. 78.016 

Sapiain P. 56.044 

Sapkota K. 58.028 

Sapkota K. 58.028, 74.011 

Sarafpoor S. 58.003 

Saravu K. 52.008 

Saribas S. 75.015 

Saribas S. 75.014, 58.011, 

53.013, 82.007 

Sarkhoo E. 74.008 

Sarkis C. 83.016, 80.015, 

81.024, 81.023 

Sarmadian H. 53.010 

Sarmento A. 58.027, 32.031 

Sarmento e Castro R. 32.028, 

13.003 

Sarno de Oliveira M. L. 83.005, 

83.004 

Sarrazine S. 84.015, 24.005 

Sarri K. 82.004 

Sassaki A. L. 27.022 

Satija N. 84.035 

Sato H. K. 24.017 

Sato H. 84.030, 84.029 

Sattari Tabrizi S. 51.013 

Saunders D. 65.008 

Saunders D. 33.011 

Saville M. 36.002 

Savio E. 13.002 

Savioli L. 39.001 

Saxena R. 76.009 

Saxena S. K. 76.009 

Sayfutdinova S. 34.021, 65.007 

Scapellato P. G. 82.013 

Scarpellini B. 55.011 

Schachter J. 75.010 

Schaefer J. 74.014 

Schiel X. 30.004 

Schliep T. 77.018 

Schmaltz L. E. P. R. 79.005 

Schmidt M. 56.044 

Schmieder R. 76.017 

Schmittmann M. 28.033 

Schnabel D. 57.037 

Schneewind O. 66.003 

Schneider E. 40.002 

Schneider M. C. 76.029 

Schneider M. C. 57.034 

Schoenfeld D. 32.004, 32.005 

Schönian G. 82.010 

Schop W. 34.027 

Schouten M. 76.024 

Schreter I. 53.012 

Schteinschnaider A. 32.024 

Schuller E. 83.012 

Schuth I. 30.004 

Schutte H. D. 52.022 

Schwaber M. 41.003 

Schwartz B. S. 32.004 

Schwarzkopf-Steinhauser G. 

30.004 

Schweiger M. 81.010 

Scott A. L. 29.010 

Scott P. 27.009 

Seas C. 21.002 

Secatto A. 73.006, 73.005 

Sedaghat M. 30.008 

Seghrouchni F. 75.007 

Segovia M. 78.014 

Seguro A. C. 77.005 

Seifert H. 23.009 

Seljan P. 51.005 

Seljordslia B. 56.011 

Semenakova-Cvetkovska V. 

84.047 

Sementsova A. O. 28.014, 

75.019 

Sengee S. 34.024 

Sensakovic J. 77.019 

Seoane M. 82.013 

Seow H. F. 47.007, 73.014 

Sergeev A. N. 73.004, 28.014 

Sergeev A. 73.004, 28.012 

Sesso M. L. T. 25.004 

Sethi G. R. 80.004 

Sethi P. 65.006 

Setiawaty V. 57.019 

Sevcik P. 75.037 

Shaaban H. 27.028 

Shafei A. 84.033 

Shafiq N. 80.003 

Shah L. 21.002 

Shahbazi M. 57.003 

Shahid M. 58.009 

Shahin Y. 57.035 

Shahzad A. 30.017 

Shakya G. 57.014 

Shampur M. 83.022 

Shamshiri A. R. 77.003 

Shankar E. 78.005 

Shanker R. 47.009 

Shapovalov D. 33.008 

Sharif A. 75.003 

Sharkhuu T. 34.024 

Sharma A. 29.011 

Sharma M. 56.022, 52.017 

Sharma M. 24.011, 47.010 

Sharma N. 75.008, 52.006 

Sharma N. 34.001 

Sharma S. K. 25.005, 29.004 

Sharvadze L. 55.008 

Sharvadze L. 30.021 

Sharvadze L. 53.032, 53.025 

Shastry B. 52.008 

Shaw G. 17.002 

Shaw J. 46.003 

Shay D. K. 65.003 

Shayevich C. 75.010 

Shebbe M. 29.013 

Shehu N. 55.009 

Sheikh Ali S. 53.011 

Shemyakin I. 59.011 

Shen H. 57.015, 57.016 

Shenoy A. 56.001 

Shental Y. 50.004 

Sherman J. 21.004 

Sherwani S. 49.001 

Sheward D. 17.003 

Shi M.-H. 75.020 

Shi Q. 57.016, 57.015 

Shibl A. 14.002 

Shigeru M. 84.007 

Shih C.-M. 34.009 

Shikov A. N. 75.019 

Shimada J. 28.008 

Shin S. Y. 56.035, 56.036 

Shin S. Y. 59.007, 53.009 

Shin S. Y. 28.035 

Shinogami M. 75.026 

Shinogami M. 25.007 

Shintani Y. 56.015 

Shirai C. 28.025 

Shirreff G. 27.029 

Shishkina L. N. 28.012, 

73.004, 28.014 

Shkedy Z. 81.012 

Shoae Hassani A. 33.010, 

48.004 

Shoaei P. 53.018 

Shodhan S. 81.006 

Shokrzadeh L. 52.005 

Shrestha C. D. 74.011 

Shrestha J. 74.011 

Shrestha N. 84.014 

Shrestha S. 65.008 



Shrivastwa N. 77.028 

Shtannikov A. 58.029 

Shuetsu F. 84.007 

Shujatullah F. 58.009 

Shwartz J. I. 33.001 

Shytaj K. 77.001 

Siba P. 72.005 

Siddiqui T. 49.001 

Sieger B. 77.027 , 77.026 

Siegfried L. 53.012 

Siegfried L. 30.025 

Sierra A. 80.009 

Sierra-Moros M. J. 28.019 

Sieswerda L. 81.007 

Sifuentes J. 56.031 

Sifuentes-Osornio J. 23.028 

Silpasakorn S. 58.013 

Silva A. 28.050 

Silva A. R. 32.028 

Silva A. 32.028 

Silva C. L. 73.006 

Silva C. 79.010 

Silva C. 28.050 

Silva E. F. R. 54.002 

Silva J. M. K. 78.016 

Silva J. C. 57.034 

Silva J. F. 51.017 

Silva R. 27.021 

Silva-Graca A. 54.003 

Silvério Amâncio O. M. 27.013, 

27.012 

Final Program ~ 225

Authors Index 


Silvia S. 58.022 

Simaku A. 84.017, 51.007 

Simanek A. 80.016 

Simões L. C. 25.018 

Simonovic J. 53.023 

Singaravelu K. 56.028, 78.009 

Singh G. 52.017, 56.022 

Singh G. 47.009 

Singh K. P. 40.001 

Singh M. 80.003 

Singh S. 58.028 

Singh S. 53.006 

Singh U. 33.006 

Singh Y. 34.010 

Singhi P. D. 58.004 

Singhi S. 71.004, 56.022 

Sinha S. 82.006 

Sipova I. 56.023 

Sivagnanam K. 56.024 

Sivapalan V. 77.018, 78.012, 

78.009, 78.010, 56.028 

Sivay M. 65.007, 34.021 

Skarnovich M. O. 28.014 

Skowronski D. M. 65.006 

Slezak T. 57.009 

Slim J. 77.019, 27.028 

Sloan T. 47.004 

Slovak M. 24.004 

Slusarczyk J. 53.030 

Sluzewski W. 53.017, 53.016 

Smayevsky J. 56.034 

Śmiechowicz F. 77.006 

Smieja M. 75.005 

Smirnova M. 49.007 

Smith R. W. P. 84.031 

Smith R. M. 76.029 

Smouse S. 24.008 

Snevold I. 56.011 

Soares C. M. P. M. 55.011 

Soares E. 73.006 

Soares E. M. 73.005 

Sobarzo A. 84.011 

Sobreyra Oropeza M. 56.019 

Soca A. 28.007 

Socias L. C. 29.015 

Socolich C. 32.022 

Soeiro C. M. O. 78.018 

Soentjens P. 30.012 

Sofian M. 59.005, 53.010 

Sohn J.-W. 56.039 

Solano M. 34.020 

Soleimani M. 75.027, 75.028 

Soleymani T. 77.019 

Soliman S. 33.002 

Soloaga R. 23.020 

Solomon S. 78.005 

Solorzano Santos F. 76.018 

Sombrero L. 21.005 

Sonder G. J. B. 21.001 

Song G. 73.011 

Song J. Y. 56.039 

Song L. 28.003, 28.002 

Song Y. G. 59.007 

Soo Youn S. 28.034 

Sooka A. 52.014 

Soon E. 59.022 

Sopwith W. 32.011 

Sordelli N. 78.013 

Soriano F. 52.019 

Sorvor E. 57.004 

Sosa M. M. 21.008, 32.029 

Sosa Estani S. 03.004 

Sosnovtsev S. 47.006 

Sossa M. 28.053 

Sotelo Morales J. 07.001 

Soto R. 30.016 

Souza C. 76.030 

Souza M. 76.030 

Souza M. A. 56.042 

Souza R. 24.017 

Souza V. 76.030 

Souza Pinto V. 33.007 

Speil C. 23.014 

Spichler A. 77.005 

Spina A. 57.012 

Sponseller B. 34.033 

Sprenger M. 56.007 

Sramek V. 75.037 

Srikanth P. 56.024 

Srinivas R. 75.008 

Srinivasan U. 77.028 

Srivastava S. 40.001 

Ssekabira U. 72.007 

Stahl J. 56.002 

Stamboulian D. 81.023, 77.007, 

32.020, 83.021, 25.020, 

25.009, 81.024, 53.027, 

32.027, 32.015, 32.034, 

25.008, 78.011 

Stammen R. 24.005, 84.015 

Stanek D. 51.026 

Stark G. 73.007, 73.008 

Stavroulakis P. 77.002 

Stecher D. 83.026 

Steckelberg J. M. 25.017 

Steffen R. 12.002 

Stein A. 53.029, 57.012, 53.035, 

53.028 

Steingisser J. 77.021 

Stepanshina V. N. 59.011 

Stephan R. 34.018 

Stevens A. 81.007 

Stevens L. F. 81.006, 26.011 

Stevens M. P. 26.011, 81.006 

Stigler F. 56.007 

Stiles-Ocran J. 81.021 

Stimac D. 74.004 

Stockman L. J. 40.002 

Stone L. 76.016 

Strait E. 34.033 

Strukova E. 49.007 

Stryjewski M. 28.004 

Study Group N. 28.011 

Sturba E. 53.027, 32.027 

Suarez J. A. 80.011, 84.034 

Suarez-Allen R. 79.004 

Suarez-Ognio L. 53.037, 79.009 

Sucari A. 25.020, 25.008 

Sucupira M. C. A. 55.011 

Sudtasay S. 33.008 

Sueyoshi M. 34.013 

Suganaga R. 77.008 

Suljagic V. 56.017 

Summerville S. 81.022 

Sumner J. 75.005 

Sun Y.-J. 27.032, 55.010 

Sundaram S. 82.006 

Sundareshan V. 23.014 

Sungpradit S. 29.010 

Suputtamongkol Y. 58.013 

Surcel H.-M. 40.008 

Suttithum W. 32.007 

Suzuki A. 24.017 

Suzuki A. 21.005, 84.036, 

26.005, 65.001 

Svirtlih N. 53.023 

Swaminathan B. 81.018 

Syed Q. 32.011 

Sylvan S. 57.007, 51.002, 

51.001 

Syversen G. 56.011 

Szejnfeld V. L. 27.010, 27.011 

Szymanowski P. 40.006 

Tabatabaei A. 56.006 

Tabatabaei S. 84.013 

Taha S. 47.003 

Tahami Zanjani N. 77.003 

Tajbakhsh M. 34.015 

Takayama I. 84.029 

Takimoto K. 77.008 

Takoungang I. 27.030 

Taljaard J. 30.012 

Talukder K. A. 72.006 

Tamaki R. 21.005, 84.036 

Tamashiro H. 77.012 

Tambyah P. A. 50.005 

Tan A. 76.002 

Tan B. H. 84.042 

Tan T. 36.004 

Tan Y.-H. 73.014 

Tan Y. 57.015 

Taneja N. 52.017, 56.022 

Tang B.-Z. 75.039, 53.034 

Tanganelli C. B. 75.038 

Tanh T. N. T. 57.030 

Tarkhan-Mouravi O. 28.018 

Tate J. 40.002, 40.003 

Tato M. 57.038 

Tatsuno K. 77.013 

Tatulescu D. 77.016 

Tavakkoly Fard A. 77.003 

Tavares R. 73.012 

Távora L. F. 31.003 

Tawakol H. 84.033 

Tay S. T. 23.013 

Tchaporgina E. A. 76.005 

Tchouamani H. 27.030 

Teixeira T. 32.028 

Tellez I. 38.001 

Tellez L. 84.040 

Tellez L. 75.036 

Tellez L. 84.043, 73.015 

Temporiti E. 28.004 

Tengan C. 24.017 

Tenore S. B. 54.002 

Tenorio A. 75.042 

Teo C.-G. 53.038 

Teodor A. 23.019 

Teófilo C. R. 31.003 

Teoh E. 83.019 

Teper A. 28.011 

Teplyakova T. V. 28.014 

ter Waarbeek H. 57.025 

Ternovoy V. A. 75.019 

Tetsuya M. 84.007 

Tevzadze L. 26.012 

Thamlikitkul V. 48.005 

Thartori E. 51.007 

The SARA team G. 55.013 

Thebus R. 17.003 

Theme-Filha M. 57.012 

Then C. 28.041 

Thierer J. 77.007, 25.020, 

25.009, 25.008 

Thissen J. 75.024, 75.031, 

57.009, 76.007 

Thomas L. 40.002 

Thomé Barbosa Gouvea A. D. F. 

27.012, 27.010 

Thompson G. 28.033 

Thomson K. 41.002 

Thong K.-L. 23.023 

Thoresen H. 56.011 

Thormann M. 28.041 

Timenetsky M. D. C. S. T. 

28.028, 28.030 

Timmermans A. 65.008 

Titanti P. 53.027, 28.040 

Titanti P. 50.002 

Tjon-A-Tsien A. M. 34.027 

Tleyjeh I. M. 25.013, 25.011 

To K. 73.010 

Tobon A. 78.019 

Tokarska-Rodak M. 77.006 

Tolough G. 25.010 

Tondella M. L. 57.031 

Toniatti F. 28.050 

Tonsawan P. 56.003 

Toplak N. 28.016 

Torabi P. 34.015 

Torfeh M. 59.001 

Tormo Palop N. 75.017 

Torrado L. 78.013 

Torres C. 73.015, 75.036 

Torres J. 03.001, 64.004 

Torres J. 76.018 

Torres Hernández H. 56.019 

Torrico F. 34.020 

Torroija C. 32.034, 32.027 

Torun M. M. 53.013, 58.011 

Toshev M. 52.013 

Totten S. 65.011 

226 ~ Final Program

Authors Index 


Totusek P. 56.023 

Trabasso P. 56.038 

Trakulsomboon S. 48.005 

Travancas P. R. 25.018 

Travassos C. E. P. F. 34.025 

Treadwell T. 55.014 

Triantafillidou D. 77.002 

Trivedi J. B. 32.029, 21.008 

Trivi M. 25.020 

Trotman M. 46.003 

Trujillo J. 34.033 

Trupl J. 30.022 

Tsafaraki A. 74.017 

Tsai H.-C. 75.020 

Tsai T. 65.005 

Tsai Y. T. 40.005 

Tsakris A. 74.012 

Tsang K. L. 76.013 

Tsao K.-C. 76.015 

Tsaras G. 25.017 

Tseren-Ochir E.-O. 34.024 

Tserennorov D. 76.005 

Tsertsvadze T. 53.032, 30.021, 

53.025, 55.008 

Tsibris A. 32.005 

Tsouri A. 23.002, 74.017 

Tulloh R. 29.013 

Tumpey A. 81.014 

Turchi M. 51.022, 53.035, 

79.005, 56.042 

Turki A. 56.008, 56.013 

Turnbull E. 17.002 

Tweheyo R. 56.041, 27.033, 

27.034, 83.023, 26.010 

Twimba M. 29.013 

Tyagi I. 23.014, 23.029 

Tyson C. 56.012 

Tzanetou K. 82.004 

Uchejuru I. O. 29.007 

Uchendu U. 21.006, 81.020 

Uchida D. 77.008 

Uçkay I. 14.001 

Uddin M. 65.003 

Ude C. 57.041 

Udo E. 74.008 

Udorji O. 57.041 

Uemoto S. 56.033 

Uemura R. 34.013 

Ugoagwu P. 55.009 

Uhlenhaut C. 47.006 

Ukoli C. 78.004 

Ulrich M. 75.021 

Umoh A. 56.020 

Umoh J. U. 26.001 

Umubyeyi Nyaruhirira A. 68.002 

Uneke C. J. 79.001 

Ungchusak K. 65.008 

Upadhyay S. 56.028 

Urushibara N. 75.016, 74.007 

Usoro N. 29.007 

Ustanikova K. 24.004 

Usuf E. 21.006 

Vadivelu J. 23.023 

Vaheri A. 84.023 

Vajpayee P. 47.009 

Vakili Z. 75.003 

Valcheva V. 33.003 

Valdes F. 33.014 

Valencia B. 75.043, 75.025 

Valentin T. 30.001 

Valero Rodríguez J. E. 56.019 

Valle V. 77.024 

Valsalan R. 77.009 

Van de Paar E. 47.002 

Van de Weg C. 76.014 

Van den Berg T. 47.002 

Van Den Hoek J. A. R. 21.00 

van der Goot E. 57.013 

Van der Stuyft P. 81.012 

Van Genderen P. J. J. 21.001 

Van Gorp E. 76.014, 51.003 

Van Rie A. 55.013 

Van Rijckevorsel G. 21.001 

Van Zandt K. 73.007 

Vanden Eynde J. J. 82.005 

Vanegas A. 76.027 

Vanegas B. 80.009 

Vapalahti O. 84.023 

Vardar F. 84.032 

Vargas M. 76.018, 31.005 

Varma S. 52.006 

Varthalitis I. 23.002 

Vasanthapuram R. 24.015 

Vasconcellos R. C. 24.002, 

53.003 

Vasconcelos Beltrão S. 27.011 

Vashakidze E. 26.012 

Vasiljeva I. 58.029 

Vasques M. R. G. 25.018 

Vásquez L. V. 56.027 

Vasquez Y. 50.006 

Vassos D. 26.008 

Vatopoulos A. 26.008 

Vauterin L. 75.023 

Vauterin P. 75.023 

Vaz T. M. I. 51.008 

Vazquez G. 74.019 

Vazquez M. S. 77.024 

Vazquez V. 80.015 

Vdovichenko G. 28.012 

Vega Patin R. 27.011, 27.012, 

27.010, 27.013 

Vela E. 84.015, 24.005 

Veland N. 75.043 

Velapatiño B. 21.004 

Velasco I. 52.019 

Velasco J. M. 65.008 

Velasquez Portocarrero D. E. 

73.016 

Velazquez E. 76.018 

Ventura F. 73.012 

Vera D. 57.011 

Verastegui M. 82.014, 73.016, 

58.024 

Verdaguer V. 32.034, 32.020, 

32.027 

Vergara T. R. C. 55.011 

Verma A. 83.015 

Verma P. 68.001 

Verne E. 80.023 

Verrall A. 59.021 

Vescina C. 52.021 

Vidiella G. 56.030, 28.040, 

78.011, 53.027 

Vidor A. C. 57.012 

Vieira J. D. G. 56.042 

Vielma S. 84.043 




Viet T. L. 57.030 

Vijay S. 29.011 

Vijayan T. 57.006 

Vila J. 20.004 

Villacres Á. 56.017 

Villalon D. 78.017 

Villasboas M. 52.004 

Villaseñor-Sierra A. 77.014 

Villegas L. 81.022, 51.023, 

81.025 

Viña A. 80.008, 80.010 

Vinetz J. 32.004 

Vinisi H. 81.022 

Visser L. G. 21.001 

Vita A. 23.019 

Vitone J. 28.050 

Vitral C. L. 53.003 

Vivancos R. 32.010, 32.011 

Vizcaya C. 28.039, 80.024 

Vizzi E. 84.034, 80.011 

Vizzotti C. 83.025 

Vizzotti C. 25.009, 25.008 

Vizzotti C. 83.026 

Voidarou X. 26.008 

Volanis E. 74.017 

Vos M. C. 34.027 

Voundi E. 27.030 

Vozza L. 80.015 

Vozza M. L. 77.024, 30.019 

Vranes J. 74.004, 23.005 

Vujacich C. 81.023, 81.024 

Vujacich C. 78.011 

Vujacich C. 53.027 

Vujcikova J. 78.002 

Vukovic D. 79.003 

Wacheck S. 34.018 

Wada K. 28.021 

Wadegu M. 57.037 

Waeckerlin R. 57.024 

Wakatake H. 25.003 

Walia K. 79.007 

Walke H. 27.017 

Wallace M. 77.027 

Wallace M. R. 79.006, 50.003, 

75.006 

Walsh A. F. 75.006, 77.027 

Walsh B. 32.013 

Wamala J. 28.027 

Wamani H. 27.033 

Wanachiwanawin D. 58.013 

Wander G. S. 56.037 

Wang X. 73.011, 73.013 

Wang F.-D. 34.005 

Wang H. 73.013, 73.011 

Wang Q.-Q. 53.034, 53.033 

Wang Q. 28.003 

Wang Q. 84.039 

Wang T.-H. 28.032 

Wang W. 59.009, 33.004 

Wang X. 47.005 

Wang Y.-F. 84.016 

Wannet W. J. 34.027 

Wareham D. 23.010 

Warrell D. 08.001 

Wasko A. 73.008 

Watanabe A. 84.030 

Watanabe J. 21.004 

Watanabe S. 77.010, 74.007 

Watcharasamphankul W. 75.044 

Waterman S. H. 65.003 

Watson C. M. 40.002 

Waywa D. 58.013 

Waziri N. E. 26.001 

Weightman N. 77.017 

Weinberg J. 23.027 

Weisent J. 57.028 

Weiss P. 65.002 

Weiss S. 27.024 

Weksler C. 21.010 

Wenger M. 51.010 

Wenzel R. 70.004 

Wertheim H. F. 57.030 

West A. 34.033 

Westcott M. 40.002 

Wetsteyn J. C. F. M. 21.001 

Wey S. 70.003 

Whalen C. 33.001 

Whittembury A. 79.009, 53.037 

Wibowo H. A. 57.019 

Wilairatana P. 32.007 

Wilke L. D. 58.002 

Wilkerson R. C. 29.012 

Williams C. 81.014 

Williams P. 47.004 

Williamson C. 17.003 

Willis R. 52.012 

Willison D. J. 65.006 

Willner D. 76.017 

Wilson M. E. 32.029, 21.008 

Wilson W. R. 25.017 

Win M. K. 76.002 

Winnips C. 30.007, 49.003 

Wirsing von König C. H. 36.003 

Wise R. P. 29.014 

Wiseman S. 28.049 

Wolff M. 55.002 

Wong C. 73.010 

Wong R. 72.005 

Wong S. J. 34.014 

Wong T. 81.002, 65.011 

Wongstitwilairoong T. 65.008 

Wonhrathi M. 76.030 

Final Program ~ 227

Authors Index 


Woo J. H. 56.040 

Woo P. C. Y. 76.013, 84.025 

Wood J. 59.008 

Woodall J. 57.030 

Wörl R. 75.021 

Wu C.-T. 84.038, 49.006 

Wu J. 81.002 

Wu T. S. 50.005 

Wu Z. 73.011 

Wu Z. 73.013 

Wuryaninggsih E. 34.030 

Xerinda S. 58.027 

Xia Y.-G. 34.005 

Ximenes R. 53.035 

Ximenez R. 53.028, 53.029, 

57.012 

Xu B. 33.004, 59.009 

Yacoub S. 29.013 

Yadav A. 28.052, 28.029 

Yadegarynia D. 23.011 

Yadon Z. 57.034, 39.003 

Yaghubi T. 23.011 

Yalcıner A. 53.013 

Yale G. 40.007 

Yamada C. 25.007 

Yamada C. 75.026 

Yamada Y. 74.009 

Yamamoto D. 84.012 

Yamamomto S. 25.001 

Yan W. 73.013, 73.011, 47.005 

Yan Y. 81.002 

Yanagihara K. 74.009 

Yanai M. 25.003 

Yang H.-Q. 53.034 

Yang H. 17.002 

Yang J. 57.016, 57.015 

Yang R.-D. 53.034, 53.033 

Yang X. 73.013 

Yanni E. 32.003, 32.005, 

57.005, 32.004 

Yantorno M. L. 32.016 

Yantorno S. 28.042 

Yao J.-H. 34.005 

Yarlett N. 82.005 

Yauri V. 73.016 

Yavelsky V. 84.011 

Yazici H. 30.006, 30.005 

Ye Q. H. 23.016 

Yegneswaran B. 23.008 

Yenen O. S. 75.014 

Yeo C. L. 50.005 

Yeo K. L. 24.012, 73.002 

Yerino G. A. 77.024 

Yerino G. 80.008, 80.010 

Yew W. W. 49.002 

Yim M. 77.021 

Yip C. Y. 84.025 

Yoneda M. 84.030 

Yong V.-C. P. 47.007 

Yoon I.-K. 65.008 

Yoshida H. 77.008 

Yoshino Y. 77.013 

Yotebieng M. 55.013 

Yotsuyanagi H. 56.015 

You J. 53.033, 75.039, 53.034 

Youn Y. K. 56.039 

Youssefi M. R. 51.013, 51.025 

Yu A. L. F. 28.030, 57.018, 

28.026 

Yu A. L. F. L. F. 28.028 

Yu C.-K. 84.016 

Yuen K. Y. 84.025 

Yuksel P. 58.011, 75.014, 

75.015, 53.013 

Yusdja Y. 34.026 

Yusof M. Y. 23.023 

Yusuke S. 84.007 

Yusuph H. 59.015 

Zabaznoska L. 84.047 

Zabihullah Z. 80.019 

Zaheer H. A. 27.017 

Zaidi A. 43.002 

Zaidi M. B. 21.003, 26.003 

Zainoodin S. A. K. 75.012 

Zakhashvili K. 28.018 

Zali M. R. 53.024, 34.015, 

58.026 

Zali M. R. 52.005 

Zalwango S. 33.001 

Zambrano J. L. 80.011 

Zambriski J. A. 34.020 

Zamudio C. 21.002 

Zangeneh T. 55.005 

Zanin Palchetti C. 27.012, 

27.011, 27.010, 27.013 

Zapata M. A. 80.009 

Zaporojan I. 84.048 

Zárate M. 56.034 

Zarinfar N. 53.010 

Zarkotou O. 74.012 

Zavala Castro J. 24.001 

Zavalani F. 56.014 

Zavalani F. 80.006 

Zelichenko G. 50.004 

Zengin K. 58.011 

Zerjav S. 53.023 

Zewde T. 27.023 

Zhang G. 28.051 

Zhang S. 48.003 

Zhang X. 53.033, 53.034 

Zhang Y.-F. 53.034 

Zheng P. 57.006 

Zheng Y.-J. 34.005, 28.001 

Zhou Y. 57.016 

Zhou Y. 82.012 

Zhu C. 73.011 

Zhu W. 57.016 

Zhuang L. 53.033, 53.034, 

75.039 

Zhuang W. L. 84.039 

Zhuravlev V. 59.019 

Ziapour S. P. 51.013, 51.025 

Zimic M. 21.004 

Zimmerman P. 72.005 

Zimmermann K. 30.003 

Zinner S. 49.007 

Zitto T. 81.016 

Zivkovic Gojovic M. 65.010, 

28.048 

Zojaji H. 52.005 

Zollner-Schwetz I. 30.001 

Zorman Rojs O. 28.016 

Zou Y. 73.011, 73.013 

Zrimec A. 28.016 

Zulaina S. 26.004 

Zurak I. 58.008 

Zyrina E. 58.029 

228 ~ Final Program

A Decade of Experience 

With PCV7: 

Helping to Prevent Pneumococcal 

Disease Then and Now 


12:30 - 14:15 • South Hall 

James L. Knight International Center & Hyatt Regency Miami 

Miami, Florida, United States 

Introduction and Opening Remarks 

Pneumococcal Disease: Global Epidemiology and Antibiotic Resistance 

Pneumococcal Disease Prevention: 

Efficacy and Effectiveness of PCV7 Worldwide 

Assessing Challenges in Pneumococcal Disease Prevention 

Question and Answer Session 

Gail L. Rodgers, MD (Chair) 

Keith P. Klugman, MD, PhD 

Sarah S. Long, MD 

Gail L. Rodgers, MD 

Faculty Panel 

Indication for Prevnar ® , Pneumococcal 7-valent Conjugate 

Vaccine (Diphtheria CRM 197 Protein) 

• Prevnar ® is indicated for active immunization of infants and toddlers 

against invasive disease caused by S. pneumoniae due to capsular 

serotypes included in the vaccine (4, 6B, 9V, 14, 18C, 19F, and 23F). 

The routine schedule is 2, 4, 6, and 12 to 15 months of age. 

• The decision to administer Prevnar ® should be based primarily on 

its efficacy in preventing invasive pneumococcal disease. As with 

any vaccine, Prevnar ® may not protect all individuals receiving the 

vaccine from invasive pneumococcal disease. 

• Prevnar ® is also indicated for active immunization of infants and 

toddlers against otitis media caused by serotypes included in the 

vaccine. However, for vaccine serotypes, protection against otitis 

media is expected to be substantially lower than protection against 

invasive disease. Additionally, because otitis media is caused by 

many organisms other than serotypes of S. pneumoniae 

represented in the vaccine, protection against all causes of otitis 

media is expected to be low. 

• This vaccine is not intended to be used for treatment of active infection. 

Important Safety Information for Prevnar ® 

• In clinical trials (n=18,168), the most frequently reported adverse 

events included injection site reactions, fever (≥38ºC/100.4ºF), 

irritability, drowsiness, restless sleep, decreased appetite, vomiting, 

diarrhea, and rash. 

• Risks are associated with all vaccines, including Prevnar ® . 

Hypersensitivity to any vaccine component, including diphtheria 

toxoid, is a contraindication to its use. Prevnar ® does not provide 

100% protection against vaccine serotypes or protect against 

nonvaccine serotypes. 

Please see accompanying Prescribing Information 

for Prevnar ® . 

This program is a satellite symposium sponsored 

by Pfizer. 

Manufactured by Wyeth Pharmaceuticals Inc. 

Marketed by Pfizer Inc. 

263801-01 © 2010 Pfizer Inc. All rights reserved. Printed in USA/February 2010

Creating vaccines, 

protecting life 

WORLDWIDE, OUR VACCINES PROTECT AGAINST: 

CHICKENPOX • CHOLERA • DIPHTHERIA • HAEMOPHILUS INFLUENZAE type b 

INFECTIONS • HEPATITIS A • HEPATITIS B • INFLUENZA • JAPANESE ENCEPHALITIS • 

MEASLES • MENINGOCOCCAL MENINGITIS (serogroups A, C, Y and W-135) • MUMPS • 

PERTUSSIS • PNEUMOCOCCAL INFECTIONS • POLIOMYELITIS • RABIES • RUBELLA • 

TETANUS • TUBERCULOSIS • TYPHOID FEVER • YELLOW FEVER

FINAL PROGRAM - EpiSouth

Create successful ePaper yourself

Delete template?

Save as template?